**ЦИТИРАНИЯ НА НАУЧНИ ТРУДОВЕ**

**БЕЗ АВТОЦИТАТИ В НАУЧНИ ПУБЛИКАЦИИ И В ПАТЕНТИ ЗА ИЗОБРЕТЕНИЯ У НАС И В ЧУЖБИНА:**

**ОБЩО 3015**

**В ЧУЖДИ ЛИТЕРАТУРНИ ИЗТОЧНИЦИ - 2535**

**В БЪЛГАРСКИ ЛИТЕРАТУРНИ ИЗТОЧНИЦИ - 480**

**h index – 24**

**g – index – 45**

**TSANKOV N. PhD Thesis, 1979**

**Цитати 2**

1. Kadurina M, Bocheva G, Tonev S. Penicillin and semisynthetic penicillins in dermatology.  Clinics in Dermatology 2003; 21 (1):12-23
2. Kadurina, M, Bocheva, G, Tonev S. "Penicillin and semisynthetic penicillins in dermatology." *Disease-a-Month* 50, no. 6 (2004): 291-314.

**Цанков Н., Бонев А. Остра неалергична реакция към бензацилин композитум (клинично наблюдение на един случай). Дерматол и венерол, 1979, 18, 2, 94-96.**

**Цитати – 2**

1. Kadurina, M., Bocheva, G., Tonev, S. (2003). Penicillin and semisynthetic penicillins in dermatology. *Clinics in dermatology*, *21*(1), 12-23.

2. Kadurina, M, Bocheva, G, Tonev S. "Penicillin and semisynthetic penicillins in dermatology." *Disease-a-Month* 50, no. 6 (2004): 291-314.

**Stransky L, TSANKOV N. Contact dermatitis from parsley. Contact Derm 1980,6,3,233-234**

**Цитати-16**

1. Chaudhary, S. K., O. Ceska, C. Tétu, P. J. Warrington, M. J. Ashwood-Smith, and G. A. Poulton. « Oxypeucedanin, a Major Furocoumarin in Parsley. » *Planta medica* 1986 ; 52, (6) 462-464.
2. Niinimaka A. Scratch-chamber tests in food handler dermatitis. Contact Dermatitis 1987; 16, 1, 11-20
3. Gazella JG, Pinto JT. Herbs: use and abuse. Current concepts and perspectives in nutrition.A Nutrition Information Service for the Medical Profession. 6,2, 1987
4. Beier R et al. Linear furanocoumarins and graveolone from the common herb parsley. Phytochemistry, 1994;Vol 36, Issue 4, 869–872
5. Steinman H. Parsley. Allergens within Food of Plant Origin. Immunocap Allergens, 2004
6. Ready, Am I., and Bariatric Fashion Show. “Las Palmas Medical Center.”*Women* 915 (2011): 533-2217.
7. Home, N. Y. U. L. M. C., and Make a Gift. “Petroselinum crispum, Petroselinum hartense, Petroselinum sativum.”,2015

**В монографии**

1. Beier RG, Ivie GW, Oertli EH. Psoralens as Phytoalexins in food Plants of the family to storage and processing (Review)AGS SympS Umbelliferae In: Xenobiotics in Foods and Feeds. **Ed by** John W. Finley, Daniel E. Schwass, 1983, 234, 295-310
2. Hansel R. Keller K, Rimler H, Schneider G. Hagers Handbuch. Drogen P-Z., Springer,1994, p. 119
3. Stellman JM Encyclopaedia of Occupational Health and Safety, Chapter 64, 1998 , Technology & Engineerin
4. Beier R, Nigg H. Toxicology of Naturally Occurring Chemicals in Food. In Y. H. Hui, R. A. Smith, David G. Foodborne disease Handbook. Spoerke, 2000, p.1
5. Mayer M. Les Problemes D’Environement et D’Sante Publique dans Le Secteur Agricule. In: Stellman JM Encyclopédie de sécurité et de santé au travail, 2002;Volume 3,64.79
6. Charles DJ. Parsley. In Peter K.V. Handbook of Herbs and Spices,Vol 2, Woodhead Publishing Ltd, 2004, p. 239
7. Meier J F, Rudd, G E, Molnar, A J, Jerson DD, Mendelsohn M A, & Weir, DF Physical, Inorganic, and Analytical.2009; Chapter 14, pp 151–175
8. Wagstaff D. J. International Poisonous Plants Checklist: An Evidence-Based Reference 2008;p298
9. Charles DJ. Parsley. InHandbook of Herbs and Spices (Second Edition), Volume 1 2012 (pp. 430-451).

**Andreev VC. Boyanov L. TSANKOV N. Generalized acanthosis nigricans. Dermatologica 1981, 163:19-24.**

**Цитати – 49**

1. Heymans G., Simonis A, Lustmanmarechal J et al. Acanthosis nigricans and associated pathologies. Act Clin B 1982; 37: 141-147
2. Friedman –Birnbaum R, Haim S. Seborrheic keratosis and papillomatosis – markers of breast adenocarcinoma. Cutis 1983; 32: 161-162
3. [Czarnecki DB](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Czarnecki%20DB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Rotstein H](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rotstein%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [O’Brien TJ](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22O%27Brien%20TJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Lyall IG](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lyall%20IG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Hanna MJ](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hanna%20MJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). The sign of Leser-Trélat. [Australas J Dermatol.](javascript:AL_get(this,%20'jour',%20'Australas%20J%20Dermatol.');) 1983;24(3):93-99
4. Achten Gedouxcorbusier M, Goens J. Classification and pathogenesis of cutaneous para-neoplastic syndromes. Ann Med Interne 1984; 135: 646
5. Rudolph Andrew and James Callen. A NIGRICANS – Medical complications of malignancy, 1984 – Wiley
6. Smalley SR, Rubin J, Leiferman KM. Neurofibrosarcomand the Sign of Leser-Trelat.CA Cancer J Clin 1984;34;295-298
7. Jeanmougin M.Acanthosis nigricans Ann Dermatol Venereol 1985; 112: 531-544
8. Holdines MR. The sign of Leser-Trelat. Int J Dermatol 1986; 25: 564
9. Sedano HO, Gorlei RJ. Acanthosis nigricans. Oral Surg O 1987; 63: 462-467
10. Dudenko LI, Pryadkin VA, Vinnichenko VV.Paraneoplastic dermatoses. V Derm Ven 1988; p. 52-55
11. Heng MCY, Soohoo K, Levine S. Linear seborrheic keratoses associated with underlying maoignancy. J Am Acad Dermatol 1988; 18: 1316-1321
12. Holdines MR.On the classification of the sign of Leser-Trelat. J Am Acad Dermatol 1988; 19: 754-757
13. Kameya S, Noda A, Osobe E, et al. The sign of Leser-Trelat associated with carcinoma of the stomach. Am J Gastro 1988; 83: 664-666
14. Cohen PR, Grossman ME, Almeida L, et al. Tripe palms and malignancy. J Clin Oncol 1989; 7: 669-678
15. Rampen FHJ, Schwemgle LEM. The sign of Leser-Trelat – does it exist. J Am Acad Dermatol 1989; 21: 50-55
16. Gheeraert P; Goens J; Schwartz R. A; Lambert W. C; Schroeder F; Debusscher L. Florid cutaneous papillomatosis, malignant acanthosis Nigricans, and pulmonary squanmous cell carcinoma. International journal of dermatology, 1991,  30, 3,193-197
17. Duarte H, Ramos AVB. Youthful benign Acanthosis nigricans. An bras Dermatol, 1991,66(2): 81-82,
18. Schmidt KT, Massa MC, Welykyj SE. Acanthosis nigricans and a rectal carcinoid. J Am Acad Dermatol 1991; 25:2, 361-365.
19. Nomura J, Tagawa T. Acanthosis nigricans with oral lesions and a malignant visceral tumor – a case report. J Oral Maxil Surg, 1992; 50:169-172
20. Reverte M, Ferrier M, Foger H, et al. Nevoid cutaneous florid papillomatosis disclosing a pulmonary neoplasia. Ann Dermatol Venereol 1992; 119: 850-852
21. Shelley WB. Advanced Dermatologic Diagnosis… - 1992 – WB Saunders Co
22. Cohn MS, Classen R. The sign of Leser-Trelat associated with adenocarcinoma of the rectum. Cutis, 1993,51,4,255-257
23. Cohen PR, Grossman ME, Silvers DN, Kurzrock R Tripe palms and cancer.. Clinics in Dermatology 1993, 11(1):165-73
24. Politi Y, Ophir K, Brenner S. Cutaneous paraneoplastic syndromes. Acta Derm-Venereol 1993; 73: 161-170
25. Schwartz RA. Florid cutaneous papillomatosis Clin Dermatol. 1993 Jan-Mar;11(1):89-91.
26. Akovbyan VA, Talanin NY, Arifov SS, et al. Successful treatment of acanthosis nigricans with etretinate. J Am Acad Dermatol 1994; 31:1, 118-120
27. Schwartz RA. Sign of Leser-Trelat. J Am Acad Dermatol 1996; 35:1, 88-95
28. Ramirez-Amador V, Esquivel-Peedraza L, Caballero-Mendoza E, et al. Oral manifestations as a hallmark of malignant acanthosis nigricans, J Oral Pathol Med,1999,28,6,278-281
29. Mansouri P, Lotfi M, Mortazavi MR, Naraghi ZS. Florid cutaneous papillomatosis, malignant acanthosis nigrica, palmoplantar keratoderma and gastric adenocarcinoma. Acta Medica Iranica, 1999,37,1,63-67
30. Klimopoulos S, Kounoides C, Pantelidaki C, et al. The Leser-Trelat sign in association with carcinoma of the ampulla of Vater. Am J Gastroenterol, 2001,96, 5,16-23
31. Skiljevic DS, Nikolic MM, Jakovlljevic A, et al. Generalized acanthosis nigricans in early childhood. Pediatr Dermatol, 2001, 18, 3,213-216
32. Aydogan K, Baskan EB, Tunalı S. Akcier Adenokarsinomu ile Birlikte Olan Generalize Malin Akantozis Nigrikans Olgusu. Turkderm 2001; 35: 329-333
33. Pentenero M, Carrozzo M, Pagano M, Gandolfo S. Oral acanthosis nigricans, tripe palms and sign of leser-trélat in a patient with gastric adenocarcinoma International Journal of Dermatology,2004, 43 (7), 530–532.
34. Dogra S, Handa S, Kanwara J. Dexamethasone pulse therapy for scleredema. Pediatric, 2004, 21 (3), 280–281.
35. Schwartz RA. Florid Cutaneous Papillomatosis. E-medicine, 2007.
36. Canjuga I, Mravak-Stipetić M, Kopić V, Galić J. Oral acanthosis nigricans: case report and comparison with literature reports. Acta Dermatovenerol Croat. 2008;16(2):91-5.
37. Damm D et al. Diffuse oral papillomatosis with corrugated lesions of skin. **Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology,2008,** Volume 106, Issue 5 , Pages 630-636,
38. Woo Victoria L., Rafik Abdelsayed. Oral Manifestations of Internal Malignancy and Paraneoplastic Syndromes. Dental Clinics of North America,2008 Volume 52, Issue 1, Pages 203-230
39. Dourmishev LA, Draganov PV Paraneoplastic dermatological manifestation of gastrointestinal malignancies. World J Gastroenterol. 2009; 15(35): 4372–4379.
40. Khorgami Z, Anbara T, Mohammadnejad A, Mahmoodzadeh H. Photoclinic. Archives of Iranian medicine. 2012 Apr 1;15(4):257.
41. Орлова ЕВ, Халдин АА, Брико НИ, Бутенко АВ. Современные представления о кожных паранеопластических заболеваниях и синдромах. Российский журнал кожных и венерических болезней. 2010(3):32-8.

**В монографии**

1. Gorlin RJ, Cohen MM, Hennekam RCM. Chapter 12. Hamartoneoplastic syndromes. In: Syndromes of the Head and Neck,2001,4. Ed, Oxford University press,p.431
2. Heidrun Rotterdam Horatio T. Enterline, Sheldon C Sommers. Pathology of the Stomach and Duodenum, 1989, Springer
3. Stein E. Acanthosis nigricans. In: Proctologie.Lehrbuch und Atlas. 4. Auflage, Springer,2002,p202
4. Stein E. Perianal skin diseases. Anorectal and Colon Diseases: Textbook and Color Atlas of Proctology 4. Auflage, Springer,2003,p194
5. Damm D, Roddy S, D . White. Diffuse oral papillomatosis with corrugated lesions of skin.  Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology , 2008, 106 ,5 , 630 – 636
6. Woo V, R. Abdelsayed Oral Manifestations of Internal Malignancy and Paraneoplastic Syndromes.Dental Clinics of North America, 2008, 52,1,203 – 230
7. Weeden D. Weedon’s Skin Pathology: Expert Consult – Online and Print London : Elsevier Health Sciences UK, 2009.Ref.117
8. Pramatarov K. Skin signs of systemic Neoplastic Diseases and Paraneoplastic Cutaneous Syndromes. In Emergency Dermatology, ed. By R. Wolf, Cambridge University Press, 2011. Chapter 26, 266-270

**Андреев В, Михайлов П, Дурмишев А, Цанков Н. Нашият опит от лекуването с ароматни ретиноиди. Дерматол и венерол, 1982, 21, 4, 234-239.**

**Цитиране – 1**

1. Samsonov VA. Vestn Dermatol Venereol 1990; p. 17.

**Dourmischev AL, Tsankov NK. Serum levels of copper and iron in patients with ampicillin rash. Dermatologische Monatschrift. 1982 Jul;168(7):469.**

**Цитиране – 1**

1. Solomons NW. Biochemical, metabolic, and clinical role of copper in human nutrition. Journal of the American College of Nutrition. 1985 Jan 1;4(1):83-105.

**Michailov P, Berowa N, Tsankov N, Lalowa A, Dimow W. Der Einfluss der Hochgebirgsklimatherapie auf die Hautreaktivität gegenüber den Prostaglandinen E1, E2 und F1 bei allergischen Dermatosen. Dermatol Monatsschr, 1983, 169, 5, 305-310.**

**Цитиране – 2**

### Wüthrich B, Joller-Jemelkaet H al. Influence of mountain climate on immune parameters in atopic dermatitis, psoriasis and controls. Immunology of Skin, 1990

### Juncke S. Geschichte der Atiologie und Therapie der Neurodermitis von 1970 bis 2000 und die Therapie des Internisten Hans-Joachim von Leitner. Diss, Universitatsklinikum Hamburg-Eppendorf, 2013

**Arzneimittelexantheme bei der Behandlung mit Betablockern. Berowa N, TSANKOV N, Gruev A. Dt Derm, 1984, 32, 1082-1086.**

**Цитиране – 2**

1. Meyler’s side effects of drugs. Amsterdam, Exc. Medica, 1991 (многотомен наръчник)
2. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010,49,12,1351-61

**Dimitrowa J, Obreshkowa E, TSANKOV N, Zaimova Z: Pemphigus vulgaris induziert durch ultraviolette Strahlen und das Pestizid Baytan. Dt Derm 1984; 32: 971-6.**

**Цитиране – 10**

1. Brenner S., Wolf R, Ruocco V. Contact pemphigus: a subgroup of induced pemphigus. International Journal of Dermatology.1994, 33 (12), 843–845.
2. Vozza A, Ruocco V, Brenner S, Wolf R. Contact Pemphigus. Int J Dermatol, 1996.
3. Tur E, Brenner S. Diet and pemphigus.In Pursuit of Exogenous Factors in Pemphigus and Fogo Selvagem Arch Dermatol. 1998;134:1406-1410
4. Orion E, Barzilay D, Brenner S. Pemphigus vulgaris induced by diazinon and sun exposure. Dermatology 2000; 201: 378-379
5. Goldberg I, Sasson O, Brenner S. A case of phenol-related contact pemphigus. Dermatology 2001; 203: 355-356.
6. Fassman A et al. Manifestation of Pemphigus vulgaris in the orofacial region. Case report. SCRIPTA MEDICA (BRNO) – 2003;76 (1): 55–62,
7. E. Ruocco, A. Baroni, L. Rossiello, V. Ruocco. Imiquimod contact pemphigus: a comment.  European Journal of Obstetrics & Gynecology and Reproductive Biology, 2004, 115,  2, 242-243
8. **Селисский  Г. Д. , Н. И. Измерова  З. К. Хубиева  Ф. В. Лепшокова .** Современные аспекты профессиональной и экологической дерматологии. Часть 1. Вестник дерматологии и венерологии, 2007,1,8-12
9. Нажмутдинова ДК, et al. “Заболевания кожи, связанные с агрокультурой.” (2010).

**В монографии:**

1. Kanerva L. Occupational diseases of the oral mucosa. In Kanerva L. Handbook of occupational dermatology,2000,Springer,p 258

**TSANKOV N, Mateev G. Anaphylaktischer Schock durch eine Tablette Pyramidon bei einem Kranken mit Psoriasis vulgaris inveterate. Dt Derm,1986,34,3,303-309**

**Цитиране – 1**

* 1. Burgdorf W, Katz S. Treatment of psoriasis in Dermatology: Progress and perspectivesp.Informa Healthcare, 1993, p.691

**Botev-Zlatkov N, TSANKOV N, Tonev S. Drug therapy deteriorates the course of psoriasis. – 17th World Congress of Dermatology, Part II, 1987**

**Цитати – 2**

1. Basavaraj, Kabbur Hanumanthappa, et al. „The role of drugs in the induction and/or exacerbation of psoriasis.” *International journal of dermatology* 49.12 (2010): 1351-1361.
2. Kim, Grace K., and James Q. Del Rosso. „Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance.” *The Journal of clinical and aesthetic dermatology* 3.1 (2010): 32.

**TSANKOV N, Dimitrova J, Obreschkowa E, Lasarowa A. Induzierter Pemphigus durch das Pestizid Phosphamid. Z Hautkr 1987, 62, 3, 196–201.**

**Цитиране – 23**

1. Jeng HD. Induzierter pemphigus durch Pestizid. Berufsdermatosen, 1987, 35, 216.
2. Wolf R, Tamir A, Brenner S. Drug-induced versus drug-triggered pemphigus. Dermatologica 1991; 182: 207-210.
3. Brenner S., Wolf R, Ruocco V. Contact pemphigus: a subgroup of induced pemphigus. International Journal of Dermatology .1994, 33 (12), 843–845.
4. Vozza A, Ruocco V, Brenner S, Wolf R. Contact Pemphigus. Int J Dermatol 1996, 35 (3), 199-201.
5. Tur E, Brenner S.Contributing exogenous factors in pemphigus. Int J Dermatol 1997; 36: 888-893.
6. Tur E, Brenner S. Diet and pemphigus – in pursuit of exogenous factors in pemhigus and fogo ravell. Arch Dermatol,1998,134,11,1406-1410
7. Stransky L. Contact pemphigus vulgaris. Contact Dermatitis. 1998, 38(1):45.
8. Stransky L.The so-called contact dermatoses. Contact Dermatitis .1998, 38 (4), 216–216.
9. Goldberg I, Kashman Y ,Brenner S. The induction of pemphigus by phenol drugs. Int J Dermatol 1999; 38 (12): 888-892.
10. Orion E, Barzilay D, Brenner S. Pemphigus-Vulgaris Induced by Diazinon and Sun Exposure. Dermatology 2000; 201 (4): 378-379.
11. Ruocco E, Aurilia A, Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology 2001; 203 (3): 201-207.
12. Goldberg I, Sasson O, Brenner S. A case of phenol-related contact pemphigus. Dermatology 2001; 203 (4): 355-356.
13. Brenner S, Tur E, Shapiro J, et al. Pemphigus vulgaris& enviromental factors. Occupational behavioral, medical and quaalitative food frequency questionnaire. Int J Dermatol 2001; 40: 562-569.
14. Fassmann A, Dvorakova N., Izakovicova L., Vanek J. Wotke J. Manifestation of pemphigus vulgaris in the orofacial region.Case report. SCRIPTA MEDICA (BRNO) 2003, 76 (1): 55–62
15. Brenner S, Srebrnik A, Goldberg I .Pemphigus can be induced by topical phenol as well as by foods and drugs that contain phenols or thiols. Journal of Cosmetic Dermatology. 2003, 2 (3-4), 161–165.
16. Brenner S, Mashiah J, Tamir E, Goldberg I, Wohl Y. PEMPHIGUS: An Acronym for a Disease with Multiple Etiologies. SKINmed 2003; 2:3: 163–167.
17. Ruocco V, Ruocco E. Pemphigus and ravellingal factors. Digital Dermatol Venereol 2003; 138:299-309
18. Ruocco E., Baroni A., Rossiello L., Ruocco V. Imiquimod contact pemphigus: a comment.  European Journal of Obstetrics & Gynecology and Reproductive Biology, 2004, 115, 2,  242-243
19. **Селисский  Г. Д. , Н. И. Измерова  З. К. Хубиева  Ф. В. Лепшокова .** Современные аспекты профессиональной и экологической дерматологии. Часть 1. Вестник дерматологии и венерологии, 2007,1,8-12
20. Higginbotham, Raymond, et al. “Pesticide-associated pemphigus vulgaris.”*Cutis* 82 (2008): 51-54.
21. 林周次郎, 籏持淳, 中野敦子, 石川里子, 濱崎洋一郎, 山崎雙次, 高野幸一, 石川智子, 酒井英紀, 今井裕. 非 SH 薬による薬剤誘発性天疱瘡と考えられた 1 例. 西日本皮膚科. 2010 Jun 1;72(3):204-8.
22. Pietkiewicz P, Gornowicz-Porowska J, Bartkiewicz P, Bowszyc-Dmochowska M, Dmochowski M. Reviewing putative industrial triggering in pemphigus: cluster of pemphigus in the area near the wastewater treatment plant. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii. 2017 Jun;34(3):185.

**В монографии:**

1. Kanerva L. Occupational diseases of the oral mucosa. In Kanerva L. Handbook of occupational dermatology,2000,Springer,p 258

TSANKOV N, Tonev S. Ghirlandajo’s Gemalde “Grossvater und Enkel” im Blick des Dermatologen. Hautarzt, 1988, 39, 10, 677-679.

**Цитиране – 2**

1. Korting GW. Comment on the contribution by N. Tsankov and S. Tonev: Ghirlandajo’s painting “Grandfather and Grandchild” from the viewpoint of the dermatologist. Hautarzt 1989; 40: 465.
2. Schindera N, Deutsch J, Quinkenstein E, Schindera I.The restored masterwork. The old man, his rhinophyma and the child. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 54:6 2003 Jun pg 548-9

[**Zlatkov N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Zlatkov%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**TSANKOV N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tsankov%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Pramatarov K**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pramatarov%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Konstantinov K**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Konstantinov%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**. Bullous lichen planus and lichen planus pemphigoides.** [**Dermatol Monatsschr.**](javascript:AL_get(this,%20'jour',%20'Dermatol%20Monatsschr.');) **1988;174(6):339-44.**

**Цитиране – 3**

1. Zlosky P, MachackovaJ, Minovska V et al. Lichen ruber and bullous pemphigoid. Dermatol Mschr, 1990, 176, 357-361.
2. Paige D, Bhogal B, Black M., HARPER J. Lichen planus pemphigoides in a child—immunopathological findings. Clinical and Experimental Dermatology. 1993, 18 (6), 552–554.
3. 陈谦明　李秉琦. **类天疱疮样扁平苔藓及副肿瘤性天疱疮.** Chinese journal of stomatology, 1999年　第34卷　第5期　vol.34 no.5, 223-225.

**TSANKOV N, Vassileva S, Lazarova A, Berowa N, Botev-Zlatov N. Onset of psoriasis coincident with tetracycline therapy. Australasian journal of dermatology  (Australas. J. Dermatol.)  1988, vol. 29, no2, pp. 111-112 (11 ref.)**

**Цитиране – 12**

1. Meyler L: Side effect of Drugs. Amsterdam, Exc Medica, 1991.(многотомен наръчник)
2. Brenner S, Wolf R, Landau M, et al. Psoriasiform eruption induced by anticonvulsants. Isr J Med Sci 1994; 30: 283-286.
3. Condon C, Phelan M, Lyons JF. Penicillamine-induced type II bullous systemic lupus erythematosus. Br J Dermatol 1997; 136: 465-479.
4. 可能诱发和加重银屑病的药物. 中华皮肤科杂志.2005年07期 靳培英
5. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.
6. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010,49,12,1351-61
7. Monk E, et al. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacological Research, 2011, Volume 63, Issue 2, Pages 130–145
8. Ayala-Fontanez, Nilmarie. "Paradoxical onset of psoriasis after IL-6 receptor blockade." PhD diss., Case Western Reserve University, 2015.
9. Rose, Carlos D., James D. Lewis, and Brian L. Strom. "Antibiotic Exposure, Infection, and the Development of Pediatric Psoriasis A Nested Case-Control Study." (2015).
10. Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, Strom BL. Antibiotic exposure, infection, and the development of pediatric psoriasis: a nested case-control study. JAMA dermatology. 2016 Feb 1;152(2):191-9.
11. Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckland, NZ). 2016;6:7.

**В монографии:**

1. Dika E, Bardazzi F, Balestri R, Maibach HI. Enviromental factors and psoriasis 1. In Tur E (ed): Environmental Factors in Skin Diseases. Curr Probl Dermatol. Basel, Karger, 2007, vol 35, pp 118-135

**TSANKOV N, Botev-Zlatkov N, Lazarova A, Kostova M, Popova L, Tonev S. Psoriasis and drugs: Influence of tetracyclines on the course of psoriasis. J Am Acad Dermatol 1988;19:629-32**

**Цитиране – 29**

1. Bergner T, Przybilla B. Psoriasis and tetracyclines. J Am Acad Dermatol, 1990, 22, 770.
2. Coignet M, Sayag J. Collyre beta-bloquant et psoriasis . Nouv Dermatol, 1990, 9, 552-553.
3. Humbert P, Traffel P, Chapins JF, et al. The tetracyclines in dermatology. J Am Acad Dermatol. 1991, 25, 691-698.
4. Meyler L. Side effects of drugs. Amsterdam, Exc. Medica, 1991.
5. 坂昌範, et al. “Interferon-alpha 投与により乾癬の悪化をみた多発性骨髄腫.” *西日本皮膚科* 53.5 (1991): 925-929.
6. Abel A. Diagnosis of drug induced psoriasis. Seminars Dermatol,1992,11,269-274
7. Ferrier M, Souteryrand P. Psoriasis et anitinflammatoires non steroides. Ann Dermatol Benerol 1992,119,591-596
8. Burgdorf W, Katz S. Treatment of psoriasis in Dermatology: Progress and perspectivesp.Informa Healthcare, 1993, p.691
9. Yamamoto T, Minatohara K. Minocycline-induced acute generalized exanthematous pustulosis in a patient with generalized pustular psoriasis showing elevated level of s ELAM-1. Acta Derm venereal,1997,77,168-169
10. Fetil E, Ilknur T, Birgin B, Özkan Ş, Güneş AT, Öztürk B, Unsay E, Aǧdanli D. Drug induced psoriasis. [Ilaçla uyarilan psoriyazis]. Turkderm (Deri Hastaliklari ve Frengi Arsivi) 2002; 36 (2): 105-109.
11. Perotti-Abad M.J.,. Arrese J.E, Piérard G.E.. L’image du mois . Une onychopathie ponctuée en dé à coudre. Rev Med Liege 2002; 57 : 3 : 129-130
12. Latini A, Carducci M. Psoriasis during therapy with olanzepine. Eur K Dermatol,2003,13,404-405
13. Mulder W.M.C.,. Meinardi M.M.H.M, D.P.Bruynzeel. Stoppen is meestal niet nodig. Psoriasis en psoriasiforme reacties door geneesmiddelen Pharmaceutisch Weekblad. 2003,138,492-495
14. Scott St. John and Robert Tbrodell. For Problem psoriasis, Remember to Check the “Nails”.An easy-to-recall mnemonic summarizes drugs that commonly exacerbate psoriasis. Practical Dermatology, June 2005
15. 可能诱发和加重银屑病的药物. 中华皮肤科杂志.2005年07期 靳培英
16. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.
17. Dawn AG, Dawn ME, Yosipovitch G?code=200B‌. Psoriasis in the elderly.[Aging Health](http://www.futuremedicine.com/loi/ahe) 2007; 3, 5, 611-623
18. Fry L., Baker B.Triggering psoriasis: the role of infections and medications.  Clinics in Dermatology, 2007, 25,  6,  606-615
19. Rongioletti F, Fiorucci C, Parodi A. Psoriasis induced or aggravated by drugs.J Rheumatol Suppl. 2009 Aug;83:59-61.
20. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010,49,12,1351-61
21. Monk E, et al. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacological Research, 2011, Volume 63, Issue 2, Pages 130–145
22. Ogretmen, Zerrin, et al. “Triggering drug use in patients with psoriasis: an investigative report from Turkey.” Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii 31.5 (2014): 294.
23. Rose CD, Lewis JD, Strom BL. Antibiotic Exposure, Infection, and the Development of Pediatric Psoriasis A Nested Case-Control Study.
24. Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, Strom BL. Antibiotic exposure, infection, and the development of pediatric psoriasis: a nested case-control study. JAMA dermatology. 2016 Feb 1;152(2):191-9.
25. Gonzalez EM, inventor; MUCIDERM SA, assignee. Pharmaceutical composition for preventing, treating, and curing psoriasis including snail slime, chamomile, and honey. United States patent application US 15/501,129. 2017 Aug 3.

**В монографии**

1. Midtvedt T. Penicillines, cephalosporines and tetracylines. In Side effects of drugs. Annual -15, Editors N Dukes, K Aronson, Elsevier, Amsterdam,1991,254-265
2. Stephen M, Breathnach HH. Adverse drug reactions and the Skin. Blackwell, Oxford, London etc,1992
3. Zurcher K, Krebs A. Cutaneous drug reactions.2nd edition, Karger, 1992, p.514
4. Breathnach SM. **Chapter 73: Drug Reactions. In** Rook’s Textbook of Dermatology (Seventh Edition)2004, **p. 3765-3944**

**Lazarova A, TSANKOV N, Zlatkov NB. Psoriasis induced by topically applied indomethacin. Clin Exp Dermatol 1989; 14: 260–261**

**Цитиране – 11**

1. Garioch J., Simpson N. B. Etretinate and severe nail plate dystrophies. Clinical and Experimental Dermatology.1989, 14 (3), 261–262.
2. Ferrier MC, Souteyrand P. Psoriasis et antiinflammatoires non steroidens. Ann Dermatol Venerol, 1992, 119, 591-596.
3. Gupta AK, Sibbald RG, Knowles SR et al. J Am Acad Dermatol 1997; 36: 858-862.
4. Cohen AD, Bonneh DY,   Reuveni H,  Vardy DA,  Naggan L, Halevy S. Drug Exposure and Psoriasis Vulgaris: Case-Control and Case-Crossover Studies. Acta Dermato-Venereologica 2005; 85(4): 299 – 303.
5. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.
6. Fry L., Baker B.Triggering psoriasis: the role of infections and medications.  Clinics in Dermatology, 2007, 25, 6, 606-615
7. Honda T et al. Prostaglandin E2–EP3 signaling suppresses skin inflammation in murine contact hypersensitivity . Journal of Allergy and Clinical Immunology,  [2009,124, 4](http://www.sciencedirect.com/science/journal/00916749/124/4), 809–818.e2
8. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010,49,12,1351-61
9. Wu S, Han J, Qureshi AA. Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study. Acta dermato-venereologica. 2015 Feb 1;95(2):217-23.
10. Parker, S. "Oral Chinese herbal medicine for psoriasis vulgaris." Doctor of Philosophy (PhD), Health Sciences, RMIT University (2015).

**В монографии:**

1. Dika E, Bardazzi F, Balestri R, Maibach HI. Enviromental factors and psoriasis In: Tur E (ed): Environmental Factors in Skin Diseases. Curr Probl Dermatol. Basel, Karger, 2007, vol 35, pp 118-135

**TSANKOV N, Lazarova A, Vasileva S, Obreshkova E.** **Lupus erythematosus – like eruption due to D-penicillamine in progressive systemic sclerosis. Int J Dermatol 1990; 29 (8): 571-4**

**Цитати – 16**

1. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994; 20: 61-86.
2. Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus 1994; 3 (6): 455-459.
3. Condon C, Phelan M, Lyouns JF. Penicillamine-induced type II bullous systemic lupus erythematosus. Br J Dermatol,1997,136,474-475
4. Pramatarov K. Drug induced lupus erythematosus. Clin Dermatol 1998; 16: 367-377,
5. Zhang W, Winkler T, Kalden JR, Reichlin M. Isolation of human antiidiotypes broadly cross-reactive with anti-dsDNA antibodies from patients with systemic-lupus-erythematosus. Scand J Immunol 2001; 53 (2): 192-197.
6. Faghihi Gita, Asilian Ali, Wali Anahita The side effects of D-penicillamine on human skin Arch Rheumatol 2002; 6: 1
7. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug induced lupus erythematosus. Autoimmunity, Volume 38, Number 7, Number 7/November 2005 , pp. 507-518(12)
8. Atzeni F., Marrazza M.G., Sarzi-Puttini P., Carrabba M. Drug induced lupus erythematosus.Reumatismo, 2003; 55(3):147-154
9. Pramatarov K. Chronic cutaneous lupus erythematosus—clinical spectrum. Clinics in Dermatology, 2004, 22,  2, 113-120
10. Vitiello, Magalys, et al. „An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist’s Point of View.” *The Journal of clinical and aesthetic dermatology* 5.7 (2012): 33.

**В монографии**

1. Zurcher K, Krebs A. Cutaneous Drug Reactions: An integral synopsis of Today’s systemic drugs. Karger, 2d ed., 1992, ref # 5561.
2. Breatnach, Hintner (Eds.). Adverse Drug Reactions and the Skin. 1992, Blackwell, Oxford, p. 118.
3. Wallace DJ, Hahn BH. In: Dubois lupus erythematosus (4th edition), Lea, Febiger 1993
4. Aronson JK. Penicillamine. In: Meyler’s Side Effects of Analgesics and Anti-inflammatory Drugs By Jeffrey K.,Elsevier, 2010, p641
5. Sylvia LM. Drug allery, Pseudoallergy and Cutaneous Diseases. In: Drug induced diseases- Prevention, Detection and management.ed. by James E. Tisdale, Douglas A. Miller, ASHS, 2010, sec ed., p 114
6. Calonje JE, Brenn T, Lazar A, McKee PH. Pathology of the Skin, 2011 Elsevier Health Sciences

**Lazarova A, Durmishev A, Balabanova M, Tsankov N. Association d’une urticaire pigmentaire et d’atrophie blanche. Rev Eur Dermatol, 1990, 2, 213-216.**

**Цитати – 3**

1. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.
2. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010,49,12,1351-61

**В монографии:**

1. Dika E, Bardazzi F, Balestri R, Maibach HI. Enviromental factors and psoriasis 1. In Tur E (ed): Environmental Factors in Skin Diseases. Curr Probl Dermatol. Basel, Karger, 2007, vol 35, pp 118-135

**TSANKOV N, Stransky L, Kostowa M, Mitrowa T, Obreschkowa E. Induced pemphigus caused by occupational contact with Basochrom. Dermatosen Beruf Umwelt – Occup Environ Dermat 38:91-93 (1990).**

**Цитати – 35**

1. Zosmer A, Kogan S, Frumkin A, Dgani R, Lifschitzmercer B. Unsuspected Involvement of the Female Genitalia in Pemphigus-Vulgaris. Eur J Obstet Gyn R B 1992; 47 (3): 260-263.
2. Ruocco V, Brenner S. Pemphigus registry – Genetic and Inducing Factors to Be Explored. Int J Dermatol 1994; 33 (4): 287-288.
3. Brenner-S Wolf-R. Possible Nutritional Factors in Induced Pemphigus. Dermatology 1994; 189 (4): 337-339.
4. Bigazzi PE. Autoimmunity and heavy metals. Lupus 1994; 3 (6): 449-453.
5. Brenner S, Wolf R, Ruocco V. Contact pemphigus: a subgroup of induced pemphigus. International Journal of Dermatology. 1994, 33 (12), 843–845.
6. Vozza A, Ruocco V, Brenner S, Wolf R. Contact Pemphigus. Int J Dermatol, 1993.
7. Brenner S, Ruocco V, Wolf R, Deangelis E, Lombardi ML. Pemphigus and Dietary Factors – In-Vitro Acantholysis by Allyl Compounds of the Genus Allium. Dermatology 1995; 190 (3):197-202.
8. Vozza-A Ruocco-V Brenner-S Wolf-R. Contact Pemphigus. Int J Dermatol 1996, 35, 3, 199-201.
9. Ruocco-V Wolf-R Ruocco-E Baroni-A. Viruses in Pemphigus – A Casual or Causal Relationship. Int J Dermatol 1996, 35, (11): 782-784.
10. Stransky L.Contact mycosis fungoides? Contact Dermatitis,1996, 35 (2), 121–121.
11. Stransky L, Vasileva S, Mateev G. Contact bullous pemphigoid. Contact Dermatitis 1996; 35: 182.
12. Lear J T, Tan BB, Lovell CR,English JSC. Irritant contact dermatitis from *Cerastium tomentosum* (snow-in-summer).Contact Dermatitis 1996,35 (3), 182–182.
13. Tur E, Brenner S. The role of the water system as an exogenous factor in pemphigus. Int J Dermatol 1997; 36: 810-816.
14. Tur E, Brenner S. Contributing exogenous factors in pemphigus. Int J Dermatol 1997; 36: 888-893.
15. Stransky L. Contact pemphigus vulgaris. Contact Dermatitis. 1998 ; 38(1):45.
16. [Stransky L](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Stransky%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Bardarov E](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bardarov%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Contact lupus erythematosus? [Contact Dermatitis.](javascript:AL_get(this,%20'jour',%20'Contact%20Dermatitis.');) 1998 Jul;39(1):37
17. Stransky L. The so-called contact dermatoses. Contact Dermatitis. 1998;38(1):216-217
18. Tur E, Brenner S. Diet and pemphigus – in pursuit of exogenous factors in pemphigus and fogo ravell. Arch Dermatol 1998; 134: 1406-1410.
19. Bigazzi-PE. Metals and Kidney Autoimmunity. ENVIRONMENTAL HEALTH PERSPECTIVES 1999; 107(S5): 753-765.
20. Goldberg-I Kashman-Y Brenner-S. The induction of pemphigus by phenol drugs. Int J Dermatol 1999; 38 (12): 888-892.
21. Frank I , Bieger W. P. Immuntoxikologie chronischer Quecksilberbelastung. Rubrik: Umweltmedizin, Fr, 29.09.2000 online
22. Ruocco E, Aurilia A, Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology 2001; 203 (3): 201-207.
23. Goldberg I, Sasson O, Brenner S. A case of phenol-related contact pemphigus. Dermatology 2001; 203 (4): 355-356.
24. Gallo R, Massone C, Parodi A, Guarrera M. Allergic contact dermatitis from thiurams with pemphigus-like autoantibodies. Contact Dermatitis 2002; 46 (6): 364-365.
25. Ruocco V, Ruocco E. Pemphigus and ravellingal factors. Digital Dermatol Venereol 2003; 138:299-309
26. [Wohl Y](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wohl%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Brenner S](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Brenner%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Pemphigus in Israel–an epidemiologic analysis of cases in search of risk factors. [Isr Med Assoc J.](javascript:AL_get(this,%20'jour',%20'Isr%20Med%20Assoc%20J.');) 2003;5(6):410-412
27. Ruocco E., Baroni A., Rossiello L., Ruocco V. Imiquimod contact pemphigus: a comment.  European Journal of Obstetrics & Gynecology and Reproductive Biology,2004, 115, 2, 242-243
28. United Nations environment programme. International labour office. World health organization. International programme on chemical safety, February 2005 EHC on Principles and Methods for Assessing Autoimmunity Associated with Exposure to Chemicals, p.152
29. Environmental Health Criteria 236 ; Principles and methods for assessing autoimmunity associated with exposure to chemicals. World Health Organisation 2006,WHO press. Geneva, ISBN 92 4 157236 1 (NLM classification: WD 305),ISBN 978 92 4 157236 1,ISSN 0250-863X
30. **Селисский  Г. Д. , Н. И. Измерова  З. К. Хубиева  Ф. В. Лепшокова .** Современные аспекты профессиональной и экологической дерматологии. Часть 1. Вестник дерматологии и венерологии, 2007,1,8-12
31. Давиденко, ЕБ, НВ Махнева, ЛВ Белецкая. „Современный взгляд на патогенез и факторы, способствующие развитию аутоиммунной пузырчатки.” (2013).
32. Теплюк, Наталия Павловна. "Истинная акантолитическая пузырчатка и психосоматические расстройства." Диссертация на соискание ученой степени кандидата медицинских наук. Москва (2017).

**В монографии:**

1. Kanerva L. Occupational diseases of the oral mucosa. In Kanerva L. Handbook of occupational dermatology,2000,Springer,p 258
2. Fuchs J. Future direction. In: Environmental Stressors in Health and Disease, 2001, Marcel-Dekker Inc, p.76
3. Vassileva S. Acute severe bullous dermatoses. In Emergency in Dermatology Ed. By L.Parish,2010, Cambridge University press, p.230

**Lazarova A, TSANKOV N, Psoriasis and tetracyclines – reply. J Am Acad Dermatol 1990; 23: 770–771**

**Цитати – 2**

1. Meyler L. Side effects of drugs. Amsterdam, Experta Medica 1991.
2. Basavaraj, Kabbur Hanumanthappa, et al. „The role of drugs in the induction and/or exacerbation of psoriasis.” *International journal of dermatology* 49.12 (2010): 1351-1361.

**TSANKOV N, Stoimenov A, Lazarova A. Psoriasis induit par la Chloroquine chez un malade ayant un lupus erythemateux discoide. Rev Eur Dermatol. MST, 1990, 2, 453-458.**

**Цитати – 3**

1. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.
2. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010,49,12,1351-61

**В монографии:**

1. Dika E, Bardazzi F, Balestri R, Maibach HI. Enviromental factors and psoriasis 1. In Tur E (ed): Environmental Factors in Skin Diseases. Curr Probl Dermatol. Basel, Karger, 2007, vol 35, pp 118-135

**Cheshmedjieva S, TSANKOV N, Kolev N.et al. Effect of fish oil and selective UV phototherapy on psoriasis vulgaris. J Derm treatment,1991,2,107-110**

**Цитати – 4**

1. Picó M, Lugo-Somolinos A, Sánchez JL, Burgos-Caldfrón R. Cutaneous alterations in patients with chronic renal failure.International Journal of Dermatology.1992, 31 (12), 860–863.
2. Chung B, Walton Sh, Wyatt EH, Bury HP. Spitz nevus , International Journal of Dermatology. 1993,32 (5), 354–357.
3. Grimminger F, Mayser P. Lipid mediators, free fatty acids and psoriasis. Review- prostaglandins, leukotriens and essential fatty acids. 1995, 52, 1, 15.

**В монографии:**

1. Burgdorf W, Katz S. Treatment of psoriasis. In Dermatology: Progress and perspectivesp.Informa Healthcare, 1993, p.691

**TSANKOV N, Krasteva M. Rifampicin in severe forms of psoriasis. J Derm Treat,1992,3,69-71**

**Цитати – 9**

1. Ross JB, Vincent F.Rifampin in Dermatology. J Am Acad Dermatol 1993, 29 (6): 1057-1057.
2. Kazandjieva J, Kamarashev J, Hinkov G. Alleviation of psoriasis by rifampicin treatment of pulmonary tuberculosis. J Dermatol Treat, 1993, 4, 163-164.
3. Coskey RJ. Dermatologic therapy – 1992, J Am Acad Dermatol, 1993, 29, 595-608.
4. Epstein ME, Amodio-Groton M, Sadick MS. J Am Acad Dermatol 1997; 37: 365-381.
5. Owen CM, Chalmers RJG, O’Sullivan T, Griffiths CEM. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD001976.
6. Sadick N.Antibiotics: unapproved uses or indications.  Clinics in Dermatology, 2000,18, 1, 11-16
7. Dika E, Varott C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.
8. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010 Dec;49(12):1351-61

**В монографии:**

1. Burgdorf W, Katz S. Treatment of psoriasis in Dermatology: Progress and perspectivesp.Informa Healthcare, 1993, p.691

**TSANKOV N. Bulgarian dermatology. Int J Dermatol, 31,1992, 60-65**

**Цитати – 1**

## Parish LC, Crissey JT, Parish JL. Bibliography of secondary sources on the history of dermatology. I. Journal articles in English supplemented through 1995. Int J Dermatol. 1996;35(6):430-437.

## **Lasarowa A, TSANKOV N, Stoimenov A. Lichenoid eruptions after gold therapy. Report of two cases. Hautarzt 1992; 43(8):514-6.**

**Цитати – 5**

1. Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol,1998,16,325-332
2. Payette MJ, Weston G, Humphrey S, Yu J, Holland KE. Lichen planus and other lichenoid dermatoses: kids are not just little people. Clinics in dermatology. 2015 Nov 1;33(6):631-43.

**В монографии**

1. Kauppinen K, Kariniemi AL. Clinical manifestation and histological characteristics. In Kauppinen K, Alanko K, Hannuksela M, Maibach H.Skin reactions to drug.1998, CRC Press LLC,p.48
2. Böer, Almut. "Dermatopathology: Practical & Conceptual." (2002).
3. Nambi R. Dermatological Manifestations of Metal Poisoning. Rook's Textbook of Dermatology, Ninth Edition. 2016 Jul 15:1-2.

**Vassileva S, Krasteva M, Marina S, TSANKOV N. Widespread granuloma annulare and cervical adenocardnoma. Int J Dermatol. 1992, 31, 819**

**Цитати – 14**

1. Cohen PR.Granuloma annulate associated with malignancy. South Med J 1997; 90: 1056-1059.
2. Kutukculer N, Tutunguolu S, Yilmaz D, et al. Turkish J Pediatr,1998,40,279-282
3. Fernandes-Lopez E et al. Dermatosis paraneoplásicas: nuevos cuadros. Publicado en Piel. 2001;16:172-4. – vol.16 núm 04
4. Li AL, Hogan DJ, Sanusi ID, et al. Granuloma annulare and malignant neoplasms. Am J Dematopathol,2003,25,113-116
5. Akyol M et al. Granuloma annulare associated with prostate carcinoma . J Eur Acad Dermatol Venereol, 2003,17,464-465
6. Hernandes C, Giraldez A, Corbi R. Et al. Granuloma anular de dispocion lineal asociado a neoplasia esophagica. Med Cutan Iber Lat Am,2003,31,4,252-255
7. Herron MD, Florell SR Disseminated granuloma annulare accompanying mycobacterium tuberculosis lymphadenitis International Journal of Dermatology.2004, 43 (12), 961–963.
8. Stein R, Herman S, Phelps R, Sapadin AN. Florid eruption of seborrheic keratoses associated with elevated insulin-like growth factor, ravellingal, and solitary fibrous tumor of the pleura International Journal of Dermatology .2004,. 43 (12), 944–947.
9. [Cohen PR](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cohen%20PR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Granuloma annulare, relapsing polychondritis, sarcoidosis, and systemic lupus erythematosus: conditions whose dermatologic manifestations may occur as hematologic malignancy-associated mucocutaneous paraneoplastic syndromes. Int J Dermatol. 2006;45(1):70-80
10. Shimizu S, Yasui C, Tsuchiya K.Atypical generalized granuloma annulare associated with two visceral cancers.  Journal of the American Academy of Dermatology, 54, 5, 236-238
11. Minaudo C.,Granuloma annulare and mesenchymal cancer. Report of two cases. Dermatol Argent 2008;14(2):113-117
12. Parish LC et al, Granuloma annulare not as simple as it seems. Skinmed J, 2008,255-6
13. Thornsberry, Laura A., and Joseph C. English III. „Etiology, diagnosis, and therapeutic management of granuloma annulare: an update.” *American journal of clinical dermatology* 14.4 (2013): 279-290.
14. Lukács J, Schliemann S, Elsner P. Treatment of generalized granuloma annulare–a systematic review. Journal of the European Academy of Dermatology and Venereology. 2015 Aug 1;29(8):1467-80.

**TSANKOV N, Pramatarov K, Kamarachev J. Psoriasis placata, die unter der Einwirkung der Beta-Blocker in eine Psoriasis pustulosa ubergeht. Dtsch Dermatologe, 1992, 12, 1702 – 1706**

**Цитати – 3**

1. Dika E, Varott C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11
2. Basavaraj, Kabbur Hanumanthappa, et al. „The role of drugs in the induction and/or exacerbation of psoriasis.” *International journal of dermatology* 49.12 (2010): 1351-1361.
3. Kim, Grace K., and James Q. Del Rosso. „Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance.” *The Journal of clinical and aesthetic dermatology* 3.1 (2010): 32.

**Syndrome de Sneddon avec anticorps antiphospholipides et cardiopathie valvulaire. Tsankov N, Krasteva M, Mateev G, Nikolov K. Ann Dermatol Venereol 1992; 119: 47.**

**Цитати- 1**

1. Richard MA, Grob JJ, Durand JM, et al. Sneddons Syndrome. Ann Dermatol Venereol 1994; 121 (4): 331-337.

**TSANKOV N, Kamarashev J. Rifampin in Dermatology. IntJDermatol, 32, 1993, 401-406.**

**Цитати – 14**

1. Ross JB, Vincent F. Rifampin in Dermatology. Int J Dermatol 1994; 33 (3): 223-223.
2. Hoss DM, Feder HM. Addition of Rifampin to Conventional Therapy for Recurrent Furunculosis. Arch Dermatol 1995; 131 (6): 647-648.
3. Mirensky Y, Parish LC, Witkowski J. Recent advances in antimicrobial therapy of bacterial infections of the skin. Current Opinion in Dermatology 1995, 2 :179 -184
4. Carlotti DN. Rifampicin is always an antituberculotic – Replay. Pract Med Chir Anim,1996,31,421-422
5. Feder HM, Pond KE. Addition of rifampin to cephalexin therapy for recalcitrant staphylococcal skin infections – an observation. CLINICAL PEDIATRICS 1996, 35 (4): 205-208
6. Obregon C. Antibacterianos en dermatología: nuevos usos / Antibacterials in dermatology: new use. Dermatol. Venez;34(2):43-52, 1996.
7. Montazeri A, Kanitakis J, Basex. Psoriasis and HIV Infection. J. Int J Dermatol 1996; 35(7):475-79.
8. Epstein ME, Amodio-Gotron M, Sadick NS. Antimicrobial agents for the dermatologist.2. Macrolides, fluoroquinolones, rifamycins, tetracylines, trimethoprim-sulfamethazole, and clindamycin. J Am Acad Dermatol,1997,37,365-381
9. Sadick NS. Systemic antibiotic agents. Dermatol Clin 2001,19,1
10. Fernandez-Obregon A, Rohrback J, Reichel MA, Willis C. Current use of anti-infectives in dermatology. Future drugs, [Expert Review of Anti-infective Therapy](http://www.future-drugs.com/loi/eri), 2005, 3, 4, 557-591
11. Trabelsi S et al. Lésions cutanées bulleuses graves induites par l’isoniazide. Thérapie , 2005,Volume 60, Numéro 6,
12. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010 Dec;49(12):1351-61
13. Fu J et al. Immunosuppressive effects of Rifampicin on a tuberculosis patient after renal transplant. Pakistan Journal of Medical Sciences, Vol 27, No 3 (2011)

**В монографии**

1. In Levin N, Levine CC. Dermatology Therapy A to Z Essentials. Springer, 2004, p.506

**Кazandjieva J, Mateev G, TSANKOV N. Is Pityriasis rubra pilaris an infectious disease? Derm Monatsschr, 1993, 179, 3, 105-107.**

**Цитирания – 3**

1. Kadurina M, Bocheva G, Tonev S. Penicillin and semisynthetic penicillins in dermatology.  Clinics in Dermatology 2003; 21 (1):12-23.
2. Kadurina, M., Bocheva, G., & Tonev, S. (2004). Penicillin and semisynthetic penicillins in dermatology. Disease-a-Month, 50(6), 291-314.
3. Ahn, S. Y., Kim, J. H., Ahn, S. K., & Oh, Y. S. (2011). Clinical improvement of pityriasis rubra pilaris with antibiotic therapy. European Journal of Dermatology,21(1), 106

**TSANKOV N, Krasteva M. On rifampin treatment of psoriasis(letter). JAAD, 1993; 29(6):1057.**

**Цитирания -4**

1. Montazeri A, Kanitakis J, Basex. Psoriasis and HIV InfectionJ. Int J Dermatol 1996; 35(7):475-79.
2. Obregón, Carmen. „Antibacterianos en dermatología: nuevos usos.” *Dermatología Venezolana* 34.2 (1996).
3. Dubrac, Sandrine, et al. „Modulation of T lymphocyte function by the pregnane X receptor.” *The Journal of Immunology* 184.6 (2010): 2949-2957.
4. Цискаришвили, Н. В., Н. И. Цискаришвили. „Противотуберкулезные Препараты В Лечении Псориаза.” *Georgian Medical*: 25.

**Chronic mucocutaneous candidosis with osteolysis of the frontal bone. Mateev G, Kantardjiev T, Vassileva S, TSANKOV N. Int J Dermatol 1993; 32: 888-889.**

**Цитиране – 4**

1. Rybojad M, Abimelec P, Feuilhade M, Morel P, Bourrat E. Familial candidiasis endocrinopathy syndrome – treatment with fluconazole in 3 cases. Ann Dermatol Venereol 1999; 126: 54-56
2. De Hoog GS, Guarro J, Gene J & Figueras MJ (Eds.). Atlas of Clinical Fungi, 2d Ed, 2000.
3. Prillinger H, Lopandic K, Schweigkofler W, Deak R, Aarts HJM, Bauer R, Sterflinger K, Kraus GF, Maraz A. Phylogeny and ravelling of the fungi with special reference to the ascomycota and basidiomycota. Chemical Immunology 2002; 81: 207-295.
4. Malamos D, Scully C. Sore or swollen lips part 1: causes and diagnosis. Dental Update. 2016 Nov 2;43(9):874-82.

**Vassileva S, Mateev G, Balabanova M, TSANKOV N. Burn induced bullous pemphigoid. – J Am Acad Dermatol, 1994,30,6,1027-1028**

**Цитати – 16**

1. Kirtschig G, Walken VM, Venning VA, Wojnarowska FT. Bullous pemphigoid and multiple-sclerosis – a report of 3 cases and review of the literature. Clin Exp Dermatol 1995; 20: 449-453.
2. Balato N.Burn induced bullous pemphigoid. Reply. International Journal of Dermatology, 1995,34,7,516-517
3. Kirtschig G, Chow ETY, Venning VA, Wojnarowska FT. Acquired subepidermal bullous diseases associated with psoriasis – A clinical, immunopathological and immunogenetic study. Br J Dermatol 1996; 135: 738-745.
4. Knees-Matzen S., Proksch E., Meigel W.N. Dyshidrosiform bullous pemphigoid: trigger factors. JEADV, 7, 3, 1996 , pp. 257-262(6)
5. Soni BP, Mcalvany JP, Fleischer AB, Sherertz EF. Bullous pemphigoid mimicking contact dermatitis Contact Dermatitis 1996; 35: 314.
6. Vassileva S. Drug-induced pemphigoid. Clin Dermatol1998,16,379-387
7. Vermeulen C, Janier M, Panse I, Daniel F. Localized bullous pemphigoid induced by thermal burn. Ann Dermatol Venereol 2000; 127: 720-722
8. Morritt D, Pabari A, Gilbert PhM, Dheansa BS. **Bullous Pemphigoid Mistaken for a Burn.** Journal of Burn Care & Research. 2006, 27 (4) : 548-551.
9. Hong-Hui XU,Ting XIAOmChun-Di HE,Guang-Yu JIN,Ya-Kun WANG,Xing-Hua GAO,Hong-Duo CHEN. Bullous pemphigoid triggered by a boiling water burn. EJD, 2008,18, 4, 466-467
10. Bachmeyer, Cl et al. Bullous Pemphigoid After Boiling Water Burn. Southern Medical Journal: 2010, 103,11, 1175-1177
11. Vassileva, Snejina, Kossara Drenovska, and Karen Manuelyan. „Autoimmune blistering dermatoses as systemic diseases.” *Clinics in dermatology* 32.3 (2014): 364-375.

## Damevska K, GocevG, Nikolovska S. A Case of Burn-Induced Bullous Pemphigoid. Journal of Burn Care & Research:2014; 35, 4,281-2

## Cozzani E, Gasparini G, Burlando M, Drago F, Parodi A. Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects. Autoimmunity reviews. 2015 May 31;14(5):438-45.

## Woźniak K, Dmochowski M, Placek W, Waszczykowska E, Żebrowska A, Nowicki R, Flisiak I, Czajkowski R, Szepietowski J, Maj J, Kaszuba A. Pemphigoid–diagnosis and treatment. Polish Dermatological Society Consensus. Przegląd Dermatologiczny/Dermatology Review. 2016;103(1):19-34.

**В монографии:**

1. Vassileva, Snejina. „Acute, Severe Bullous Dermatoses.” In:Emergency Dermatology Cambridge University press(2011): 215.

## Schmidt E, Borradori L, Sprecher E, Marinovic B, Sinha AA, Joly P. Genetic and Environmental Risk Factors of Autoimmune Bullous Diseases. InBlistering Diseases 2015 (pp. 131-139). Springer Berlin Heidelberg.

### **TSANKOV N, M Gantcheva, M Pecheva. Doxycicline induced psoriasis vulgaris.**

**- Dermatol i Venerol (Sofia), 1994 (Цанков Н**, Ганчева М, Пешева М, Кадурина М. Псориазис вулгарис, индуциран от Doxycyclin. Дерматол и венерол, 1994, 33, 2-3, 31-32.)

**Цитати – 1**

1. Basavaraj, Kabbur Hanumanthappa, et al. „The role of drugs in the induction and/or exacerbation of psoriasis.” *International journal of dermatology* 49.12 (2010): 1351-1361.

**Vassileva S, Mateev G, TSANKOV N, Balato N. BURN-INDUCED BULLOUS PEMPHIGOID. AUTHOR'S REPLY. International journal of dermatology. 1995;34(7):516-7.**

**Цитирания -5**

1. Blaise G, Pierard C, Quatresooz P, Pierard G. Le cas clinique du mois. Pemphigoide bulleuse apres brulure thermique. Revue Médicale de Liège. 2008;63(4):182-3.
2. Ljubojevic S, Lipozenčić J. Autoimmune bullous diseases associations. Clinics in dermatology. 2012 Feb 29;30(1):17-33.
3. Damevska K, Gocev G, Nikolovska S. A case of burn-induced bullous pemphigoid. Journal of Burn Care & Research. 2014 Jul 1;35(4):e281-2.
4. Cozzani E, Gasparini G, Burlando M, Drago F, Parodi A. Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects. Autoimmunity reviews. 2015 May 31;14(5):438-45.
5. Woźniak K, Dmochowski M, Placek W, Waszczykowska E, Żebrowska A, Nowicki R, Flisiak I, Czajkowski R, Szepietowski J, Maj J, Kaszuba A. Pemphigoid–diagnosis and treatment. Polish Dermatological Society Consensus. Przegląd Dermatologiczny/Dermatology Review. 2016;103(1):19-34.

**Кazandjieva J, Kamarashev J, Kadurina M, TSANKOV N. Unprofessional Tattoos in Bulgaria- psychological aspects. JEADV, 1995, 4, 254-259.**

**Цитати – 3**

1. Vassileva S, Hristakieva E. Medical applications of tattooing. Clin Dermatol,2007,25,367-374
2. Latreille J, Levy J-L, Guinot C. Decorative tattoos and reasons for their removal: a prospective study in 151 adults living in South of France,JEADV,2011,25,2,181-7
3. Neluis, Thomas, et al. „Prevalence and implications of genital tattoos: A site not forgotten.” *British Journal of Medical Practitioners* 7.4 (2014).

[**Baleva M**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Baleva%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Chauchev A**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chauchev%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Dikova C**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Dikova%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Stamenov B**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Stamenov%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Nikoevski N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nikoevski%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**TZANKOV N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tzankov%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Nikovov K**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nikovov%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**.** **Sneddon’s syndrome: echocardiographic, neurological, and immunologic findings. Stroke 1995 Jul;26(7):1303-1304**

**Цитати – 19**

1. Devuyst G, Sindic C, Laterre EC, et al.Neuropathological findings of a Sneddon’s syndrome presenting with dementia no precede by clinical cerebrovascular events. Stroke 1996;27,1008-1009
2. Riley RS, Friedlin J, Rogers JS. Antiphospholipid antibodies: standartization and testing. Clin Lab Med,1997,17,395
3. Muerza FM, Gonzalez G, Ortiz E, et al. Cerebral hemorrhage in Sneddon syndrome. Rev Neurologia,1998,27,74-76
4. Wright RA, Kokmen E. Gradually progressive dementia without discrete cerebrovascular events in a patient with Sneddon’s syndrome. Mayo Clin Proc,1999,74,57-61
5. Kalashnikova LA, Korzyn AD, Shavit S, et al. Antibodies to prothrombin in patients with Sneddon’s syndrome.Neurology,1999,53,223-225
6. Baleva M, Boyanovski B, Nikilov K, et al. High levels of IgA anticardiolipin antibodies in patients with lupus erythematosus sustematisatys, Henoch-Schoenlein pusrpura, Sneddon’s syndrome and recurrent pregnancy losss. Thromn Haemostasis,1999,82,1774-1775
7. Deev AS, Zakharushkina IV. Cerebral strokes at young age. Zh Nevropathol Psikh 2000, 100, 14-17.
8. Adair JC, Digre KB, Swanda RN, et al. Sneddon’s syndrome - A cause of cognitive decline in young adults. Neuropsy BE, 2001, 14,197-204.
9. Leal R, Buffon L, Sarpieri A et al. Sneddon’s syndrome: a case report and revision of literature. Ann Brasil de Dermatologia, 2001, 76, 3, 309-316, maio/jun. 2001.
10. Flöel A, Imai T, Lohmann H, Bethke F, Sunderkötter C, Droste D.Therapy of Sneddon Syndrome. Eur Neurol 2002;48:126–132
11. Kraemer M, Linden D, Berlit P. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review. J Neurol. 2005 Oct; 252(10):1155-66.
12. Tietjen GE, Al-Qasmi MM, Gunda P, Herial NA. Sneddon’s syndrome: another migraine–stroke association? Cephalalgia, 2006, 26, 3, 225-232(8)
13. Kraemer M, Baumgaertel M, Berlit P. Miscarriage, peripheral thromboses and aortic aneurysm in antiphospholipid-antibody-negative Sneddon’s syndrome. J Neurol. 2007 Nov; 254(11):1599-600.
14. Legierse, Catharina M., et al. „Sneddon syndrome and the diagnostic value of skin biopsies–Three young patients with intracerebral lesions and livedo racemosa.” *European Journal of Dermatology* 18.3 (2008): 322-328.
15. Valtchev, Valentin, and Ivelina Yordanova. „SNEDDON’S SYNDROME.” *Journal of IMAB–Annual Proceeding Scientific Papers* 14.1 (2008): 72-75.
16. Turc, Guillaume, et al. „Skin involvement in Susac’s syndrome.” *Journal of the neurological sciences* 305.1 (2011): 152-155.
17. Wu S, Xu Z, Liang H. Sneddon’s syndrome: a comprehensive review of the literature. Orphanet journal of rare diseases. 2014 Dec 31;9(1):215.
18. Bottin L, Francès C, de Zuttere D, Boëlle PY, Muresan IP, Alamowitch S. Strokes in Sneddon syndrome without antiphospholipid antibodies. Annals of neurology. 2015 May 1;77(5):817-29.
19. Bersano A, Morbin M, Ciceri E, Bedini G, Berlit P, Herold M, Saccucci S, Fugnanesi V, Nordmeyer H, Faragò G, Savoiardo M. The diagnostic challenge of Divry van Bogaert and Sneddon Syndrome: Report of three cases and literature review. Journal of the neurological sciences. 2016 May 15;364:77-83.

**Pramatarov K, Vassileva S, TSANKOV N. Alopecia psoriatica. Dermatol Venereol (Sofia) , 1995**, **1, 18-20**

**Цитати – 3**

1. Schwartz RA, Krysicka C.Alopecia areata. Cutis,1997,59,238-241
2. Papadopoulos, A. J., R. A. Schwartz, and C. Krysicka Janniger. „Alopecia areata: emerging concepts.” *Acta Dermatovenerologica Alpina Panonica Et Adriatica* 9.3 (2000): 83-91.
3. Papadopoulos, Anthony J., Robert A. Schwartz, and Camila Krysicka Janniger. „Alopecia Areata.” *American journal of clinical dermatology* 1.2 (2000): 101-105.

**Gantcheva M, TSANKOV N, Pramatarov K. Erythema gyratum repens without internal malignancy (letter). JEADV, 1995, 5, 67-69.**

**Цитати -1**

### Pramatarov K. Skin Signs of Systemic Neoplastic Diseases and Paraneoplastic Cutaneous Syndromes. In Emergency Dermatology, ed. By R. Wolf, Cambridge University Press, 2011. Chapter 26, 265-274

**TSANKOV N, Kamarashev J. Spa therapy in BulgariaClin Dermatol, 1996**, **14, 675-678**

**Цитати – 14**

## van Tubergen A, van der Linden S. A brief history of Spa therapy. Ann Rheum Dis 2002; 61(3): 273-275

## 彭华.On the Development and Study of Hot Spring Tourism. 桂林旅游高等专科学校学报, 2004

## 彭华.A Comprehensive Analysis of the Main Influential Factors in the Development of Spa Tourism. 旅游学刊, 2004

## Zhang Jian. A Study on Hot Spring Tourism Resources Development in China. 干旱区资源与环境, 2005年06期

# Peroni A et al. Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. Derm Therapy, 2008,21, Suppl 1, 31-38

1. Jin-Yong Lee. A review on occurrence, health risk and mitigation measure of uranium, radium and radon in groundwater. J of the Geol Soc of Korea, 2008, 44,3,341-52

# Lowry CA et al. That warm fuzzy feeling: brain serotonergic neurons and the regulation of emotion. J Psychopharmacol *June 2009 vol. 23 no. 4 392-400*

# Boeckstein MS. Revitalising the hea.ing tradition health tourism. Potential of thermal springs in the western cape. PhD Thesis, Faculty of Business at the Cape Peninsula University of Technology, 2012

# Golušin Z, Jovanović M, Jeremić B, Jolić S. Balneotherapy of psoriasis. Serbian Journal of Dermatology and Venereology. 2014 Sep 1;6(3):105-12.

# Golušin Z, Jovanović M, Magda N, Stojanović S, Matić M, Petrović A. Effects of Rusanda Spa balneotherapy combined with calcipotriol on plaque psoriasis. Vojnosanitetski pregled. 2015;72(11):1010-7.

# Курманалиев БА. Оздоровительный и лечебный туризм в Кыргызстане: перспективы, проблемы и пути решения. Медицина Кыргызстана. 2015;1(4):45-7.

# Hamidizadeh N, Simaeetabar S, Handjani F, Ranjbar S, Moghadam MG, Parvizi MM. Composition of minerals and trace elements at Mamasani thermal source: A possible preventive treatment for some skin diseases. Journal of education and health promotion. 2017;6.

# В монографии

## In :Altman N. Healing springs: The ultimate guide to taking the waters. Healing Arts press, Rochester, Vermont, 2000,p.27

## In: Health and Wellness Tourism: Spas and Hot Springs Ed. By Patricia Erfurt-Cooper, Malcolm Cooper, 2009

## **Krushkov I, Durmishev A, TSANKOV N. Reference book of adverse reactions - Medicina i Fiscultura (Sofia), 1996**

**Цитати – 2**

1. Kadurina M, Bocheva G, Tonev S. Penicillin and semisynthetic penicillins in dermatology.  Clinics in Dermatology 2003; 21 (1):12-23.
2. Kadurina, Miroslava, Georgeta Bocheva, and Stojan Tonev. "Penicillin and semisynthetic penicillins in dermatology." *Disease-a-Month* 50.6 (2004): 291-314.

# Papacharalambous V.G., Pramatarov K.D., Tsankov N.K. Development of pemphigus in a patient with rheumatoid arthritis during a course of gold therapy. Eur J Dermatol, 1997,7,65-66.

**Цитати – 10**

1. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol,1998,16,393-397
2. Goldberg I, Kashman Y, Brenner S. The induction of pemphigus by phenol drugs. Int J Dermatol 1999; 38 (12): 888-892.
3. Schmidt E, Brocker EB, Zillikens D. Pemphigus – loss of desmosomal cell-cell adhesion. Hautarzt 2000; 51(5): 309-318.
4. Ruocco E, Aurilia A, Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology 2001; 203 (3): 201-207.
5. Orion E, Barzilay D, Brenner S. Pemphigus-Vulgaris Induced by Diazinon and Sun Exposure. Dermatology 2000; 201 (4): 378-379.
6. Kanitakis-J Souillet-AL Faure-M Claudy-A. Ketoprofen-Induced Pemphigus-Like Dermatosis – Localized Contact Pemphigus. Acta Derm-Vener 2001, Vol 81, Iss 4, pp 304-305.
7. Goldberg I, Sasson O, Brenner S. A case of phenol-related contact pemphigus. Dermatology 2001; 203 (4): 355-356.
8. Gallo R, Massone C, Parodi A, Guarrera M. Allergic contact dermatitis from thiurams with pemphigus-like autoantibodies. Contact Dermatitis 2002; 46 (6): 364-365.
9. Ghaffarpour G, Aziz Jalali MH, Yaghmaii B, Mazloomi Sh, Soltani-Arabshahi R. Chloroquine/hydroxychloroquine-induced pemphigus.International Journal of Dermatology.2006, 45 (10), 1261–1263.
10. Yamamoto T. Cutaneous manifestations associated with rheumatoid arthritis. Rheumatology International 2009,[29, 9](http://www.springerlink.com/content/0172-8172/29/9/), 979-988,

# Gantcheva M, TSANKOV N. Acute generalized exanthematous pustulosis in a child caused by penicillin. Eur J Dermatol,1997,7,8,587-588

**Цитати – 2**

1. Phenoxymethylpenicillin: Acute generalised exanthematous pustulosis in a child: case report. Reactions Weekly. (687):11, February 7, 1998.
2. Lalova A, Popov J, Dourmishev L, Gantcheva M, Zdravkova A, Kirkoryan V. Two cases of drug induced acute generalized exanthematous pustulosis (AGEP). CEEDVA bulletin. 2003;5:52-5.

**Кazandjieva J, Kamarashev J, Hinkov G, TSANKOV N. Rifampin und Psoriasis. Akt Dermatol, 1997, 23, 2, 78-81.**

**Цитирания – 3**

1. НВ Цискаришвили, НИ Цискаришвили. Противотуберкулезные препараты в лечении псориаза.Georgien Medical News.,2009
2. Dubrac S, Elentner A, Ebner S, Horejs-Hoeck J, Schmuth M. Modulation of T lymphocyte function by the pregnane X receptor.The Journal of Immunology*,* 2010, 184, 2949 -2957
3. Pradhan S, Madke B, Kabra P, Singh AL. Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology. Indian journal of dermatology. 2016 Sep;61(5):469.

**TSANKOV N, Kazandjieva J, Gantcheva M. Contact pemphigus induced by dihydrodiphenyltrichlorethane. Eur J Dermatol 1998; 8: 442-443.**

**Цитирания – 31**

1. Goldberg I, Kashman Y, Brenner S. The induction of pemphigus by phenol drugs. Int J Dermatol 1999; 38: 888-892.
2. Orion E, Barzilay D, Brenner S. Pemphigus vulgaris induced by diazinon and sun exposure. Dermatology 2000; 201: 378-379.
3. Schmidt E, Brocker EB, Zillikens D. Pemphigus – loss of desmosomal cell-cell adhesion. Hautarzt 2000; 51: 309-318.
4. Brenner S, Tur E, Shapiro J, et al. Pemphigus vulgaris: environmental factors. Occupational, ompoundst, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001; 40: 562-569.
5. Goldberg I, Sasson O, Brenner S. A case of phenol-related contact pemphigus. Dermatology 2001; 203: 355-356.
6. Kanitakis J, Souillet AL, Faure M, Claudy A. Ketoprofen-induced pemphigus-like dermatosis: Localized contact pemphigus. Acta dermato-venereol 2001; 81: 304-305.
7. Ruocco E, Aurilia A, Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology 2001; 203: 201-207.
8. Gallo R, Massone C, Parodi A, Guarrera M. Allergic contact dermatitis from thiurams with pemphigus-like autoantibodies. Contact dermatitis 2002; 46: 364-365.
9. Krauze E, Wygledowska-Kania M, Kaminska-Budzinska G, et al. Radiotherapy induced pemphigus vulgaris. Ann Dermatol Venereol 2003; 130: 549-550.
10. Brenner S, Mashiah J, Tamir E, Goldberg I, Wohl Y. PEMPHIGUS: An Acronym for a Disease with Multiple Etiologies. SKINmed 2003; 2:3: 163–167.
11. Hahn-Ristić K.Klinische und immunpathologische Veränderungen bei Patienten mit Pemphigus und subepidermal blasenbildenden Autoimmundermatosen an der Universitäts-Hautklinik Würzburg zwischen 1989 und 1998. Doctorthesis. Medizinischen Fakultät der Bayerischen Julius-Maximilians-Universität zu Würzburg; Würzburg, Juli 2003.p.93
12. Ruocco V, Ruocco E. Pemphigus and ompoundstal factors. Digital Dermatol Venereol 2003; 138:299-309
13. Lapière K, Caers S, Lambert J. A Case of Long-Lasting Localized Pemphigus vulgaris of the Scalp. Dermatology 2004; 209:162-163.
14. Kavaklieva S, Drenovska K, Kapnilov D, Vassileva S, Tsankov N. Contact bullous pemphigoid due to pesticides. Case presentation 3rd Spring symposium EADV,2005, 36-37
15. Wohl Y, Goldberg I, Shirazi I, Brenner S. Chlorpyrifos exacerbating pemphigus vulgaris: A preliminary report and suggested in vitro immunologic evaluation model. SKINmed 2006; 5:3: 111–113.
16. Cocklin CL, Shackelford K, Wolverton SE, Fett DD. Pemphigus Foliaceus with Epidermal Detachment: Adverse Events from Patch Testing. Dermatitis 2006; 17(1):32-35.
17. Hee H.E. et al. Study of immune toxicity mechanism of toxic ompounds on immune system. The Annual Report of KFDA, 2007,11,
18. Valikhani M, Kavusi S, Chams-Davatchi C, Daneshpazhooh M, Barzegari M, Ghiasi M, Abedini R. Pemphigus and associated environmental factors: a case–control study. Clinical and Experimental Dermatology 2007; 32(3): 256–260.
19. Ruocco E, Baroni A, Rossiello L, Ruocco V.Imiquimod contact pemphigus: a comment. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2007, 115,2, 242-243
20. Dagestan S, Goregen M, Miloglu O, Cakur B. Oral pemphigus vulgaris: a case report with revue of the literature. J Oral Sci, 2008,50,3,359-362
21. Baican A , Chiriac G , Baican C , Macovei V , Ciuce D , Fritsch A , Sitaru C . Metal sensitization precipitates skin blistering in epidermolysis bullosa acquisita. The Journal of Dermatology,2010, [Vol 37, 3](http://www3.interscience.wiley.com/journal/123304199/issue),  280 – 282
22. Oberkirchner U,Linder KE, Dunston S, Bizikova P, Olivry T. Metaflumizone–amitraz (Promeris)-associated pustular acantholytic dermatitis in 22 dogs: evidence suggests contact drug-triggered pemphigus foliaceus. Veterinary Dermatology,2011
23. Bizikova P, Keith E Linder, Thierry Olivry. Fipronil-amitraz-S-methoprene-triggered pemphigus foliaceus in 21 dogs: clinical, histological and immunological characteristics. Veterinary Dermatology 04/2014; 25(2):103-e30.
24. Pietkiewicz P, Gornowicz-Porowska J, Bartkiewicz P, Bowszyc-Dmochowska M, Dmochowski M. Reviewing putative industrial triggering in pemphigus: cluster of pemphigus in the area near the wastewater treatment plant. Postepy Dermatologii i Alergologii. 2017 May 1;34(3):185.
25. Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Archives of dermatological research. 2017 Nov 6:1-2.

в монографии:

1. Penagos H, Manuskiatti W, Abrams K, Hogan D, Maibach HI, O’Malley M. The reported skin effects of pesticides by use and structural category. Pesticide Dermatosis By Homero Penagos, Howard I. Maibach, Michael O’Malley, Published 2000 [Informa Health Care](http://books.google.com/books?q=inpublisher:%22Informa+Health+Care%22)
2. Kanerva L. Occupational diseases of the oral mucosa. In Kanerva L. Handbook of occupational dermatology,2000,Springer,p 258
3. Meggs W, Langley R, James P. Farm toxicology. In Goldfrank L, Flomenbaum NE., Lewin NA, Howland MA, Hoffman R, Nelson L. Goldfrank’s Toxicologic Emergencies, 7th Ed,2002,Mc Grow-Hill Professional, p.1698
4. Vassileva S. Acute severe bullous dermatosis. In Emergency Dermatology, ed. By R. Wolf, Cambridge University Press, 2010. Chapter 22,215-231
5. McKee’s Pathology of the Skin. By J. Eduardo Calonje, Thomas Brenn, Alexander J Lazar, Phillip H. McKee, Chapter 5: Acantholytic disorders
6. Schmidt E, Groves R. Immunobullous diseases. Rook's Textbook of Dermatology. 2016.

**TSANKOV, N. High mountain climatotherapy. Clinics in Dermatol., 16, 1998, 699**-**708.[**

Цитати – 8

1. Öztürkcan S, Havlucu D. Mechanisms of Sun Damage . Dermatose 2005; 4(3): 116-121
2. Schuh, Angela. „Die Evidenz der Klima-und Thalassotherapie.” *Schweizerische Zeitschrift für Ganzheitsmedizin/Swiss Journal of Integrative Medicine* 2 (2009): 96-104.
3. Gutenbrunner, Christoph, et al. „A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology.” *International journal of biometeorology* 54.5 (2010): 495-507.
4. Schuh, Angela. „Die Evidenz der Klima-und Thalassotherapie. Ein Review.” *Schweizerische Zeitschrift für Ganzheitsmedizin/Swiss Journal of Integrative Medicine* 21.2 (2010): 96-104.
5. Reimers, Carlos Emilio González, and Matilde Arnay de la Rosa. „Consideraciones teóricas acerca del efecto del clima de Las Cañadas (Tenerife) sobre la tuberculosis y otras afecciones respiratorias.” *Estudios canarios: Anuario del Instituto de Estudios Canarios* 54 (2010): 223-236.
6. Schuh, A., and D. Nowak. „Klimatherapie im Hochgebirge und im Meeresklima.” *DMW-Deutsche Medizinische Wochenschrift* 136.04 (2011): 135-139.
7. Schuh A, Immich G. Hochgebirgsklima–Klimatherapie im Hochgebirge. Zeitschrift für Komplementärmedizin. 2015 Jun;7(03):12-7.

В монографии:

1. Schuh A. In Klima- und Thalassotherapie : Grundlagen und Praxis. Georg Thiem Verlag, 2004 ,p.165

TSANKOV N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998; 16: 334-352

**Цитирания - 77**

1. Ortonne N, Ortonne JP. Pathogenesis of Psoriasis. Presse Medicale 1999; 28: 1259-1265.
2. Mommers JM. Emergent Epidermal phenotyping in psoriasis. Universitat Nijmegen, 2000
3. Baran R.Alterations ungueales iatrogenes consecutives au declenchement de certaines dermatoses.Le journal faxe de dermatologie, Le 27 novembre 2001
4. Baran R, Roujeau J. New millennium, new nail problems. Dermatologic Therapy 2002; 15 (2):64-70.
5. Fetil E, Ilknur T, Birgin B, Özkan Ş, Güneş AT, Öztürk B, Unsay E, Aǧdanli D. Drug induced psoriasis. [Ilaçla uyarilan psoriyazis]. Turkderm (Deri Hastaliklari ve Frengi Arsivi) 2002; 36 (2): 105-109.
6. Huntley AC. Psoriasiform Drug Eruption Associated With Metformin Hydrochloride: A Case Report Dermatol Online J 2003;9(3):
7. Kadurina M, Bocheva G, Tonev S. Penicillin and semisynthetic penicillins in dermatology. Clinics in Dermatology 2003; 21 (1):12-23.
8. Koca R, Altinyazar HC, Yenidünya S, Tekin NS. Psoriasiform drug eruption associated with metformin hydrochloride: A case report. Dermatology Online Journal 2003; 9 (3):134-139.
9. Smith J. RXR-and RAR selective retinoids in psoriasis and premalignant skin disorders. Thesis University, Medical center Nijmegen, Netherland. 2003
10. Tsankov N, D Antonov, Grozdev I: Tetrazykline bei psoriasis. Hautarzt 2003, 54:1095. (IF 2003 0.521)
11. Kadurina M, Bocheva G, Tonev S. Penicillin and semisynthetic penicillins in dermatology. Disease-a-Month 2004; 50 (6):291-314.
12. Koo J, Lee E, Lee C, Lebwohl M. Psoriasis. JAAD, 50, 4,  613-622,2004
13. Tan B, Foley P. Guttate psoriasis following Ecstasy ingestion. Australasian Journal of Dermatology 2004; 45 (3):167-169.
14. 王新华.卤米松乳膏治疗湿疹皮炎等皮肤病疗效观察. Chinese journal of dermatology 2005; 38: 462-464.
15. Пирузян, Анастас Левонович. **Метаболическая и генетическая паспортизация человека для ранней диагностики и индивидуализированной фармакотерапии псориаза.** Диссертация, Москва, 2005
16. Capella G.-L. Psoriasis worsened by propafenone [Aggravation d’un psoriasis par la propafénone]  Annales de Dermatologie et de Venereologie 2005 ; 132 (4) : 370-371.
17. Documentos SER de Revisión de la Evidencia y Consenso en Espondiloartropatías. Edita: You&Us, S.A., 2005 Ronda de Valdecarrizo, 41 A 28760 Tres Cantos – Madrid, p.94.
18. Jordan JK. Efalizumab for the treatment of moderate to severe plaque psoriasis.  Annals of Pharmacotherapy 2005; 39 (9):1476-1482.
19. Jurado SF, González S, Garibay AR, Vargas JC, GarcíaC, Arista G. Psoriasis pustulosa. Reporte de un caso. Rev Cent Dermatol Pascua 2005, Vol. 14, Núm. 2 87-92
20. Mallbris L. Psoriasis. Studies of phenotype at oncet and of associated cardiovascular morbidity. PhD thesis. Department of Medicine, Dermatology and Venereology Unit, Karolinska Institutet, Stockholm, Sweden, 2005
21. Mallbris L, Larsson P, Bergqvist S, Vingård E, Granath F, Ståhle M. Psoriasis phenotype at disease onset: Clinical characterization of 400 adult cases  Journal of Investigative Dermatology 2005;124 (3): 499-504.
22. **Nockowski P, Baran W.** Novel approaches to the treatment of psoriasis**.** Terapia 2005, Vol 3, 1 (163),20-24
23. Antonov D, Grozdev I, Pehlivanov G, Tsankov N. Psoriatic erythroderma associated with enalapril. Skinmed, 5:90-2, 2006
24. Dika E, Varott C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.
25. Herman SM, Shin MH, Holbrook A, Rosenthal D. The role of antimalarials in the exacerbation of psoriasis: A systematic review  American Journal of Clinical Dermatology 2006; 7 (4): 249-257.
26. Ilknur T, Feti E, Akarsu S. Development of psoriasis after meloxicam. Eur J Dermatol 2006; 16 (4): 444-445.
27. Lemay R. Pharmacothérapie du psoriasis. Québec Pharmacie 2006; 53(3): 141-149.Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-α-induced psoriasis  Journal of Rheumatology 2006; 33 (7):1411-1414.
28. Ståhle M. Behandling av psoriasis – Bakgrundsdokumentation. Information från Läkemedelsverket 2006; 5:.17-21.
29. Thornton A, Honeywell M, LeBron AL, Henderson A, Jones J. **Understanding Treatment Options for Psoriasis. U.S. Pharmacist** 2006;April 30
30. Kalajci B. The relatıonship between serum endothelin-1 and nitric oxide levels and severity of psoriasis. Tez Danismani, Inonu Univesitesi Arastirma, 2006
31. Atenolol 93. Atenolol Reactions. Information on the drug Atenolol. eLook.org. Resource and information Center,Nov, 2007
32. Fisher T. Synopsis of causation. Psoriasis.Ministry of defence, Service Personnel and Veterans Agency, September, 2007
33. Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N. Efalizumab-Associated Papular Psoriasis. Arch Dermatol. 2007; 143: 900-906.
34. Yones SS, Palmer RA, Garibaldinos TM, Hawk J. **Randomized Double-blind Trial of Treatment of Vitiligo. Efficacy of Psoralen–UV-A Therapy vs Narrowband–UV-B Therapy.**Arch Dermatol. 2007;143(5):578-584
35. Sampaio-Barros PD, Azevedo VF, Bonfiglioli R, Campos W, Carneiro S, CarvalhoM, Gonçalves CR, Hilário MO, Keiserman M, Leite N, Mallmann K, Meirelles E, Vieira W, Ximenes AC. First Update on the Brazilian Consensus for the Diagnosis and Treatment of Spondyloarthropathies: Ankylosing Spondylitis and Psoriatic Arthritis. Rev Bras Reumatol 2007, 47,.4, 233-242
36. Sivamani RK, Lam S, Isseroff RR. Betaadrenergic receptors in keratinocytes. Dermatol Clin,2007,25,643-653
37. Suomela S, Kainu K, Onkamo P. Clinical associations of the risk alleles of HLA-Cw6 and CCHCR1\*WWCC in psoriasis.Acta Dermato-Venereologica 2007; 87 (2):127-134.
38. Brauchli Y.B., Jick S.S., Curtin F., Meier C.R. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. British Journal of Dermatology (2008) 158 (6) , 1299–1307
39. Fisher T, Medical Author, Medical Text, Edinburgh. **Veteran Agency. Synopsis of causation. Psoriasis, Ministry of Defense , published on line, September, 2008**
40. **Yamamoto M et al.** Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol, 2008,35, 11, 732–736,
41. Brauchli, Yolanda B. PhD, MSc; Jick, Susan S. DSc; Curtin, François MD; Meier, Christoph R. Lithium, Antipsychotics, and Risk of Psoriasis. Journal of Clinical Psychopharmacology: 2009,29,2,134-140
42. Brauchli, Yolanda B. Population-based Studies on the Natural History of Psoriasis – and their Role in the Drug Development Process and in Clinical Practice. Inauguraldissertation, Basel, 2009,p.153
43. Jafferany M. Lithium and Psoriasis: What Primary Care and Family Physicians Should Know, J Clin Psychiatry. 2008; 10(6): 435–439.
44. Dolenc-Voljc M, Dolenc P. Koza in Antihypertenzijska Zdravila. XVIIIStrokovni sestanek,2009
45. Miguel A. Psoriase. MedicinaPratica.Tudo Sobre Medicina, 2009
46. [Romagosa MB, Pérez Bruzón](http://www.bvs.sld.cu/revistas/san/vol13_3_09/san09308.htm#categ#categ) M.Elementos más importantes en la patogenia de la psoriasis. Most important elements in the  psoriasis pathogeny  MEDISAN 2009;13(3)
47. Tuzun Y,Yardimci G. Lithium and Psoriasis. J Turk Acad Dermatol,2009,3,4
48. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010, 49, 12, 1351–1361
49. Ziółkowska E, Biedka M, Żyromska A, Makarewicz R. Psoriasis exacerbation after hormonotherapy in prostate cancer patient—Case report. Reports of Practical Oncology & Radiotherapy, 2010,15, 4, 103-106
50. Castro K et al. Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients. Clinical and Developmental Immunology, 2011, Article ID 352686, 5 pages
51. Ganeva M, Gancheva T, Baldaranov I, Troeva J, Hristakieva E. Treatment of adverse drug reactions in a dermatology department. Central European Journal of Medicine 2011,Vol 6, 1, 37-44
52. Kansal NK, Chawla O, Singh A, et al.. THE CUTANEOUS ADVERSE EFFECTS OF LITHIUM. Journal of Clinical and Diagnostic Research [serial online] 2011
53. Stahle M. Lakemedelsbehandling av psoriasis – bakgrundsdokimentation. Information fran Lakemedelsverket, 2011,4,25-28
54. Ege, M. R., Güray, Y., Güray, Ü., & Demirkan, B. (2012). Palmar psoriasis, a rare side effect of beta-blocker theraphy: a case report. *Turk Kardiyol Dern Ars*,*40*(5), 451-453.
55. Plsikova, Jana, et al. "3, 6-Bis (3-alkylguanidino) acridines as DNA-intercalating antitumor agents." European Journal of Medicinal Chemistry (2012),57, 283–295
56. Shmidt, Eugenia, et al. "Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010."*Journal of the American Academy of Dermatology* 67.5 (2012): e179-e185.
57. Coumbe, Ann G., Marc R. Pritzker, and Daniel A. Duprez. "Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors." The American journal of medicine (2013).
58. 李鹏飞, et al. "银屑病与锂制剂." *实用皮肤病学杂志 ISTIC* 3 (2013).
59. CĂRUNTU, CONSTANTIN, et al. "In vivo imaging techniques for psoriatic lesions." *Rom J Morphol Embryol* 55.3 Suppl (2014): 1191-1196.
60. Coumbe, Ann G., Marc R. Pritzker, and Daniel A. Duprez. "Cardiovascular risk and psoriasis: beyond the traditional risk factors." *The American journal of medicine* 127.1 (2014): 12-18.
61. Benson, Max M., and William H. Frishman. "The Heartbreak of Psoriasis: A Review of Cardiovascular Risk in Patients With Psoriasis." *Cardiology in review*23.6 (2015): 312-316.
62. Hussein, Mahmoud Rezk Abdelwahed. "Drug-induced skin reactions: a pathologist viewpoint." *Cutaneous and ocular toxicology* ahead-of-print (2015): 1-13.
63. Narasimharao, T. V., Neelakanta Babu Rasineni, and S. Nageswaramma. "Psoriasis and psoriatic arthritis during lithium therapy." *Innovative Journal of Medical and Health Science* 5.1 (2015): 9-11.
64. ULUSOY, Rıfat Eralp, and Hande ULUSAL. "Beta Blocker Induced Parapsoriasis: Case Report." *Turkiye Klinikleri Journal of Case Reports* 23.2 (2015): 173-175.
65. D’ÉTAT TP. *AZOT Axelle Alice* (Doctoral dissertation, UNIVERSITÉ PARIS DIDEROT-PARIS).2016
66. El Jadi H, Guerboub AA, Meftah A, Moumen A, Elmoussaoui S, Belmejdoub G. Éruption psoriasiforme secondaire à la metformine: Une situation rare à connaître. Médecine des Maladies Métaboliques. 2016 Jun 30;10(4):306-8.
67. Hussein MR. Drug-induced skin reactions: a pathologist viewpoint. Cutaneous and ocular toxicology. 2016 Jan 2;35(1):67-79.
68. Ning J, Hu L, Zhang Q, Jiao Y, Li M, Gu K, Sun G. Psoriasis aggravation due to capecitabine in a colon cancer patient: a case report and literature review. IJCEM. 2016 Jan 1;9(8):16399-402.
69. Sudhakar R, George MK, Yasaswini B, Sundararajan N, Mariyam AS. ADVERSE DRUG REACTIONS ASSOCIATED WITH ANTI-HYPERTENSIVE DRUGS AND ITS MANAGEMENT. International Journal of Pharmaceutical Sciences and Research. 2016 Mar 1;7(3):898.
70. Kožurková M, Sabolová D, Kristian P. A review on acridinylthioureas and its derivatives: biological and cytotoxic activity. Journal of Applied Toxicology. 2017 Jan 1.
71. Rosa G, Fernandez AP, Schneider S, Billings SD. Eosinophils are rare in biopsy specimens of psoriasis vulgaris. Journal of Cutaneous Pathology. 2017 Sep 13.

В монографии:

1. Lee A, Thompson J. Drug-induced skin reactions. In Adverse Drug Reactions, 2nd edition (ISBN: 0 85369 601 2) © Pharmaceutical Press 2006; 126-154.
2. Sylvia L. Drug Allergy, pseudoallergy and cutaneous diseases. Drug induced dermatological diseases. Chapter VI. In Drug-Induced Diseases: Prevention, Detection, and Managementр. 2 Editon ed. By Tisdale JE, Miller DA.,2010, American Society of Health System Pharmacist
3. Prins M. Dithranol in psoriasis day-care. Thesis University Njimgen, Netherland, 2002,p.26
4. McKee’s Pathology of the Skin. By J. Eduardo Calonje, Thomas Brenn, Alexander J Lazar, Phillip H. McKee, Chapter 14: Cutaneous adverse reactions to drug Elsevier, 2012,
5. Aggozino M et al. Hyperkeratotic dermatitis in Reflectance Confocal Microscopy for Skin Diseases, edited by Rainer Hofmann-Wellenhof, Giovanni Pellacani, Joseph Malvehy, Hans Peter Soyer, Springer, 2012
6. Wong U, Cross RK. Noninfectious and Nonmalignant Complications of Anti-TNF Therapy. InTreatment of Inflammatory Bowel Disease with Biologics 2018 (pp. 231-260). Springer, Cham.

## **Gantcheva M, TSANKOV N. Livedo reticularis and cerebrovascular accidents (Sneddon’s syndrome) as a clinical expression of antiphospholipid syndrome. JEADV,1999,12,157-160**

**Цитати – 17**

1. Gupta, Somesh, et al. „Surgical pearl: punch excision and grafting for removal of mole.” *Journal of the American Academy of Dermatology* 41.4 (1999): 635-637.
2. Lahti J, Yu T, Burnett JW, et al. Sneddon’s syndrome: A case report. Cutis,2001,67,211-214
3. Woglrab J, Fischer M, Wolter M, et al. Diagnostic ompact and sensitivity of skin biopsies in Sneddon’s syndrome. A report of 15 cases, Br J Dermatol,2001,145,285-288
4. Mascarenhas R, Santo G, Goncalo M, et al. Familial Sneddon’s syndrome. Eur J Dermatol,2003,13,283-287
5. Jenerowicz, D., Czarnecka-Operacz, M., & Silny, W. Postępy Dermatologii i Alergologii/Advances in Dermatology and Allergology. 2003; XX, 2: 80–86
6. Tietjen GE, Al-Qasmi MM, Gunda P, Herial NA. Sneddon’s syndrome: another migraine–stroke association? Cephalalgia, 2006, 26, 3, 225-232(8)
7. Da Silva A, Rocha N, Pinto M, Alves V, Farinha F, Correia A.P, Coelho T, MagalhãesM. **Tremor as the first neurological manifestation of Sneddon’s syndrome.** Movement Disorder,20,2, **248-251**
8. شرف الدين زاده, ناصر, and باورصاد شهريپور. "گزارش يک مورد بيمار مبتلا سندراسندون و8 نوبت مرگ داخل رحمی." *مجله دانشگاه علوم پزشكي اراك* 10.4 (2007): 92-98.‎
9. Sharafaddin-zadeh, Naser, and Reza Bavarsad Shahripoor. „A case report of Sneddon syndrome with 8 times intrauterine fetal deaths.” *Arak Medical University Journal* 10.4 (2007): 92-98.
10. Radouane, B., M. Jidal, S. Chaouir, T. Amil, A. Hanine, and M. Benameur. „Le syndrome de Sneddon.”
11. Valtchev V, Yordanova I. „SNEDDON’S SYNDROME.” *Journal of IMAB–Annual Proceeding Scientific Papers* 14.1 (2008): 72-75.
12. Charlín, Raúl, et al. „Síndrome de Sneddon: A Propósito de un Caso.” *Rev. Chil. Dermatol* 25.1 (2009): 46-48.
13. **Gerkowicz A et al. Opis przypadku Zespół antyfosfolipidowy – manifestacja kliniczna, diagnostyka i przegląd piśmiennictwa.** Post Dermatol Alergol 2010 ; XXVII, 1 : 69–75
14. Kriet M et al. Syndrome de Sneddonand anticorps antiphospholipids: une ethiologie d’hemianopsie laterale homonyme. Bull Soc Belge Ophtalmol, 2010, 316,43-48
15. Homonyme, laterale. „Syndrome de Sneddon et anticorps anti-phospholipides: une etiologie d’hemianopsie.” *Bull. Soc. Belge Ophtalmol* 316 (2010): 43-48.
16. Pinto-Almeida, Teresa, et al. „Cutaneous manifestations of antiphospholipid syndrome: a review of the clinical features, diagnosis and management.” (2013).
17. Macro, Margaret, Kazuko Mizuno-Ikeda, Toshihisa Hamada, Daisuke Suzuki, Shin Morizane, Toshiyuki Watanabe, Masahide Imada et al. „Médecine et Santé Tropicales.” *Hépato-Gastro* 21, no. 3 (2014).

**Topical modalities for the treatment of cutaneous vasculitis. TSANKOV N, Angelova I, Kazandjieva J. Clin Dermatol 1999; 17: 649-653.**

**Цитирания –9:**

1. De Araujo TS, Kirsner RS. Vasculitis. Wounds 2001; 13: 99-112.
2. Especialidades, Ysus. “nudosa ravellin.” *Piel* 16 (2001): 15-23.
3. Ochaita PL. Panarteritis nоdosa infantile. Piel, 2001,16,15-23
4. 万方数据资源系统. 中国麻风皮肤病杂志 China journal of leprosy and  
   skin diseases 2001 Vol.17 No.4 P.281-283. 数字化期刊.
5. Katsambas A, Riga P. Purpura and vasculitis: Unapproved treatments. Clin Dermatol 2002; 20: 626-633.
6. Katsambas A, Stefanaki C. Life-threatening ravell and vasculitis  Clin Dermatol 2005; 23 (3): 227-237
7. Rayner R. Small-vessel vasculitis. Primary Intention 2006; 14(2): 76, 78-80.
8. Rayner R,K Carville, J Keaton, J Prentice, Santamaria N. Leg ulcers: atypical presentations and associated comorbidities.Wound practice and Research,2009, 17,4,170-185

В монографии:

1. Orfanos K, Garbe C. Therapie der Hautkrankheiten. 2.Aufgabe, 2002, Springer, p 661

**Bulgarian Dermatology. TSANKOV N, Angelova I, Кazandjieva J. CEEDVA, Bull, 1999, 1, 9-15.**

**Цитирания – 1**

1. Parish LC, Crissey JT, Parish J. Bibliography of Secondary Sources on the History of Dermatology, Journal Articles in English – Supplemented through 2000

Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980-1995). TSANKOV N, Vassileva S, Kamarashev J, Кazandjieva J, Kuzeva V. Int J Dermatol 2000; 39: 104-108

**Цитирания – 87**

1. Brenner S, Tur E, Shapiro J, et al. Pemphigus vulgaris: environmental factors. Occupational, ravelling, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001; 40: 562-569.
2. Gonzales AZ. Epidemiología de enfermedades ampollosas autoinmunotarias en costa rica. Dermatologia, Servicio de Emergencias Hospital Monseñor Sanabria, Puntarenas
3. Friedlander AH. The physiology, medical management and oral implications of menopause. J Am Dent Assoc 2002; 133: 73-81.
4. Hahn-Ristic K, Rzany B, Amagai M, et al. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol 2002; 16: 68-71.
5. Brenner S, Mashiah J, Tamir E, Goldberg I, Wohl Y. PEMPHIGUS: An Acronym for a Disease With Multiple Etiologies. SKINmed 2003; 2:3: 163–167.
6. Kolodziej T, Bialynicki-Birula R. Wystepowanie pecherzyzy na Dolnym Slasku.( The incidence of pemphigus in Lower Silesia). Dermatologia Kliniczna, 2003,5,4,211-213
7. Wohl Y, Brenner S. Pemphigus in Israel –An Epidemiologic Analysis of Cases in Search of Risk Factors. IMAJ 2003;5:410-412
8. Rivera R, Postigo C, de la Mano D, Vanaclocha F, Iglesias L. Pemphigus – a retrospective study of 52 cases. Actas Dermosifiliogr, 2004, 95,4,213-8
9. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, Barzegari M, Akhiani M, Ghodsi Z, Mortazavi H, Naraghi Z. Pemphigus: Analysis of 1209 cases. International Journal of Dermatology 2005; 44(6): 470–476.
10. Endogru E. Pemgicuslu 66 hastada klinik seyir ve prognoz (6 yillik haydarpasa deneyimi). Istanbul, 2005,p.46
11. **Gazit** **E, Loewenthal R.** The immunogenetics of pemphigus vulgaris. Autoimmunity Reviews, **2005, 4, 1, 1-78**
12. Golušin Z, Poljački M, Jovanoviç M, Duran V, Stojanovic S, Rajic N. Some epidemiological features of pemphigus chronicus in South Vojvodina: A 12-year retrospective study. International Journal of Dermatology 2005; 44(9): 792–793.
13. Gunasti S. Pemfiguslu hastalarin saglikli birinci derece akrabalarinda pemfigus otoantikorlarinin sikliginin arastirilmasi. Tez Danismani. Adana, 2005
14. Макарова, Янина Юрьевна. **Оценка роли иммунного статуса на развитие осложнений кортикостероидной терапии истинной акантолитической пузырчатки. Дисертация, Москва, 2005**
15. Решетникова, Татьяна Борисовна. Роль иммунопатологических процессов в генезе истинной акантолитической пузырчатки и методы их коррекции. Дисертация, Новосибирск, 2005
16. Šustić N, Ručević I, Barišić-Druško V. Epidemiology of Acquired Bullous Diseases in Eastern Croatia: A Retrospective Prewar to Postwar Study. Acta Dermatovenerol Croat 2005; 13(4):228-232.
17. Sánchez-Pérez, Javier; García-Díez, Amaro Pénfigo.Publicado en Actas Dermosifiliogr. 2005; 96,6:329-56.
18. Asilian A, Yoosefi A, Faghihi G. Pemphigus Vulgaris in Iran: Epidemiology and Clinical Profile. SKINmed 2006; 5(2): 69–71.
19. Salmanpour R, Shahkar H, Namazi MR, Rahman-Shenas MR. Epidemiology of pemphigus in south-western Iran: A 10-year retrospective study (1991–2000). International Journal of Dermatology 2006; 45(2):103–105.
20. Uzun S, Durdu M, Akman A, Gunasti S, Uslular C, Memisoglu HR, Alpsoy E. Pemphigus in the Mediterranean region of Turkey: A study of 148 cases. International Journal of Dermatology 2006; 45(5): 523–528.
21. Abdolsamadi HR, Abdollahzadeh Sh, Vaziri PB, Beheshti A, Vahedi M. Epidemiology of Pemphigus in Tehran, Iran: A 20-Year Retrospective Study. JODDD, Vol. 1, No. 3 Autumn 2007
22. Esmaili N, Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Balighi K, Hallaji Z, Barzegari M, Akhyani M, Ghodsi ZS, Mrotazavi H, Naraghi ZS, Toosi S. Pemphigus vulgaris in Iran: a clinical study of 140 cases. International Journal of Dermatology, 2007 46:11, 1166–1170
23. Foster J, Papadopoulos C, Dadzie L, Jayasinghe N. A review of tobacco and alcohol use literature in the native and migrant Greek community. J Substance Use, 12, 5,2007 , 323 – 335
24. Heymann AD, Chodick G, Kramer E, Green M, Shalev V. Pemphigus Variant Associated With Penicillin Use A Case-Cohort Study of 363 Patients From Israel. Arch Dermatol*.* 2007;143(6):704-707.
25. Jayasinghe N. A review of tobacco and alcohol use literature in the native and migrant Greek community. Journal of Substance Use, 2007
26. Javidi Z, Tayyebi Meibodi N, NahidiY. Epidemiology of pemphigus in northeast Iran: A 10-year retrospective study. Indian Journal of Dermatology, 2007, 52, 4, 188-191
27. Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos M, Mourellou O, Antoniades D. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: Retrospective study of 129 patients. International Journal of Dermatology 2007; 46(4): 356–361.
28. Momeni AZ, Iraji F, Aminjavaheri M, Emami MR, Momeni A. The use of oral cyclophosphamide with dexamethasone pulse therapy in the treatment of pemphigus vulgaris. J Dermatolog Treat. 2007;18(5):275-8
29. Tang MM. Autoimmune Bullous Diseases in Ipoh Malaysia. A 5-year retrospective study. Malaysian J Dematol, 2007, 57-61
30. Turgutalp SÇ, Harman M. Pemfiguslu Hastaların Klinik Özellikleri. Dicle Tıp Dergisi 2007; 34(2 ):116-119.
31. Valikhani M, Kavusi S, Chams-Davatchi C, Daneshpazhooh M, Barzegari M, Ghiasi M, Abedini R. Pemphigus and associated environmental factors: a case–control study. Clinical and Experimental Dermatology 2007; 32(3): 256–260.
32. V’lckova-Laskoska M, Laskoski D, Kamberova S, Caca-Biljanovska N, Volckova N. Epidemiology of pemphigus in Macedonia: A 15-year retrospective study (1990–2004). International Journal of Dermatology 2007; 46(3): 253–258.
33. Yu KJ, Yang LJ, Kuan YZ, HoHC, Hong HS. Pemphigus – clinical analysis of 129 cases. Dermatol Sinica, Jun, 2007,95-102
34. J徐辉欢　周曾同**. 国外有关天疱疮流行病学研究现状**Journal Clin Stomatol,2007 Vol.23 No.8 P.502-504
35. Beyhan S. 1995 – 2008 yillari arasinda izlenen 140 pemfigus’lu hastanin klinik araştirma sonuçlari. Deri ve Zührevi Hastalıklar Uzmanlık Tezi. Istanbul 2008.
36. Esmaili N, Chams-Davatchi C, Valikhani M, Farshidfar F, Parvaneh N, Tamizifar B.Treatment of Pemphigus vulgaris with Mycophenolate mofetil as a steroid- sparing agent. Eur J Dermatol, 2008,18,2,159-64
37. Karincaoǧlu, Y. Pemphigus: Epidemiology and pathogenesis | [Pemfigus: Epidemiyoloji ve patogenez] 2008 *Turkderm Deri Hastaliklari ve Frengi Arsivi* 42 (SUPPL.1), pp. 1-4
38. Chmurova N, Svecova D. Pemphigus vulgaris: a 11-year review. Bratisl Lek Listy. 2009;110(8):500-3
39. Halaiji Z et al. Prognostic factors of pemphigus vulgaris disease: a study on 119 patients. Tehran University Medical J.,2009, 66,12,913-918
40. Marazza G, Pham HC, Scharer L, Pedrazzetti PP, Hunziker T, Trüeb RM, Hohl D, Itin P, Lautenschlager S., Naldi L., Borradori L. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol, 2009
41. Akman A, Uzun S, Alpsoy E. Immuncpathologic Features of Pemphigus in the East Mediterranean Region of Turkey: A Prospective Study . Skin Med, 2010, 1,8,12-16
42. Baican A , Baican C , Chiriac G, Chiriac M,, Macovei V, Zillikens D, Ciuce D, Sitaru C. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol, 2010, Vol.49,7,768-774
43. Günaşti, S., Uzun, S. Investidation of frequency of pemphigus autoantibodies in healthy first degree relatives of pemphigus patients.| *Turkiye Klinikleri Journal of Medical Sciences,* 2010,30 (2), pp. 571-576
44. **Meyer N., Misery L.** Geoepidemiologic considerations of auto-immune pemphigus. Autoimmuniti Rewies.2010,9,5,
45. Santiago Sánchez-Mateos, D., Pérez Gala, S., Eguren Michelena, C., Navarro, R. Autoimmune bullous diseases | [Enfermedades ampollosas autoinmunes]. 2010 *Medicine* 10 (48), pp. 3204-3212
46. Thomas M., Paul C., Berard E., Fortenfant F., Mazereeuw-Hautier J., Livideanu C., Viraben R., Meyer N. Incidence of Auto-Immune Pemphigus in the Midi-Pyrénées Region in 2002-2006, Dermatology 2010;220:97-102
47. Zivanovic, D; Medenica, L; Tanasilovic, S; Vesic, S; Skiljevic, D; Tomovic, M, Nikolic, M. Dexamethasone-Cyclophosphamide Pulse Therapy in Pemphigus: A Review of 72 Cases. American Journal of Clinical Dermatology, Vol 11, 2, 2010 , 123-129(7)
48. Yazdanfar A. Epidemiology of pemphigus in Hamedn (west of Iran): A 10 year retrospective study (1995-2004). Int J Pharm Biomed Res, 2010,1,4,157-160
49. CIN I. Pemphigus vulgaris, Archive of SID.
50. Alpsoy E. Epidemiology of Autoimmune bullous diseases. Turkderm, 2011,45,3-7
51. Amak Ozet. Pemfigusta Risk Faktörleri/Risk Factors in Pemphigus. Faqs org,2011
52. Demirci GT et al. Risk factors in pemphigus. Turkderm, 2011,45,140-5
53. Arundhathi, S. „The Clinicopathological spectrum of cutaneous vesiculobullous lesions in conjunction with direct immunofluorescence.” (2012).
54. Bozdag, Kübra, and Ilgül Bilgin. « Epidemiology of pemphigus in the western region of Turkey: retrospective analysis of 87 patients. » Cutaneous and Ocular Toxicology 00 (2012): 1-8.
55. Daneshpazhooh M. Spectrum of autoimmune bullous diseases in Iran: a 10-year review. Int J Dermatol, 2012, 51,1,35-41
56. Javanbakht MH et al. Serum Selenium, Zinc, and Copper in Early Diagnosed Patients with Pemphigus Vulgaris. Iranian J of Public Health, 2012;41;5,105-9
57. Huang Yu-Huei, Chang-Fu Kuo, Yi-Hua Chen, Ya-Wen Yang. Incidence, Mortality, and Causes of Death of Patients with Pemphigus in Taiwan: A Nationwide Population-Based Study. Journal of Investigative Dermatology (2012) 132, 92–97;
58. Noorbala, M. T., et al. “Pemphigus in central part of Iran.” Journal of Pakistan Association of Dermatologists 22.3 (2012): 197-199.
59. Robati R, Rahmati-Roodsari M, Dabir-Moghaddam P, Farnaghi A, Mahboobi-rad F, Rahimi H, Toossi P. Mucosal manifestations of pemphigus vulgaris in ear, nose, and throat; before and after treatment. JAAD,2012
60. Suliman, Nada M., et al. „Clinical and histological characterization of oral pemphigus lesions in patients with skin diseases: a cross sectional study from Sudan.” *BMC oral health* 13.1 (2013): 66.
61. Wardhana, M., and L. M. Rusyati. “Prevalence and quality of life of pemphigus patients at sanglah general hospital bali-indonesia.” *Bali Medical Journal* 2.1 (2013).
62. Vassileva S, Kossara Drenovska, and Karen Manuelyan. „Autoimmune blistering dermatoses as systemic diseases.” *Clinics in dermatology* 32.3 (2014): 364-375.
63. Karagöz, Gizem, Kıvanç Bektaş-Kayhan, and Meral Ünür. „Evaluation of Pemphigus Cases Involving Oral Mucosa.” *Oral health and dental management* 13.3 (2014): 605-609.
64. Alpsoy, Erkan, Ayse Akman-Karakas, and Soner Uzun. „Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid.” *Archives of Dermatological Research* (2015): 1-8.
65. Deepti SP, Sulakshana MS, Manjunatha YA, Jayaprakash HT. Ahistomorphological study of bullous lesions of skin with special reference to immunofluorescence. Int J Curr Res Aca Rev. 2015;3:29-51.
66. Koga H, Recke A, Iwata H, Juhl D, Siegfried G, Henschler R, Hashimoto T, Schmidt E, Zillikens D, Ibrahim SM, Ludwig RJ. Prevalence of pemphigus and pemphigoid autoantibodies in the general population. Orphanet Journal of Rare Diseases. 2015 May 15;10: 63-.
67. Lezcano L, Di Martino B, Masi MR, Bolla L. Estudio clínico y epidemiológico de las enfermedades ampollosas autoinmunes en la Cátedra de Dermatología de la Facultad de Ciencias Médicas de la Universidad Nacional de Asunción. Años 2002–2007. InAnales de la Facultad de Ciencias Médicas 2015 Feb 17 (Vol. 42, No. 1, pp. 37-44).
68. Metin, M. S., Kizilyel, O., Elmas, Ö. F., Bilen, H., Akdeniz, N., Çalik, M., & Atasoy, M. (2015). 102 Pemfigus hastasinin retrospektif degerlendirilmesi/A retrospective study of 102 patients with pemphigus. *Turkderm*, *49*(2), 125.
69. Prüßmann, Wiebke, Jasper Prüßmann, Hiroshi Koga, Andreas Recke, Hiroaki Iwata, David Juhl, Siegfried Görg et al. "Prevalence of pemphigus and pemphigoid autoantibodies in the general population." *Orphanet journal of rare diseases* 10, no. 1 (2015): 1-8.
70. Svecova, Danka. "Pemphigus vulgaris: a clinical study of 44 cases over a 20‐year period." *International journal of dermatology* 54, no. 10 (2015): 1138-1144.
71. Zhao CY, Murrell DF. Autoimmune blistering diseases in females: a review. International Journal of Women's Dermatology. 2015 Feb 28;1(1):4-12.
72. Baum S, Astman N, Berco E, Solomon M, Trau H, Barzilai A. Epidemiological data of 290 pemphigus vulgaris patients: a 29-year retrospective study. European Journal of Dermatology. 2016 Jun 13;1(1).
73. Milinković M, Janković S, Medenica L, Nikolić M, Reljić V, Popadić S, Janković J. Inzidenz von bullösen Autoimmunerkrankungen in Serbien: eine retrospektive Studie über 20 Jahre. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2016 Oct 1;14(10):995-1006.
74. Tavakolpour S, Mirsafaei HS, Delshad S. Management of pemphigus disease in pregnancy. American Journal of Reproductive Immunology. 2016 Nov 1.
75. Sobhan M, Farshchian M, Tamimi M. spectrum of autoimmune vesiculobullous diseases in Iran: a 13-year retrospective study. Clinical, cosmetic and investigational dermatology. 2016;9:15.
76. Živanović DP. *Polimorfizam HLA-DR i HLA-DQ alela kod pacijenata sa pemfigus vulgarisom* (Doctoral dissertation, Univerzitet u Beogradu-Medicinski fakultet).2016
77. Akarsu S, Özbağçivan Ö, Dolaş N, Aktan Ş. Possible triggering factors and comorbidities in newly diagnosed autoimmune bullous diseases. Turkish Journal Of Medical Sciences. 2017 Jun 12;47(3):832-40.
78. Gil JM, Weber R, Rosales CB, Rodrigues H, Sennes LU, Kalil J, Chagury A, Miziara ID. Study of the association between human leukocyte antigens (HLA) and pemphigus vulgaris in Brazilian patients. International Journal of Dermatology. 2017 May 1;56(5):557-62.
79. Saleh MA, Salem H, El Azizy H. Autoantibodies other than anti-desmogleins in pemphigus vulgaris patients. Indian journal of dermatology. 2017 Jan;62(1):47.
80. Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunologic research. 2018 Feb 26:1-6.
81. Kudligi C, Thirunavukkarasu A, Kuntoji V, Bhagwat PV, Rathod R, Girian S, Sharma A, Andanappanavar V. Clinical and pathological study of autoimmune vesiculobullous disorders. *Journal of Pakistan Association of Dermatology*. 2018 Feb 8;27(3):270-8.
82. Lai O, Recke A, Zillikens D, Kasperkiewicz M. Influence of cigarette smoking on pemphigus–a systematic review and pooled analysis of the literature. Journal of the European Academy of Dermatology and Venereology. 2018 Feb 25.

В монографии:

1. Sampaio-Barros PD, Carvalho MAP, Azevedo VF,Campos WR, Carneiro SCS, Giorgi RDN,Gonçalves CR, Hilário MOE, Keiserman MW,Leite NH, Pereira IA, Vieira WP, Vilela EG, Xavier RM, Ximenes AC. Еspondiloartropatias: Espondilite Anquilosante e Artrite Psoriásica. Projeto Diretrizes Associação Médica Brasileira e Conselho Federal de Medicina, 21 de junho de 2004 p.8
2. Endoğru E. Pemfiguslu 66 hastadaklinik seyir ve prognoz (6 yillik haydarpaşa deneyimi). T.c.sağlik bakanliğihaydarpaşa numune eğitim ve araştirma hastanesi deri ve zührevi hastaliklar kliniği. İstanbul -2005,p.34,35.
3. Vassileva S. Acute severe bullous dermatosis. In Emergency Dermatology, ed. By R. Wolf, Cambridge University Press, 2011. Chapter 22, 315-331
4. Лукьянов, А. М., and Ю. В. Колос. “эпидемиологические характеристики аутоиммунных буллезных дерматозов в республике беларусь.”
5. Schmidt, E., Borradori, L., & Joly, P. (2015). Epidemiology of Autoimmune Bullous Diseases. In *Blistering Diseases* (pp. 251-263). Springer Berlin Heidelberg.

Drug induced psoriasis. Recognition and management. Tsankov N, Angelova I, KAZANDJIEVA J. Am J Clin Dermatol 2000; 1: 159-165.

**Цитирания – 181**

1. Scott LJ, Dunn Ch, Goa KL. Calcipotriol Ointment: A Review of its Use in the Management of Psoriasis.Drug Evaluation. American Journal of Clinical Dermatology. 2(2):95-120, 2001.
2. Antonov D, Tsankov N. Severe psoriatic flare induced by systemic corticosteroid treatment – a case report and review of the literature. CEEDVA Bulletin, 4:44-47, 2002
3. Ghoreschi K, Rocken M. Immunopathogenesis of psoriasis. J Dtsch Dermatol Ges. 2003 Jul;1(7):524-32.
4. Hadjolian E, Ivanov M, Enev I, Groudev D. Homeopathic management of a patient with psoriasis vugaris. CEEDVA, Bull 2002; 4: 73-76.
5. Huntley AC. Psoriasiform Drug Eruption Associated With Metformin Hydrochloride: A Case Report. Dermatol Online J 2003; 9(3).
6. Koca R, Altinyazar HC, Yenidünya S, Tekin NS. Psoriasiform drug eruption associated with metformin hydrochloride: A case report  Dermatology Online Journal 2003;9 (3): 134-139
7. Latini A, Carducci M. Psoriasis during therapy with olanzapine. Eur J Dermatol 2003; 13: 404-405.
8. Ockenfels HM. Triggermechanismen der Psoriasis. Hautarzt 2003; 3: 215-223.
9. Allan SJR, Kavanagh GM, Herd RM, Savin JA. The effect of inositol supplements on the psoriasis of patients taking lithium& a randomized placebo-controlled trial. Br J Dermatol 2004;l150 ( 5): 966-969
10. Dika E, Maibach HI. Exogenous Factors and Psoriasis. Exog Dermatol 2004;3:214-222
11. Мусаева ЕО. **Оптимизация лечения больных псориазом детей с учетом роли активности процессов пероксидации**. Диссертация кандидата медицинских наук, Москва 2004
12. Tan B, Foley P. Guttate psoriasis following Ecstasy ingestion. Australasian Journal of Dermatology 2004; 45 (3):167-169.
13. Tzaphlidou M. **Collagenous Tissues upon Lithium Treatment: A Quantitative Ultrastructural Study**.      The ScientificWorldJOURNAL , 2004, 4, 605-621
14. Tjiu JW et al. Severe Generalized Pustular Psoriasis Provoked by oral Terbinafine. Dermatol Sinica, 22,187-192,2004.
15. Vergés, J et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con artrosis tratados con condroitín sulfato: descripción de tres casos [Nota clínica] s:.; Medicina clínica, 2004; 123(19)
16. Cohen AD, Bonneh DY,   Reuveni H,  Vardy DA,  Naggan L, Halevy S. Drug Exposure and Psoriasis Vulgaris: Case-Control and Case-Crossover Studies. Acta Dermato-Venereologica 2005; 85(4): 299 – 303.
17. Łuczkowska M, Żaba R. Psoriasis. Przewodnik lekarza,2005,7,38-49
18. Pariser D, Gordon K, Papp K, Leonardi C, Kwon P, Compton P, Rundle A, Walicke P, Lebwoh, Mark. Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I. J Cut Med Surg, 9, 6, 2005, 303-312(10)
19. Schön M, Boehncke W.Psoriasis. N Engl J Med 2005;352:1899-912.
20. Vergés J, Montell E, Herrero M, Perna C, Cuevas J, Dalmau J, Pérez M, Möller I. Coindritín sulfato: un nuevo tratamiento para la psoriasis? A propósito de 11 casos.Actualidad en farmacología y terapéutica 2005; 3(3):203 -205.
21. Winand HPM. Pathogenesis based treatment for psoriasis. Thesis University Medical Center Nijmegen, Netherland, 2005, p.51
22. 新英格兰医药杂志. Psoriasis 当前位置: [首页](http://www.100md.com/) > [期刊](http://paper.100md.com) > [《新英格兰医药杂志》](http://www.100md.com/index/paper/8888-0110/index.htm) [2005年第18期](http://www.100md.com/index/paper/8888-0110/o518/index.htm) > 正文
23. Абрамова ТВ. Клинико-эпидемиологические особенности псориаза в субрегионах Чувашии, диагностика и лечение. Дисертация, Российская Медицинская Академия, Последипломного образования. Москва, 2006
24. DikaE, Varotti C, Bardazzi F, Maibach H. Drug-Induced Psoriasis: An Evidence-Based Overview and the Introduction of Psoriatic Drug Eruption Probability Score. Informa Healthcare, 2006, Vol. 25, No. 1 , 1-11
25. Elston GE, Charles-Holmes R, Carr RA. Precipitation of generalized pustular psoriasis by prednisolon. Clinical and Experimental Dermatology 2006; 31(1): 133–134.
26. Fanti P, Dika E, Vaccari S, Miscial C, Varotti C.Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermato (2006) 45 (12), 1464–1465.
27. Gaspari JA. Innate and adaptive immunity and the pathophysiology of psoriasis. Am Acad Dermatol 2006; 54(3 Suppl 2):67-80
28. Herman SM, Shin MH, Holbrook A, Rosenthal D. The Role of of antimalarials in the exacerbation of psoriasis: A systematic review  American Journal of Clinical Dermatology 2006;l 7 (4): 249-257.
29. Ilknur T, Fetil E, Akarsu S. Development of psoriasis after meloxicam.European Journal of Dermatology, 2006; 16 (4): 444-445.
30. Krissel H. Dose finding of a new Vitamin D analogue for the treatment of plaque type psoriasis. Digitale Dissertation. FU Berlin,2006,233
31. Mastrolonardo M, Picardi A, Dlicino D, Bellomo D, Pasquini P. Cardiovascular Reactivity to experimental stress in psoriasis: a controlled investigation. Acta Dermato-Venereologica 2006; 86 (4): 340 – 344.
32. Prugovecki V. Ergebnisqualität einer dermatologischen Fachklinik:Outcome der stationären Versorgung von Patienten mit Psoriasis vulgaris. Doctorthesis, Klinik für Dermatologie und Venerologie der Universität zu Lübeck, Lübeck 2006;p87
33. Volpe A, Caramaschi P, Carletto A, Pieropan S, Bambara LM, Biasi D. Psoriasis onset during infliximab treatment: description of two cases. Rheumatology International 2006; 26(12):1158-60.
34. Wojas-Pelc A, Ciszek M, Kurnyta M, Marcinkiewicz J. [Cytokine network in psoriasis. Cross-talk between keratinocytes and cells.](http://www.gdziesieleczyc.pl/magazine.php?magazine_id=10&article_id=7464&magazine_subpage=FULL_TEXT) Centr Eur J Immunol 2006; 31 (3-4): 111-116.
35. Yi Li L, Brimhall AK, Menter A. Systemic therapy for moderate-to-severe psoriasis. Future Drugs – Expert review of Dermatology 2006; 1(1): 77-92.
36. Benoit S, Hamm H.Childhood psoriasis.  Clin Dermatol,2007,  25, 6, 555-562
37. Blume [**JE, Helm T, Ehrlich M, Camisa C.**](http://www.emedicine.com/cgi-bin/foxweb.exe/screen@/em/ga?book=derm&authorid=11370&topicid=104) Drug eruptions. E-medicine 2007;last updated March 28, 2007
38. Bruzzese V. Diffused suberitrodermic psoriasis induced by infliximab. Reumatismo, 2007; 59(4):328-331
39. CEN Jian-ping ZHU Ke-jian JIN Na LIN Ai-hua  CHENG Hao. Effects of drugs known to trigger psoriasis on HaCaT keratinocytes. ACTA PHARMACEUTICA SINICA, 2007, 42(10)
40. Fry L, Baker B. Triggering psoriasis: the role of infections and medications.  Clin Dermatol,2007,  25, 6,  606-615
41. HUANG Jun JIANG Xian WANG Sheng. A Case of Eczematous Psoriasis. Chinese journal of dermatovenereology,2007,21,5
42. Joly P, Benoit-Corven C, Baricault S, Lambert A, Hellot M, Josset V, Barbaud A, Courville Ph, Delaporte E, Collet E, Carvalho P, Modeste-Duval A, Lacour J, L'Anthoën-Arditi M, Thuillez Ch, Benichou J. Chronic Eczematous Eruptions of the Elderly Are Associated with Chronic Exposure to Calcium Channel Blockers: Results from a Case–Control Study. Journal of Investigative Dermatology advance online publication 23 August 2007
43. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2007; 298(7): 309–319.
44. Sabat R, Philipp S, Hoflich C, Kreutzer S, Wallace E, Asadullah K, Volk HD, Sterry W, Wolk K. Immunopathogenesis of psoriasis. Experimental Dermatology 2007; 16: 779–798.
45. Wojas-Pelc A, Marcinkiewicz J. What is a role of haeme oxygenase-1 in psoriasis? Current concepts of pathogenesis International Journal of Experimental Pathology, 88, 2, 2007 , 95-102(8)
46. Carlen L. Study of the psoriasis proteome and analysis of MHC class 1 expression and function., Karolinska institutet, Stockholm, 2008, Thesis
47. Chan Ch-Y S, Browning JC , Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis . Dermatology Online Journal 2008,14 (9): 12
48. Gerdes S, Zahl VA, Knopf H,Weichenthal M, Mrowietz U. **Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis.** British Journal of Dermatology,2008, 159(5):1116-1123
49. Gulliver W. **Long-term prognosis in patients with psoriasis.** British Journal of Dermatology. 2008,159 Suppl 2:2-9.
50. Feld A et al. Electrocardiographic Findings in Psoriatic Arthritis: A Case-Controlled Study. J Reumatol, 2008
51. Hauben M ?code=200B‌, Lester R?code=200B‌, Suzanne M,?code=200B‌ Ahyeon S.?code=200B‌Drug-Induced Psoriasis: Results from Pharmacovigilance Tools Under Investigation.2008, Vol. 27, No. 1, Pages 55-59
52. **Lier GC,** Mrowietz U**,** **Wolfart M,** **Warnke PH.,** **Wiltfang** **J , Springer ING.** Psoriasis of the tongue. [Journal of Cranio-Maxillofacial Surgery](http://www.sciencedirect.com/science/journal/10105182),2008
53. Jafferany, Mohammad **Lithium and skin: dermatologic manifestations of lithium therapy.** International Journal of Dermatology. 2008,47(11):1101-1111
54. Jafferany Mohammad. Lithium and Psoriasis: What Primary Care and Family Physicians Should Know., J Clin Psychiatry. 2008; 10(6): 435–439
55. Yamamoto M, Ikeda M, Kodama H, Sano Sh. Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. The Journal of Dermatology [**Volume 35 Issue 11**](http://www3.interscience.wiley.com/journal/121540185/issue)**, Pages 732 – 736**
56. **van der Kerkoff P.** Options for the treatment of psoriasis: a multifactorial approach*.* **Clin Dermatol,2008,26,5** , 419-423,
57. van Lingen RG. Between pathogenesis and treatment of psoriasis: a surch for discriminating marcers and therapeutic applications. Thesis Radboud University Nijmegen, Netherland, 2008, p.70
58. Wilson MSLJ. Associacaodo gene KIR2DS1 na psoriase vulgar em populacao caucasoide brasileira. Dissertacao de Mestrado, Universidade Federal do Rio Grande do Sul,2008, p.30
59. Wango, Dr Francis Omondi. "Clinical Patterns Of Psoriasis Vulgaris In Patients At Kenyatta National Hospital."PhD thesis, University of Nairobi 2008
60. Biedka, M., Ziółkowska, E., Makarewicz, R., Pietrusińska, E., Kubiak, M.A patient with cancer and psoriasis - Difficulties following oncology treatment | [Pacjent z choroba̧ nowotworowa̧ i łuszczyca̧ - Trudności w trakcie postȩpowania onkologicznego] 2009 *Wspolczesna Onkologia* 13 (6), pp. 339-342
61. Brauchli, Yolanda B.; Jick, SS. ; Curtin, F; Meier, CR. Lithium, Antipsychotics, and Risk of Psoriasis. Journal of Clinical Psychopharmacology: 2009,29,2,134-140
62. Brauchli, Yolanda B. Population-based Studies on the Natural History of Psoriasis – and their Role in the Drug Development Process and in Clinical Practice. Inauguraldissertation, Basel, 2009,p.153
63. Blum J, Helm T, Ehrlich M, Camisa Ch. Drug eruptions. Emedecine, Jan, 2009
64. Chen Yi-Lu. Biomarkers of metabolic syndrome and cardiovascular diseases in psoriasis. Electronic Theses and Dissertations service, National Chung Hsing University Institutional Repositor, Department of Life Science, 2009
65. Dobosz A. Clinical study of psoriasis with an age of onset above 30 years and the value of the modified PCR procedure of typing of HLA – Cw 06 allele – a marker of genetic heterogenenity of the disease. Rozprawa habilitacyjna, Gdansk, 2009, p.102
66. Echeverri M et al. The role of Th 17 cells in the immunopathogenesis of psoriasis. Rev Asoc Colomb Dermatol,2009,17,3-9
67. Federman DG., Michael L. Shelling, Srdjan Prodanovich, Craig G. Gunderson, Robert S. Kirsner Cardiovascular Health for Patients with Psoriasis: A Précis for Front-Line Clinicians, OWM,2009,55,5,38-47
68. Federman, D G, Shelling M, Prodanovich S; Gunderson C G; Kirsner R*.***Psoriasis: an opportunity to identify cardiovascular risk.** British Journal of Dermatology. 160(1):1-7, January 2009
69. Giraldo Sierra C. Psoriasis: revision del tema con enfasis en la immunopatogenesis. Iatreia, 2009,22,3,272-83
70. Gonzales C et al. Caracterizacion epidemiologica de la psoriasis en el Hospital Militar Central. Rev Asoc Col Dermatol,2009,17,1,11-17
71. Guven E. The effects of short term acitretin and ciclosporin treatments on IL–2 and TNF-α levels in moderate to severe plaque type psoriasis. Uzmanlik tezi, Gazianteb Universitasi, 2009
72. Icen M et al. Trends in incidence of adult-onset psoriasis over three decades: A population-based study. **JAAD,** 2009**, 60,3,** 394-401
73. **Lier G, Mrowietz U, Wolfart M, Warnke PH., Wiltfang J,. Springer IN.G** Psoriasis of the tongue. Journal of Cranio-Maxillofacial SurgeryVolume 37, Issue 1, January 2009, Pages 51-53
74. **Lin Lynnette Tan Pei , Seow Khee Kwek.** Onset of psoriasis during therapy with fluoxetine. General Hospital Psychiatry, 2009
75. Ma L. J,· You Y., Bai B. X, Yu-Zhen Li. Therapeutic eVects of heme oxygenase-1 on psoriasiform skin lesions in guinea pigs. Arch Dermatol Res (2009) 301:459–466
76. Park, JJ et al. Psoriasiform Drug Eruption Induced by Anti-tuberculosis Medication: Potential Role of Plasmacytoid Dendritic Cells. Acta dermatovenereologica, 2009, Nov.23
77. [Roy S](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Roy%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Goel D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Goel%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Unusual cutaneous reaction with sodium valproate. Neurol India. 2009 Mar-Apr; 57(2):216-7.
78. Rongioletti F, Fiorucci C, Parodi A. Psoriasis induced or aggravated by drugs. J Rheumatol Suppl. 2009 Aug; 83:59-61.
79. Salem CB et al.Psoriasis. N Engl J Med 2009; 361:1710
80. Shihab, H. M.,Feld, J. J.,Lutwama, F.,Piloya, T.,Colebunders, R. Successful treatment of psoriasis-like lesions in HIV infected patients in Uganda with chloroquine. Open Infectious Diseases Journal,2009,3,50-54
81. Smith T. Application of fluorescence diagnosis and photodynamic therapy in psoriasis and squamous premalignancy of the skin. Thesis Radboud University, Nijmegen. Netherlands, 2009,p.160
82. Tuzun Y, Yardimci G. Lithium and Psoriasis. J Turk Acad Dermatol,2009,3,4
83. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol, 2010,49,12,1351-61
84. Biedka M, Makarewicz R, Lebioda A, Kardymowicz H, Goralewska A.**Naczyniowo-śródbłonkowy czynnik wzrostu C jako czynnik predykcyjny w raku szyjki macicy?**Współczesna Onkologia (2010), 14; 2 (87–92)
85. Boehncke W, Katsambas A, J-P Ortonne, L Puig. EADV preceptorship: advances in dermatology. JEADV, 2010,24,5,2-24

# Gwiazdowska A, Brzezicka-Ciach U, Sobieszek-Kundro A. **Współistnienie kiły drugorzędowej nawrotowej z ciężką wysiewną łuszczycą**.****Przegl Dermatol 2010, 97, 395–397

1. Lamba G, Palaniswamy C, Singh T, Shah D, Lal S, Vinnakota R, Charrow E , Forman L. Psoriasis Induced by Losartan Therapy: A Case Report and Review of the Literature. American Journal of Therapeutics, 2010
2. Keeren K. Funktionell Charakterisierung de Toleranz-assoziierterGens TOAG-1. Medizinischen Fakultat Charite – Universitatsmedizin Berlin, 2010, p.98
3. Kim, G.K., and Del Rosso, J.Q.Drug-provoked psoriasis: Is it drug induced or drug aggravated? understanding pathophysiology and clinical relevance  *Journal of Clinical and Aesthetic Dermatology* 2010, 3 (1), pp. 32-38

# Lynnette Tan Pei, Seow Khee Kwek. Onset of psoriasis during therapy with fluoxetine.General Hospital Psychiatry, 2010,32, 4, 446-446.

1. Möller I, Pérez M, Monfort J, Benito P, Cuevas J, Perna C, Doménech G, Herrero M, Montell E, Vergés J. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2010;18 Suppl 1:S32-40.
2. Pace J. Psoriasis triggered by Mefloquine. Skinmed, 2010,8,5,301-302
3. Park, J.-J., Choi, Y.D., Lee, J.-B., Kim, S.-J., Lee, S.-C., Won, Y.H., Yun, S.J. Psoriasiform drug eruption induced by anti-tuberculosis medication: Potential role of plasmacytoid dendritic cells . 2010 *Acta Dermato-Venereologica* 90 (3), pp. 305-306
4. Sierra, C.G., Lopera, M.M.V.Psoriasis: A review with emphasis on immunopathogenesis | [Psoriasis: Revisión del tema con énfasis en la inmunopatogénesis]  *Iatreia* 2009, 22 (3), pp. 272-283
5. **Tollefson M.M, Crowson S, McEvoy M, Kremers HM.** Incidence of psoriasis in children: A population-based study ,2010, JAAD
6. Ткаченко С, Кондрашова В. Кардиометаболический риск у болньiх псориазом. Дерматологiя та Венерологiя, 2010,2,48,11-17
7. Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Mazzaglia G, Peserico A, Guerra AP , Sini G, Cassano N, Cricelli C. Incidence of psoriasis and association with comorbidities in Italy: A 5-year observational study from a national primary care database. EJD, 2010,20,5,593-8
8. Ткаченко СГ, Кондрашова ВБ. Кардиометаболический риск у больных псориазом. Дерматологiя та венерологiяр 2010,2,48,11-17
9. Biedka M et al. **Carcinoma of the urachus and the role of PET-CT in disease recurrence – case report.** Contemporary Oncology (2011) vol. 15; 2 (111–114)
10. Ganeva M, Gancheva T, Baldaranov I, Troeva J, Hristakieva E. Treatment of adverse drug reactions in a dermatology department. Central European Journal of Medicine 2011,Vol 6, 1, 37-44
11. Jager MEA. Childhood Psoriasis. Dissertation, 2011
12. Lecluse L; Dowlatshahi E;.. Limpens JM, de Rie MA., Jan D. Bos,; Phyllis I. Spuls, Etanercept. An Overview of Dermatologic Adverse Events.*Arch Dermatol.* 2011;147(1):79-94.
13. Lamba G et al. Psoriasis Induced by Losartan Therapy: A Case Report and Review of the Literature. American Journal of Therapeutics: 2011,18, 3,e78-e80
14. Bashko-Pluska JL, Petronic-Rosic V. Psoriasis: Epidemiology, Natural History, and Differential diagnoses. Dovepress, 2012, 2;67-76
15. Erfan, Gamze, et al. "Precipitation and exacerbation of psoriasiform eruption due to leuprolide acetate." *The Journal of dermatology* 40.1 (2013): 54-55.
16. Failla V, Nikkels-Tassoudjie N, Sabatiello M et al. Childhood Herpes Zoster-Triggered Guttate Psoriasis. The Open Derm J, 2012,6,9-12
17. Coumbe Ann G, Marc R Pritzker, Daniel A Duprez.  [Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors](http://www.researchgate.net/publication/258102115_Cardiovascular_Risk_and_Psoriasis_Beyond_the_Traditional_Risk_Factors?pli=1&loginT=I3lmvgMxOAd9qJ93_ejFZUOChg_6RQ09&cp=re243_i_p11&ch=reg). The American journal of medicine 10/2013
18. Denadai, Rafael, et al. "Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases." *Journal of Crohn's and Colitis* 7.7 (2013): 517-524.
19. Selam, Meltem. "Psoriasis aggravation due to lapatinib." *BMJ case reports*2013 (2013).
20. Takenaka, Saya, Tomoo Itoh, and Ryoichi Fujiwara. "Expression pattern of human ATP‐binding cassette transporters in skin." *Pharmacology Research & Perspectives* (2013).
21. Torres, Joana, et al. "Skin Side Effects of Inflammatory Bowel Disease Therapy." *Inflammatory bowel diseases* 19.5 (2013): 1086-1098.
22. Zhang, Peng, et al. "Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris." *Journal of autoimmunity* (2013).
23. Wiggin Wu, Maya Debbaneh, Homayoun Moslehi, John Koo, Wilson Liao. Tonsillectomy as a treatment for psoriasis: A review. Journal of Dermatological Treatment 11/2013;
24. 张冉, 杨森, and 张学军. "药物诱发加重银屑病的研究进展." *国际皮肤性病学杂志 ISTIC* 39.3 (2013).
25. Ahronowitz, Iris, and L. Fox. "Severe drug-induced dermatoses." *Semin Cutan Med Surg* 33, no. 1 (2014): 49-58.
26. Blume, Jonathan E., L. Ali, M. Ehrlich, and T. M. Helm. "Drug Eruptions." *E Medicine2010* (2014).
27. Fujiwara [R](https://www.researchgate.net/researcher/39376771_Ryoichi_Fujiwara) , [STakenaka](https://www.researchgate.net/researcher/2049664617_Saya_Takenaka), [M Hashimoto](https://www.researchgate.net/researcher/2049684667_Mitsuhiro_Hashimoto), [T Narawa](https://www.researchgate.net/researcher/35547323_Tomoya_Narawa),[T Itoh](https://www.researchgate.net/researcher/50645915_Tomoo_Itoh). Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders. Scientific reports 01/2014; 4:5251
28. García Morin M, González Ruiz De León E, Tolín Hernani M, Sánchez Sánchez C. Psoriasis inducida por infliximab en una adolescente con colitis ulcerosa. InAnales de Pediatría 2014 (Vol. 80, No. 1, pp. e18-e19)..
29. Gohel D, Bhatt SK, Malhotra S. Evaluation of dermatological adverse drug reaction in the outpatient department of dermatology at a tertiary care hospital. Indian Journal of Pharmacy Practice. 2014 Jul;7(3):42-9.
30. Kizilyel, Okan. "Psoriyazisli Hastalarda Oksidan Ve Antioksidan Seviyelerinin Araştirilmasi." Phd Diss., 2014.
31. Khmaladze, Ia. *Understanding inflammatory mechanisms in rheumatic diseases*. Inst för medicinsk biokemi och biofysik/Dept of Medical Biochemistry and Biophysics, 2014.
32. Megha M Tollefson. Diagnosis and Management of Psoriasis in Children. Pediatric Clinics of North America 04/2014; 61(2):261-277.
33. Morris, Brian S. "Psoriasis: Medications and Other Environmental Factors." Proceedings of UCLA Healthcare 18 (2014).
34. Ogretmen Z, Askin U, Hiz M.[Triggering drug use in patients with psoriasis: an investigative report from Turkey.](http://www.researchgate.net/publication/268282424_Triggering_drug_use_in_patients_with_psoriasis_an_investigative_report_from_Turkey?pli=1&loginT=lpXj7uk96J1UguA9AMKNwCr8q9LRTWvl&uid=a44df99f-e2a5-4e69-8e51-cda9f55de192&cp=re243_x_p11&ch=reg)  Postȩpy dermatologii i alergologii 10/2014 31(5):294-8
35. Said, A, Stephanie Bock, G Müller, G Weindl. "Chloroquine Promotes IL-17 Production by CD4+ T Cells via p38-Dependent IL-23 Release by Monocyte-Derived Langerhans-like Cells." *The Journal of Immunology* 193, no. 12 (2014): 6135-6143.
36. Said, A. "Funktionelle Charakterisierung dendritischer Zellen unter entzündlichen Bedingungen in vitro und Integration in humane Vollhautäquivalente." PhD diss., Freie Universität Berlin, 2014.
37. Song, James E., and Robert Sidbury. "An update on pediatric cutaneous drug eruptions." *Clinics in dermatology* 32, no. 4 (2014): 516-523.
38. Stanford, Carol W., Ramya Kollipara, Ann M. Melookaran, and John C. Hall. "Palmoplantar Pustular Psoriasis Following Initiation of a Beta-blocker: Disease Control With Low-Dose Methotrexate." *Am J Orthop* 94, no. 3 (2014): 153-155.
39. Τσάλτα, Αλίκη. "Συσχέτιση πολυμορφισμών γονιδίων με την απόκριση σε θεραπεία σε ασθενείς με ψωρίαση στον ελληνικό πληθυσμό." Master's thesis, 2014.
40. Tollefson MM. Diagnosis and management of psoriasis in children. Pediatric Clinics. 2014 Apr 1;61(2):261-77.
41. Van Peet, P. G. S. P., J. W. Ek, and H. Lantinga. "NHG-standaard psoriasis (derde herziening)." *Huisarts Wet* 57 (2014): 128-135.
42. Wu, Wiggin, Maya Debbaneh, Homayoun Moslehi, John Koo, and Wilson Liao. "Tonsillectomy as a treatment for psoriasis: A review." *Journal of Dermatological Treatment* 25, no. 6 (2014): 482-486.
43. Zaïem A, Mebazaa A, Lakhoua G, Badri T, Sahnoun R, Kastalli S, Daghfous R, El Aidli S. Clarithromycin induced psoriasis in a 37-year old man. Current drug safety. 2014 Mar 1;9(1):77-8.
44. Ayala-Fontanez, Nilmarie. "Paradoxical onset of psoriasis after IL-6 receptor blockade." PhD diss., Case Western Reserve University, 2015.
45. Ancheril, Ittoop J., et al. "A Clinical Study On The Efficacy Of Karanja Beeja Taila Along With Dooshivishari Agada In The Management Of Psoriasis." *Global Journal of Research on Medicinal Plants and Indigenous Medicine* 4.8 (2015): 162-171.
46. Benhabib, Meryem Ghizlene. *Determination des marqueurs du stress oxydatif chez les femmes psoriasiques dans la region de tlemcen*. Diss. 2015.
47. Bronckers, I. M. G. J., et al. "Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities." *Pediatric Drugs* (2015): 1-12.
48. Fontánez, Nilmarie Ayala. "Paradoxical onset of psoriasis after IL-6 receptor blockade." PhD diss., Case Western Reserve University, 2015.
49. Girolomoni G, Griffiths CE, Krueger J, Nestle FO, Nicolas JF, Prinz JC, Puig L, Ståhle M, van de Kerkhof PC, Allez M, Emery P. Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. Journal of Dermatological Treatment. 2015 4;26(2):103-12.
50. Kayhan, M.. Bir ikinci sağlık kuruluşunun dermatoloji polikliniğine başvuran hastaların klinik tanılarının, yaş, cinsiyet ve mevsimsel farklılıklarının aile hekimliği bakış açısı ile değerlendirilmesi. 2015Aile Hekimliği Koleksiyonu
51. Khmaladze, I., K. S. Nandakumar, and R. Holmdahl. "Reactive Oxygen Species in Psoriasis and Psoriasis Arthritis: Relevance to Human Disease."*International archives of allergy and immunology* 166.2 (2015): 135-149.
52. Parker SJ. *Oral Chinese herbal medicine for psoriasis vulgaris* (Doctoral dissertation, RMIT University).2015
53. Santana, Miguel Angel Cardenes. "Psoriasiform reaction to atenolol: a case report." *Research* (2015).
54. *Axelle A.* D’état Tp. *Azot* (Doctoral dissertation, Université Paris Diderot-Paris).2016
55. Ayala-Fontánez, Nilmarie. "Current knowledge on psoriasis and autoimmune diseases." (2016).
56. Baggio R, Le Treut C, Darrieux L, Vareliette A, Safa G. Psoriasiform Diaper Rash Possibly Induced by Oral Propranolol in an 18-Month-Old Girl with Infantile Hemangioma. Case Reports in Dermatology. 2016 Dec 22;8(3):369-73.
57. El Jadi H, Guerboub AA, Meftah A, Moumen A, Elmoussaoui S, Belmejdoub G. Éruption psoriasiforme secondaire à la metformine: Une situation rare à connaître. Médecine des Maladies Métaboliques. 2016, 30;10(4):306-8.
58. Ning J, Hu L, Zhang Q, Jiao Y, Li M, Gu K, Sun G. Psoriasis aggravation due to capecitabine in a colon cancer patient: a case report and literature review. IJCEM. 2016 Jan 1;9(8):16399-402.
59. Sherin R, Udaykumar P. Assessment of Possible Drug Interactions in Patients with Psoriasis and Associated Comorbid Medical Conditions: An Observational Study. Reviews on recent clinical trials. 2016 Jun 1;11(2):128-34.
60. Sudhakar R, George MK, Yasaswini B, Sundararajan N, Mariyam AS. Adverse Drug Reactions Associated With Anti-Hypertensive Drugs And Its Management. Intl J Pharmaceutical Sciences and Research. 2016 1;7(3):898.
61. Thomas, Jayakar. "Treating pediatric plaque psoriasis: challenges and solutions." (2016).
62. Veliyev V, İbrahim Özmen SY, Gürsoy E, Köklü M, Çelik M. The success of ivabradine treatment for IST-associated car-diomyopathy has been reported in 2 patients in the literature (8, 9). With the improvement of tachycardia, the patients’ clinical symptoms and LVEF also improved, and reduction in MR was observed. (2016).
63. Adamu UG, Aisha A, Stephen AO, Joseph TC. Metoprolol-induced Psoriasiform Drug Eruption: A Case Report. 2017 9(2): 1-4,
64. Alin L. Tatu and Lawrence C. Nwabudike.Metoprolol-Associated Onset of Psoriatic Arthropathy. American Journal of Therapeutics, 2017, Volume 24, Number 3, Page e370
65. Альменова ЛТ, Бейсебаева УТ, Хабижанов АБ, Баев АИ, Шортанбаева ЖА, Нурушева СМ, Карибаева ДО, Заттыбеков АО. Особенности клинического течения и развития псориаза на современном этапе. InScientific research-2017 2017 (pp. 30-46).
66. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckland, NZ). 2017;7:87.
67. Chepure AH, Ungratwar AK. Olanzapine-induced Psoriasis. *Indian journal of psychological medicine*. 2017 Nov;39(6):811.
68. Chiu IM. Infection, Pain, and Itch. *Neuroscience bulletin*. 2017 Jan 31:1-1.
69. Iamsumang W, Sriphojanart T, Suchonwanit P. Psoriatic Alopecia in a Patient with Systemic Lupus Erythematosus.Case Reports in Dermatology, 2017, Volume 9, Number 1, Page 51
70. Gonzalez EM, inventor; MUCIDERM SA, assignee. Pharmaceutical composition for preventing, treating, and curing psoriasis including snail slime, chamomile, and honey. United States patent application US 15/501,129. 2017 Aug 3.
71. Lee, Y.J., Bae, J.H., Kang, SG. et al. Pro-oxidant status and Nrf2 levels in psoriasis vulgaris skin tissues and dimethyl fumarate-treated HaCaT cells. Arch. Pharm. Res. (2017) 40: 1105.
72. Laurentiu TA. Teză De Abilitare Habilitation Thesis. Universitatea Transilvania Din Braşov, 2017
73. Palaia G. Oral psoriasis: case report in a patient without skin lesions. Senses and Sciences. 2017;4(4).
74. Tatu AL, Nwabudike LC. Metoprolol-Associated Onset of Psoriatic Arthropathy. American journal of therapeutics. 2017 1;24(3):e370-1
75. Chiu HY, Chang WL, Tsai TF, Tsai YW, Shiu MN. Risk of psoriasis following terbinafine or itraconazole treatment for onychomycosis: a population-based case-control comparative study. Drug safety. 2018 Mar 1;41(3):285-95.
76. Kamiya, Koji, et al. "Risk factors for the development of psoriasis." *International journal of molecular sciences* 20.18 (2019): 4347.
77. Lübow, Charlotte, Judith Bockstiegel, and Günther Weindl. "Lysosomotropic drugs enhance pro-inflammatory responses to IL-1β in macrophages by inhibiting internalization of the IL-1 receptor." *Biochemical pharmacology* 175 (2020): 113864.
78. dos Reis Neto, Edgard Torres, et al. "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases." *Advances in Rheumatology* 60.1 (2020): 1-11.

В монографии:

1. Cristophers E, Mrowietz U. Psoriasis. Chapter 42. in Fitzpatrick’s Dermatology in General Medicine. 6th edition\ May 23,2003
2. Harris: Kelley's Textbook of Rheumatology, 7th ed. 2005, Saunders
3. van der Kerkoff P. Textbook of Psoriasis. Blackwell,2003, Chapter 1, p.28,
4. Treatment of skin disease. Comprehensive therapeutic strategies (second edition). Eds. Marc Lebwohl, Warren T, Heymann J, Berth-Jones, Ian Coulson.
5. Bologna JL, Jorizzo J, Rapini R. Dermatology. Mosby, Vol.1,2003,Edinburg
6. González JLG. PSORIASIS. LOKI & DIMAS, 2006 (MADRID)
7. Dika E, Bardazzi F, Balestri R, Maibach H. Environmental Factors and Psoriasis. In  
   Tur E (Ed): Environmental Factors in Skin Diseases. Curr Probl Dermatol. Basel, Karger, 2007, vol 35, pp 118-135
8. Vajdaya V, Schmidt CH. Evaluation of psychosocial problems. In Principles of Ambulatory medicine, Ed. by Fiebach N, Kern D, Thomas P, Ziegelstein R. 7th edition. Lippincott, Williams and Wilkins, 2007, Chapter 19, 279-349
9. Goodwin Frederick K., Kay R. Jamison., Manic-depressive illness: bipolar disorders and recurrent depression, Vol 1, Oxford University Press, Second Ed, 2007, p.1262
10. Brown AJ, Korman NJ.Chapter: Psoriasis and psoriatic arthritis: a clinical review. In: Weinberg JM. Milestones in Drug Therapy. Treatment of Psoriasis. Birkhäuser Basel, 2008, p.23-39
11. Effendy I, Kuschela K. Skin disease caused by changes in the immune system and infection. Chapter 53 Textbook of health in aging men
12. Hymes Sh, Chon C, Ciurea A. Skin Disorders Difficult to Distinguish from Infection. In Principles and Practice of Cancer Infectious Diseases, Chapter 21, Current Clinical Oncology, Editor Amar Safdar, 2011, Part 2, 233-253
13. McKee's Pathology of the Skin. By J. Eduardo Calonje, MD, DipRCPath, Thomas Brenn, Alexander J Lazar, MD, PhD and Phillip H. McKee, MD, FRCPath, Elsevier, 2012
14. Grozdev, Ivan, and Neil J. Korman. "Psoriasis: epidemiology, potential triggers, disease course." In Advances in Psoriasis, pp. 27-37. Springer London, 2014.
15. Özkaya E, Yazganoğlu KD. General Aspects of Adverse Cutaneous Drug Reactions. InAdverse Cutaneous Drug Reactions to Cardiovascular Drugs 2014 (pp. 3-63). Springer, London.

|  |
| --- |
|  |
|  |
|  |
|  |  |

1. Lester, Elizabeth B., Deborah L. Cook, and Gretchen W. Frieling. "Psoriasiform Drug Eruptions and Drugs That Flare Psoriasis." In *Cutaneous Drug Eruptions*, pp. 141-155. Springer London, 2015.

|  |
| --- |
|  |
|  |
|  |
|  | . |

# Epidemiology of syphilis in Bulgaria, 1990–1998. Dencheva R; Spirov G; Gilina K; Niagolova D; Pehlivanov G; Tsankov N. **:** International Journal of STD & AIDS, Volume 11, Number 12, 1 December 2000 , pp. 819-822(4)

Цитирания – 11

1. Bjekic-M Vlajinac-H Sipetic-S Kocev-N. Trends of Gonorrhea and Early Syphilis in Belgrade, 1985-99. Sexually Transmitted Infections. 2001, Vol 77, Iss 5, pp 387-388
2. Kabakchieva E, Amirkhanian TA, Kelly JA, et al. High levels of sexual HIV/STD risk behaviour among Roma men in Bulgaria: patterns and predictors of risk in a representative community sample, Int J STD AIDS,2002,13,184-191
3. Rawstron S; Mehta S, Bromberg K.**Evaluation of a Treponema pallidum-Specific IgM Enzyme Immunoassay and Treponema pallidum Western Blot Antibody Detection in the Diagnosis of Maternal and Congenital Syphilis.** Sexually Transmitted Diseases. 2004, 31(2):123-126,
4. Salakhov E; Tikhonova L; Southwick K; Shakarishvili A; Ryan C; Hillis S.**Congenital Syphilis in Russia: The Value of Counting Epidemiologic Cases and Clinical Cases.** Sexually Transmitted Diseases. 2004, 31(2):127-132.
5. Barquisimeto V. Grado des satissfacion de las adolescents primigestas sobre el control prenatalen centros foraneusatendidas en el departamento de obstetricia y ginicologia del hospital universitario “Dr. Antonio Maria Pineda”. PhD thesis , 2008
6. 卜今, et al. „影响全球梅毒流行的因素.” *国际皮肤性病学杂志* 6 (2009): 402-404.
7. Uusküla A et al. Trends in the epidemiology of bacterial sexually transmitted infections in eastern Europe, 1995–2005 Sex Transm Infect 2010;86:6-14
8. Cornier N et al. Optimising the management of vaginal discharge syndrome in Bulgaria: cost effectiveness of four clinical algorithms with risk assessment Sex Transm Infect *2010;86:303-309*

**В монографии:**

1. Rechel B, McKe M. Healing the Crisis: A Prescription for Public Health Action in South Eastern Europe., Published by the London School of Hygiene & Tropical Medicine, 2003,p6
2. O. Shentov et al. Prostitution and human ravelling. Organized Crime in Bulgaria: Markets and Trends. Ed., CSD, ,2007, p.130
3. Mental Health Aspects of Women’s Reproductive Health: A Global Review of the literarure. Gynaecological conditions. Ed. By Jane Fisher, Jill Astbury et al., WHO, 2009, Chapter 6, p.106

**Кazandjieva J, Popov Y, Tsankov N. History of dermatological moulages in Sofia, Bulgaria. CEEDVA, Bull, 2000, 2, 55-56.**

**Цитирания – 3**

1. Parish LC, Crissey JT, Parish J. Bibliography of Secondary Sources on the History of Dermatology, Journal Articles in English - Supplemented through 2000
2. Gelmetti, C. (2014). Scienza e arte nella storia della dermatologia e della venereologia: le cere dermatologiche. In *Storia della Dermatologia e della Venereologia in Italia* (pp. 193-204). Springer Milan.
3. Tataru, Alexandru-Dumitru, et al. "The history of an unknown dermatological wax collection from Cluj-Napoca University “Iuliu Hatieganu”, Romania." *Wiener Medizinische Wochenschrift* (2017): 1-4.

[**Stoitchkov**](http://lib.bioinfo.pl/auth:Stoitchkov,K) **K ,**  [**Letellier**](http://lib.bioinfo.pl/auth:Letellier,S) **S,**  [**Garnier**](http://lib.bioinfo.pl/auth:Garnier,JP) **J P ,** [**Toneva**](http://lib.bioinfo.pl/auth:Toneva,M) **M ,**  [**Naumova**](http://lib.bioinfo.pl/auth:Naumova,E) **E ,**  [**Peytcheva**](http://lib.bioinfo.pl/auth:Peytcheva,E) **E,**  [**TZANKOV**](http://lib.bioinfo.pl/auth:Tzankov,N) **N,**  [**Bousquet**](http://lib.bioinfo.pl/auth:Bousquet,B) **B ,**  [**Morel**](http://lib.bioinfo.pl/auth:Morel,P) **P,**  [**Le Bricon**](http://lib.bioinfo.pl/auth:Le%20Bricon,T) **T.** [**Evaluation of standard tyrosinase RT-PCR in melanoma patients by the use of the LightCycler system.**](http://lib.bioinfo.pl/pmid:11282104) **[My paper] Clin Chim Acta. 2001 Apr ;306 (1-2):133-8 11282104**

**Цитирания -8**

1. Goessl C. Noninvasive molecular detection of cancer – the bench and the bedside. CURRENT MEDICINAL CHEMISTRY 2003; 10 (8): 691-706.
2. Keilholz U, Goldin-Lang P, Bechrakis N, Max N et al. Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. Clinical Cancer Research 2004*,* 10, 1605–1612.
3. Barbado M., Preisser L., Boisdron-Celle M., Verriele V., Lorimier G, Gamelin E, More A.Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype. Cancer Letters, 2006, 242, 2, 168-179
4. Faries MB,  Gupta RK,  Xing Ye, Lee Ch,  Yee R,  Leopoldo Z,  Essner R,   Foshag L J,   Elashoff D, Morton DL. A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients. [Cancer Investigation](http://www.informaworld.com/smpp/title~content=t713597231~db=all), 2007 ,[25](http://www.informaworld.com/smpp/title~content=t713597231~db=all~tab=issueslist~branches=25#v25), [5,](http://www.informaworld.com/smpp/title~content=g780908899~db=all)  285 – 293
5. Markowitz J, MacKerel A, Weber DJ. A Search for Inhibitors of S100B, a Member of the S100 Family of Calcium-Binding Proteins. [Mini Reviews in Medicinal Chemistry](http://www.ingentaconnect.com/content/ben/mrmc;jsessionid=3gc6ivg1itmrc.alexandra), 2007 ,7, 6, 609-616(8)
6. Faye R S, Paus E, Maelandsmo G M, Berner A, Hoifodt HK, Fodstad O, Aamdal S. ***S100B* in bone marrow aspirates in healthy individuals and malignant melanoma patients.** Melanoma Research, 2008,18(2):134-140,.
7. Charitoudis G, Schuster R, Joussen AM, Keilholz U, Bechrakis NE. Detection of tumour cells in the bloodstream of patients with uveal melanoma: influence of surgical manipulation on the dissemination of tumour cells in the bloodstream. British Journal of Ophthalmology. 2015 Aug 17:bjophthalmol-2015.

**В монографии:**

1. in Pantel K. Micrometastasis.Kluwer Academic Publisger,2003

**Brenner S, Tur E, Shapiro J, Ruocco V, D’Avino M, Ruocco E, TSANKOV N, Vassileva S, Drenovska K, Brezoev P, Barnadas MA, Gonzalez M J, Anhalt G, Nousari H, Ramos- e Silva M, Pinto K, Miranda MF.Pemphigus vulgaris: environmental factors. Occupational, ravelling, medical, and qualitative food frequency questionnaire .International Journal of Dermatology (2001) 40 (9), 562–569.**

**Цитати – 137**

* 1. Drazer G, Koplik J, Khusid B, Acrivos A. Deterministic and stochastic behaviour of non-Brownian spheres in sheared suspensions. Journal of Fluid Mechanics. 2002 Jun;460:307-35.
  2. Hogervorst E, Smith AD. The interaction of serum folate and estradiol levels in Alzheimer’s disease. Neuroendocrinol Lett,2002,23,155-160
  3. Sullivan TP, Elgart GW, Kirsner RS. Pemphigus and smoking. Int J Dermatol,2002,41,528-530
  4. Scully C, Challacombe SJ. Pemphigus vulgaris: Update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol M,2002,13,397-408
  5. Brenner S, Mashiah J, Tamir E, Goldberg I, Wohl Y. PEMPHIGUS: An Acronym for a Disease with Multiple Etiologies. SKINmed 2003; 2:3: 163–167.
  6. Cartellier A. Screening mechanisms and induced agitation in bubbly flows at finite particle Reynolds numbers: experiments and preliminary modeling attempts using an hybrid approach. Ercoftact Bull. 2003;56.
  7. Dmochowski M, Dmochowska M, **Wywołanie skórnych zmian pęcherzycowych przez uraz chirurgiczny u chorej na pęcherzycę zwykłą.** Postępy Dermatologii i Alergologii, 2003,5
  8. Maciborski JD, Dolez PI, Love BJ. Construction of iso-concentration sedimentation velocities using Z-axis translating laser light scattering. Materials Science and Engineering: A. 2003 Nov 25;361(1-2):392-6.
  9. Freiman A, Bird G, Metelitsa AI, Barankin B, Lauzon G. Cutaneous Effects of Smoking. Journal of Cutaneous Medicine and Surgery. 2004, 8:6, 415
  10. Grando S. New Approaches to the Treatment of Pemphigus. Journal ofInvestigative Dermatology Symposium Proceedings.2004, **9**, 84–91;
  11. Kurzen, H. Das extraneuronale cholinerge System der Haut: Grundlagen und klinische Relevanz. Der Hautarzt, 2004 ,55,  5, 453-459
  12. Seal A, Chattopadhyay D, Sharma AD, Sen A, Maiti HS. Influence of ambient temperature on the rheological properties of alumina tape casting slurry. Journal of the European Ceramic Society. 2004 Jul 1;24(8):2275-83.
  13. Wolf R, Orion E, Matz H, Maitra S, Rowland-Payne C. Smoking can be good for you. Journal of Cosmetic Dermatology .2004, 3:2, 107–111
  14. Black M, Scully M. Number II Pemphigus vulgaris. Oral Diseases.2005,11:3, 119–130
  15. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, Barzegari M, Akhiani M, Ghodsi Z, Mortazavi H, Naraghi Z. Pemphigus: Analysis of 1209 cases. International Journal of Dermatology 2005; 44(6): 470–476.
  16. Ettlin D. Pemphigus.  Dental Clinics of North America,2005,49, 1, 107-125
  17. Gazit E, et al. The immunogenetics of pemphigus vulgaris, Autoimmun Rev, 2005,4,1,16-20
  18. Mashiah J., Brenner S. Medical Pearl: First step in managing pemphigus—addressing the etiology.  Journal of the American Academy of Dermatology, 2005, 53,4, 706-707
  19. Nunes LG, Moresco R, Marley G, Cristina da Silva B, Matesanz P. Pénfigo vulgar – Caso clínico. Av Odontoestomatol,.21,.4,  Madrid jul.-ago. 2005
  20. Rosa LG, Ventura RM, Silva MG, Baumgart CD, Matesanz Pérez P. Pénfigo vulgar: caso clínico. Avances en odontoestomatología. Madrid. Vol. 21, no. 4 (jul./agosto 2005), p. 189-193. 2005.
  21. Šustić N. Epidemiology of Acquired Bullous Diseases in Eastern Croatia: A Retrospective Prewar to Postwar Study. Acta dermatovenerologica Croatica. 2005 Apr 1;13(4).
  22. Hashmi SA, Dwivedi UK. Simulation of compositional profile in functionally graded materials. Polymer Engineering & Science. 2006 Nov 1;46(11):1660-6.
  23. Hashmi SA. Attaining a controlled graded distribution of particles in polymerizing fluid for functionally graded materials. Journal of applied polymer science. 2006 Mar 15;99(6):3009-17.
  24. Heilig L, Cerahill C, Freeman S, Johnson K, Hester E, Kozak K, Schilling L, Cooke T, Dellavalle R. Tobacco smoking cessation for treating acne. status and date: Edited (no change to conclusions), published in. 2006(3).
  25. Grando SA. Cholinergic control of epidermal cohesion. Experimental Dermatology (2006) 15:4, 265–282
  26. Kanwar AJ, Ajith AC, Narang T. Pemphigus in North India. Journal of cutaneous medicine and surgery. 2006 Jan;10(1):21-5.
  27. Kurzen H et al. Significance of autoimmunity to non-desmoglein targets in pemphigus,2006; Autoimmunity, Volume 39, Number 7, pp. 549-556(8)
  28. Sanchez A et al. Penfigo vulgar. Estudio ravellingal y ravelli de posibles factores de riesgo de mortalidad. Dermatologia Rev Mex, 2006,50;50-53
  29. Wohl Y, Goldberg I, Shirazi I, Brenner S. Chlorpyrifos exacerbating pemphigus vulgaris: A preliminary report and suggested in vitro immunologic evaluation model. SKINmed 2006; 5:3: 111–113.
  30. Yonit W, Ilan G, Idit S, Sarah B. Chlorpyrifos exacerbating pemphigus vulgaris: a preliminary report and suggested in vitro immunologic evaluation model. SKINmed: Dermatology for the Clinician. 2006 Jan 1;5(1):111-3.
  31. Belgnaoui, Fatima Zahra, et al. „Prédisposition aux infections des malades ayant un pemphigus: étude rétrospective de 141 cas.” *La Presse Médicale* 36.11 (2007): 1563-1569.
  32. Chaidemenos G Ch, Mourellou O, Koussidou T, Tsatsou. F An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study. Journal of the European Academy of Dermatology and Venereology. 2007, 21:10, 1386–1391
  33. Chiapa M, Becker I. Pénfigo vulgar: una revisión de la inmunopatología. Bioquimia. 2007;32(3).
  34. Esmaili N, Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Balighi K, Hallaji Z, Barzegari M, Akhyani M, Ghodsi ZS, Mrotazavi H, Naraghi ZS, Toosi S. Pemphigus vulgaris in Iran: a clinical study of 140 cases. International Journal of Dermatology, 2007, 46:11, 1166–1170
  35. Heymann AD, Chodick G, Kramer E,Green M, Shalev V. **Pemphigus Variant Associated With Penicillin Use A Case-Cohort Study of 363 Patients From Israel** Arch Dermatol. 2007;143(6):704-707
  36. Mashiah J., Brenner S.. Discovering the cause helps the cure. Clinical and Experimental Dermatology.2007,32:4, 447–447
  37. Mena González, Francisco Camilo. "Sedimentación y fluctuaciones en suspensiones confinadas." (2007).
  38. Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos M, Mourellou O, Antoniades D. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: Retrospective study of 129 patients. International Journal of Dermatology 2007; 46(4): 356–361.
  39. Takemura N, Fujii N, Tanaka T. Epidermal cysts: the best surgical method can be determined by ultrasonographic imaging. Clinical and Experimental Dermatology: Viewpoints in dermatology. 2007 Jul;32(4):445-7.
  40. Valikhani M, Kavusi S, Chams-Davatchi C, Daneshpazhooh M, Barzegari M, Ghiasi M, Abedini R. Pemphigus and associated environmental factors: a case–control study. Clinical and Experimental Dermatology 2007; 32(3): 256–260.
  41. Benchikhi H, Ghafour S, Disky A, Bichra L, Nejjam F, Lakhdar H. **Pemphigus: analysis of 262 cases.** International Journal of Dermatology. 2008, 47(9):973-975
  42. Chavolla TM, Memije ME, Mosqueda Taylor A, Gamboa EL. Pénfigo vulgar en pacientes menores de 30 años. Informe del manejo clínico y terapéutico de 17 casos. Dermatología Cosmética, Médica y Quirúrgica. 2008 May 5;6(2):87-92.
  43. Cook, B.P., Bertozzi, A.L. and Hosoi, A.E., 2008. Shock solutions for particle-laden thin films. *SIAM Journal on Applied Mathematics*, *68*(3), pp.760-783.
  44. Cichocki B, Sadlej K. Stokesian Dynamics—The BBGKY Hierarchy for Correlation Functions. Journal of Statistical Physics. 2008 Jul 1;132(1):129-51.
  45. Edgin WA et al. Pemphigus Vulgaris and Paraneoplastic Pemphigus. Oral and Maxillofacial Surgery Clinics of North America,2008, 20, 4, 577–584
  46. Higginbotham, Raymond, et al. “Pesticide-associated pemphigus vulgaris.” *Cutis* 82 (2008): 51-54.
  47. Joanides D et al. Pemphigus. JEADV, 2008,22,12,1478-1496
  48. Kavusi S, Daneshpazhooh M ,Farahani F, Abedini R, Lajevardi V, Chams-Davatchi C. Outcome of pemphigus vulgaris. [Journal of the European Academy of Dermatology and Venereology](http://www3.interscience.wiley.com/journal/118534789/home),2008, [22, 5](http://www3.interscience.wiley.com/journal/121403583/issue)**, 580 – 584**
  49. Kumar KA. Incidence of pemphigus in Thrissur district, south India. Indian J Dermatol Venereol Leprol 2008;74:349-51
  50. Mimouni D, Bar H, Gdalevich M, Katzenelson V, David . Pemphigus – analysis of epidemiological factors in 155 patients.[Journal of the European Academy of Dermatology and Venereology](http://www3.interscience.wiley.com/journal/118534789/home),2008,  [22, 10](http://www3.interscience.wiley.com/journal/121403583/issue)**, 1232 – 1235**
  51. **Sarobe MJ.** Smoking and the Skin. Actas Dermo-Sifiliográficas (English Edition),2008, 99, 3, 2008, P 173–184
  52. Valikhani M, Kavusi S, Chams-Davatchi C, Hallaji Z, Esmaili N, Ghandi N, Farahani F, Lajevardi V. Impact of smoking on pemphigus. International Journal of Dermatology, 2008, [47, 6](http://www3.interscience.wiley.com/journal/120082588/issue)**, 567 – 570**
  53. **Wadhera A. Pemphigus vulgaris. Am Coll Phys, 2008**
  54. Chmurova N, Svecova D. Pemphigus vulgaris: a 11-year review. Bratisl Lek Listy. 2009;110(8):500-3
  55. Groves, Richard W. „Pemphigus: a brief review.” *Clinical medicine* 9.4 (2009): 371-375.
  56. Ingram J R. Nicotine: does it have a role in the treatment of skin disease? Postgrad Med J 2009;85:196-201
  57. Hashmi SA, Dwivedi UK. SiC dispersed polysulphide epoxy resin based functionally graded material. Polymer Composites. 2009 Feb 1;30(2):162-8.
  58. Hashmi SA, Dwivedi UK, Chand N. Concentration profile of glass fiber bundles in epoxy‐based gradient composites during centrifugation. Journal of applied polymer science. 2009 Sep 15;113(6):3840-6.
  59. Joanides D et al. Pemphigus. CME-CPD on line April 09,
  60. Limtanjakul P et al. Tobacco use and skin diseases… Thai J Dermatol, 2009,25,4,229-244
  61. 根管治疗期间并发症发生原因探讨牟夏萍 – 口腔医学, 2009 , Stomatology
  62. 沈晓云, and 刘晓松. „似复发性口腔溃疡样寻常型天疱疮 2 例.” *口腔医学* 28.11 (2009): 570-570.
  63. 丁小洁, et al. „青年寻常型天疱疮误诊 1 例.” *皮肤病与性病* 2 (2010): 60-61.
  64. Bin Mohamed, Abdul Hafiz. Pemphigus Vulgaris : Mekanisme Dan Penanggulangannya (Laporan Kasus). USU Repository Perpustakaan UniversitasSumatera Utara, 2010
  65. Zumaquero Martínez, Esther C. "Mecanismos de acción de CD38 en señalización, migración celular y patologías autoinmunes." (2010).PhD thesis Universitad de Granada
  66. 青年寻常型天疱疮误诊 1 例, JOURNAL OF DERMATOLOGY AND VENEREOLOGY 年，卷(期)： 2010, 32(2)
  67. Caldarola, G. A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris? Expert Review of Clinical Immunology, 2011 , 7,  2, 187-191(5)
  68. De Carli JPD et al. Pênfigo e suas variações. Odonto, Odonto jul/dez 2011; 19 (38)
  69. Demirci GT, Mansur AT, Aydingöz IE. Pemfigusta Risk Faktörleri/Risk Factors in Pemphigus. Turkderm. 2011 Jul 1;45(3):140.
  70. Eid H, El-Gama BCytokine profiles in the sera of Egyptian patients with oral pemphigus vulgaris. Brazilian Journal of Oral Sciences, 2011, 10, 2, 83-87
  71. Gupta, Vibha K., et al. „A globally available internet-based patient survey of pemphigus vulgaris: epidemiology and disease characteristics.” *Dermatologic clinics* 29.3 (2011): 393-404
  72. Hasan, Shamimul. „Oral Signs In Muco-Cutaneous Disorders-Report Of Three Cases And Review Of Literature.”
  73. Hasan, S., Ahmed, S., Khan, N. I., & Tarannum, F. (2011). Pemphigus vulgaris—a case report and detailed review of literature. *Indian Journal of Dentistry*, *2*(3), 113-119.
  74. Jaafari-Ashkavandi Z et al. Oral Mucocutaneous Diseases: Clinicopathologic Analysis and Malignant Transformation. Ournal of Craniofacial Surgery: 2011, 22 – Issue 3 – pp 949-951
  75. Said S, Golitz Lvesiculobullous eruptions of the oral cavity. Otolaryngol Clin North Am. 2011;44(1):133-60, vi.
  76. Venugopal SS, Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. DermatolClin, 2011, 29(3):373-80
  77. Grando S. Pemphigus autoimmunity: Hypotheses and realities. Autoimmunity,2012, 45, 1, 7-35
  78. Ljubojevic, Suzana, and Jasna Lipozenčić. „Autoimmune bullous diseases associations.” *Clinics in dermatology* 30.1 (2012): 17-33.
  79. Mukhatar Ahmed Javali, Heena Zainab. „Pemphigus vulgaris presenting as gingival involvement.” *Indian dermatology online journal* 3.3 (2012): 202.
  80. Murell D. Autoimmune Diseases of the Skin, An Issue of Immunology and Allergy Clinics. Immunol Allergy Clin North America, 2012,32,2
  81. Ocampo V, Óscar Jairo, and Margarita M. Velásquez Lopera. „Inmunopatogenia del pénfigo vulgar y el pénfigo foliáceo.” *Iatreia* 24.3 (2012): Pág-272.
  82. Sungkorn R, Derksen JJ. Simulations of dilute sedimenting suspensions at finite-particle Reynolds numbers. Physics of Fluids. 2012 Dec;24(12):123303.
  83. Vijayakumar, Subash, P. Alekhya, and Dharak RC Sasikala. „Pemphigus vulgaris–A Short Review.” *IJPPR* 3 (2012): 64-72.
  84. Zhao M et al. Aberrant epigenetic modifications in peripheral blood mononuclear cells from patients with pemphigus vulgaris. BJD,2012,523-31
  85. Hasan S, Khan NI, Sherwani OA, Bhatt V, Srivastava H.Pemphigus vulgaris an inside of conventional and emerging treatment modalities. International Research Journal Of Pharmacy.2013 (4),3,8-12
  86. Hertl M, Sitaru C. Pathogenesis, clinical manifestations, and diagnosis of pemphigus. UpToDate. Dostupno na URL adresi: http://www. uptodate. com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus. Datum pristupa informaciji. 2013;10(6).
  87. Khezri, Somayeh, et al. „Anal Involvement in Pemphigus Vularis.” Autoimmune Diseases,Volume 2013 (2013), Article ID 609181, 4 pages
  88. Ruocco, V et al. „Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies.” *Clinics in dermatology* 31.4 (2013): 374-381.
  89. Saraceno, Rosita, et al. „A case of pemphigus foliaceus successfully treated with anti-Ig-Ab immunoadsorption.” Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis 49.1 (2013): 87
  90. Shah, Amit Aakash, and Animesh A. Sinha. „Oxidative stress and autoimmune skin disease.” *European Journal of Dermatology* 23.1 (2013): 5-13.
  91. Shah AA, Sirois D, Werth V, Zrnchik W, Seiffert-Sinha K, Sinha AA. Development of a disease registry for autoimmune bullous diseases: Initial analysis for the pemphigus vulgaris subset. Journal Of Investigative Dermatology 2013 May 1 (Vol. 133, pp. S89-S89).
  92. Suliman, Nada M. „Oral Mucosal Lesions and Oral Health-Related Quality of Life in Persons Attending a Dermatology Clinic in Khartoum, Sudan.” (2013).
  93. Suliman, Nada M., et al. „Clinical and histological characterization of oral pemphigus lesions in patients with skin diseases: a cross sectional study from Sudan.” *BMC oral health* 13.1 (2013): 66.
  94. Mozafari, Nikoo, Reza M. Robati, and Shima Younespour. „Serum Leptin Levels in Pemphigus: A Case Control Study.” *BioMed Research International* 2014 (2014).
  95. Saha, M., et al. „Prognostic factors in pemphigus vulgaris and pemphigus foliaceus.” *British Journal of Dermatology* 170.1 (2014): 116-122.
  96. Shah A.A et al. Development of a Disease Registry for Autoimmune Bullous Diseases: Initial Analysis of the Pemphigus Vulgaris Subset. Acta Accepted Mar 20, 2014Acta Derm Venereol; Epub ahead of print Apr 2,2014
  97. Vassileva, Snejina, Kossara Drenovska, and Karen Manuelyan. „Autoimmune blistering dermatoses as systemic diseases.” *Clinics in dermatology* 32.3 (2014): 364-375.
  98. Alpsoy, Erkan, Ayse Akman-Karakas, and Soner Uzun. „Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid.” *Archives of dermatological research* (2015): 1-8.
  99. Baican A, Chiorean R, Leucuta DC, Baican C, Danescu S, Ciuce D, Sitaru C. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study. Orphanet journal of rare diseases. 2015 Dec;10(1):48.
  100. Chernyavsky A, Chen Y, Wang PH, Grando SA. Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis. International immunopharmacology. 2015 Nov 1;29(1):76-80.
  101. Kim, Jaehwan, Michael Hertl, Neil J. Korman, and Dédée F. Murrell. "Pemphigus vulgaris." In *Blistering diseases*, pp. 283-288. Springer, Berlin, Heidelberg, 2015.
  102. Najafi S, Esmaili N, Heidari M, Ghassemi F, Mahmoudi M, Mohammadzadeh M, Mohamadnia A, Bahrami N. Association between the serotonin-transporter-linked polymorphic region (5-HTTLPR) and pemphigous disease in Iranian patients. Journal of Craniomaxillofacial Research. 2015 Jun 15;3(2):185-90.
  103. Najafi S, Mohammadzadeh M, Gholizadeh N, Esmaeili N, Ghasemi F. SERUM ANTIOXIDANT LEVEL IN PEMPHIGUS VULGARIS PATIENTS. The Journal of Urmia University of Medical Sciences. 2015;26(2):148-55.
  104. Sharma, Lata, and V. Deepak. "A Clinicoepidemiological Study of Pemphigus in India." (2015).
  105. Shah AA, Seiffert-Sinha K, Sirois D, Werth VP, Rengarajan B, Zrnchik W, Attwood K, Sinha AA. Development of a disease registry for autoimmune bullous diseases: initial analysis of the pemphigus vulgaris subset. Acta dermato-venereologica. 2015 Jan 15;95(1):86-90.
  106. Sugita, K., et al. "Effect of electrostatic interactions on the velocity fluctuations of settling microspheres." *Physics of Fluids (1994-present)* 27.1 (2015): 013304.
  107. ZrnchiK, Kristopher AttWooD, and Animesh A. SinhA. "Development of a Disease Registry for Autoimmune Bullous Diseases: Initial Analysis of the Pemphigus Vulgaris Subset." *Acta Derm Venereol* 95 (2015): 86-90.
  108. Abhinay S, Mazumder R, Seal A, Sen A. Tape casting and electrical characterization of 0.5 Ba (Zr 0.2 Ti 0.8) O 3–0.5 (Ba 0.7 Ca 0.3) TiO 3 (BZT–0.5 BCT) piezoelectric substrate. Journal of the European Ceramic Society. 2016 Oct 31;36(13):3125-3
  109. Atarzadeh F, Daneshfard B, Dastgheib L, Jaladat AM, Amin G. Early Description of Diet-Induced Blistering Skin Diseases in Medieval Persia: Avicenna's Point of View. Skinmed. 2016;14(5):367-70.
  110. Jaladat AM. Early Description of Diet-Induced Blistering Skin Diseases in Medieval Persia: Avicenna’s Point of View. Proven efficacy has another profile with Finacea® Foam. 2016;14:367-70.
  111. Oh DD, Zhao CY, Murrell DF. A review of case–control studies on the risk factors for the development of autoimmune blistering diseases. Journal of the European Academy of Dermatology and Venereology. 2016 Apr 1;30(4):595-603.
  112. Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, Cantarini L, Bogdanos DP, Antonelli A. Smoke and autoimmunity: the fire behind the disease. Autoimmunity reviews. 2016 Apr 30;15(4):354-74.
  113. Scully C. Dermatoses of the oral cavity and lips. Rook's Textbook of Dermatology. 2016.
  114. Straub RH, Schradin C. Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs. Evolution, medicine, and public health. 2016 Jan 1;2016(1):37-51.
  115. Živanović DP. *Polimorfizam HLA-DR i HLA-DQ alela kod pacijenata sa pemfigus vulgarisom* (Doctoral dissertation, Univerzitet u Beogradu-Medicinski fakultet).2016
  116. Akarsu S, Özbağçivan Ö, Dolaş N, Aktan Ş. Possible triggering factors and comorbidities in newly diagnosed autoimmune bullous diseases. Turkish Journal Of Medical Sciences. 2017 Jun 12;47(3):832-40.
  117. Bai YD, Sankarapandian S, Aditi R. A Wide Spread Red Lesion on the Surface of the Tongue-A Case Report and Review of Differential Diagnosis. Journal of clinical and diagnostic research: JCDR. 2017 Jun;11(6):ZD07.
  118. Celere BS, Vernal S, La Serra L, Brochado MJ, Moschini LE, Roselino AM, Segura-Muñoz SI. Spatial Distribution of Pemphigus Occurrence over Five Decades in Southeastern Brazil. The American journal of tropical medicine and hygiene. 2017 Dec 6;97(6):1737-45.
  119. Gue S, Huang G, Moore L, Hammond P, Boros CA. Pemphigus Vulgaris and Eosinophilic Esophagitis in a 13‐Year‐Old Boy: Case Report and Review of the Literature. Pediatric Dermatology. 2017 Mar 1;34(2).
  120. Habte MA, Wu C. Influence of wall motion on particle sedimentation using hybrid LB-IBM scheme. Science China Physics, Mechanics & Astronomy. 2017 Mar 1;60(3):034711.
  121. Norisuye T. Structures and dynamics of microparticles in suspension studied using ultrasound scattering techniques. Polymer International. 2017 Feb 1;66(2):175-86.
  122. Patel F, Wilken R, Patel FB, Sultani H, Bustos I, Duong C, Zone JJ, Raychaudhuri SP, Maverakis E. Pathophysiology of autoimmune bullous diseases: Nature versus nurture. Indian Journal of Dermatology. 2017 May;62(3):262.
  123. Pietkiewicz P, Gornowicz-Porowska J, Bartkiewicz P, Bowszyc-Dmochowska M, Dmochowski M. Reviewing putative industrial triggering in pemphigus: cluster of pemphigus in the area near the wastewater treatment plant. Postepy Dermatologii i Alergologii. 2017 May 1;34(3):185.
  124. Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Archives of dermatological research. 2017 Nov 6:1-2.
  125. Thongprasom K, Yanyongkasemsuk W. Recurrent Oral Ulceration Unexpectedly Diagnosed as Pemphigus. Journal of Autoimmune Disorders. 2017 May 29;3(2).
  126. 則末智久, 杉田一樹, 中西英行, 宮田貴章. 超音波散乱法による微粒子分散系の新しいナノ・ミクロン構造解析. 高分子論文集. 2017 Jul 25;74(4):319-33.
  127. Kridin K, Comaneshter D, Batat E, Cohen AD. COPD and lung cancer in patients with pemphigus-a population based study. Respiratory medicine. 2018 Mar 1;136:93-7.
  128. Kridin K, Comaneshter D, Batat E, Cohen AD. Pemphigus and smoking‐insights from a big data analysis. Journal of the European Academy of Dermatology and Venereology. 2018 Apr 28.
  129. Lai O, Recke A, Zillikens D, Kasperkiewicz M. Influence of cigarette smoking on pemphigus–a systematic review and pooled analysis of the literature. Journal of the European Academy of Dermatology and Venereology. 2018 Feb 25.
  130. Li S, Zhang Q, Wang P, Li J, Ni J, Wu J, Liang Y, Leng RX, Pan HF, Ye DQ. Association between HLA-DQB1 polymorphisms and pemphigus vulgaris: A meta-analysis. Immunological investigations. 2018 Jan 2;47(1):101-12.
  131. Serwin AB, Koper M, Flisiak I. Incidence of pemphigus vulgaris and pemphigus foliaceus in North‐East Poland (Podlaskie Province)–a 15‐year (2001–2015) bicentric retrospective study. International Journal of Dermatology. 2018.

В монографии

* 1. Owen JH.. Smoking and Health: New Research. Nova science publisher, 2005
  2. Weedon D. Weedon’s Skin Pathology : Expert Consult – Online and Print,2009
  3. Venugopal S et al. Diagnosis and Prevention of Bullous Diseases. In Preventive Dermatology ed. By Norman R, Springer Verlag , 2010, Part 2, 115-135
  4. Beigi PK, Maverakis E. Epidemiology and Etiology. InAcrodermatitis Enteropathica 2015 (pp. 7-28). Springer, Cham.
  5. Schmidt E, Borradori L, Sprecher E, Marinovic B, Sinha AA, Joly P. Genetic and Environmental Risk Factors of Autoimmune Bullous Diseases. InBlistering Diseases 2015 (pp. 131-139). Springer Berlin Heidelberg.
  6. de la Feld, Salma Faghri, and Naveed Sami. "Local Treatments and Supportive Care." In *Autoimmune Bullous Diseases*, pp. 243-262. Springer, Cham, 2016.

**Казанджиева Ж., Цанков Н. Светът на татуировките. С. Ун. Изд. “Св. Климент Охридски”, 2001.**

Цитати - 1

1. López, B. A., & Santacana, R. G. Complicaciones dermatológicas de los tatuajes y los piercings. *Monogr Dermatol 2010; 23: 55-66*

[**Stoitchkov K**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Stoitchkov%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Letellier S**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Letellier%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Garnier JP**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Garnier%20JP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Bousquet B**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bousquet%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**TSANKOV N.**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tsankov%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Morel P**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morel%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Ghanem G**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ghanem%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Le Bricon T**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Le%20Bricon%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**.Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B. Melanoma Res.2002,12,1-8**

**Цитати – 18**

## [Carlson JA](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Carlson%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Slominski A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Slominski%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Linette GP](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Linette%20GP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Mihm MC Jr](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mihm%20MC%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Ross JS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ross%20JS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Biomarkers in melanoma: staging, prognosis and detection of early metastases. Expert Rev Mol Diagn. 2003;3(3):303-30

## [Carlson JA](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Carlson%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Ross JS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ross%20JS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Slominski A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Slominski%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Linette G](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Linette%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Mysliborski J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mysliborski%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Hill J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hill%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Mihm M Jr](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mihm%20M%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Molecular diagnostics in melanoma. J Am Acad Dermatol. 2005 ;52(5):743-75;

## KAN Yao-dong – 诊断学理论与实践, 2005

## [Linette GP](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Linette%20GP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Carlson JA](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Carlson%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Slominski A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Slominski%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Mihm MC](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mihm%20MC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Ross JS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ross%20JS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Biomarkers in melanoma: stage III and IV disease. Expert Rev Mol Diagn. 2005 ;5(1):65-74

## [Markowitz J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Markowitz%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Design of Inhibitors for S100B. Curr Top Med Chem. 2005;5(12):1093-108.

## Templier I et al. Mutation du gène CDKN2A et perte d’activité de la protéine p16 chez un malade traité par L-Dopa et atteint de mélanomes sporadiques multiples. CDKN2A gene mutation and loss of p16 protein activity in a patient on levodopa presenting sporadic multiple primary melanoma. Annales de Dermatologie et de Vénéréologie ,2006, Volume 133, Issue 10, , Pages 777–780

## [Wilder PT](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wilder%20PT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Lin J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lin%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Bair CL](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bair%20CL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Charpentier TH](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Charpentier%20TH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Yang D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yang%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Liriano M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Liriano%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Varney KM](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Varney%20KM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Lee A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lee%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Oppenheim AB](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Oppenheim%20AB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Adhya S](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Adhya%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Carrier F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Carrier%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Weber DJ](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Weber%20DJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim Biophys Acta. 2006 ;1763(11):1284-97.

## Garnier J., Letellier S., Cassinat B., Lebbé C., Kerob D., Baccard M., Morel P., Basset-Seguin N., Dubertret L., Bousquet B.. Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.  European Journal of Cancer, 2007,43, 4, 816-821

## [Faries MB](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Faries%20MB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Gupta RK](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gupta%20RK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Ye X](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ye%20X%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Lee C](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lee%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Yee R](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yee%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Leopoldo Z](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Leopoldo%20Z%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Essner R](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Essner%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Foshag LJ](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Foshag%20LJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Elashoff D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Elashoff%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Morton DL](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morton%20DL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest. 2007,25(5):285-93.

## [Markowitz J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Markowitz%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [MacKerell AD Jr](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22MacKerell%20AD%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Weber DJ](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Weber%20DJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteinsMini Rev Med Chem. 2007,7(6):609-16

## Faye R et al. SS100B in bone marrow aspirates in healthy individuals and malignant melanoma patients. Melanoma Res. 2008 Apr;18(2):134-40.

### Hohn A. Vergleich der Tumormarker S-100B und MIA bei Patienten mit Malignem Melanom in der Tumornachsorge in Abhängigkeit von der Tumorlast. 2010 – Universitätsbibliothek der TU

## Rappu P et al. Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay. Int J Cancer. 2011 May 15;128(10):2382-92

## Mori Takeshi and Jeong-Hun Kang. Biomarkers for Melanoma Diagnosis and the Technologies Used to Identify Them. Breakthroughs in Melanoma Research,399-410

## Gerger, A., S. Koller, and T. Kern. „1.3. Frage I. 6., I. 7., I. 8., VII. 6. Ausbreitungsdiagnostik bei Patienten mit malignem Melanom–De-novo-Recherche.” *Ergänzung zum Leitlinienreport* 15 (2013): 237-241.

## Revin, S. Brillians, and S. Abraham John. „Electrochemical marker for metastatic malignant melanoma based on the determination of l-dopa/l-tyrosine ratio.” *Sensors and Actuators B: Chemical* 188 (2013): 1026-1032.

1. Song, Yu-qiao, et al. „A novel approach to determine the tyrosine concentration in human plasma by DART-MS/MS.” *Analytical Methods* (2015).
2. Dakubo GD. Melanoma Biomarkers in Circulation. InCancer Biomarkers in Body Fluids 2017 (pp. 1-39). Springer, Cham.

**КAZANDJIEVA J, Popov J, Dencheva R, Kiriakova N, Tsankov N. Thalassotherapy of psoriasis patients in Bulgaria. XX World Congr Dermatol, Paris, 2002, Ann Dermatol Venerol, 2002, 129, 1S759, P1985.**

**Цитирания – 1**

1. Alina M. Viqueira Fuentefría Actualización terapéutica en Psoriasis. Tratamiento tópico, tópico con radiación y sistémico. Primera parte.Dra.

**Popov J, Kirjakova N, Dencheva R, Кazandjieva J FA, Tsankov N. Somepsychosomatic aspects of patients with psoriasis vulgaris treated at the Bulgarianseaside. CEEDVA, Bull. 2002;4:29-31.**

**Цитирания – 2**

1. Zhelezova G, Yocheva L, Tserovska L, Mateev G, Vassileva S. Prevalence Of Helicobacter Pylori Seropositivity In Patients With Psoriasis. Problems of infections and parasitic diseases, 2010;60(576):13.
2. Golušin Z, Jovanović M, Jeremić B, Jolić S. Balneotherapy of psoriasis. Serbian Journal of Dermatology and Venereology. 2014 Sep 1;6(3):105-12.

**TSANKOV N, Broshtilova V, Кazandjieva J. Tetracyclines in dermatology. Clin Dermatol, 2003, 21, 1, 33-39.**

**Цитирания - 26**

1. Michalova E, Novotna P, Schlegelova J. Tetracyclines in veterinary medicine and bacterial resistance to them. Veterinarni Medicina 2004; 49 (3): 79-100.
2. Ruz N, Zabala M, Kramer MG, Campanero MA, Dios-Viéitez MC, Blanco-Príeto MJ. Rapid and simple determination of doxycycline in serum by high-performance liquid chromatography: Application to particulate drug delivery systems. Journal of Chromatography, 2004; 1031 (1-2): 295-301.
3. Tüzün Y, Dolar N . Güncel Akne Tedavisi. Sistemik Tedavi. Dermatose 2004; 3(4): 220-229
4. Sánchez-Saldaña L, Sáenz-Anduaga E, Pancorbo-Mendoza J, Lanchipa-Yokota P, Zegarra-Del-Carpio R.Antibióticos sistémicos en dermatología. Segunda parte: Tetraciclinas, lincosaminas, fluoroquinolonas, sulfonamidas, rifamicinas, cloranfenicoles, ácido fusídico, metronidazol y nuevos antibióticos. Systemic antibiotics in dermatology. Part 2: Tetracyclines, lincomycines, flluoroquinolones, sulfonamides, rifamycins, chloramphenicols, fusidic acid, metronidazole and news antibiotics. Dermatol. Peru.  v.14 n.3 Lima sep. /dic. 2004,161-164.
5. Weinberg JM. The anti-inflammatory effects of tetracyclinesCutis 2005; 75 (4 SUPPL.):6-11.
6. Anderson RB, Dupree M. A Case Study of ANA Negative Minocycline-inducedLupus. Journal of the American Osteopathic College of Dermatology 2006;l 6 (1): 54-55.
7. Palmeiro B, Morris D, Goldschmidt M, Mauldin E. Cutaneous reactive histiocytosis in dogs: a retrospective evaluation of 32 cases. Veterinary Dermatology 2007; 18 (5): 332–340.
8. Bender A, Zapolanski T, Watkins S, Khosraviani A. Tetracycline suppresses ATPÎ³S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Experimental Dermatology, 2008. [Volume 17 Issue 9](http://www3.interscience.wiley.com/journal/121371475/issue)**, Pages 752 - 760**
9. Simonart T., Dramaix M., De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. British Journal of Dermatology 2008,58, 2, 208-216(9)
10. Schuttelaar MLA, Coenraads PJ. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. [Journal of the European Academy of Dermatology and Venereology](http://www3.interscience.wiley.com/journal/118534789/home), 2008, [Volume 22 Issue 9](http://www3.interscience.wiley.com/journal/121381034/issue)**, Pages 1076 – 1082**
11. Bakar Ö, Demircay Z, E Toker, S Çakır Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving … Journal of the European Academy of Dermatology &Venereology, 2009
12. de Castro AU, Neto NMA, Viana JA. Uso tópico do mel de abelha, oxitetraciclina e hidrocortisona, na reparação de feridas. Crevista ceres.56,038-044,2009
13. **Ghosh VK, Naghore DH, Kadbhane KP, Patil MJ.** Different approaches of alternative medicines in acne vulgaris treatment. **Oriental Pharmacology and Experimental Medicine, 2011, 11,1**, 1-9,
14. Oudrhiri, Lamia, et al. "Successful treatment of Miescher’s cheilitis in Melkersson-Rosenthal syndrome with betamethasone injections and doxycycline." *Pan African Medical Journal* 13.75 (2012).
15. Sache-de Peufeilhoux L L, E Raynaud, A Bouchardeau, S Fraitag, C Bodemer. Familial benign chronic pemphigus and doxycycline: a review of 6 cases. JEADV, 10/2012;
16. Kayhan, Serap, et al. "Akne Vulgaris Tedavisinde Oral Azitromisin ile Topikal Adapalen ve Oral Doksisiklin ile Topikal Adapalen Etkinliğinin ve Güvenirliğinin Karşılaştırılması ve bu Tedavilerin Yaşam Kalitesi Üzerine Etkilerinin Ölçülmesi." Turkderm,2012,46,151-5
17. Navarrete-Dechent, Cristián P., Loreto Farias, and Mauricio Sandoval. "Foto-onicólisis y foto-ónico pigmentación inducida por doxiciclina." *Piel* (2013).
18. Eichenfield, Lawrence F., et al. "Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne." *Pediatrics* 131.Supplement 3 (2013): S163-S186.
19. 郝飞, 宋志强, and 钟华. "激素依赖性皮炎: 如何界定?." *中华皮肤科杂志* 46.007 (2013): 528-529.
20. de Castro, Alene Uchoa, Napoleão Martins Argôlo Neto, and José Antônio Viana. "Uso tópico do mel de abelha, oxitetraciclina e hidrocortisona, na reparação de feridas cutâneas, por segunda intenção, em coelhos." *Ceres* 56, no. 1 (2015).
21. Carter-Wale RL, Prior TD. Case Study: An intraoperative finding of black bone disease in a podiatric surgery patient. The Foot. 2016 Dec 31;29:6-10.

В монографии:

1. Comprehensive dermatologic drug therapy. Second edition. S. Wolverton, Saunders, Elsevier, 2007
2. Riviere J, Papich M. Tetracycline Antibiotics. In:Veterinary Pharmacology & Therapeutics. 9 Ed. Wiley Blackwell,2009, p. 913
3. Kligman, Albert M. "The Role of Adenosine Triphosphate in the Pathogenesis of Rosacea: An Explanation for the Mode of Action of Tetracyclines for the Treatment of Rosacea." *Pathogenesis and Treatment of Acne and Rosacea*. Springer Berlin Heidelberg, 2014. 641-643.
4. Lam, C., & Zaenglein, A. L. (2015). Pediatric and Adolescent Acne. In *Pediatric Skin of Color* (pp. 341-362). Springer New York.

В български списания:

1. Кадурина М, Бочева Ж. Роля на тетрациклините в лечението на розацея. Дерматология и венерология, 2011, XLIX бр. 2, 17-21

**TSANKOV N, Angelova I. Rifampin in dermatology. Clin Dermatol. 2003;21:50-55.**

**(Reprinted with permission in Disease-a-month, 2014)**

**Цитати – 27**

1. **Calleja I, Blanco-Príeto MJ, Ruz N, Renedo MJ, Dios-Viéitez MC.** High-performance liquid–chromatographic determination of rifampicin in plasma and tissues Journal of Chromatography, 2004, 1031,1-2, 289-294
2. Nollens, Hendrik Hans. "Poxvirus infections in north american pinnipeds." PhD diss., University Of Florida, 2005.
3. Forget EJ ?code=200B‌, Menzies D. Adverse reactions to first-line antituberculosis drugs. Summary. [Expert Opinion on Drug Safety](http://www.expertopin.com/loi/eds). 2006, 5, 2, 231-249
4. **Du L, Neis M, Ladd P, Keeney D.** Differentiation-Specific Factors Modulate Epidermal *CYP1–4* Gene Expression in Human Skin in Response to Retinoic Acid and Classic Aryl Hydrocarbon Receptor Ligands. **Journal of Pharmacology And Experimental Therapeutics *Fast Forward* ,** First published on September 19, 2006;
5. Koca R, Tekin NS, Yenidunya S, Conar S, Altonyazar HC. The efficiency of rifampicin and clindamycin treatment in a case of tufted folliculitis. Turkderm 2006;40(1):30-32
6. Deep AT. Drug Interactions in Dermatology. US Pharm. 2007;4:17.
7. Rochester C. Drug Interactions in Dermatology. Are They Just Skin Deep? US Pharmacist e-connect, Vol. No: 32:4 Posted: 4/17/2007
8. Nolens HH et al. In vitro susceptibility of sea lion poxvirus to cidofovir. Antiviral Res. 2008 Oct;80(1):77-80.
9. Weng Chyn Chan MB ChB. Rifampicin. DermNet NZ, 2004, last updated,09.Jan.2008
10. Gener G et al, Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148-54.
11. Kim SK et al. Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells. Korean J Physiol Pharmacol. 2009 Dec;13(6):475-82
12. Marcus DV et al. Granuloma annulare treated with rifampin, ofloxacin, and minocycline combination therapy. Arch Dermatol. 2009 Jul;145(7):787-9.
13. van der Zee HH et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219(2):143-7.
14. Цискаришвили НВ, Цискаришвили НИ. Противотуберкулезные препараты в лечение псориаза. Gerogian Medical News, 2009,9,25-28
15. Dubrac S. Et al. Modulation of T lymphocyte function by the pregnane X receptor. J Immunol. 2010 Mar 15;184(6):2949-57.
16. Bi, Wei, et al. „Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation.” *Brain research* 1395 (2011): 12-20.
17. Belhabib, Zineb. "Maladie de VERNEUIL à propos de 107 cas." PhD diss., 2012.
18. Bi, Wei, et al. „Inhibition of 26S protease regulatory subunit 7 (MSS1) suppresses neuroinflammation.” *PloS one* 7.5 (2012): e36142.
19. García CP, Riveiro RP. Systemic Antimicrobials: Antibiotics, Antifungals, Antivirals, Antiparasitics. Dermatological Treatments. 2012 Sep 7:210.
20. Dupnik, Kathryn Margaret, et al. „Intolerance to leprosy multi-drug therapy: more common in women?.” *Leprosy review* 84.3 (2013): 209-218.
21. Samehab, Trabelsi, et al. „High-Performance Liquid Chromatographic Quantification of Rifampicin in Human Plasma: Method for Therapeutic Drug Monitoring.” *Series B: Biological Sciences*.Pac J sci ind res, 2013, 56(1)29-35
22. Lacerda, Loreana, et al. „Development and evaluation of pH-sensitive sodium alginate/chitosan microparticles containing the antituberculosis drug rifampicin.” *Materials Science and Engineering: C* 39 (2014): 161-167.
23. Deckers IE, Prens EP. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016 Feb 1;76(2):215-29.
24. Jameel AA, Zhou BR, Luo D. Drug Therapy for Hidradenitis suppurativa: An Update. Science Letters. 2016;4(2):108-17.
25. Kim SH, Lee KM, Lee GS, Seong JW, Kang TJ. Rifampicin Alleviates Atopic Dermatitis-Like Response in vivo and in vitro. Biomolecules & therapeutics. 2017 Nov;25(6):634.

**В монографии**:

1. Oprica C, Nord C. Chapter 11. Bacteriology of Hidradenitis suppurativa. In Hidradenitis suppurativa Gregor B. E. Jemec, Jean Revuz and James J. Leyden, Springer Berlin Heidelberg,2006, p.92
2. Oprica, Cristina, and Carl Erik Nord. „Bactériologie de l’hidradénite suppurée.” *Hidradénite suppurée*. Springer Paris, 2008. 94-103.

**Broshtilova V, Antonov D, Bardarov E, TSANKOV N. Severeerythrodermic atopic dermatitistreated with montelukast *Skinmed* 2003; 2: 134-6.**

**Цитати – 6**

1. Ejaz A, Raza N. Management of atopic dermatitis – A review.Journal of Pakistan Association of Dermatologists2004; **14**: 140-7.
2. **Riccioni G, Di Ilio C, Conti P, Theoharides TC, D’Orazio N.** Advances in Therapy with Antileukotriene Drugs. Annals of Clinical & Laboratory Science.2004,34:379-387
3. Capella, Giovanni Luigi. „BACK TO THE FUTURE: MODULATION OF LEUKOTRIENE-MEDIATED SKIN INFLAMMATION THROUGH THE ADMINISTRATION OF ANTI-HlSTAMINE DRUGS.” *Prostaglandins: New Research* (2006): 1.
4. Riccioni G et al. Antileukotriene Drugs: Clinical Application, Effectiveness and Safety. Curr Med Chem. 2007;14(18):1966-77.
5. Ehlayel MS., Bener A. Does Montelukast Reduce the Treatment Cost in Children with Moderately Severe Atopic Dermatitis. Curr Pediatr Res 2008; 12 (1 & 2): 1-4
6. Broshtilova, Valentina, and Mary Gantcheva. „Therapeutic hotline: cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis.” *Dermatologic therapy* 23.1 (2010): 90-93.

[**Ortonne JP**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Ortonne%20JP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Humbert P**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Humbert%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Nicolas JF**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Nicolas%20JF%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**TSANKOV N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Tsankov%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Tonev SD**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Tonev%20SD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Janin A**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Janin%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Czernielewski J**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Czernielewski%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Lahfa M**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Lahfa%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Dubertret L**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=Search&Term=%22Dubertret%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**.Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.** [**Br J Dermatol.**](javascript:AL_get(this,%20'jour',%20'Br%20J%20Dermatol.');) **2003 Feb;148(2):326-33.**

**Цитати – 76**

1. van de Kerkhof P.C.M., Vissers W.H.P.M.The Topical Treatment of Psoriasis. Skin Pharmacology and Applied Skin Physiology 2003;16:69-83
2. Orpinell X. Traramiento ravel de la psoriasis. Revision de publicaciones recientes.Piel, 2003,18 ,9,509-14
3. Clark C. Psoriasis: first-line treatments. The Pharmaceutical Journal, 2004,l274,21
4. Ruzicka, T., Trompke, C. Behandlung der Kopfhaut-Psoriasis: Gute Wirksamkeit und Sicherheit durch Tacalcitol-Emulsion. Der Hautarzt, 2004 ,55,  2, 165-170(6)
5. Trompke, C. „Behandlung der Kopfhaut-Psoriasis.” *Der Hautarzt* 55.2 (2004): 165-170.
6. Allwood MC et al. Formulations used in nutrition. Side Effects of Drugs Annual, 2005, 28, 383–390
7. Carboni I, C de Felice, A Bergamin, S Chimenti. Topical use of calcitriol 3 µg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study. Journal of the European Academy of Dermatology and Venereology.2005, 19 (s3), 11–13.
8. Finnish Medical Society Duodecim. Psoriasis. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2005 May 25
9. Kroft EBM, Erceg A, Maimets K, Vissers W, van der Valk PGM, van de Kerkhof PCM.Tacrolimus ointment for the treatment of severe facial plaque psoriasis Journal of the European Academy of Dermatology and Venereology ,2005, 19 (2), 249–251.
10. Marty P, Lafforgue C, Grossiord JL, Soto P.Rheological properties of three different vitamin D ointments and their clinical perception by patients with mild to moderate psoriasis. Journal of the European Academy of Dermatology and Venereology,2005, 19 (s3), 7–10.
11. Vissers WHPM, Roelofzen J, De Jong EMGJ, Van Erp PEJ, Van de Kerkhof PCM. Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation. European J Dermatol. 15, 1, 13-7, 2005
12. Wang G, Li Ch, Gao T, Liu Y. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study. Eur J Dermatol 2005; 15 (3): 176-8
13. [van de Kerkhof PC](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22van%20de%20Kerkhof%20PC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Kragballe K](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kragballe%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Recommendations for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2005, 19(4):495-9
14. van de Kerkhof, P. C. M. The topical treatment of psoriasis. Clinical & Experimental Dermatology, 30,2, 2005 , 205-208
15. Henri F et al. Comment je traite … un psoriasis en plaques par l’association calcipotriol-dipropionate de betamethasone. Revue Médicale de Liège, 2006, 61,3,139-41
16. Prugovecki V. Ergebnisqualität einer dermatologischen Fachklinik:Outcome der stationären Versorgung von Patienten mit Psoriasis vulgaris. Doctorthesis, Klinik für Dermatologie und Venerologie der Universität zu Lübeck, Lübeck 2006;

### Thielen AM et al. Übersicht der behandlungen bei chronischer psoriasis vulgaris. Newsletter, 2006,8,1-20

1. 晋红中， 王宝玺， 甘戈， 谢勇， 刘跃华， 何志新 – 中国临床药理学杂志, 2006 – 维普资讯 Chin J Clin PharmacoI 95 Vo1．22 No．2 March 20O6
2. de Groot AC et al. Psoriasis: behandelmogelijkheden in de huisartsenpraktijk. Bijblijven, 2007,23,2,5-11
3. Körver JEM, Vissers WHPM, Van Rens DWA, Pasch MC, Van Erp PEJ, Boezeman JBM., Van De Kerkhof PCM. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation.Br J Dermatol ,2007, 156 (1), 130–137.
4. Liao YH, Chiu HC, Tseng YS, Tsai TF.Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg g-1 ointment and tacrolimus 0·3 mg g-1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial .British Journal of Dermatology.2007, 157 (5), 1005–1012.
5. Menter A et al. Current and future management of psoriasis. The Lancet, 2007, Vol 370, Issue 9583, 272 – 284
6. Nast A., Kopp I., Augustin M., Banditt K. B., Boehncke W. H., Follmann M., Friedrich M., Huber M., Kahl C., Klaus J., Koza J., Kreiselmaier I., Mohr J., Mrowietz U., Ockenfels H. M., Orzechowski H. D., Prinz J., Reich K., Rosenbach T., Rosumeck S.,. Schlaeger M, Schmid-Ott G.,. Sebastian M, Streit V., Weberschock T., Rzany B. German evidence-based guidelines for the treatment of Psoriasis vulgaris. Arch Dermatol Res. 2007; 299(3): 111–138.
7. Oliver, Paula. „Flexural psoriasis: a missed diagnosis?.” *Independent Nurse* (2007)
8. Piérard-Franchimont C, Paquet P, Quatresooz P, Piérard GE. Smoothing the mosaic subclinical melanoderma by calcipotriol. Journal of the European Academy of Dermatology and Venereology.2007, 21 (5), 657–661.
9. Vena GA, Cassano N, Alessandrini G, Fal D, Gabellone M, Ligori P, Malvidi C, Mancino A, Pelle S, Rinaldi F, Sodo MR. Treatment of mild to moderate plaque psoriasis with calcitriol ointment applied with or without a dosing device. European Journal of Inflammation. 2007, 5, 2, 89-95
10. [van de Kerkhof PC](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22van%20de%20Kerkhof%20PC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Murphy GM](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Murphy%20GM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Austad J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Austad%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Ljungberg A](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ljungberg%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Cambazard F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cambazard%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Duvold LB](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Duvold%20LB%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**.** Psoriasis of the face and flexures. J Dermatolog Treat. 2007, 27;:1-10
11. Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, Andres P. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 μg/g ointment vs. Calcipotriol 50 μg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. JEADV, 2007, 21, 4, 466-472
12. Jacobi **A,** Braeutigam M, Mahler V, Schultz E, HertlM. Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study. Dermatology 2008;216:133-136
13. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clinics in Dermatology, 2008, Volume 26, Issue 5, Pages 448-459

### Becker E et al. Calcipotriol ointment. A new option for topical psoriasis therapy. Skin and Allergy news, 2009,1-12

1. Bowes, Mark P. „Calcitriol Ointment: A New O.” (2009).

### Del Rosso J. What’s new in the medicine cabinet? J Clin Aesthetic, 2009,Volume 2• Number 4] Supplement 3-15

### Del Rosso J. What’s new in the medicine chest? Suppl. To Skin and Aging, 2009,4-7

1. Feldmann SR. Treatment of psoriasis. UpToDate, Online, 2009
2. Fraiser K. 67th Annual Meeting of the American Academy of Dermatology: San Francisco, California, American Journal of Clinical Dermatology: 2009,10, 3, 205-210
3. Kovalzick L. Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol. Clin Cosmet Investig Dermatol. 2009; 2: 153–159.

### Koo J. New developments in topical therapy of psoriasis. Suppl. To Skin and Aging, 2009,12-13

1. Lebwohl M. Psoriasis- New developments. Supplement to Skin & Aging, 2009,8-11
2. Patches, Red Pruritic, and Scaly Red Plaques. „What’s New in the Medicine Cabinet?.” *WHAT’S NEW IN THE MEDICINE CABINET?* 8 (2009): 3.
3. Sigmon J et al. Calcitriol ointment : A review of a topical vitamin D analog for psoriasis. J Derm Treatment, 2009, 20, 4 , 208-212
4. Thielen, Anne-Marie, and Emmanuel Laffitte. „Traitements topiques du psoriasis en 2009.” *Dermatologie* 200.16 (2009): 876-881.

### 骨化三醇软膏与卡泊三醇软膏治疗银屑病多中心随机研究

季素珍， 陈喜雪， 王宝玺， 晋红中， 赵广， 王毅霞… - 中华皮肤科杂志, Chinese J Dermatol, 2009

1. Aristízabal, Ana María, et al. „Comparación de calcitriol más PUVA con respecto a la monoterapia con PUVA en pacientes con psoriasis.” *CES Medicina* 23.1 (2010): 87-96.
2. Choi J.W., et al. High-concentration (20 μg g−1) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial. BJD, 2010, 162,6, 1359–1364

### Gold stein L et al. Topical therapies for psoriasis. Suppl. To Skin and Aging, 2010,16-19

1. Hong SP et al. Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids BJD, 2010, 162,6, 1251–1260
2. Kim Grace K. The Rationale Behind Topical Vitamin D Analogs in the Treatment of Psoriasis. Where Does Topical Calcitriol Fit In? J Clin Aesthetic Dermatol, 2010,3,46-53
3. Shah, N. V., et al. „A Review On Etiology, Types And Treatment Of Psoriasis.”Pharmacologyonline, 2010, 159-179
4. Zeichner, Joshua A., Mark G. Lebwohl, Alan Menter, Jerry Bagel, James Q. Del Rosso, Boni E. Elewski, Steven R. Feldman et al. „Optimizing Topical Therapies for Treating Psoriasis.” *Practitioner* 86, no. 3S (2010).
5. Brodell RT, et al. A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis. J Drugs Dermatol. 2011;10(2):158-64.
6. Syed Z et al. Inverse Psoriasis: Case Presentation and Review. Am J Clin Dermatol, 2011 12,  2, , pp. 143-146(4)
7. TrémezayguesL et al. Vitamin D analogs in the treatment of psoriasis. Where are we standing and where will we be going? Dermatoendocrinol. 2011 ; 3(3): 180–186.
8. TrémezayguesL et al. Minireview: Endocrine Vitamin D System in Human Skin. A Research Focus at the Department of Dermatology of the Saarland University Hospital. Akt Dermatol 2011; 37(1/02): 12-18
9. Lebwohl M et al. Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis*.* J Clin Aesthet Dermatol*. 2012;5(2):28–33*
10. Wong, Jillian W., et al. „Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm.” *Skin Therapy Lett* 17.5 (2012): 6.
11. Zsuzsanna B. Psoriasis vulgaris.A protocoll alkamalzaszi*. Doctor th.*
12. Feldman, Steven R., and Daniel J. Pearce. „Treatment of psoriasis.” *UpToDate2013*.
13. Bourée, P., J. Lofandjola Masumbuku, Y. Coppieters, Jean-Philippe Chippaux, W. Yamego, S. Kouanda, A. Berthé et al. „JEPU 2014.” *Bulletin du Cancer* 101, no. 3 (2014).
14. Jabbar-Lopez, Z. K., K. C. P. Wu, and N. J. Reynolds. „Newer agents for psoriasis in adults.” *Bmj* 349 (2014): g4026.
15. Levin, Ethan, et al. „Supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis: Interim results of an open label pilot study.” *Journal of Dermatological Treatment* 0 (2014): 1-3.
16. Микрюков АВ. „Оптимизация методов лечения бълньх псориазом с избьточной массой тела и ожирением.”Канд. Дис. Москва, 2014, Московский государствений, медикостоматологический университет им. А.И.Евдокимова
17. Zweegers, J., et al. „Summary of the Dutch S3-Guidelines on the treatment of psoriasis 2011.” *Dermatology online journal* 20.3 (2014).
18. Levin E, Debbaneh M, Malakouti M, Brown G, Wang E, Gupta R, Butler D, Huynh M, Leon A, Koo JY. Supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis: Interim results of an open label pilot study. Journal of Dermatological Treatment. 2015 Jan 2;26(1):16-8.
19. Omland SH, Gniadecki R. Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?. Clinics in dermatology. 2015 Aug 31;33(4):456-61.
20. Arndt KA, LeBoit PE, Wintroub BU. Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.2016
21. Feldman SR, Pearce DJ, Dellavalle RP, Duffin KC. Treatment of psoriasis. UpToDate. 2016 May.
22. Hawkes JE, Duffin KC. Topical and systemic therapies for moderate-to-severe psoriasis. InPsoriatic Arthritis and Psoriasis 2016 (pp. 253-266). Springer International Publishing.
23. Levin E, Nguyen CM, Danesh MJ, Beroukhim K, Leon A, Koo J. An open label pilot study of supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis. Journal of Dermatological Treatment. 2016 May 3;27(3):210-3.
24. Levy Z, Taliercio M, Nia JK, Kimmel G, Hashim PW. Inverse Psoriasis: A Review of Topical Therapies. Journal of Psoriasis and Psoriatic Arthritis. 2016 Dec;2(1):38-43.
25. Amin M, No DJ, Wu JJ. 45-Year-Old with Red Rash on Face. InClinical Cases in Psoriasis 2017 (pp. 35-40). Springer International Publishing.
26. Sarma N. Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: Palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis. Indian journal of dermatology. 2017 Mar;62(2):113.
27. Kivelevitch D, Frieder J, Watson I, Paek SY, Menter MA. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert opinion on pharmacotherapy. 2018 Apr 13;19(6):561-75.

В монографии

1. Chaudhari PR, Stern DK, Lebwohl MG**.**Topical therapy I. Corticosteroids and Vitamin D analogs: in Milestones in Drug Therapy. Treatment of Psoriasis Ed. By Jeffrey M. Weinberg , Birkhäuser Basel,2007,p.41-55

### Kragball K. Management of difficult to treat locations of psoriasis. In Management of psoriasis, ed. By N Yawalkar , Karger, 2009, p.160

### Ryan C, Haugh I. Inverse Psoriasis and Genital Disease. InPsoriasis, Second Edition 2017 Apr 11 (pp. 85-88). CRC Press.

**Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res (2003) 13:587–593**

**Цитати – 20**

## Ugurel S. Serum markers for melanoma. Hautarzt, 2005,56,2,173-186

## Garnier J., Letellier S., Cassinat B., Lebbé C., Kerob D., Baccard M., Morel P., Basset-Seguin N., Dubertret L., Bousquet B. Clinical value of combined determination of plasma l-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.  European Journal of Cancer, 2007,Volume 43, Issue 4, Pages 816-821

## Le Bricon, Thierry, et al. „Measurement of Plasma L‐DOPA and L‐Tyrosine by High‐Performance Liquid Chromatography as a Tumor Marker in Melanoma.” *Chromatographic Methods in Clinical Chemistry and Toxicology* (2007): 56-66.

## Utikal J, Schadendorf D, Ugurel S. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res. 2007; 298(10): 469–477

## Schadendorf D, Utikal J, Matharoo-Ball B,  Rees RC, Ugurel S. Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches [Current Cancer Therapy Reviews](http://www.ingentaconnect.com/content/ben/cctr;jsessionid=3i9sajee163jh.alice), 2008 , 4, 2, 96-104

## Ugurel S et al. Tumor Biomarkers in Melanoma.Cancer control, 2009,16,3,219-224

## Palmers SR et al. Circulating Serologic and Molecular Biomarkers in Malignant Melanoma. **Mayo Clinic Proceedings, 2011,**86, 10 , 981-990

## Tandler, Nadine, Birgit Mosch, and Jens Pietzsch. „Protein and non-protein biomarkers in melanoma: a critical update.” *Amino acids* 43.6 (2012): 2203-2230.

## Utical J et al. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. [Current Clinical Pathology](http://www.springerlink.com/content/u4wx16/), 2012, 9-18,

## El Hajj, P., et al. „Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.” *British journal of cancer* 108.8 (2013): 1641-1647.

## Gerger, A., S. Koller, and T. Kern. „1.3. Frage I. 6., I. 7., I. 8., VII. 6. Ausbreitungsdiagnostik bei Patienten mit malignem Melanom–De-novo-Recherche.” *Ergänzung zum Leitlinienreport* 15 (2013): 237-241.

## Revin, S. Brillians, and S. Abraham John. „Electrochemical marker for metastatic malignant melanoma based on the determination of l-dopa/l-tyrosine ratio.” *Sensors and Actuators B: Chemical* 188 (2013): 1026-1032.

## Vereecken, Pierre. „Serum Markers in Clinical Management of Malignant Melanoma.”Intech, (2013).

## Vereecken, P. „Présentation et implications cliniques des marqueurs sériques dans le mélanome malin cutané.” *Oncologie* 15.2 (2013): 83-90.

## Petra EL. New prognosis markers and new targets for therapy in high risk melanoma: Evaluation of TYRP1 as a melanoma prognostic marker and its regulation by miRNA (s).

## Song, Yu-qiao, et al. „A novel approach to determine the tyrosine concentration in human plasma by DART-MS/MS.” *Analytical Methods* (2015).

## Mittal PJ, Jain M. Proteomics: An indispensable tool for novel biomarker identification in melanoma. J Data Mining Genomics Proteomics. 2016;7(204):2153-0602.

## Dakubo GD. Melanoma Biomarkers in Circulation. InCancer Biomarkers in Body Fluids 2017 (pp. 1-39). Springer, Cham.

В монографии

## Bertholf RL et al. Chapter 4. Measurement of Plasma L-DOPA and L-Tyrosine by High-Performance Liquid Chromatography as a Tumor Marker in Melanoma In: Chromatographic Methods in Clinical Chemistry and Toxicology,2007

## Utical J et al. Diagnostic and Prognostic Biomarkers in Melanoma. Current stay of play. in Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma, Springer, 2012

**TSANKOV N, Weinberg J. Antimicrobials in dermatology. Clin Dermatol,2003,21,1.**

**Цитати – 2**

1. Vassileva S, Drenovska K, Serafimova D, **Tsankov N**. Paraneoplastic pemphigus – 2 cases associated with chronic lymphocytic leukaemia. CEEDVA, Bull, 2004, 6, 13-16.
2. Dika E, Varott C, Bardazzi F, Maibach HI. Drug-induced psoriasis: An evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and Ocular Toxicology 2006; 25 (1):1-11.

**Bochev V, Angelova I, Tsankov N. Centrofacial actinomycosis – report of two cases. Acta Dermatoven APA, 2003, 12, 105-108.**

**Цитати – 11**

### Guvercin M et al. Cervicofacial actinomycosis: a case report. OHDMBSC, 2005,IV,2

1. EZİRGANLI, Şeref, and Serkan POLAT. „A Management Approach for Periapical Actinomycosis: A Rare Case Report.” *Türkiye Klinikleri Diş Hekimliği Bilimleri Dergisi* 17.3 (2011): 305-309.
2. Vidaković, Bruno, et al. „Actinomycosis of the Cheek.” *Srpski arhiv za celokupno lekarstvo* 142.7-8 (2014): 472-475.

## Kul Bhushan Bali et al. Neck abscess: an unusual presentation of actinomycosis. JPMS,2012, 2, 1

1. Maher, Nigel Gordon, et al. „Actinomycosis Is an Important Diagnosis Consideration in the Presentation of a Perimandibular Mass: A Case Report and Review of Idiopathic Cervicofacial Actinomycosis.” *Infectious Diseases in Clinical Practice* 20.6 (2012): 367-369.
2. Jain, Anshu, et al. „Cervicofacial actinomycosis mimicking sebaceous cyst.” *BMJ case reports* 2013 (2013): bcr2012008429.
3. Moghimi, Meshkan, et al. „Treatment of Cervicofacial Actinomycosis: A report of 19 cases and review of literature.” *Medicina oral, patologia oral y cirugia bucal* 18.4 (2013): e627.
4. Günaştı, Suhan, and Varol L. Aksungur. „Granulomatous disorders.” *Clinics in dermatology* 32.1 (2014): 47-65.
5. Vidaković B, Macan D, Perić B, Manojlović S. Actinomycosis of the Cheek. Srpski arhiv za celokupno lekarstvo. 2014;142(7-8):472-5.
6. Chatterjee RP, Shah N, Kundu S, Mahmud SA, Bhandari S. Cervicofacial actinomycosis mimicking osseous neoplasm: a rare case. Journal of clinical and diagnostic research: JCDR. 2015 Jul;9(7):ZD29.
7. Abbaszadeh H, Sheibani MS. Actinomycotic osteomyelitis of mandible. Journal of Craniofacial Surgery. 2016 Jul 1;27(5):e452-4.

**Tsankov N, Antonov D, Grozdev I. Doxycycline: réponse à J.M. Bonnetblanc (Letter), 2003,130, p.789.**

**Цитати – 1**

1. Aupee, O.; [Almeras, D.](http://www.cabdirect.org:80/search.html?q=au%3A%22Almeras%2C+D.%22); [Garlantezec, P. Le](http://www.cabdirect.org:80/search.html?q=au%3A%22Garlantezec%2C+P.+le%22); [Bohand, X](http://www.cabdirect.org:80/search.html?q=au%3A%22Bohand%2C+X.%22). La doxycycline. J

Médecine Tropicale 2009 Vol. 69 No. 6 pp. 556-558

**Iliev E, Tsankov N, Broshtilova V. Short communication: omega-3, -6 atty acids in the improvement of psoriatic symptoms. Seminars in integrative medicine. 2003, 1,4, 211-214**

**Цитати – 1**

1. Sulindro-Ma, Maria, Charise L. Ivy, and Amber C. Isenhart. „Nutrition and supplements for pain management.” *Integrative pain medicine*. Humana Press, 2008. 417-445.

[**Naidenov N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Naidenov%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Dencheva R**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Dencheva%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**,** [**Tsankov N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tsankov%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**. Recurrence rate of basal cell carcinoma after topical aminolevulinic acid-based photodynamic therapy.**[**Acta Dermatovenerol Croat.**](javascript:AL_get(this,%20'jour',%20'Acta%20Dermatovenerol%20Croat.');) **2003;12(3):157-61.**

**Цитати – 10**

## Cohen Ph, Schulze K**, Cutaneous Carcinoma with Mixed Histology: A Potential Etiology for Skin Cancer Recurrence and an Indication for Mohs Microscopically Controlled Surgical Excision.** Southern Medical Journal, 2005. 98(7):740-747

## Cohen Ph, Schulze K, Nelson B. Basal Cell Carcinoma with Mixed Histology: A Possible Pathogenesis for Recurrent Skin Cancer. Dermatologic Surgery. 2006, 32 (4), 542–551 .

## Bøgelund, Fie Saabye, Peter Ashlede Philipsen, and Robert Gniadecki. „MATERIALS AND METHODS Patients and data capture.” *Acta Derm Venereol* 87 (2007): 330-334.

1. Saabye BF, Philipsen PA, Gniadecki R.Factors Affecting the Recurrence Rate of Basal Cell Carcinoma. Acta Dermato-Venereologica,2007, 87,4,330-334
2. Chew R .Destruction of the orbit and globe by recurrence of basal cell carcinoma.  Optometry – Journal of the American Optometric Association,2008 ,78 ,7 , 344 – 351
3. Zemelman, Viviana, et al. „Heterogeneidad histológica intratumoral del carcinoma basocelular.” *Rev. Chil. Dermatol* 24.1 (2008): 23-27.
4. Devidas, M. „An Evidence Scoping Review of Photodynamic Therapy (PDT) in the Treatment of Cancers.” *J Anal Bioanal Techniques S* 1 (2011): 2.
5. Roozeboom MH, et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and non-randomized trials.BJD, 2012
6. Menon, Devidas, Tania Stainski. „An Evidence Scoping Review of Photodynamic Therapy (PDT) in the Treatment of Cancers.” *Journal of Analytical & Bioanalytical Techniques* 3 (2012).
7. Bahner, Jennifer D., and Jeremy S. Bordeaux. „Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.” *Clinics in dermatology* 31.6 (2013): 792-798.

**Vassileva S, Drenovska K, Serafimova D, Tsankov N**. **Paraneoplastic pemphigus – 2 cases associated with chronic lymphocytic leukaemia. CEEDVA, Bull, 2004, 6, 13-16.**

**В монографии**

**Цитати – 1**

### Pramatarov K. Skin Signs of Systemic Neoplastic Diseases and Paraneoplastic Cutaneous Syndromes. In Emergency Dermatology, ed. By R. Wolf, Cambridge University Press, 2011. Chapter 26, 265-274

**Drug induced Lupus erythematosus. Antonov D, Кazandjieva J,** **Etugov D, Gospodinov D, TSANKOV N. Clin in Dermatol,2004,22(2),157-66**

**Цитирания -118**

1. Wiley J. **Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and drug safety 2004; 14( 1): p(i-vi)**
2. Chantaravekin Y. Drug induced lupus erythematosus*.* Oral Diseases Group of Thailand October, 2004
3. Lapenta RJ. The Terbinafine antifungal secret X files. Data-Medicos Dermagic/Express No. 6-(X-10) 30 julio 2004 /30 July 2004
4. Abedi-Valugerdi, M, Nilsson C, Zargari A, Gharibdoost F, Depierre JW, Hassan M.Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice. Clinical and Experimental Immunology 2005; 141 (2):238-247.
5. Cetkovská P. Drug-induced autoimmune skin diseases | [Kožní autoimunitní nemoci indukované léčbou] Cesko-Slovenska Dermatologie 2005; 80 (6): 322-325.
6. John Wiley & Sons, Ltd. Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2005;**14(1)**
7. Jury EC, Ehrenstein MR. Statins: Immunomodulators for autoimmune rheumatic disease?  Lupus 2005 ; 14 (3) :192-196.
8. Kamen DL, Gilkeson GS.Medical management of systemic lupus erythematosus  Journal of Clinical Outcomes Management 2005; 12 (7):367-374.
9. Montoroa J, Freixenet N, Lozano A, Bertomeu F. An unusual adverse drug reaction?  Allergologia et Immunopathologia 2005; 33 (4):235-237.
10. 任韵清　杨森　张学军. 米诺环素应用新进展. Chinese journal of dermatology 2005; 38(12):777-779.
11. Amerio P, Innocente C, Feliciani C, Angelucci D, Gambi D, Tulli A. Drug-induced cutaneous lupus erythematosus after 5 years of treatment with carbamazepine  European Journal of Dermatology 2006;16 (3):281-283.
12. Birnbaum B, Sidhu GS, Smith RL, Pillinger MH, Tagoe CE. Fulminating hydralazine-induced lupus pneumonitis. Arthritis Care and Research 2006; 55 (3):501-506.
13. Egger SS, Studer IG, Rätz Bravo AE, Krähenbühl S. Minocycline-induced lupus erythematodes | [Minocyclin-induzierter lupus erythematodes] Schweizerische Rundschau fur Medizin - Praxis 2006; 95 (35):1297-1303
14. Finks SW, Finks AL, Self TH. Hydralazine-induced lupus: Maintaining vigilance with increased use in patients with heart failure. Southern Medical Journal 2006; 99 (1):18-22.
15. Kang M-J, Lee Y-H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.  Journal of Korean Medical Science 2006;21 (5):946-949.
16. Kim JW, Kang HW. Two cases of anti-Ro and La antibody-positive cutaneous lupus erythematosus probably caused by terbinafine. Korean Journal of Dermatology 2006; 44 (2): 201-205
17. Meunier LP. Lupus induits medicamenteux. Le Journal faxe de dermatologie, 10.05.2006.
18. Nieradko-Iwanicka B, Majdan M, Piotrowski M, Radwan P, Kwiatkowsk P. Association of ulcerative colitis and lupus nephropathy - Report of two cases | [Skojarzenie wystȩpowania wrzodzieja̧cego zapalenia jelita grubego z nefropatia̧ toczniowa̧ - Analiza kliniczna dwóch przypadków chorobowych].  Polskie Archiwum Medycyny Wewnetrznej 2006,115 (6): 559-564.
19. Rami AF, Barkan D, Mevorach D, Leitersdorf E, Caraco Y. Clozapine-induced systemic lupus erythematosus.  Annals of Pharmacotherapy 2006; 40 (5):983-985.
20. Park CO, Goo J, Ahn SK. A case of propylthiouracil-induced lupus erythematosus. Korean Journal of Dermatology 2006; 44 (4): 467-469.
21. Statines, point sur les effetsindésirables. Minidossier 2006 n°3.QXP 18/07/06 10:24 Page 1
22. Tam L.-S, Li EK, Tomlinson B. Premature atherosclerosis in systematic lupus erythematosus: Pathogenesis and therapeutic considerations. Hong Kong Journal of Nephrology 2006; 8 (2): 48-54.
23. Tam L-S, Tomlinson B. Modifiable risk factors for premature atherosclerosis in systemic lupus erythematosus. Vascular Disease Prevention 2006; 3 (1): 61-72.
24. Üskül TB, Türker H, Melikoğlu A.Bilateral Plevral Efüzyonla Başvuran Karbamazepine Bağlı Lupus Olgusu - Olgu Sunumu. Archives of Lung 2006; 7: 121-4.
25. Üskül TB, TürkerH, Meliko¤lu A. Carbamazepine Induced Lupus Case Hospitalized with Bilateral Pleural Effusion. Akci¤er Arflivi 2006; 7: 121-4.
26. Blume [**JE, Helm T, Ehrlich M, Camisa C.**](http://www.emedicine.com/cgi-bin/foxweb.exe/screen@/em/ga?book=derm&authorid=11370&topicid=104) Drug eruptions. E-medicine 2007;last updated March 28, 2007
27. Giordano N, Amendola A, Papakostas P, Cipolli F, Rollo F, Martini G, Ciacci G, Nuti R. A clinical case of drug hypersensitivity syndrome with phenobarbital administration: Drug-induced rash with eosinophilia and systemic symptoms or lupus-like sydrome? Clinical and Experimental Rheumatology 2007; 25 (2): 339.
28. Kulczycka L, Kierstan M, Robak E. Drug induced Lupus erythematosus and systemic lupus erythematosus – differences and similarities. Przeglad Lekarski, 2007,64,7-8
29. Lupus induït per fàrmacs. íFarmacovigilància de Catalunya Vol. 5, n.º 5 • octubre - desembre 2007
30. Macrodantine. 2004-2007, Online Pharmacy LTD
31. da Mota HLM; Haddad GP; Corrêa Lima RA; de Carvalho J F; Muniz-Junqueira MI; Luiz dos Santos Neto L; Corrêa Lima FA. Drug-induced lupus – from basic to spplied immunology. Rev. Bras. Reumatol. vol.47 no.6 São Paulo Nov./Dec. 2007
32. Oh SR, Cho M, Ryu HS, Lee JH, et al. A Case of Isoniazid Induced Systemic Lupus Erythematosus. 대 한 류 마 티 스 학 회 지Vol. 14, No. 4, December, 2007
33. Saha S, Powell J, Tharakaram S. Terbinafine therapy and SCLE. Healthcarerepublic e-mail bulletin ,on line, Oct 2007
34. Smith DL, Dong X, Du S, Oh M, Singh RR, Voskuhl RR. A female preponderance for chemically induced lupus in SJL/J mice  Clinical Immunology 2007; 122 (1):101-107.
35. Valeyrie-Allanore L., Sassolas B, Roujeau JC. **Drug-Induced Skin, Nail and Hair Disorders.** Drug Safety. 30(11):1011-1030, 2007.
36. Uz E, Bavbek N, Hilmi F, Kanbay TM, Kaya A, Akcay A. Cefuroxime-Induced Lupus. Journal of the National Medical Association, 2007, vol. 99, no. 9, p.1066-1067
37. Chedraoui, A et al. Adrenergic Urticaria in a Patient with Anti-double-stranded DNA Antibodies. Acta Demato-Venereologica, 2008,88,3,263-66
38. Cirillo D. The effect of statin use on incident immune-mediated and infectious conditions among U.S. veterans. University of Jowa, Thesis, 2008,p.302
39. Dam C, Bygam A. Subacute Cutaneous Lupus Erythematosus Induced or Exacerbated by Proton Pump Inhibitors. Acta Dermatovenereologica, 2008, Case report
40. Leitlinien der Deutschen Dermatologischen Gesellschaft, 2008, AWMF on line, 12/2008
41. Lorentz K, Booken N, Goerdt S, Goebeler M. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature.J Dtsch Dermatol Ges 2008 [Volume 6 Issue 10](http://www3.interscience.wiley.com/journal/121426276/issue)**, p. 823 – 827**
42. Marie I Sclérodermie systémique et syndromes sclérodermiformes d’origine médicamenteuse et toxique, et syndrome de Cléopâtre..[Médecine thérapeutique. Volume 14, Numéro 4, 226-36, Juillet-Août 2008, Dossier](http://www.john-libbey-eurotext.fr/fr/revues/medecine/met/sommaire.phtml?cle_parution=3068)
43. Marie I Lupus, polymyosites, dermatomyosites et syndrome de Sjögren d’origine médicamenteuse et toxique. [Médecine thérapeutique. 2008,14, 4, 237-246,](http://www.john-libbey-eurotext.fr/fr/revues/medecine/met/sommaire.phtml?cle_parution=3068)
44. Mounach A, Ghazi M, Nouijai A, Ghozlani I, Achemlal L, Bezza A, El Maghraoui A. Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab. Clinical & Experimental Rheumatology. 2008 Nov 1;26(6):1116.
45. Özçakar Z B, Yalçınkaya F, Çağlar Ö, EkimM. Oxcarbazepine and valproic acid-induced lupus in a 7-year-old boy. [Acta Pædiatrica](http://www3.interscience.wiley.com/journal/117988202/home), 2008, [Volume 97 Issue 8](http://www3.interscience.wiley.com/journal/120736360/issue)**, p 1000 - 1001**
46. **Qingping Yao, Bevra Hahn.** Sulfasalazine-induced Lupus and Hypersensitivity. [UCLA Department of Medicine](http://www.med.ucla.edu),2008, Last Revised: Wed, 10-Sep-2008
47. van Duinen, K. F., S. H. Kardaun. "Subacute cutane lupus erythematodes door hydrochloorthiazide." *Dermatologie Venereologie* (2008): 363.
48. Yang, Cuihong. Regulation of autoimmune responses by dendritic cells and regulatory T cells in murine models of systemic lupus erythematosus. Dissertation Abstracts International. Vol. 69, no. 11, suppl. B, 2008.
49. Yao Q, Hahn B.Sulfasalazine-induced Lupsu and Hypersensitivity . Proceedings of UCLA Healthcare, 2008,12, 1-5
50. Crespel A, R Velizarova, M Agullo, P GélisseEthosuximide-induced de novo systemic lupus erythematosus with anti-double-strand DNA **…**Epilepsia, 2009**, 50, 8,  2003 - 2003**
51. Kasperkiewicz M, Anemüller W, Angelova I. Subacute cutaneous lupus erythematosus associated with terbinafine.- Clinical and experimental dermatology, 2009
52. LU Zhi-yong  ZHENG Jie. Pathogenesis of SLE but also beneficial to the reasonable prevention and treatment of SLE. Int J dermatol and Venereol 2009, 35(5)
53. Marzano AV P Vezzoli, C Crosti Drug-induced lupus: an update on its dermatologic aspects. Lupus, 2009
54. Vedove C, M Giglio, D Schena, G Girolomoni. Drug-induced lupus erythematosus [Archives of Dermatological Research](http://www.springerlink.com/content/100398/?p=ec977c28fb2643eca583b9eaaf556e82&pi=0), [2009,301, 1](http://www.springerlink.com/content/u3g26p836644/?p=ec977c28fb2643eca583b9eaaf556e82&pi=0), 99-105
55. Yılmaz S, K Akar Cimen Pegylated interferon alfa-2B induced lupus in a patient with chronic hepatitis B virus …- Clinical Rheumatology, 2009,28, 10,1241-1243
56. Blaszczyk M. Prace specjalne leki jako czynnik prowokujacy choroby tkanki tacznej. Przegl Dermatol 2010, 97, 159–170
57. Na HH, Hong SW, Kim MC et al. A Case of Lupus-Like Syndrome after Kidney Transplantation.  J Korean Soc Transplant. 2010 Jun; 24(2):110-113.
58. Pongsiriwet S, Kuntharaniranan T, Thosaporn W. Oral discoid lupus erythematosus. Chiang Mai Dent J. 2010 May 26;31:21-31.
59. AlGhamdi KM, Khurrum H, Rikabi A. Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. Journal of cutaneous medicine and surgery. 2011 Sep;15(5):280-4.
60. Almagro, Blanca Moyano, et al. "Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil." Journal of Clinical Oncology 29.20 (2011): e613-e615.
61. Jun JB, Kim JK, Kim TH, Na YI, Choi CH, Kim YH. Inhibition of the IL-1β-induced expression of matrix metalloproteinases by controlled release of IL-1 receptor antagonist using injectable and thermo-reversible gels in human osteoarthritis chondrocytes. Journal of Rheumatic Diseases. 2011 Jun 1;18(2):85-93.
62. Kim B.S, Hong Y M, Park SM, et al. A Case of Angiotensin Converting Enzyme Inhibitor-Induced Systemic Lupus Erythematosus. J Rheum Dis. 2011 Dec;18(4):288-291.
63. Liakou AI, Brunner M, Theodorakis MJ, Makrantonaki E, Zouboulis CC. Recurrent subacute cutaneous lupus erythematosus following exposure to different drugs. Acta Derm Venereol. 2011 ;91(5):586-7
64. Marzano A.V., Lazzari R., Polloni I., Crosti C., Fabbr P., Cugno M.Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol, 2011, 165,2, 335-341
65. Min, Sang-Il, et al. "Optimal system for deceased organ donation and procurement in Korea." The Journal of the Korean Society for Transplantation25.1 (2011): 1-7.
66. Moyano-Almagro B, Steyls M, Navarro N, et al. Occurrence of Subacute Cutaneous Lupus Erythematosus After Treatment With Systemic Fluorouracil. JCO, 2011:e613-e615;
67. Ravindran V. Lamotrigine‐induced lupus: a case report. International journal of rheumatic diseases. 2011 Aug;14(3):e47-8.
68. 白山純実, 辻真紀, 今中愛子, 八幡陽子. 円形脱毛斑が先行した塩酸ミノサイクリンによる薬剤誘発性ループスの 1 例. 臨床皮膚科. 2011 Dec 1;65(13):1022-6.
69. Ahn KS, Kang KJ. Liver Transplantation for the Curative Treatment of Hilar Cholangiocarcinoma-Model of the Mayo Clinic. The Journal of the Korean Society for Transplantation. 2012 Mar 1;26(1):1-5.
70. Chen TK, Haddican MM, Phelps RG, Spiera H. Etanercept-Induced Lupus Panniculitis with Continued Improvement after Treatment with Adalimumab for Psoriatic Arthritis. InPsoriasis Forum 2012 Sep (Vol. 18, No. 3, pp. 142-146). Sage CA: Los Angeles, CA: SAGE Publications.
71. Dalle Vedove, Camilla, Jan C. Simon, and Giampiero Girolomoni. "Drug‐induced lupus erythematosus with emphasis on skin manifestations and the role of anti‐TNFα agents." JDDG: Journal der Deutschen Dermatologischen Gesellschaft(2012). 10,  12, 889–897
72. Diaz L, Cuire A.Cutaneous and systemic adverse reactions to antibiotics. Dermatologic Therapy, 2012;25, Issue 1, pages 12–22,
73. Esen, Bahar Artım, et al. "Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study."*Rheumatology international* 32.1 (2012): 79-83.
74. Meidhof W et al. Lupus: An Overview of the Disease and Management Options. P& T. 2012, l; 37(4): 240-246, 249.
75. Pretel, M., L. Marquès, and A. España. "Lupus eritematoso inducido por fármacos." Actas Dermo-Sifiliográficas (2012).
76. Rabbi M et al. Environment, Immune Dysfunction, and Systemic Lupus Erythematosus. In: [Immunotoxicity, Immune Dysfunction, and Chronic Disease](http://www.springerlink.com/content/978-1-61779-811-5/) . [Molecular and Integrative Toxicology](http://www.springerlink.com/content/v6kt7k/), 2012, Part 3, Chapter 8, 193-213
77. Seo JY et al. Methimazole-Induced Bullous Systemic Lupus Erythematosus: A Case Report. J Korean Med Sci. 2012 July; 27(7): 818–821.
78. Gyöngyösi, Nóra, et al. "Infliximabterápia mellett jelentkező lupus erythematosus." *Orvosi Hetilap* 154.15 (2013): 590-598.
79. Hamdam J. *Role of the Redox Responsive Transcription Factor, NRF2, in Immune Cell Function* (Doctoral dissertation, University of Liverpool).
80. Tóth, Veronika, Beáta Somlai, Judit Hársing, Zsófia Hatvani, and Sarolta Kárpáti. "Melanomás betegek stádium szerinti megoszlása egy hazai centrumban." (2013).
81. Abilkassem, R. "Lupus érythémateux disséminé induit par l’éthosuximide : à propos d’une observation pédiatrique." *Research fr* (2014), 1, 988.
82. Araújo-Fernández, S., M. Ahijón-Lana, and D. A. Isenberg. "Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced." *Lupus*(2014): 0961203314523871.
83. Blume, J.E., Ali, L., Ehrlich, M. and Helm, T.M., 2014. Drug Eruptions. *E Medicine2010*.
84. Garcia AM, Racaza GZ, Macasaet PS, Mejia AD. Drug-induced Hypersensitivity Syndrome in an ANA-negative, anti-dsDNA-negative Systemic Lupus Erythematosus Patient. Actamedica philipina.com, 2014
85. Harnett, D.T., Chandra-Sekhar, H.B., Hamilton, S.F. Drug-Induced Lupus Erythematosus Presenting With Cardiac Tamponade: A Case Report and Literature Review. Canadian Journal of Cardiology, 30, 2, 2014,. 247e11-247e12
86. Lindsey Yeo, Anthony D Ormerod.Treatment of Acne in Children.American Journal of Clinical Dermatology (Impact Factor: 1.84). 01/2014;
87. Patel K. On drug induced lupus erythematosus.Quorterderm:2014,91,4,5-11.
88. Pretel, M., Marquès, L., España, A.Drug-Induced Lupus Erythematosus.Actas Dermo-Sifiliograficas (English Edition)volume 105, 1, 2014, pp. 18 – 30
89. Seo, J. G., & Kim, C. W. (2014). Alternative formats. *ETRI Journal*, *36*(6), 894-904.
90. Yeo L, Ormerod AD. Treatment of acne in children. American journal of clinical dermatology. 2014 Apr 1;15(2):77-86.
91. Dos Santos L.C., Dos Santos R.C., Arantes, DAP., et al. Lúpus induzido por drogas mimetizando lúpus eritematoso sistêmico: relato de caso., Universidade Federal do Triângulo Mineiro, Uberaba-MG, Brasil 2015
92. Nagarajappa, Anil Kumar, and Divya Pandya. "ADVERSE DRUG EFFECTS IN MOUTH."Int J med appl sci, 2015,4 (1),82-91
93. Pinna, S. Proteomic analysis of human plasma and peripheral blood mononuclear cells in Systemic Lupus Erythematosus patients. Doctoral Thesis. (2015) Università di Sassari 01-a Nuovi Dipartimenti dal 2012 Scienze Biomediche
94. Roberts, Amy Lynn, and Denise Rizzolo. "Systemic lupus erythematosus: An update on treat-to-target." *Journal of the American Academy of Physician Assistants* 28.9 (2015): 22-28.
95. Schnitzler, Fabian. "Serum Reaction, Lupus-Like Syndrome." (2015): 132-137.
96. Totri, Christine R., and Sharon E. Jacob. "Drug-Induced Lupus Erythematosus." *Journal of the Dermatology Nurses' Association* 7.4 (2015): 237-239.
97. Jung D, Kim SH, Choi SO, Park SY. Ramsay Hunt Syndrome in a Living-donor Kidney Transplantation Recipient: Unusual Clinical Course Case. The Journal of the Korean Society for Transplantation. 2016 Jun 1;30(2):86-8.
98. Kürtüncü M, Altunrende B, Demir GA. Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar.Epilepsi, 2016, 22, \Suppl.1\ 53-66
99. Owens RE. Timothy H. Self, PharmD, and Ryan E. Owens, PharmD, BCPS. Consultant. 2016 , 8.
100. Tetikkurt C. Drug-induced Lupus Syndrome. J Vasc. 2016;2(100115):2.
101. 林静, 董秀芹. 420nm 强脉冲光治疗中重度痤疮的临床观察. 现代诊断与治疗. 2016;27(8):1383-4.
102. Clark AK, Shi VY, Sivamani RK. Unique urticarial presentation of minocycline-induced lupus erythematosus. Dermatology Online Journal. 2017 Jan 1;23(8).
103. Momen SE, Kirkham B, Barker JN, Smith CH. TNF antagonist induced lupus: a critically appraised topic. British Journal of Dermatology. 2017 Aug 3.
104. Pinna S, Pasella S, Deiana M, Baralla A, Mannu A, Masala AG, Pileri PV, Deiana N, Scognamillo F, Pala C, Zinellu A. Proteomic analysis of human plasma and peripheral blood mononuclear cells in Systemic Lupus Erythematosus patients. Journal of Immunological Methods. 2017 Jul 31;446:37-46.
105. Priyadharshini BS, Ummar IS. Prevalence and sociodemographic profile of lithium-induced cutaneous side effects in bipolar affective disorder patients: A 1-year prospective observational study in South India. Indian journal of psychological medicine. 2017 Sep;39(5):648.
106. 岡思帆, 松尾佳美, 原田直江, 平郡隆明, 山本匡, 秀道広. スルピリドによる薬剤誘発性ループスの 1 例. 日本皮膚アレルギー・接触皮膚炎学会雑誌. 2017 Jan 31;11(1):45-9.
107. Vorčáková K, Juraj P, Tatiana P, Klára M. Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors. InAntibody Engineering 2018. InTech.

в монографии:

1. Uetrecht J P. CHAPTER 5 Idiosyncratic Drug Reactions: Clinical Evidence for Mechanistic Hypotheses in Advances in Molecular Toxicology By James C Fishbein, Published 2006  
   Elsevier
2. Fischbein JC. Idiosyncratic Drug reactions. Advances in Molecular Toxicology, Elsevier, 2006
3. Pollard KM, Ch.22. Enviromental factors that contribute to Autoimmunity. In: Autoanribodies and Autoimmunity: Molecular mechanisms in Health and disease. Wiley-VCH,2006
4. Uetrecht J P. CHAPTER 26. Drug-induced autoimmune disease. Immunotoxicology and Immunopharmacology by Robert W. Luebke, Robert V. House, Ian Kimber Published 2007, CRC Press, Taylor and Francis group,465-464
5. Hubbard A. Chapter 4. Mechanisms of Hypersensitivity and Drug allergy. In Smith B. Immunology and Immunotherapeutics, 4th Ed, Am Soc of Health System Pharmacists, 2008, 73
6. Gal A. Drug and Radiation Toxicity. In: Dail and Hammar's Pulmonary Pathology: Nonneoplastic lung diseaseBy David H. Dail, Samuel P. Hammar, Philip T. Cagle, p.828, 2008, Springer
7. Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ. Fitzpatrick's Dermatology in General Medicine, 7th Ed. Drug eruptions. References 61. SPP BOOKS MELBOURNE, 2008
8. Sylvia L. Drug Allergy, pseudoallergy and cutaneous diseases. Drug induced dermatological diseases. Chapter VI. in Drug-Induced Diseases: Prevention, Detection, and Managementр. 2 Editon ed. by Tisdale JE, Miller DA.,2010, American Society of Health System Pharmacist
9. Joy M, Dooley M. Drug-induced lupus. In Marc Hochberg Rheumatology. Chapter 129: Drug-induced lupus Rheumatology, 5th Edition,2012
10. Patel, D. and Richardson, B., 2013. Drug-induced lupus: etiology, pathogenesis, and clinical aspects. In *Dubois' Lupus Erythematosus and Related Syndromes (Eigth Edition)* (pp. 484-494).
11. Ardern‐Jones MR, Lee HY. Benign Cutaneous Adverse Reactions to Drugs. Rook's Textbook of Dermatology. 2016.

**Decroix J, Pres H, TSANKOV N., Poncet M, Arsonnaud S. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis. 2004 Sep;74(3):201-6.**

**Цитати – 27**

1. [Lowe N](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lowe%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Feldman SR](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Feldman%20SR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Sherer D](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sherer%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Weiss J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Weiss%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Shavin JS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shavin%20JS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Lin YL](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lin%20YL%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Foley V](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Foley%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Soto P](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Soto%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. [J Dermatolog Treat.](javascript:AL_get(this,%20'jour',%20'J%20Dermatolog%20Treat.');) 2005 ;16(3):158-64.
2. **Feldman SR.** Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Current therapeutic research,2005, 66,3,154-171
3. 陈周　张建中. **寻常型银屑病的外用药物.** Сhinese journal of drug application and monitoring.2005 Vol.2 No.5 P.34-37
4. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? Journal of Drugs in Dermatology,2006, 01-Jun-06
5. Nast A, et al.S3-Leitlinie zur Therapie der Psoriasis vulgaris. JDDG .2006, 4 (s2), 1–126.
6. Nast A, Kopp I, et al.Evidence-based guidelines for the treatment of psoriasis vulgaris. J D DG. 2007 ; 5 Suppl 3:1-119.
7. Nast A, Kopp I, Augustin M, et al. Psoriasis – Leitliniengruppe 2006. Leitlinien der Deutschen Dermatologischen Gesellschaft. Therapie der Psoriasis Vulgaris. Arch Dermatol Res. 2007 June; 299(3): 111–138.
8. Krueger GG, Duffin KC. Topical agents in the treatment of moderate-to-severe psoriasis. InModerate-to-Severe Psoriasis, Third Edition 2008 Dec 22 (pp. 56-81). CRC Press.
9. Pels R, Sterry W, Lademann J. Clobetasol propionate--where, when, why?. Drugs of Today. 2008 Jul 1;44(7):547.
10. Feldman SR, Yentzer BA. Topical Clobetasol Propionate in the Treatment of Psoriasis. American journal of clinical dermatology. 2009 Dec 1;10(6):397-406.
11. Свирщевская ЕВ, Матушевская ЕВ. Применение сильных топических стероидов в терапии псориаза и атопического дерматита. Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2009;4(4):71-2.
12. Gold D, Almohizea SI. Topical Treatment of Mild to Moderate Psoriasis. InPsoriasis Forum 2010 Jun (Vol. 16, No. 2, pp. 17-25). Sage CA: Los Angeles, CA: SAGE Publications.
13. Zampetti A, Feliciani C, Tulli A, Amerio P. Pharmacotherapy of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses focus on clobetasol propionate. Clinical Medicine Insights: Therapeutics. 2010 Jan;2:CMT-S1993.
14. Castella E et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. JEADV,2012, 26,Suppl 3,34-36
15. Castella E et al. Topical corticosteroids in plaque psoriasis: a systematic review of of risk of adrenal axis suppression and skin atrophy, JEADV,2012, 26,Suppl 3,47-51
16. Nast A et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version), Arch Dermatol Res, 2012, 304, 2 , 87-113
17. Nast, Alexander, et al. „S3–Guidelines on the treatment of psoriasis vulgaris (English version). Update.” *JDDG: Journal der Deutschen Dermatologischen Gesellschaft* 10.s2 (2012): S1-s95.
18. Kaštelan M, Puizina-Ivić N, Čeović R, Jukić Z, Bulat V, Simonić E, Prpić-Massari L, Brajac I, Krnjević Pezić G. Smjernice Za Dijagnostiku I Liječenje Vulgarne Psorijaze. Liječnički vjesnik. 2013;26:135(7-8):0-.
19. Samarasekera, E. J., et al. „Topical therapies for the treatment of plaque psoriasis: systematic review and network meta‐analyses.” *British Journal of Dermatology* 168.5 (2013): 954-967.
20. Zweegers, J., et al. „Summary of the Dutch S3-Guidelines on the treatment of psoriasis 2011.” *Dermatology online journal* 20.3 (2014).
21. Medeiros L. Psoríase Em Placa Moderada A Grave: Tratamentos Tópicos.Sociedade Brasileira de Dermatologia,2015
22. Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, Thaci D. Reformulations of well‐known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. Journal of the European Academy of Dermatology and Venereology. 2017 Apr 17.
23. Das A, Panda S. Use of topical corticosteroids in dermatology: An evidence-based approach. Indian Journal of Dermatology. 2017 May;62(3):237.
24. Hazra A, Gogtay N. Biostatistics series module 9: Survival analysis. Indian Journal of Dermatology. 2017 May;62(3):251.
25. Setia MS. Methodology series module 9: Designing questionnaires and clinical record forms–Part II. Indian journal of dermatology. 2017 May;62(3):258.
26. Das A, Panda S. An Evidence Based Approach of Use of Topical Corticosteroids in Dermatology. In A Treatise on Topical Corticosteroids in Dermatology 2018 (pp. 41-72). Springer, Singapore.
27. Brandi N, Starace M, Alessandrini A, Bruni F, Piraccini BM. Treatment of nail psoriasis with topical application of clobetasol propionate0. 05% solution: a pilot study. European Journal of Dermatology. 2018 Jan 16;1(1).

**TSANKOV N, Weinberg JM. Commentary: antimicrobials in dermatology. Disease-a-Month. 2004 Jun 1;50(6):268-9.**

Цитирания – 1

1. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutaneous and ocular toxicology. 2006 Jan 1;25(1):1

**Gantcheva M; Lalova A; Broshtilova, V; Negenzova, Z. TSANKOV N, Vesicular Mycosis Fungoides: Vesiculöse Mycosis fungoides. Journal der Deutschen Dermatologischen Gesellschaft, 2005 ,3, 11, 898-900**

**Цитирания -10**

1. Ferahbaş, Ayten. „Mikozis fungoides, klinik varyantları ve subtipleri.” *Turkiye Klinikleri Journal of Dermatology* 17.4 (2007): 242-251.
2. Yüksek, Uzm Dr Jale, and Engin Sezer. "Mikozis Fungoides’ in Atipik Formları." Dermatose 2007;6:179-185
3. Братцева, Е. В., and С. В. Ротанов. „Современные подходы к диагностике грибовидного микоза.” *Вестник дерматологии и венерологии* 6 (2010): 16-22.
4. Ferahbas A. Dermatolog Gözü İle. Deri Lenfomalari. XXXVI. Ulusal Hematoloji Kongresi, 2010, Belek, Antalya
5. Kneitz H, Bröcker EB, Becker JC. Mycosis fungoides bullosa: a case report and review of the literature. Journal of Medical Case Reports 2010, 4:78
6. Tavlı, Yeliz Uçar. "Mikozis fungoidesli olgularda tedavi öncesi ve sonrası biyopsilerde immunhistokimyasal CD4 CD8, matrix metalloproteinaz-9 (MNP-9) ekspresyonunun değerlendirilmesi." PhD diss., Selçuk Üniversitesi Tıp Fakültesi, 2011.
7. Yamashita, Thamy, et al. „Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.” Anais brasileiros de dermatologia 87.6 (2012): 817-830.
8. Hu SW, Ratech H, Naeem R, Latkowski JA, Kamino H. Mycosis fungoides with epidermal mucinosis : a variant of mycosis fungoides with a spongiosis‐like pattern. Journal of cutaneous pathology. 2015 Oct 1 ; 42(10) :730-8.
9. Korekawa A, Kaneko T, Nakajima K, Rokunohe D, Akasaka E, Nakano H, Sawamura D, Fukui T, Takiyoshi N, Kitamura H, Harada K. Mycosis fungoides bullosa associated with bullous pemphigoid. International journal of dermatology. 2015 Sep ; 54(9) :e366-8.
10. Momtahen S, Nuovo GJ, Magro CM. Vesicular Mycosis Fungoides. The American Journal of Dermatopathology. 2015 Sep 1 ; 37(9) :724-9.

**Angelova-Fischer I, Bauer A, Hipler UC, Petrov I, Kazandjieva J, Bruckner T, Diepgen T, TSANKOV N., Williams M, Fischer TW, Elsner P, Fluhr JW. The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis. Br J Dermatol. 2005,153(4):767-73**

**Цитирания - 60**

1. Fluhr JW, Feingold KR, Elias PM.. Transepidermal water loss reflects permeability barrier status: validation in human and rodent in vivo and ex vivo models. Experimental Dermatology 2006: 15(7): 483–492.
2. Fortina AB, Tonin E, Pigozzi B, Romano I, Michelotto G, Alaibac M. IL-16 serum level in children with atopic dermatitis. International journal of immunopathology and pharmacology. 2006 Oct; 19(4):841-5.
3. LiteratureWatch. Pediatric Asthma Allergy & Immunology 2006; 19(1):70.
4. Yu Tao Zhang Yu-Huan. Advance in the research of atopic dermatitis cytokine. CHINA TROPICAL MEDICINE , 6 ,8 ,2006
5. 喻桃, and 张玉环. "特应性皮炎细胞因子研究进展." PhD diss., 2006.
6. Matsuki H, Kiyokane K, Matsuki T, Sato S, Imokawa G. Recharacterization of the Nonlesional Dry Skin in Atopic Dermatitis through Disrupted Barrier Function. Exogenous Dermatology 2005; 3(6): 282. Published online: March 9, 2006
7. Hughes B. Topical drug development: Clinical programmes in dermatology. World Pharma Network, Nov, 2007.
8. Schmitt, J; Langan S; Williams H; European Dermato-Epidemiology Network **What are the best outcome measurements for atopic eczema? A systematic review.** Journal of Allergy & Clinical Immunology. 120(6):1389-1398, 2007.
9. Clinical Guideline, December 2007 . Atopic eczema in children – manaagement of aropic exzema in children from birth up to the age of 12 years. RCOG Press, 2007
10. Breternitz M, Kowatzki D, Langenauer M, Elsner P, Fluhr J. Placebo-Controlled, Double-Blind, Randomized, Prospective Study of a Glycerol-Based Emollient on Eczematous Skin in Atopic Dermatitis: Biophysical and Clinical Evaluation. Skin Pharmacology and Physiology 2008;21:39-45
11. Kikuchi K, Tagami H. Japanese Cosmetic Scientist Task Force for Skin Care of Atopic Dermatitis. Noninvasive biophysical assessments of the efficacy of a moisturizing cosmetic cream base for patients with atopic dermatitis during different seasons. British Journal of Dermatology (2008)158:5, 969–978
12. Langan, Sinéad. "A prospective study of the effects of environmental factors on eczema in children." PhD diss., University of Nottingham, 2008.
13. Sinclair W et al. Management of Atopic Dermatitis in Adolescents and Adults in South Africa. S Afr Med J 2008,98,301-320
14. Uchida Y, Holleran W, Elias P.On the effects of topical synthetic pseudoceramides: Comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides.  Journal of Dermatological Science , 2008, Volume 51 , Issue 1 , Pages 37 – 43
15. Dulon, Skudlik, C., Nubling, M.; John, S. M. ; Nienhaus, A M Validity and responsiveness of the Osnabruck Hand Eczema Severity Index (OHSI): a methodological study.,. British Journal of Dermatology. 2009.160(1):137-142
16. National Collaborating Centre for Women's and Children's Health (UK, 2009. Excluded studies.
17. Lee O, Choi M, Ha S, Lee G, Kim J, Park G, Lee M, Choi Y, Kimр M, Oh CH.Effect of pedunculagin investigated by non-invasive evaluation on atopic-like dermatitis in NC/Nga mice. Skin Research and Technology,2010, [Volume 16 Issue 3](http://www3.interscience.wiley.com/journal/123572250/issue), Pages 371 – 377
18. Hwang SW, Kang JH, Seol JE et al. The Correlation between SCORAD Index and Instrumental Assessment in Evaluation of Atopic Dermatitis Severity. Korean J Dermatol, 2010, 48,4,266-271
19. Visscher M. Minerva Medica. G Ital Dermatol Venereol. 2010;145:11-28.
20. Hatano Y, Elias PM, Crumrine D. Efficacy of Combined Peroxisome Proliferator-Activated Receptor-α Ligand and Glucocorticoid Therapy in a Murine Model of Atopic Dermatitis. J Invest Dermatol,2011, 131, 1845–1852
21. Meital, P. C., Miriam, O., Efrat, M., Ze’evi, M. O., Dan, B. A., Hagai, Y., & Alex, Z. (2011). A dead sea water-enriched body cream improves skin severity scores in children with atopic dermatitis. *Journal of Cosmetics, Dermatological Sciences and Applications*, *2011*
22. Portugal-Cohen M, Oron M, Merrik E et al. A Dead Sea Water-Enriched Body Cream Improves Skin Severity Scores in Children with Atopic Dermatitis. J Cosm Derm Sci Applic, 2011,1,71-78
23. Ra JC. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. Journal of Translational Medicine 2011, **9**:181
24. Rehal B, Armstrong A. Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010. PloS one, 2011-12-18
25. Wu, K. G., et al. "Correlations of serum Interleukin-16, total IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis." *International journal of immunopathology and pharmacology*24.1 (2011): 15-23.
26. Amarioarei-Iftimie, Gina, Maria Lungu, and Sorin Ciovică. "IN VIVO TESTING OF P. cerasus GUM WITHIN A COSMETIC FORMULATION." *Environmental Engineering and Management Journal* 11.8 (2012): 1493-1498.
27. Back, Seung Keun, et al. "Chronically relapsing pruritic dermatitis in the rats treated as neonate with capsaicin; a potential rat model of human atopic dermatitis." *Journal of Dermatological Science* 67.2 (2012): 111-119.
28. Darlenski R, Fluhr J. Influence of skin type, race, sex, and anatomic location on epidermal barrier function. Clinics in Dermatology,2012, Volume 30, Issue 3, Pages 269-273
29. Di, Zheng-Hong, Hong-Duo Chen, Li Zhang, Li-Ping Zhao, Xing-Hua Gao, and Ya-Ni Lv. *Advances in Assessing the Severity of Atopic Dermatitis*. INTECH Open Access Publisher, 2012.
30. Firooz, Alireza, Ali Rajabi Estarabadi, and Hamed Zartab. "Methods for skin biophysical analysis and imaging: A review (Part Ι)." *Dermatology and Cosmetic* 3.4 (2012): 219-226.
31. فيروز, et al. "بررسی خصوصيات بيوفيزيکی و روش‌های تصويربرداری پوست (بخش اول)." *پوست و زیبایی* 3.4 (2012): 219-226.‎
32. Cho, Eujin, and Sang Hyun Cho. "Effects of Korean red ginseng extract on the prevention of atopic dermatitis and its mechanism on early lesions in a murine model." Journal of Ethnopharmacology 2013;145;1,294–302
33. Choi, Y. J., Lee, H. J., Lee, D. H., Woo, S. Y., Lee, K. H., Yun, S. T., ... & Kim, J. W. (2013). Therapeutic effects and immunomodulation of Suanbo mineral water therapy in a murine model of atopic dermatitis. *Annals of dermatology*, *25*(4), 462-470.
34. Ferguson, J. S., et al. "Assessment of skin barrier function in podoconiosis: measurement of stratum corneum hydration and transepidermal water loss."*British Journal of Dermatology* 168.3 (2013): 550-4
35. Omi, Tokuya, and Yuriko Ochiai. "Evaluation of the Efficacy and Safety for Atopic Dry Skin of a Medicinal Moisturizing Lotion (Mentholatum AP Soft Medicinal Moisture Lotion) Prepared by a High-Pressure Emulsification Method." *Journal of Cosmetics, Dermatological Sciences and Applications* 3.02 (2013): 145.
36. Schmitt, Jochen, et al. "Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation." *Journal of Allergy and Clinical Immunology* 132.6 (2013): 1337-1347.
37. Alzolibani, Abdullateef A. "Impact of atopic dermatitis on the quality of life of Saudi children." *Saudi medical journal* 35.4 (2014): 391-396.
38. Ciaccio, Christina E., and Manika Girdhar. "The Effect of Maternal Omega-3 Fatty Acid Supplementation on Infant Allergy." *Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology* 112.3 (2014): 191.
39. Cho, Sang Hyun. "Red ginseng for atopic dermatitis." *World J Dermatol* 3.3 (2014): 58-63.
40. Eichenfield, Lawrence F., et al. "Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies." *Journal of the American Academy of Dermatology* 71.1 (2014): 116-132.
41. Галкина, ЕМ, АВ Каракаева, and СР УТЦ. ":Методы неинвазивной оценки барьерных свойств кожи." *Саратовский научно-медицинский журнал* 10.3 (2014).
42. Kim, Heejung, et al. "7, 8, 4′-Trihydroxyisoflavone Attenuates DNCB-Induced Atopic Dermatitis-Like Symptoms in NC/Nga Mice." (2014): e104938.
43. Schmitt, Jochen, et al. "The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials." *Journal of Allergy and Clinical Immunology* 134.4 (2014): 800-807.
44. Sinclair, Werner, et al. "Diagnosis of atopic dermatitis: From bedside to laboratory." *SAMJ: South African Medical Journal* 104.10 (2014): 711-713.
45. Zając, Marcin, et al. "Assessment of the relationship between transepidermal water loss (TEWL) and severity of clinical signs (CADESI‐03) in atopic dogs."*Veterinary dermatology* 25.6 (2014): 503-e83.
46. Utz SR, Karakaeva AV, Galkina EM. Noninvasive evaluation of the barrier properties of the skin. Saratov J of Medical Sci Research, 2014,10(3),512-517
47. Tuzova, Marina, et al. "CCR4+ T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16." *Leukemia & lymphoma* 56.2 (2015): 440-449.
48. Zając, M., Szczepanik, M. P., Wilkołek, P. M., Adamek, Ł. R., Pomorski, Z. J., Sitkowski, W., & Gołyński, M. Assessment of a correlation between Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) and selected biophysical skin measures (skin hydration, pH, and erythema intensity) in dogs with naturally occurring atopic dermatitis. *Canadian Journal of Veterinary Research*, (2015).*79*(2), 136-140.
49. Bożek A, Reich A. Assessment of the severity of atopic dermatitis. Przegląd Dermatologiczny/Dermatology Review. 2016;103(6):479-85.
50. Hanna S, Kim M, Murrell DF. Review: Validation studies of outcome measures in pemphigus. International Journal of Women's Dermatology. 2016 Dec 10.
51. 吕娅妮, 姜启君, 于华. AD 儿童皮肤屏障功能客观评估. 世界最新医学信息文摘 (电子版). 2016(24):64-5.
52. 唐苏为, & 谢韶琼. (2016). 皮肤瘙痒程度评价方法进展. *中国皮肤性病学杂志*, *30*(1), 84-85.
53. Andersen HH. *Studies on itch and sensitization for itch in humans* (Doctoral dissertation, Aalborg Universitetsforlag).2017
54. Bożek A, Reich A. Assessment of Intra-and Inter-Rater Reliability of Three Methods for Measuring Atopic Dermatitis Severity: EASI, Objective SCORAD, and IGA. Dermatology. 2017 May 12.
55. Зайнуллина ОН, Хисматуллина ЗР, Печкуров ДВ. Современные методы оценки состояния кожи при атопическом дерматите у детей. Аллергология и иммунология в педиатрии. 2017(4) :4-9.

В монографии:

1. Fluhr JW, Darlenski R. [Skin Barrier](http://www.springerlink.com/index/t160154625067136.pdf) In: Life-Threatening Dermatoses and Emergencies in Dermatology. Ed. by Jean Revuz, Jean-Claude Roujeau, Francisco A. Kerdel Laurence Valeyrie-Allanore. Springer Berlin Heidelberg, 2009, 3-18
2. Angelova-Fischer, Irena, Swen Malte John, and Sanja Kezic. "Acute Irritancy Testing for Predicting Increased Susceptibility to Irritant Contact Dermatitis in Atopic Individuals." *Textbook of Hand Eczema*. Springer Berlin Heidelberg, 2014. 247-254.
3. Fluhr, J. W., & Darlenski, R. (2014). Transepidermal Water Loss (TEWL). In*Non Invasive Diagnostic Techniques in Clinical Dermatology* (pp. 353-356). Springer Berlin Heidelberg.
4. Abbas, Sabine. *Childhood Eczema–a Holistic Approach Towards Healing: Eliminate & Prevent Childhood Eczema Naturally*. Lulu Press, Inc, 2015.
5. Finlay AY. Principles of measurement and assessment in dermatology. Rook's Textbook of Dermatology, Ninth Edition. 2016 Jul 15:1-3.

**Angelova-Fischer I,Tsankov N. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast. Acta Dermatoven APA 2005.14:115-119.**

**Цитати – 20**

1. Крылов, И. А., and ДБ УТЕШЕВ. „АНТАГОНИСТЫ ЛЕЙКОТРИЕНОВЫХ РЕЦЕПТОРОВ: ПЕРСПЕКТИВЫ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ.” *Лечебное дело* 2 (2006)
2. Scientific summary targeting multiple allegic diseases. Efficas care for Allergies and astma. Efficas Inc.
3. Caramia G et al. Mediatori lipidici, infezioni e infiammazioni : evoluzione delle conoscenze e prospettive terapeutiche. Giorn. It. Inf. Ped, 2007,15-27
4. Ehlayel MS., Bener A. Does Montelukast Reduce the Treatment Cost in Children with Moderately Severe Atopic Dermatitis. Curr Pediatr Res 2008; 12 (1 & 2): 1-4
5. Lee JK et al The effect of Montelukast in the treatment of atopic dermatitis through the SCORAD index. . Korean J Dermatol, 2008,46,1,34-9
6. Arriba-Méndez S et al. Analysis of 927T > C CYSLTR1 and -444A > C LTC4S polymorphisms in children with asthma. Allergol Immunopathol (Madr). 2008 Sep-Oct;36(5):259-63.
7. Vieth WK. Sulfidoleukotrienbestimmung bei Patienten mit atopischer Dermatitis und Nahrungsmitteladditiva-Intoleranz. Dissertation, 2008, Med Fac, Charite Berlin
8. Chembolli L et al. Montelukast Does Not Inhibit The Late Phase Reaction In Parthenium Dermatitis. Indian J Dermatol. 2009 Jan-Mar; 54(1): 94.
9. Broshtilova V, Gantcheva M. Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis. Dermatologic Therapy,2010, 23(1):90-3]
10. Nettis E et al. The Employment of Leukotriene Antagonists in Cutaneous Diseases Belonging to Allergological Field. Mediators of Inflammation, 2010 , Article ID 628171, 6 pages
11. Piuvezam MR et al. Cissampelos sympodialis (Menispermaceae): A Novel Phytotherapic Weapon Against Allergic Diseases? Allergic Diseases – Highlights in the Clinic, Mechnisms and treatment.2012, 478-498
12. 刘静, and 李邻峰. „抗白三烯药物在炎症性皮肤病中的应用.” *临床皮肤科杂志* 41.12 (2012): 772-773
13. El-Ghoneimy, Dalia H., and Zeinab A. El-Sayed. „Leukotrienes and leukotriene modifiers in pediatric allergic diseases.” *Egyptian Journal of Pediatric Allergy and Immunology (The)* 12.1 (2014): 3-12.
14. Ibrahim, Hany M., et al. „Effectiveness of montelukast in modulation of filaggrin mutation 2282del4 in atopic dermatitis Egyptian patients.” (2014).
15. Usoskin D, Furlan A, Islam S, Abdo H, Lönnerberg P, Lou D, Hjerling-Leffler J, Haeggström J, Kharchenko O, Kharchenko PV, Linnarsson S. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nature neuroscience. 2015 Jan;18(1):145.
16. Жерносек ВФ. Антилейкотриеновые препараты в лечении атопического дерматита и крапивницы у детей. Медицинские новости. 2015(11 (254)).
17. Jeon YH, Min TK, Yang HJ, Pyun BY. A double-blind, randomized, crossover study to compare the effectiveness of montelukast on atopic dermatitis in Korean children. Allergy, asthma & immunology research. 2016 Jul 1;8(4):305-11.
18. Sun S, Dong X. Trp channels and itch. InSeminars in immunopathology 2016 May 1 (Vol. 38, No. 3, pp. 293-307). Springer Berlin Heidelberg.
19. Узаков ОЖ, Сулайманов ША, Муратова ЖК, Жуманалиева МБ. Новые инновационные технологии в терапии аллергических заболеваний. Вестник КГМА им. ИК Ахунбаева. 2016(5):141-6.
20. Chin WK. Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all. Journal of clinical pharmacy and therapeutics. 2018 Feb 1;43(1):159-62.

**TSANKOV N, Kehayov A. Crisis in Lybia: Doctor and nurses under death sentence. Clin Dermatol, 2005,  23, 527.**

**Цитати – 2**

# Parish LC. Freedom for the Bulgarian nurses and a Palestinian doctor. Clin Dermatol, 2008,26,5,574

# Cohen, Philip R., Razelle Kurzrock, and Lawrence Parish. „Warning signal: Unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates.” (2013): 128.

**TSANKOV N, Grozdev I, Кazandjieva J. Eruptive psoriasis and treatment with Rifampicin. Trakia J Sci,2005,Vol.3,4,21-26**

**Цитати – 2**

1. Nikolova, Biliana, et al. “Fluorescent Imaging for Assessment of the Effect of Combined Application of Electroporation and Rifampicin on HaCaT Cells as a New Therapeutic Approach for Psoriasis.” *Sensors* 13.3 (2013): 3625-3634.
2. Dogra, Luvdeep, et al. "A controlled trial of oral rifampin in chronic plaque psoriasis." *British Journal of Medicine and Medical Research* 4.17 (2014): 3248-3254.

**Angelova-Fischer I , Hipler U C , Bauer A , Fluhr J W, TSANKOV N, Fischer T W , Elsner P. Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis-from laboratory parameters to clinical scores. [My paper] Br J Dermatol. 2006 Jun ;154 (6):1112-1117**

**Цитати – 35**

1. de Jongh, CM; Lutter R; Verberk MM; Kezic S. Differential cytokine expression in skin after single and repeated irritation by sodium laurylsulphate. Experimental Dermatology, 2007, 16, 12, 1032-1040(9).
2. Bussmann, C.; Maintz, L.; Hart, J.; Allam, J.-P.; Vrtala, S; Chen, K.-W.; Bieber, T.; Thomas, W. R; Valenta, R.; Zuberbier, T.; Sager, A.; Novak, N. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clinical & Experimental Allergy, 2007, 37,  9, 1277-1285(9)
3. Bonness S, Bieber T. **Molecular basis of atopic dermatitis.Skin allergy** Current Opinion in Allergy & Clinical Immunology. 2007, 7(5):382-386
4. Betsi GI et al. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol. 2008;9(2):93-103.
5. Conde-Taboada A et al. Dermatitis atópica infantil: revisión y actualización. Actas Dermo-Sifiliográficas,2008, Volume 99, Issue 9, Pages 690-700
6. Gregoria B, Papadavid E, Falagas M. **Probiotics for the Treatment or Prevention of Atopic Dermatitis: A Review of the Evidence from Randomized Controlled Trials.** Am J of Clinical Dermatology. 2008, 9(2):93-103
7. Mostafa GA, Tomoum HY, Salem SAA, El-Aziz MMA, El-Maged DIA, El-Far IES. Serum concentrations of CCR4 ligands in relation to clinical severity of atopic dermatitis in Egyptian children, [Pediatric Allergy and Immunology](http://www3.interscience.wiley.com/journal/118512964/home), 2008,[19, 8](http://www3.interscience.wiley.com/journal/121532000/issue)**,  756 – 762**
8. **Foekel C et al.** Dietetic effects of oral intervention with mare’s milk on the Severity Scoring of Atopic Dermatitis, on faecal microbiota and on immunological parameters in patients with atopic dermatitis. Int J Food Sci Nutr. 2009;60 Suppl 7:41-52.
9. Karaman H. Atopik Dermatitli Hastalarda topical %1 pimekrolimus teda visinin skorad enders skoru ve serum eozinofil katyonik protein uzerine etkisi. PhD thesis, Istanbul, 2009, publ. online
10. Venge P. Monitoring the allergic inflammation. Allergy Frontiers, 2009, Volume 4, I, 453-471
11. Miyata, S et al. Method for determining atopic dermatitis using protein marker. United States Patent 7820396,2010
12. Salivahti EM et al. Combined T regulatory cell and Th2 expression profile identifies children with cow’s milk allergy. Clin Immunol. 2010 Jul;136(1):16-20.
13. Salivahti EM . Cow’s milk allergy and the development of tolerance University of Helsinki, Faculty of Medicine, Institute of Clinical Medicine, Hospital for Children and Adolescents, PhD Thesis, 2010
14. van Velsen SG et al. The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity. Pediatr Dermatol. 2010 Sep-Oct;27(5):470-5.
15. Nagi G et al. Association between serum IL-16 levels and the degree of sensitization in patients with atopic dermatitis. Int Arch Allergy Immunol. 2011;156(1):69-74.
16. Bieber, T., M. Cork, and S. Reitamo. „Atopic dermatitis: a candidate for disease‐modifying strategy.” *Allergy* 67, no. 8 (2012): 969-975.
17. Lee, JaeHo, et al. „Atopic dermatitis and cytokines: recent patents in immunoregulatory and therapeutic implications of cytokines in atopic dermatitis-part I: cytokines in atopic dermatitis.” *Recent patents on inflammation & allergy drug discovery* 6.3 (2012): 222-247.
18. Lee, Jungsoo, Chang Ook Park, and Kwang Hoon Lee. „Specific Immunotherapy in Atopic Dermatitis.” *Allergy, Asthma & Immunology Research* 6 (2013).
19. Schut, Christina. „Stressbewältigungstraining bei Neurodermitis: Psychophysiologische Effekte.” (2013).
20. Akan, Ayşegül, Dilek Azkur, Ersoy Civelek, Mustafa Erkoçoğlu, Zeynep Yılmaz-Öztorun, Ayşenur Kaya, Celal Özcan et al. „Risk factors of severe atopic dermatitis in childhood: single-center experience.” *The Turkish journal of pediatrics* 56 (2014): 121-126.
21. Eberlein B et al. Influence of alpine mountain climate of Bavaria on patients with atopic diseases : studies at the Environmental Research Station Schneefernerhaus (UFS – Zugspitze) – a pilot study. Clinical and Translational Allergy2014, **4**:17
22. Keller, Sylvia, et al. „Supplementation of a dairy drink enriched with milk phospholipids in patients with atopic dermatitis–A double-blind, placebo-controlled, randomized, cross-over study.” Clinical Nutrition 33.6 (2014): 1010-1016.
23. Kriegisch, Marie SB. Einflüsse des alpinen Hochgebirgsklimas auf Parameter allergischer Erkrankungen: Untersuchungen an der Umweltforschungsstation Schneefernerhaus (UFS-Zugspitze). Diss. München, Technische Universität München, Diss., 2014, 2014.
24. Purzycka-Bohdan, Dorota, et al. „Rola interleukiny 16 w patogenezie wybranych chorób skóry.” *Dermatology Review/Przeglad Dermatologiczny* 101.1 (2014).
25. Tuzova, Marina, et al. „CCR4+ T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16.” *Leukemia & lymphoma* 0 (2014): 1-10.
26. Чусляева АА. Современнье подходь к терапии атопического дерматита у детей. Медицинский вестник Башкортостана 9.1 (2014).
27. Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. Allergy, asthma & immunology research. 2015 May 1;7(3):221-9.
28. Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, Flohr C, Hijnen D. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Current opinion in allergy and clinical immunology. 2015 Oct 1;15(5):453-60.
29. Tuzova M, Richmond J, Wolpowitz D, Curiel-Lewandrowski C, Chaney K, Kupper T, Cruikshank W. CCR4+ T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16. Leukemia & Lymphoma. 2015 Feb 1;56(2):440-9.
30. Zheng HY, Zhao L, Li CX, Li SH. Correlation between serum IL-16 and atopic dermatitis. Genet Mol Res. 2016 Mar 24;15(1).
31. Пампура АН. Проблемы и перспективы развития детской аллергологии. Российский вестник перинатологии и педиатрии. 2016 Mar 10;60(1):7-15.
32. Зайнуллина ОН. Использование биомаркеров в прогнозе атопического дерматита. Летний медицинский интернет‐форум–2017 (материалы: часть 2). 2018;8(2):81.
33. Tohgasaki T, Ozawa N, Yoshino T, Ishiwatari S, Matsukuma S, Yanagi S, Fukuda H. Enolase‐1 expression in the stratum corneum is elevated with parakeratosis of atopic dermatitis and disrupts the cellular tight junction barrier in keratinocytes. International journal of cosmetic science. 2018 Apr;40(2):178-86.
34. Liu J, Liu Y, Wang D, He M, Diao L, Liu Z, Li Y, Tang L, He F, Li D, Guo S. AllerGAtlas 1.0: a human allergy-related genes database. Database. 2018 Jan 1;2018.

**В монографии**

1. A Aland, A Allegro, G Penna, E Quartaronen. Chapter 11 Serum levels of interleukin-16 in lymphoid neoplastic diseases: Progress in Chemokine Research Editor: WP Linkes, 2007, 157-168, Nova Science Publishers

**TSANKOV N, Grozdev I, Кazandjieva J. Old drug – new indicaton. Rifampicin in psoriasis. J Dermatol Treat, 2006, 17, 18-23**

**Цитати – 11**

1. Psoriasis wirksam bei Schuppenflechte. Psoriasiswelt,2007 BSMO, online J
2. Dogan, Bilal; Karabudak, Ozlem; Harmanyeri, Yavuz **. Antistreptococcal treatment of guttate psoriasis: a controlled study.** International Journal of Dermatology. 47(9):950-952, September 2008
3. Prinz J. Bedeutung von Streptokokken für die Psoriasispathogenese. Hautartz, 2009,60,109-115
4. WANG Guo-li, LI Xiu-yun, WANG Ming-yi, XIAO De-gui, ZHANG Yong-yu, YUAN Xiao-yan, WANG Qi-you, SONG Jian-jing. Cell-wall-deficient bacteria: a major etiological factor for psoriasis? Chinese Medical Journal, 2009, Vol. 122 No. 24 : 3011-3016
5. Цискаришвили НВ, Цискаришвили НИ. Противотуберкулезные препараты в лечение псориаза. Gerogian Medical News, 2009,9,25-28
6. Bi, Wei, et al. „Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation.” *Brain research* 1395 (2011): 12-20.
7. MÄNNISTÖ, NOORA. „B-Trikalsiumfosfaattia (B-TCP) sisältävän, antibiootteja vapauttavan ja biohajoavan luun täytemateriaalin ominaisuuksien tutkimus.” (2011).
8. Bi, Wei, et al. „Inhibition of 26S protease regulatory subunit 7 (MSS1) suppresses neuroinflammation.” *PloS one* 7.5 (2012): e36142.
9. Nikolova, Biliana, et al. „Fluorescent Imaging for Assessment of the Effect of Combined Application of Electroporation and Rifampicin on HaCaT Cells as a New Therapeutic Approach for Psoriasis.” *Sensors* 13.3 (2013): 3625-3634.
10. Milčić, Danijela S. *Prevalencija metaboličkog sindroma kod obolelih od psorijaze*. Diss. Univerzitet u Beogradu-Medicinski fakultet, 2016.
11. Scheinfeld N. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system. Dermatology online journal. 2016 Jan 1;22(6).

**Antonov D, Grozdev I, Pehlivanov G, TSANKOV N. Psoriatic Erythroderma Associated With Enalapril. SKINmed(2006) 5 (2), 90–92.**

**Цитати – 19**

1. Garzona Navas, Laura, and Federico Moreira Hidalgo. „Dermatitis exfoliativa generalizada: revisión de tema.” *Revista Costarricense de Salud Pública* 15.29 (2006): 77-80.
2. 蔡艳霞， 张锡宝， 吴志华 – 岭南皮肤性病科杂志, 2007 – 维普资讯  
   Southem China Journal of Dermato．Venereology，2007, 14,1
3. Broski SE, Regan TD, Sturgill WH. Lisinopril-induced erythroderma in an 85-year-old male. J of Drugs in Dermatology, published on line, 01-FEB-08

### Fernandes N et al.Erythroderma: a clinico-laboratorial and histopathological study of 170 cases. An. Bras. Dermatol. Vol.83 no.6 Rio de Janeiro Nov./Dec. 2008

1. Federman DG et al. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol. 2009 Jan;160(1):1-7.
2. Federman DG et al. Cardiovascular health for patients with psoriasis: a précis for front-line clinicians. Ostomy Wound Manage. 2009 May 1;55(5):38-47.
3. Ткаченко С, Кондрашова В. Кардиометаболический риск у болньiх псориазом. Дерматологiя та Венерологiя, 2010,2,48,11-17
4. Kopec K et al. **Erytrodermia łuszczycowa po ogólnym zastosowaniu kortykosteroidów – opis przypadku.** Przegl Dermatol 2011, 98, 405–409
5. Біловол, А. М. „Асоціація псоріазу з синдромом резистентності до інсуліну.” *Вісник проблем біології і медицини* 4 (1) (2012): 79-82.
6. 刘海燕. „阿维 A 联合窄谱 UVB 治疗银屑病的疗效及对血管紧张素转化酶与血管紧张素 II 的影响.” *中国医药指南* 10.23 (2012): 18-20.
7. Кожанов, А. С., & Усубалиев, М. Б. (2014). Псориатическая эритродермия (клиника, дифференциальная диагностика, патоморфология). *Наука, новые технологии и инновации*, (4), 92-95.
8. Mezentsev, A. V., et al. „Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.” International journal of biomedical science: IJBS 9.3 (2013): 112.
9. Özkaya, Esen, and Kurtuluş Didem Yazganoğlu. „Angiotensin-Converting Enzyme Inhibitors.” *Adverse Cutaneous Drug Reactions to Cardiovascular Drugs*. Springer London, 2014. 67-83.
10. 蔡艳霞, et al. „寻常型银屑病皮损中血管紧张素 II 及血管紧张素转化酶的检测.” *中国麻风皮肤病杂志* 4 (2014): 226-228.
11. Bilovol, А. N.; Tkachenko, S. G. Клінічні Особливості Протікання Псоріазу, Асоційованого З Артеріальною Гіпертензією. *Inter Collegas*, 2017, 4.3: 128-131.
12. Біловол, А. М., Ткаченко, С. Г., & Татузян, Є. Г. (2017). Проблематика терапії псоріазу, асоційованого з артеріальною гіпертензією. УДК: 616.517-085:616.12-008.331.1

В монографии

1. Litt J.Enalapril. In Litt’s Drug Eruptions & Reactions Manual, 17th Edition,2011,p.228
2. Sehgal V. Erythroderma/Exfoliative Dermatitis. Chapter 21, 256-264, In Emergency Dermatology, ed. By R. Wolf, Cambridge University Press, 2011.
3. Sehgal, Virendra N.; Karadag, Ayşe Serap; Srivastava, Govind. Erythroderma/exfoliative dermatitis. *Emergency Dermatology*, 2017, 2: 193-209.

**Antonov, D., L. Mateva, V. Lozanov, M. Vlaskovska, and N. Tsankov. „Effect of captopril on the biodegradation of bradykinin and substance p in human skin.” *Dokladi na B lgarskata akademiâ na naukite* 59, no. 5 (2006): 577-584.**

Цитиране – 1

1. Petrova, Guenka, et al. „Cardiovascular medicines prescribing in bulgaria.” *Comptes Rendus De L Academie Bulgare Des Sciences* 64.2 (2011): 285-292.

**Кazandjieva J, TSANKOV N. Tattoos: dermatological complications. Clin in Dermatol, 2007, 25, 375–382**

**Цитирания –176**

1. Mallon WK. Troublesome Tattoos, Problematic Piercings, and Other Body Modification Complications. Scientific assembly, October 11, 2007, Washington State Convention and Trade Center

## Jacob ShE, Castanedo-Tardan MP, Blyumin ML. Inflammation in Green (Chromium) Tattoos during Patch Testing. Dermatitis. 2008;19(5):

## Acar, Myrna del Carmen Rodríguez, Alberto Ramos Garibay, and Martha Alejandra Morales Sánchez. „Reacción granulomatosa por tatuaje cosmético.” *Rev Cent Dermatol Pascua* 18.3 (2009)

1. Cossio, Laura. „Tattooing and Scarring: Technique and Complications.” *Dermatologic Complications with Body Art: Tattoos, Piercings and Permanent Make-Up* (2009): 29.

## Fierro MG, Escalante AR. Body art& story, ravellingal aspects, comp.ications and treatment. Rev Ecuat Pediat (quito), 2009,10 (1):44-48

1. Forte, G, Petrucci F, Cristaudo A, Bocca B. Quantification of Sensitizing Metals in Tattooing Pigments by SF-ICP-MS Technique. Chem Biomed Methods Journal, 2009,2,42-47

## GilliamAD, Donnelly L, Gopinath B. Avoidance of tattoo disruption: a further benefit of laparoscopic surgery. J Surgical Endoscopy. 2009 , 23, 2 / February, 2009

1. Hennedige A, Joseph L, Zeiton A.An unusual case of tattoo pigments and systemic lymphadenopathy.. EJD,2009,19,6,654-655
2. Kaur RR, Kirby W, Maibach H. Cutaneous allergic reactions to tattoo ink. Journal of Cosmetic Dermatology. 2009, 8, 4,  295 – 300
3. Kirby W, Desai A., Desai T, Kartono F, Patel G. The Kirby Desai Scale: A proposed scale to assess tattoo removal treatments. J Clin Aesthetic Dermatol, 2009,2(3),32-37
4. Kluger N. Skin tumors arising in tattoos: coincidental or upcoming public health issue?Expert Rev. Dermatol., 2009,4,313-315
5. Kluger N, Mathelier-Fusade P, Moguelet­ Ph. Scleroderma-like Reaction Restricted to the Red Parts of a Tattoo. Acta Derm Venereol 2009; 89: 95-96.
6. Laguna C. Zaragoza V, de la Cuadra J. Dermatitis de contacto alérgica a hidrocortisona como complicación del cuidado local de Actas Dermo-Sifiliográficas, 2009 Apr; 100(3):246-8.
7. Laumann A. A physician’s meanderings on tattooing, body piercing, and suspension practices.Clinics in Dermatology, Volume 27, Issue 5, Pages 516-518, 2009,
8. Lehman JS, Tollefson MM, Gibson LE. Lichen planus.International journal of dermatology, 2009
9. Lee JS, J Park, SM Kim, SK Yun, HU Kim. Basal Cell Carcinoma Arising in a Tattooed Eyebrow  
   - Ann Dermatol Vol, 2009

# Mataix J, Silvestre JF. Reacciones cutáneas adversas por tatuajes y piercings Actas Dermosifiliogr, 2009

# Patrizi A, Raone B, Savoia F, Bacci F, Pileri A, Gurioli C, Neri I. Tattoo-associated pseudolymphomatous reaction and its successful treatment with hydroxychloroquine. Acta Derm Venereol. 2009;89(3):327-8.

1. Rodrigues AMS, Garibay AR, Sanchez MAM.Reaccicion granulomatosa por tatuaje ravelli. Rec Cent Dermatol Pascua, 2009,18,3,100-105
2. West C, Morritt A, Pedelty L, Lam D. Cutaneous leiomyosarcoma arising in a tattoo – ‘a tumour with no humour’. Journal of Plastic, Reconstructive & Aesthetic Surgery*,*2009,62, 5, 79-80
3. **Bruneau J, Daniel M, Kestens Y.** Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study. Int J Drug Policy, 2, 2010, 477-484
4. Choudhary S, Elsaie ML, Leiva A, Nouri K. Lasers for tattoo removal: a review. Lasers in medical science, 2010
5. Deckelbaum S. et al. A Rare Morpheaform Complication of a Black Ink Tattoo. J of AOCD, 2010,18,1,24-25
6. Harper J, Losch A, Otto S. Et al. New Insight into the Pathophysiology of Tattoo Reactions following Laser Tattoo Removal. Plastic & Reconstructive Surgery, 2010 ,126, 6, 313e-314e
7. Yuan J, Li W, Xia Zh, Shan Shi-Jun, Guo Y, Hong-Duo Chen. Secondary syphilis presenting in a red tattoo. EJD, 2010,20,4,544-5
8. Karaca, Nezih, et al. „Tattoo sarcoidosis on the arm associated with systemic involvement: case report.” Turkiye Klinikleri Journal of Dermatology 20.2 (2010): 88-90.
9. Karsai S, Krieger G ,Raulin C. Tattoo removal by non-professionals – medical and forensic considerations. JEADV, 2010,24,7,756-762
10. Kluger N, Vermeulen C, Moguelet P, Cotten H, Koeb MH, Balme B, Fusade T. Cutaneous lymphoid hyperplasia (pseudolymphoma) in tattoos: a case series of seven patients. JEADV, 2010,24,2,208-213
11. Kluger N. Cutaneous complications related to permanent decorative tattooing. Expert Review of Clinical Immunology, Volume 6, Number 3, May 2010 , pp. 363-371(9)
12. Kluger N. Body art and pregnancy. EJ Obst & Gyn Repr Biol,2010,153, 1, 3-7
13. **Ko J Christine. Lymphocytoma cutis. eMedicine, 26 Mar, 2010**
14. Lollis B, Kent, R. Cluster of Nontuberculous Mycobacteria Skin Infections from Tattoos. DTIC,2010, ADA523390
15. LÓPEZ, B. A., & SANTACANA, R. G. Complicaciones dermatológicas de los tatuajes y los piercings. *Monogr Dermatol 2010; 23: 55-66*
16. Μαυρίδου, K. A., and Ι. Δ. Μπασούκας. „Από το κοινωνικό περιθώριο στη γονιδιακή Ιατρική.”Arch Helenic medicine, 2010,583-595
17. Smit J., Scheele K, Lapid O, Hoogbergen M. Management of Tattoos in the Operative Field. Annals of Plastic Surgery, 2010, 64,1, 125-127
18. Sautebin L. Cosmetovigilanza (numero 3)...Reazione allergica ad alcuni coloranti contenuti nel trucco permanente. 作成: Cogito ergo sum...Penso dunque sono 日時: 2010年12月13日 3:24
19. Tourlaki A, BoneschiV, Tosi D, Pigatto P, Brambilla L. Granulomatous tattoo reaction induced by intense pulse light treatment. Photodermatology, Photoimmunology & Photomedicine,2010,26,9,275-6
20. Wenzel S, Welzel J, Hafner Ch, Landthaler M, Baumler W. Permanent make-up colorants may cause severe skin reactions. Contact Dermatitis, 2010, 63, 4, 223–227
21. Allione A, Dutto L, Castagna E et al.Erythema multiforme caused by tattoo: a further case. Intern Emerg Med.,2011, 6, 3, 263-265
22. Camilot D. Et al. Cutaneous Pseudolymphoma Following Tattoo Application: Report of Two New Cases of a Potential Lymphoma Mimicker. Int J Surg Patholog, 2011
23. Campolmi P et al. Cutaneous pseudolymphoma localized to black tattoo. JAAD, 2011,65,5,e155-e157
24. Caucanas, M., El Hayderi, L., Lebas, E., Richert, B., Dezfoulian, B., Nikkels, A.-F. Dermatological complications of temporary and indelible tattoos | [Complications dermatologiques des tatouages définitifs et ravelling] Annales de Dermatologie et de Venereologie,2011, 138 (2), pp. 161-162
25. **Concha R M et al. Cutaneous tuberculosis: two case reports and review.** Rev. Chil. Infectol. ,28 ,3 Santiago 2011
26. Collantes J, Canarte S. CAPITULO 79: El tatuaje en dermatología. PIEL-Latinoamericana / Libreria, publ.2011El estante digital del Dermatologo Latinoamericano
27. Dupuy S, Achenbach RE , Sanchez GF. Cuál es su diagnóstico? Rev. Argent. Dermatol, 92,1 Ciudad Autónoma de Buenos Aires ene./mar. 2011
28. FRANCHIMONT, Claudine, Jean-François Hermanns, and Gérald PIERARD. „Reactions cutanees a l’encre de tatouage.” *Revue Médicale de Liège* 66.7-8 (2011).
29. Galle F. Awareness of health risks related to body art practices among youth in Naples, Italy : a descriptive convenience sample study. BMC Public Health2011, **11**:625
30. Granum B. Tatovering – Think before you ink. Toksikologen, 2011, 02,19-22
31. Hirsch R. Iatrogenic laser complications. Clin Dermatol,2011,29,6,691-5
32. Høgsberg T, Saunte D, Moller N, Serup J. Microbial status and product labelling of 58 original tattoo inks. JEADV, 2011, Dec
33. Hong P et al. A case of ravelli induced by tattooing eyebrow. International Journal of Dermatology*,* Volume 50, issue 5 (May 2011), p. 607-608.
34. Ibrahimi O et al. Treatment of tattoo allergy with ablative fractional resurfacing: A novel paradigm for tattoo removal. JAAD,2011,64,6,1111-4
35. Kluger N. Cutaneous infections related to permanent tattooing. Médecine et Maladies Infectieuses,2011,41, 3,115-122
36. Kluger N. Cutaneous Complications Related to TattooingForum for Nord Derm Ven 2011, 16, 2,43-47
37. Kluger, N., Plantier, F., Moguelet, P., Fraitag, S. Tattoos : Natural history and histopathology of cutaneous reactions [Les tatouages : Histoire naturelle et histopathologie des réactions cutanées] . Annales de Dermatologie et de Venereologie,2011, 138 (2), pp. 146-154
38. Kuo, W.E., Richwine, E.E., Sheehan, D.J. Pseudolymphomatous and lichenoid reaction to a red tattoo : A case report . Cutis, 2011, 87 (2), pp. 89-92
39. Lehner K et al. Black tattoo inks are a source of problematic substances such as dibutyl phthalate. Cont Derm, 2011,65,4,231-8
40. Lee JY et al. Clinical Observation of Tattooed Prisoners. Korean J dermatol, 2011,49,5,398-407
41. Mavridou KA, Bassukas ID. The tattoo: From social outcast to genetic medicine.Archives of Hellenic Medicine, 2011,28(5): 583-595
42. Miller, L.M., Schwartz, J.T., Cho, S. Milia: A unique reaction to tattoos. Cutis, 2011, 87 (4), pp. 195-196
43. Morte P**,** Magee L. Hyperalgesia after Volar Wrist Tattoo: A Case of Complex Regional Pain Syndrome? Jclin Neuromuscular Disease, 2011, 12 , 3, 118-121
44. Pasolini G et al. Pseudolymphoma tattoo-induced. Dermatology reports, 2011,e47
45. Piérard-Franchimont, C., Hermanns, J.-F., Piérard, G.E. Skin reactions to tattoo ink | [Réactions cutanées à l’encre de tatouage. Revue Medicale de Liege, 2011 66 (7-8), pp. 430-433
46. Sweeney, S, Hicks L, Ranallo N et al. Perforating Granulomatous Dermatitis Reaction to Exogenous Tattoo Pigment: A Case Report and Review of the Literature. American Journal of Dermatopathology,2011
47. Camilot D, Arnez ZM, Luzar B, Pizem J, Zgavec B, Falconieri G. Cutaneous pseudolymphoma following tattoo application: report of two new cases of a potential lymphoma mimicker. Int J Surg Pathol. 2012 Jun;20(3):311-5.
48. Ding Na-na et al. Application of the multiple low ravel-swithched laser for the treatment of tattoos in 21 cases. Chinese J of Aesthetic medicine, Apr, 2012,21,6,621-2
49. Garcovich, Simone, et al. “Lichenoid red tattoo reaction: histological and immunological perspectives.” European Journal of Dermatology 22.1 (2012): 93.
50. Haddad, Charles, Fern J. Webb, and Judella Haddad-Lacle. „Delayed complication from a tattoo.” *American family physician* 86.7 (2012): 669.
51. Hammes, Stefan, et al. “Treatment errors resulting from use of lasers and IPL by medical laypersons: results of a nationwide survey.” *JDDG: Journal der Deutschen Dermatologischen Gesellschaft* (2012).
52. Høgsberg T, Carlsen KH, Serup J. High prevalence of minor symptoms in tattoos among a young population tattooed with carbon black and organic pigments, JEADV, 2012, July
53. Kent K et al. Laser Tattoo Removal: A Review. Dermatologic surgery,2012
54. Kluger, Nicolas. “Acute complications of tattooing presenting in the ED.” The American Journal of Emergency Medicine 2012; 30, 9 , 2055-2063.
55. Lee HR A Clinical Study on the Tattoos of Young Korean Males. Korean J Dermatol 2012; 50 (3): 212 ~ 219
56. Ly, T., and S. Lee. „If you think you can safely ink, beware of the masking effects of tattoos.” HongKong J Derm Venereol 20.3 (2012): 106-110.
57. Maatouk, I. “Complication of a Red Tattoo.” (2012).
58. Shinohara, Michi M., et al. “The histopathologic spectrum of decorative tattoo complications.” Journal of Cutaneous Pathology (2012).
59. Suvanasuthi S et al. Mycobacterium Fortuitum Cutaneous Infection from Amateur Tattoo. Journal of the Medical Association of Thailand, 2012, Vol 95, No 6
60. Tattoo medical issues. Other dermatological reactions, Wikepedia
61. Valdez J. Eyebrow granulomatous reactin to tattoo. Dermatologia CMQ, 2012; 10(4):295-6
62. 丁娜娜, et al. “Q 开关 Nd: YAG 激光低能量祛除 21 例文身疗效观察.” *中国美容医学* 21.4 (2012): 621-623.
63. Caligiuri, Michael J. „Traditional and New Enhancing Human Cybernetic and Nanotechnological Body Modification Technologies: A Comparative Study of Roman Catholic and Transhumanist Ethical Approaches.” (2013).
64. Elegino-Steffens, Diane U., et al. “A Case of Severe Septicemia Following Traditional Samoan Tattooing.” *Hawai’i Journal of Medicine & Public Health* 72.1 (2013): 5.
65. Falsey, Ryan R., et al. “Cutaneous Inoculation of Nontuberculous Mycobacteria During Professional Tattooing: A Case Series and Epidemiologic Study.”*Clinical Infectious Diseases* (2013).
66. Haddad, Charles, Judella Haddad-Lacle, and Fern Webb. “Capillary haemangioma in a 13-year-old boy.” *BMJ case reports* 2013 (2013).
67. Hammes, Stefan, et al. “Behandlungsfehler durch medizinische Laien bei Laser‐und IPL‐Anwendungen: Ergebnisse einer bundesweiten Erhebung.”*JDDG: Journal der Deutschen Dermatologischen Gesellschaft* 11.2 (2013): 149-157.
68. Høgsberg, Trine, et al. “Microbial status and product labelling of 58 original tattoo inks.” *Journal of the European Academy of Dermatology and Venereology*27.1 (2013): 73-80.
69. Hutton Carlsen, K., and J. Serup. “Photosensitivity and photodynamic events in black, red and blue tattoos are common: A ‘Beach Study’.” *Journal of the European Academy of Dermatology and Venereology* (2013).
70. Kluger, N. „﻿ Sarcoidosis on tattoos: a review of the literature from 1939 to 2011.” Sarcoidosis vasculitis and diffuse lung disease 30.2 (2013): 86-102.
71. de Oliveira, Carla Gregório Barbosa, Simão Cohen, and Valter Alves. „Remoção de tatuagens com laser: revisão de literatura.” *Surgical & Cosmetic Dermatology* 5.4 (2013): 289-295.
72. Raulin, Christian, Syrus Karsai, and Laurenz Schmitt. “Komplikationen der Laser-und IPL-Behandlung.” *Lasertherapie der Haut* (2013): 395-406.
73. Sweeney, Sarah A., et al. “Perforating granulomatous dermatitis reaction to exogenous tattoo pigment: A case report and review of the literature.” *The American Journal of Dermatopathology* 35.7 (2013): 754-756.
74. Sardana Kabir, Vijay K Garg, Shivani Bansal. Et al. A promising split-lesion technique for rapid tattoo removal using a novel sequential approach of a single sitting of pulsed CO2 followed by Q-switched Nd: YAG laser (1064 nm).12/2013 12(4):296-305.
75. Souza, Maiara Ferreira de, and Durval Campos Kraychete. „Author notes.” *Rev. Bras. Reumatol* 54: 5.
76. Tammaro, A., et al. „Allergic Contact Dermatitis from Aminoazobenzene in Tattoo.” *J Allergy Ther* 4.159 (2013): 2.
77. Tang M M, H Beltraminelli, D Perruchoud, N Pelivani, L Borradori, D Simon. A tattoo complicated by allergic contact dermatitis and panniculitis.Journal of the European Academy of Dermatology and Venereology . 03/2013 ;
78. Villaescusa, MªT López, et al. „Reacción granulomatosa a tatuaje permanente de las cejas.” *Med Cutan Iber Lat Am* 41.4 (2013): 183-185.
79. Agüero de Zaputovich, F., and L. Gonzalez Burgos. „Reacción granulomatosa a cuerpo extraño por tatuaje cosmético tratada con laser Qs Nd Yag 1064 y triamcinolona.”
80. Bassi, Andrea, et al. „Tattoo-associated skin reaction: the importance of an early diagnosis and proper treatment.” *BioMed research international* 2014 (2014). Hindawi Publishing Corporation BioMed Research International Volume 2014,
81. Ghersetich, Ilaria, and Tommaso Tanini. „Body modifying art: adverse effects and complications.” *Prime*. Vol. 4. No. 1. London: Informa Healthcare, 2014.
82. Huynh, Thy N., Jeremy D. Jackson, and Robert Thomas Brodell. „Tattoo and vaccination sites: Possible nest for opportunistic infections, tumors, and dysimmune reactions.” *Clinics in dermatology* 32.5 (2014): 678-684.
83. Hutton Carlsen, K., and J. Serup. „Photosensitivity and photodynamic events in black, red and blue tattoos are common: A ‘Beach Study’.” *Journal of the European Academy of Dermatology and Venereology* 28.2 (2014): 231-237
84. Demehri, Shadmehr, et al. „Chronic allergic contact dermatitis promotes skin cancer.” *The Journal of clinical investigation* 124.124 (11) (2014): 5037-5041.
85. Durmuş, Muzaffer, et al. „Tatuaja Bağlı Akut Kontakt Dermatit: Olgu Sunumu.” *Türk Plastik,* Rekonstrüktif ve Estetik Cerrahi Dergisi (Turk Plast Surg) 22.2 (2014): 72-74.
86. Irimie A et al.Tattoos – history and actuality.Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences •2014, 7 (56) No. 2 – 201
87. Ko C. Cutaneous Pseudolymphoma Medication. Medscape, Dec.2014
88. Marchesi Andrea , Pier Camillo Parodi, Marco Brioschi, et al.. Tattoo Ink-Related Cutaneous Pseudolymphoma : A Rare but Significant Complication. Case Report and Review of the Literature. Aesthetic Plastic Surgery (IF : 1.26). 2014 ;
89. Pires, Lisa. „Riscos associados às tatuagens decorativas.” (2014).
90. Nourmohammadpour, Pedram, et al. „Tattoo granuloma: A clinical and demographic survey of patients referred to Razi Hospital in Tehran.” *Dermatology and Cosmetic* 5.2 (2014): 76-81.
91. Philips, Rebecca C., et al. „Mycobacterium fortuitum infection arising in a new tattoo.” *Dermatology online journal* 20.6 (2014).
92. Siorokos, C., et al. „Lymphknotenmetastase oder verschlepptes Pigment?–Malignes Melanom innerhalb einer Schmucktätowierung.” *Aktuelle Dermatologie* 40.05 (2014): 184-186.
93. Simunovic, Carolina, and Michi M. Shinohara. „Complications of Decorative Tattoos: Recognition and Management.” *American journal of clinical dermatology* 15.6 (2014): 525-536
94. Souza, Erica Sales, et al. „T-cell-predominant lymphoid hyperplasia in a tattoo.” *Anais brasileiros de dermatologia* 89.6 (2014): 1019-1021.
95. Tobin Ph et al. Dermatologic Graffiti. Advance Healthcare Network, 2014
96. Beliaeva, H., S. Gregoriou, M. Makris, G. Larios, and D. Rigopoulos. "Contact allergic dermatitis after black henna tattooing: Successful treatment with betamethasone valerate patches." *Archives of Hellenic Medicine/Arheia Ellenikes Iatrikes* 32, no. 2 (2015).
97. Bent, Sebastiaan, and Ines Schornagel. "Allergische reactie na permanente tatoeage." *Huisarts en wetenschap* 1.58 (2015): 45-45.
98. Brady, Bobbi G., Heidi Gold, Elizabeth A. Leger, and Marie C. Leger. "Self‐reported adverse tattoo reactions: a New York City Central Park study."*Contact Dermatitis* (2015).
99. Bregnbak, David, Jeanne D. Johansen, Morten S. Jellesen, Claus Zachariae, Torkil Menné, and Jacob P. Thyssen. "Chromium allergy and dermatitis: prevalence and main findings." *Contact dermatitis* (2015).
100. Høgsberg, Trine, B. M. Thomsen, and J. Serup. "Histopathology and immune histochemistry of red tattoo reactions." *Skin Research and Technology* (2015).
101. Irimie, A. O. M., Brănişteanu, D., Stoleriu, G., & Morariu, S. Tattoos-history and actuality.,2015
102. Kluger, Nicolas. "Self‐reported tattoo reactions in a cohort of 448 French tattooists." *International journal of dermatology* (2015).
103. Lerche, Catharina M., M. Sepehri, J. Serup, T. Poulsen, and H. C. Wulf. "Black tattoos protect against UVR‐induced skin cancer in mice." *Photodermatology, photoimmunology & photomedicine* (2015).
104. Sardana, Kabir, Rashmi Ranjan, and Sneha Ghunawat. "Optimising laser tattoo removal." *Journal of cutaneous and aesthetic surgery* 8, no. 1 (2015): 16.
105. Serup, Jørgen. "Seamless Prevention of Adverse Events from Tattooing: Integrated Strategy Emphasising the Customer-Tattooist Interaction." (2015): 236-247.
106. Thum, Chee K., and Asok Biswas. „Inflammatory complications related to tattooing: a histopathological approach based on pattern analysis.” *The American Journal of Dermatopathology* 37.1 (2015): 54-66.

|  |
| --- |
|  |
|  |
|  |
|  |
|  |

1. van der Bent, Sebastiaan, and Ines Schornagel. „Allergische reactie na permanente tatoeage.” *Huisarts en wetenschap* 58.1 (2015): 45-45.
2. Valdivia, Pedro Pablo Obregón, Dunia Sotolongo Díaz, Haydée de la Fuente Rodríguez, and Dinora García Martín. "Manifestaciones del arte corporal en pacientes atendidos por la misión médica Cubana en el Hospital Distrital de Micomiseng/Manifestations of body art in patients attended by the Cuban Medical at the Mission District Hospital of Micomiseng." *MediCiego* 21, no. 2 (2015).
3. Almodovar-Real A, Sánchez-López J, Navarro-Triviño F, Fernández-Pugnaire MA. Reacción liquenoide por pigmento rojo en un tatuaje. SEMERGEN-Medicina de Familia. 2016 Feb 5.
4. Attia TH. Child Abuse: Is It Accepted In Some Societies?. International Journal of School and Cognitive Psychology. 2016 Mar 25;2016.
5. Dieckmann R, Boone I, Brockmann SO, Hammerl JA, Kolb-Mäurer A, Goebeler M, Luch A, Al Dahouk S. The Risk of Bacterial Infection After Tattooing. Deutsches Aerzteblatt International. 2016 Oct 7;113(40).
6. Forbat E, Al-Niaimi F. Patterns of Reactions to Red Pigment Tattoo and Treatment Methods. Dermatology and therapy. 2016 Mar 1;6(1):13-23.
7. Islam PS, Chang C, Selmi C, Generali E, Huntley A, Teuber SS, Gershwin ME. Medical Complications of Tattoos: A Comprehensive Review. Clinical reviews in allergy & immunology. 2016 Apr 1;50(2):273-86.
8. Laux P, Tralau T, Tentschert J, Blume A, Al Dahouk S, Bäumler W, Bernstein E, Bocca B, Alimonti A, Colebrook H, de Cuyper C. A medical-toxicological view of tattooing. The Lancet. 2016 Jan 29;387(10016):395-402.
9. Kluger N. Cutaneous and systemic complications associated with tattooing. La Presse Médicale. 2016 May 6.
10. Kluger N. Réactions dites «allergiques» aux tatouages: prise en charge et algorithme thérapeutique. Annales de Dermatologie et de Vénéréologie 2016 May 12. Elsevier Masson.
11. Kluger N. Self‐reported tattoo reactions in a cohort of 448 French tattooists. International journal of dermatology. 2016 Jul 1;55(7):764-8.
12. Mushtaq J, Walker A, Hunter B. Under pressure: progressively enlarging facial mass following high-pressure paint injection injury. BMJ case reports. 2016 Jan 19;2016:bcr2015212817.
13. Piccinini, Paola, et al. "Safety of tattoos and permanent make-up Final report." (2016).
14. Shinohara MM. Complications of decorative tattoo. Clinics in dermatology. 2016 Apr 30;34(2):287-92.
15. Acuña JR, Garibay AR, Muñiz RD. Reacción granulomatosa sarcoidea asociada a tatuaje cosmético con respuesta satisfactoria al tratamiento con dapsona. Piel. 2017 Sep 22.
16. Chatterjee K, Roy A, Ghosh R, Barua JK, Halder S, Banerjee G. The bumpy face of che guevara: An interesting case. Indian journal of dermatology. 2017 Nov;62(6):675.
17. Galbarczyk A, Ziomkiewicz A. Tattooed men: Healthy bad boys and good-looking competitors. Personality and Individual Differences. 2017 Feb 1;106:122-5.
18. Sagoe D, Pallesen S, Andreassen CS. Prevalence and correlates of tattooing in Norway: A large‐scale cross‐sectional study. Scandinavian journal of psychology. 2017 Dec 1;58(6):562-70.
19. Sousa, Ronaldo Adriano C. "Syphilis Among Illicit Drugs Users in the State of Pará, Brazilian Amazon." PhD diss., Universidade Federal do Pará, 2017.
20. Shashikumar BM, Harish MR, Shwetha B, Kavya M, Deepadarshan K, Phani HN. Hypersensitive reaction to tattoos: A growing menace in rural India. Indian Journal of Dermatology. 2017 May;62(3):291.
21. Stolarczyk J, Kubiś M, Brzosko M. Autoimmunologiczny zespół indukowany przez adiuwanty (ASIA). Pomeranian Journal of Life Sciences. 2017 Mar 6;62(1).
22. Wegner T, Lüth J, Flaig B, Schäd‐Trcka S, Emmert S, Brauns B. Ulzerierende Plaque innerhalb einer Tätowierung bei einem 49‐jährigen Mann. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2017 Jun 1;15(6):678-81.
23. West SE, Kostuchenko P, Kosari P, Sangueza OP. Unusual Eruption on the Arm. The American Journal of Dermatopathology. 2017 Aug 1;39(8):e102-3.
24. Wu CH, Thong HY, Huang CC, Chen PH. Report of two cases of cutaneous Mycobacterium abscessus infection complicating professional decorative tattoo. Dermatologica Sinica. 2017 Mar 31;35(1):40-3.
25. Zarazaga IP, Arias GM, Fernández AR, Castro JG. Eliminación de tatuajes con láser. Piel. 201
26. Zipori Y, Jakobi P, Solt I, Abecassis P. The need for an epidural “window of opportunity” in pregnant women with a lumbar tattoo. International Journal of Obstetric Anesthesia. 2017 Sep 21.
27. Chung, Jina, et al. "Cutaneous infections due to nontuberculosis mycobacterium: recognition and management." *American journal of clinical dermatology* 19.6 (2018): 867-878.
28. Kruger N. Improving patient outcomes: decorative tattoos, breast cancer and lymphoedema. Wounds UK. 2018 Apr 1;14(2).
29. Olvera Cortés V, González Alcudia AA, Pulido Díaz N, Arauco O, Rhony Á, Ramírez Q, de Jesús M. Moluscum Contagiosum Infection over Tattoed Skin: A Case Report. Dermatología Cosmética, Médica y Quirúrgica. 2018 Apr 9;16(1):28-31.7 Apr 10.
30. Sadeq AG, Al-Rubaya GM, Alzahrani F, Bukhari IA. The Verrucous Butterfly Tattoo. Journal of Health Science. 2018;8(1):1-3.
31. Vellaisamy G, Tirumalae R, Inchara YK. Histopathologic spectrum of reactions to black tattoo pigment: a report of five cases from India. Egyptian Journal of Dermatology and Venerology. 2018 Jan 1;38(1):18.
32. Ameri, Amir H., et al. "IL-33/regulatory T cell axis triggers the development of a tumor-promoting immune environment in chronic inflammation." *Proceedings of the National Academy of Sciences* 116.7 (2019): 2646-2651.
33. Badavanis, George, et al. "Late-onset pseudoepitheliomatous hyperplasia developing within a red ink tattoo." *Dermatology online journal* 25.5 (2019).
34. Grodner, C., et al. "Tattooing and psoriasis: dermatologists’ knowledge, attitudes and practices. An international study." *J Eur Acad Dermatol Venereol* 33 (2019): e38-e40.
35. Kirchhof, Mark G., and Se Mang Wong. "Tattoos and human papilloma virus: A case report of tattoo-associated flat warts (verrucae planae)." *SAGE open medical case reports* 7 (2019): 2050313X19857416.
36. Nørreslet, Line Brok, et al. "Tattoos and skin barrier function: Measurements of TEWL, stratum corneum conductance and capacitance, pH, and filaggrin." *Skin Research and Technology* 25.3 (2019): 382-388.
37. Petrochko, Jameson M., et al. "Tattoo-associated complications and related topics: A comprehensive review." *International Journal of Academic Medicine* 5.1 (2019): 19.
38. Сорокина, Анастасия Валерьевна. "Современный взгляд на лечение рубцов после татуажа." *Медицина. Социология. Философия. Прикладные исследования* 6 (2019).
39. El Baraka, F. Cherkaoui, et al. "Mélanomes sur tatouage: deux observations et revue systématique de la littérature." *Annales de Dermatologie et de Vénéréologie*. Vol. 147. No. 4. Elsevier Masson, 2020.
40. Butterfield, Jesse L., et al. "Solar Freckles: Long-Term Photochromic Tattoos for Intradermal Ultraviolet Radiometry." *ACS nano* 14.10 (2020): 13619-13628.
41. Huisman, Sanne, et al. "Cutaneous non-allergic complications in tattoos: An overview of the literature." *Presse medicale (Paris, France: 1983)* 49.4 (2020): 104049.
42. FridmanSorokina, Anastasiya V. "Innovative Methods Of Miscellaneous Skin Inclusions Removal And Post-Inflammatory Hyperpigmentation Correction." *European Journal of Molecular & Clinical Medicine* 7.5 (2020): 214-221.
43. Galbarczyk, Andrzej, et al. "Association between sexual orientations of individuals and perceptions of tattooed men." *Psychology & Sexuality* 11.3 (2020): 150-160.
44. Grodner, C. A. M. I. L. L. E., et al. "Tattoo complications in treated and non‐treated psoriatic patients." *Journal of the European Academy of Dermatology and Venereology* 34.4 (2020): 888-896.
45. Grodner, C., et al. "Déterminants de la réticence des dermatologues vis-à-vis du tatouage chez les patients atteints de psoriasis. Une étude internationale." *Annales de Dermatologie et de Vénéréologie*. Vol. 147. No. 12. Elsevier Masson, 2020.
46. Kim, So Young, et al. "Evaluation of phototoxicity of tattoo pigments using the 3 T3 neutral red uptake phototoxicity test and a 3D human reconstructed skin model." *Toxicology in Vitro* 65 (2020): 104813.
47. Ogawa, Toru, Mirian Nacagami Sotto, and Mai P. Hoang. "Granulomatous dermatitis and others." *Hospital-Based Dermatopathology*. Springer, Cham, 2020. 137-198.
48. Park, Austin M., Nathanael E. Hathaway, and Kevin T. Wright. "Mycobacterium mageritense tattoo infection: a known complication with a novel species." *Dermatology online journal* 26.4 (2020).
49. Saluja, Raminder, and Richard D. Gentile. "Picosecond Laser: Tattoos and Skin Rejuvenation." *Facial plastic surgery clinics of North America* 28.1 (2020): 87-100.
50. Tomita, Shoichi, Katsuya Mori, and Hitomi Yamazaki. "A survey on the safety of and patient satisfaction after nipple-areola tattooing." *Aesthetic plastic surgery* (2020): 1-7.
51. Wennekers, Mèdelyn M., Jeffrey Damman, and Martijn van Doorn. "Een patiënt met een granulomateuze ontstekingsreactie ter plaatse van een tatoeage en een panuveïtis." *Nederlands Tijdschrift voor Dermatologie en Venereologie* 30.5 (2020): 4-5.
52. Agarwal, Pooja, et al. "Histopathological evaluation of cutaneous reactions to tattoos: Study at a tertiary care center." *Journal of Cutaneous Pathology* (2021).
53. Carlson, Craig S., et al. "On the attenuation of ultrasound by pure black tattoo ink." *SAIEE Africa Research Journal* 112.1 (2021): 24-31.
54. Chakraborty, Sagnik, et al. "Study on isotherm, kinetics, and thermodynamics of adsorption of crystal violet dye by calcium oxide modified fly ash." *Environmental Engineering Research* 26.1 (2021).
55. Gualdi, Giulio, et al. "Tattoo: Ancient art and current problems." *Journal of Cosmetic Dermatology* 20.2 (2021): 602-604.
56. Karregat, Joey JJP, et al. "Assessment of cytotoxicity and sensitization potential of intradermally injected tattoo inks in reconstructed human skin." *Contact Dermatitis* (2021).
57. Osu, Tinisha, et al. "Fluctuating asymmetry of finger lengths, digit ratio (2D: 4D), and tattoos: A pre-registered replication and extension of Koziel et al.(2010)." *Early Human Development* 152 (2021): 105273.
58. Serrano-Serra, Jose-Pablo, et al. "Epidermal Barrier Function and Skin Homeostasis in Skin with Permanent and Adhesive Tattoos: A Cross-Sectional Study." *Journal of Clinical Medicine* 10.4 (2021): 888.
59. Temiz, Selami Aykut, and Emin Özlü. "Medical Complications of Tattoos." *Journal of the Turkish Academy of Dermatology* 15.1 (2021): 1.

Top of Form



**В монографии**

1. Giusti G. Trattato di Medicina Legale e scienze affini – Vol. II: Semeiotica medico legale. Amazon.com, 2009,p.810
2. Collet E, Jeudy G. Dermatites de contact aux tatouages et piercings. In Progres en dermato-allergologie. Gerda. Ed. By Milpied H. Bordeau 2009
3. Moore-Higgs G J. Benign skin disorders: Impact on Cancer Therapy. Chapter 3. In: Principles of Skin Care and the Oncology Patient, Oncology Nursing Society,2010
4. Perez-Cotapos ML, Cuyper C, Cossio L. Tattooing and scarring. Technique and complication. In: Dermatologic complications with body art. Springer Verlag, 2010,40
5. Foregn body reactions. In:Andrew’s Diseases of the Skin: Clinical Dermatology. By William D. James, Timothy Berger, Dirk Elston, 10th edition, 2011, Elsevier
6. Raulin C, Karsai S, Schmitt L. Complications in Laser Surgery and IPL Treatment. In : Laser and IPL Technology in Dermatology and Aesthetic Medicine . Springer,2011, Part 3, 333-344,
7. Vejjabhinanta V, Caperton C, Wong C et al. Laser Treatment of Tattoos , In : Lasers in Dermatology and Medicine,ed. by K. Nouri, Springer, 2011, 83-89
8. Breitenbach, Maritza. The Cookie Book: Celebrating the Art, Power and Mystery of Woman’s Sweetest Spot. Hunter House, 2012.
9. Gaddoni, Giuseppe, and Antonella Tammaro. „Approccio allergologico e sanitario alle nuove mode giovanili: Tatuaggi e piercing.” In *Dermatologia allergologica nel bambino e nell’adolescente*, pp. 129-134. Springer Milan, 2012.
10. Gonçalo, Margarida. « Tattoo artists. » (2012). In Kannerva’s Occupational Skin Diseases
11. Wentworth, Ashley B., et al. „Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population-based study.” *Mayo Clinic Proceedings*. Vol. 88. No. 1. Elsevier, 2013.
12. Aung, Phyu P., and Meera Mahalingam. „Nodular B-Lymphocyte Reactive Patterns: Reactive Nodular B-Cell Pattern.” In *Cutaneous Hematopathology*, pp. 207-230. Springer New York, 2014.
13. Wough M. Chapter 24. Genital Adorntment, In: Genital and Perianal Diseases : A Color Handbook ed By Tomasz F. Mroczkowski, Larry E. Millikan, Lawrence Charles Parish,CRC press,2014,p 280
14. Bonadonna, Lucia. "Survey of Studies on Microbial Contamination of Marketed Tattoo Inks." (2015): 190-195.
15. Serup, Jørgen, K. Hutton Carlsen, and Mitra Sepehri. "Tattoo Complaints and Complications: Diagnosis and Clinical Spectrum." (2015): 48-60.
16. Schmidt, Andy. "Hygiene Standards for Tattooists." (2015): 223-227.
17. Boulart L, Mimoun M, Noel W, Malca N, Chaouat M, Boccara D. Dealing with tattoos in plastic surgery. Complications and medical use. InAnnales de Chirurgie Plastique Esthétique 2016 Oct 12. Elsevier Masson.
18. Serup J, Sepehri M, Hutton Carlsen K. Classification of Tattoo Complications in a Hospital Material of 493 Adverse Events. Dermatology. 2016 Dec 15.
19. Kluger N. Complications of Tattoos and its Management. TATTOO-The Invaluable Compendium for Dermatologists. 2017 Aug 31:55.
20. Serup J. How to Diagnose and Classify Tattoo Complications in the Clinic: A System of Distinctive Patterns. In: Diagnosis and Therapy of Tattoo Complications 2017 (Vol. 52, pp. 58-73). Karger Publishers.
21. Serup J. From Technique of Tattooing to Biokinetics and Toxicology of Injected Tattoo Ink Particles and Chemicals. In:Diagnosis and Therapy of Tattoo Complications 2017 (Vol. 52, pp. 1-17). Karger Publishers.
22. Serup J. Tattoo Infections, Personal Resistance, and Contagious Exposure through Tattooing. In: Diagnosis and Therapy of Tattoo Complications 2017 (Vol. 52, pp. 30-41). Karger Publishers.

**Petkov T, Pehlivanov G, Grozdev I, Kavaklieva S, TSANKOV N. Toxic epidermal necrolysis as a dermatological manifestation of drug hypersensitivity syndrome. EJD,2007,17,5,**

**Цитати – 33**

1. Valeyrie-Allanore L, Roujeau JC.Denominations and classification of severe cutaneous adverse reactions to drugs: splitters versus mergers. European Journal of Dermatology, 2007,17(5):359-60.
2. Ayd›n Yьcel, Gonca Karakufl, Suhan Gьnaflt. Dermatological Side Effects of Psychotropic Drugs and Treatment Approaches. Klinik Psikofarmakoloji Bulteni 2008;18:235-244
3. Gerkowic A et al. **Artykuł oryginalny Zastosowanie leków biologicznych w leczeniu łuszczycy paznokci.** Post Dermatol Alergol 2008; XXV, 6: 283–288
4. **Merrick BA.** The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research. Briefings in Functional Genomics and Proteomics 2008 7(1):35-49
5. Neuman MG et al. Predicting possible zonisamide hypersensitivity syndrome. Exp Dermatol. 2008 ;17(12):1045-51.
6. Bertram, L et al. Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. Acta Derm Venereol. 2009;89(3):285-7.
7. Krstić Svetozar S. Et al. Hipersenzitivna reakcija na lamotrigin kod jednog deteta – prikaz slučaja Apollinem medicum et aesculapium 2009, 7,1-2, 29-32
8. Pérez, Laura Crespo, et al. „Síndrome de hipersensibilidad a anticomiciales: una entidad para recordar.” *Gastroenterología y Hepatología* 32.10 (2009): 687-692
9. Setkowic M et al. **Opis przypadku Lamotrygina – lek przeciwdrgawkowy nowej generacji prawdopodobną przyczyną ostrej dermatozy polekowej – opis przypadku.** Post Dermatol Alergol 2009; XXVI, 6: 555–560
10. Thakor AS et al. Toxic epidermal necrolysis and neutropaenia: complications of omeprazole. Australas J Dermatol. 2009 Aug;50(3):207-1
11. Chaabane Amel,et al. DRESS Syndrome: 11 Case Reports and a Literature. Review Thérapie 2010; 65 (6): 543–550
12. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol. 2010 ;20(6):743-7.
13. Honma M, Tobisawa S. Toxic epidermal necrolysis with prominent facial pustules: a case with reactivation of human herpesvirus 7. Dermatology. 2010;221(4):306-8.
14. Meik S et al. Síndrome de hipersensibilidad a anticonvulsivantes (ravelli de DRESS): comunicación de 4 casos Dermatología Argentina, 2010,16, 4
15. Steinlein OK. Gene polymorphisms and their role in epilepsy treatment and prognosis. Naunyn Schmiedebergs Arch Pharmacol. 2010 Aug;382(2):109-18.
16. Teraki Y, Shibuya M, Izaki S. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Clin Exp Dermatol. 2010 ;35(7):723-8.
17. Cotton BA,et al. Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis. J Trauma. 2011 Aug;71(2):375-9.
18. Fadeyibi IO et al. Severe idiosyncratic drug reactions with epidermal necrolysis: A 5-year study. Indian J Plast Surg. 2011; 44(3): 467–473.
19. Wu, Zhouwei, and Weimin Shi. „Rash as the first manifestation of acute graft-versus-host disease after orthotopic liver transplantation.” *European Journal of Dermatology* 21.6 (2012): 997-998.
20. Уджуху ВЮ, Медведева АС, Иванокова МА. Клинико-иммунологическая характеристика токсидермий, в том числе с явлениями вторичной пиодермии. Российский журнал кожных и венерических болезней. 2012(5).
21. Houssam, Najwa. "Syndrome de Lyell avec choc cardiogénique fatal suite à un surdosage à la salazosulfapyridine (salazopyrine): à propos d’un cas avec revue de la littérature." PhD diss., 2013.
22. Meik, Sabrina, et al. „Anticonvulsant hypersensitivity syndrome (DRESS syndrome): report of 4 cases.” *Dermatología Argentina* 16.2010 (2013): 272-277.
23. Saral, Seçil, Bengü Nisa Akay, and Hatice Şanlı. „Sulfasalazin ile tetiklenen ilaçla ilişkili hipersensitivite sendromu.” *Archives of the Turkish Dermatology & Venerology/Turkderm* 47.2 (2013).
24. Schepis, Carmelo. „Cutaneous findings in children with intellectual disabilities.” *The Journal of dermatology* 40.1 (2013): 21-26.
25. Tiwari, Prashant, et al. „Toxic epidermal necrolysis: an update.” *Asian Pacific Journal of Tropical Disease* 3.2 (2013): 85-92
26. Weinand, C., et al. „27 years of a single burn centre experience with Stevens–Johnson syndrome and toxic epidermal necrolysis: Analysis of mortality risk for causative agents.” *Burns* 39.7 (2013): 1449-1455.
27. 杨光艳, 周小勇, and 苏飞. „32 例重症药疹回顾性分析.” *药物流行病学杂志* 011 (2013): 600-602.
28. Bertulyte, Ilma, Sofie Schwan, and Pär Hallberg. „Identification of risk factors for carbamazepine-induced serious mucocutaneous adverse reactions: A case-control study using data from spontaneous adverse drug reaction reports.” *Journal of pharmacology & pharmacotherapeutics* 5.2 (2014): 100.
29. Ordoñez L, Salgueiro E, Jimeno FJ, Manso G. Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs. Eur Rev Med Pharmacol Sci. 2015 Jul 1;19(14):2732-7.
30. 乌日嘎. "重症药疹的临床分析." *内蒙古医科大学学报* S1 (2015): 308-311.
31. Novais F, Vasconcelos JP, Telles-Correia D. Reacções adversas medicamentosas cutâneas associadas aos psicofármacos: uma revisão da literatura. Psilogos. 2015 Jun 1;13(1):106-23.
32. Díaz-Molina VL, Tirado-Sánchez A, Ponce-Olivera RM. Clinical, aetiological and therapeutic findings in Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, four years experience in a third-level Mexican hospital. Revista Médica del Hospital General de México. 2016 Jun 30;79(2):55-62.

В монографии

1. Bellamy C, Burt AD. The Liver in Systemic Disease. InMacsween's Pathology of the Liver (Seventh Edition) 2018 (pp. 966-1018).

**TSANKOV N. Drug hypersensitivity syndrome. 16th Congress of EADV, Vienna, 18-21 May, 2007**

**Цитати – 1**

1. Walsh N.Rash with fever may signal drug hypersensitivity. Skin And Allergy News, Autoimmunity/Connective Tissue, 2007,1-2

## **Kazandjieva J, Grozdev I, TSANKOV N. Temporary henna tattoos. Clinics in dermatology. 2007;25(4):383-7.**

## Цитирания – 52

1. Weykunat, Norbert, and Sitz Dresden. Ermittlung des Hygienestatus in Einrichtungen des Geltungsbereiches der Sächsischen Hygieneverordnung. Diss. 2008.

## Fierro MG, Escalante AR. Body art& story, psycological aspects, comp.ications and treatment. Rev Ecuat Pediat (quito), 2009, 10 (1):44-48

1. Polat M, Dikilitaş M, ÖztaşP, AllıN. Allergic contact dermatitis to pure henna. Dermatology Online Journal ,2009, 15 (1): 15
2. Rosmaninho A, Machado S, Amorim I, Lobo I, Selores M. Henna tattoo and Sweet’s syndrome& a possible relation. EJD,2009,19,6,642-643
3. Kharfi, M., El Fekih, N., Zayan, F., Mrad, S., Kamoun, M.R. Temporary tatooing : black henna or harkous?Medecine tropicale, 2009,69,5,527-8
4. Calogiuri G, Foti C, Bonamonte D, Nettis E, Muratore L, Angelini G. Allergic reactions to henna-based temporary tattoos and their components. Immunopharmacology and Immunotoxicology,2010,32,4 700-4
5. Krasteva M, Bons B, Tozer S et al. Contact allergy to hair colouring products The cosmetovigilance experience of 4 companies (2003-2006) EJD, 2010,20,1,85-95
6. Sinjan, E., Rutsaert, R., Druwe, P. Poisoning by a forbidden "black stone" of paraphenylene-diamine: Systemic toxicity of PPD | [Systemische intoxicatieverschijnselen bij vergiftiging met een verboden zwarte steen van parafenyleendiamine] . Tijdschrift voor Geneeskunde 2010, 66 (17), pp. 826-829
7. Martin PA. Sensibilizacion a parafenilendiamina por tatuajes temporales: estudio clinico y analitico en el area sur de gran canaria. Tesis Doctoral, Universidad de Las Palmas de Gran Canaria,2010, 252
8. Andel-Maksoud G, El-Amin AR. A Review on the materials used during the mummification processes in ancient Egypt. Mediterranean Archaeology an Archaeometry , 2011,11,2,129-150
9. Belhadjali H et al. Bullous Allergic Contact Dermatitis to Pure Henna in a 3-Year-Old Girl. Ped Dermatol,2011, 28,5,580-1
10. Erpolat S et al. Allergic contact dermatitis from temporary henna tattoo: a case report of a child. Yeni Tip Dergisi 2011,28,4,239-40
11. Herissé, C., Dubois, A., Bagny, K., Camus, M., Wierzbickahainaut, E., Guillet, G. A holiday souvenir the hair! Localized hypertrichosis at the site of henna tattoo | [Un souvenir de vacances... au poil ! Hypertrichose localisée au site de tatouage au henné].   Nouvelles Dermatologiques, 2011 30 (3), pp. 162
12. Priya, R., Ilavenil, S., Kaleeswaran, B., Srigopalram, S., Ravikumar, S. Effect of Lawsonia inermis on tumor expression induced by Dalton's lymphoma ascites in Swiss albino mice. Saudi Journal of Biological Sciences,2011, 18 (4), pp. 353-359
13. Rahiman, F.A., Taha, R.M. Plant regeneration and induction of coloured callus from henna (Lawsonia inermis syn. Lawsonia alba)Journal of Food, Agriculture and Environment ,2011,9 (2), pp. 397-399
14. Silvente San Nicasio, C., Valdivielso Ramos, M., De La Cueva Dobao, P., Balbín Carrero, E., Chavarría Mur, E., Hernanz Hermosa, J.M.Contact allergic dermatitis due to henna tattoos. Acta Pediatr Esp., 2011,69,(2):75-77
15. Silva, Joana Sofia Dantas Leite. Aplicação dermocosmética de geoprodutos. Aplicação dermocosmética de geoprodutos,2011
16. Wang, P.G., Krynitsky, A.J. Rapid determination of para-phenylenediamine by gas chromatography-mass spectrometry with selected ion monitoring in henna-containing cosmetic products. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences,2011, 879 (20), pp. 1795-1801
17. Yap, F.B.B. An itchy erythematous temporary holiday tattoo. Tzu Chi Medical Journal, 2011,23 (2), pp. 58-59
18. Almeida PJ et al. Quantification of **p**-phenylenediamine and 2-hydroxy-1,4-naphthoquinone in henna tattoos. Contact Dermatitis,2012, 66, 1, 33–37
19. Griffiths A, Murphy F. The use of henna as an alternative skin marker in breast disease. Radiography. 2012
20. Handa, Sanjeev, and Rahul Mahajan. "Contact dermatitis to hair dye: An update." Indian Journal of Dermatology, Venereology, and Leprology 78.5 (2012): 583.
21. de Groot, Anton C. "Side‐effects of henna and semi‐permanent ‘black henna’tattoos: a full review." *Contact Dermatitis* 69.1 (2013): 1-25.
22. Berih, A., & Berhanu, A. Allergic dermatitis: Black henna (para-phenylenediamine) use among the East African patient population in a general practice setting. *Australian family physician*(2014, *43*(6), 383.
23. Glatstein, Miguel M., et al. "Severe Allergic Contact Dermatitis From Temporary" Black Henna" Coloring of the Hair During Religious Cultural Celebrations: Three Different Cases, Same History." *American journal of therapeutics* (2014).
24. Gokalp, Hilal, and Kismet Kaya. "Angioedema-like allergic contact dermatitis related to black henna." *Dermatology online journal* 20.2 (2014).
25. Rodrigo-Nicolás, Beatriz, et al. "Contact Dermatitis From a Temporary Tattoo in a Boy With Contact Allergy to P-Tert Butyl Phenol Formaldehyde Resin."*Dermatitis* 25.1 (2014): 37-38.
26. Solomon, A., & Gopal, S. V. (2014). An indigenous marker for planning surgical skin incision. *International Journal of Surgery*, *12*(11), 1146-1147.
27. Chen, Tiffany, and Melanie D. Pratt. "Photo Developer Allergic Contact Dermatitis in a Photographer Following Paraphenylenediamine Sensitization from a Temporary Henna Tattoo." *Journal of cutaneous medicine and surgery*19.1 (2015): 73-76.
28. Gupta, Divya, and Devinder Mohan Thappa. "Dermatoses due to indian cultural practices." *Indian journal of dermatology* 60.1 (2015): 3.
29. El Habr, Constantin, and Hala Mégarbané. "Temporary henna tattoos and hypertrichosis: a case report and review of the literature." *Journal of Dermatological Case Reports* 9.2 (2015): 36.
30. Hasbún, A., L. Vial, F. Silva, and L. Beltrán. "Dermatitis de contacto inducida por henna: Reporte de un caso." *Revista argentina de dermatología* 96, no. 3 (2015): 68-74.
31. Al Saif F. Henna beyond skin arts: Literatures review. Journal of Pakistan Association of Dermatologists. 2016 Jan 1;26(1):58-65.
32. Diepgen TL, Naldi L, Bruze M, Cazzaniga S, Schuttelaar ML, Elsner P, Goncalo M, Ofenloch R, Svensson Å. Prevalence of Contact Allergy to p-Phenylenediamine in the European General Population. Journal of Investigative Dermatology. 2016 Feb 29;136(2):409-15.
33. Glatstein MM, Rimon A, Danino D, Scolnik D. Severe allergic contact dermatitis from temporary “black henna” coloring of the hair during religious cultural celebrations: three different cases, same history. American journal of therapeutics. 2016 Jan 1;23(1):e292-4.
34. Goodie PE, Burkhart CG. Temporary Henna Tattooing: a Case of Contact Dermatitis. Open Dermatology Journal. 2016;10:82-4.
35. Kaličanin B, Velimirović D. A Study of the Possible Harmful Effects of Cosmetic Beauty Products on Human Health. Biological trace element research. 2016 Apr 1;170(2):476-84.
36. Lee HJ, Kim WJ, Kim JY, Kim HS, Kim BS, Kim MB, Ko HC. Patch tests with commercial hair dye products in patients with allergic contact dermatitis to para-phenylenediamine. Indian Journal of Dermatology, Venereology, and Leprology. 2016 Nov 1;82(6):645.
37. Piccinini P, Pakalin S, Contor L, Bianchi I, Senaldi C. Safety of tattoos and permanent make-up Final report.European commission, 2016 JRC science fo policy report
38. Aktas Sukuroglu A, Battal D, Burgaz S. Monitoring of Lawsone, p‐phenylenediamine and heavy metals in commercial temporary black henna tattoos sold in Turkey. Contact dermatitis. 2017 Feb 1;76(2):89-95.
39. Choudhry K, Venkatramani H, Sabapathy S. A simple technique for temporary marking of the electrical stimulation points in brachial plexus injury patients. Indian Journal of Plastic Surgery. 2017 Sep 1;50(3).
40. Gürel, G., Çölgeçen, E. Geçici Kina Dövmesine Bağli Kontakt Dermatit Olgusu. Bozok Tıp Derg 2017;7(2):94-6
41. Imran M, Usman HF, Shafi H, Sarwar M, Tahir MA. Development of Rapid and Economical Colorimetric Screening Method for p‐Phenylenediamine in Variety of Biological Matrices and its Application to Eleven Fatal Cases of p‐Phenylenediamine Poisoning. Journal of forensic sciences. 2017 Mar 1;62(2):483-7.
42. Mukkanna KS, Stone NM, Ingram JR. Para-phenylenediamine allergy: current perspectives on diagnosis and management. Journal of Asthma and Allergy. 2017;10:9.
43. Peng F, Du J, Xue CH, Liu SS, Li WH, Chen Z, Zhang JZ. Henna Tattoo: Temporary or Permanent?. *Chinese medical journal*. 2017 Nov 20;130(22):2769.
44. Sinha A, Goel L, RAnjAn R, GAbA S, Kumar A. Atraumatic Acute Compartment Syndrome of Forearm Following Artificial Mehndi (Henna) Dermatitis–A Rare Case Report. Journal of clinical and diagnostic research: JCDR. 2017 Jun;11(6):RD01.
45. Vásquez-Chirinos M, Sánchez M, Brizuela A, Rivera I. Tatuajes: de la tinta a la dermatología. Dermatología Venezolana. 2017;55(1).

В монографии

1. Perez-Cotapos ML, Cuyper C, Cossio L. Tattooing and scarring. Technique and complication. In: Dermatologic complications with body art. Springer Verlag, 2010,29-41
2. De Cuyper Ch., D'hollander D. Materials Used in Body Art. In: Dermatologic complications with body art. Springer Verlag, 2010, 13-28
3. Lawsonia inermis. In :American Herbal Products Association’s Botanical Safety Handbook, Second Edition edited by Zoë Gardner, Michael McGuffin,2013, p. 508
4. Mroczkowski, Tomasz F., Larry E. Millikan, and Lawrence Charles C. Parish. *Genital and Perianal Diseases: A Color Handbook*. CRC Press, 2013.
5. Kavya M. Tattoo Alternatives. TATTOO-The Invaluable Compendium for Dermatologists. 2017 Aug 31:139.

**КazandjievA J, TSANKOV N. Tattoos and piercings. Clin in Dermatol, 2007, 25, 361**

**Цитирания – 11**

1. Kaatz M, Elsner P, Bauer A. Body-modifying concepts and dermatologic problems: tattooing and piercing.Clin Dermatol 2008;26(1):35-44.
2. De Cuyper, Christa. „Permanent makeup: indications and complications.” *Clinics in dermatology* 26.1 (2008): 30-34.

## Fierro MG, Escalante AR. Body art& story, psycological aspects, comp.ications and treatment. Rev Ecuat Pediat (quito), 2009,10 (1):44-48

1. De Cuyper C. Permanent makeup: indications and complications. Clin Dermatol 2008;26(1):30-4.
2. Parish LC. Dermatologic complications with body art. JAMA. 2010;303(13):1314-1315
3. Scheinfeld N. Dermatologic complications with body art:Tattoos, Piercings, and Permanent Make-Up. SkinMed,2011,9,1,68
4. American College of Obstetricians and Gynecologists. Resource Guide Adolescents and Body Modification.
5. Huynh, Thy N., Jeremy D. Jackson, and Robert Thomas Brodell. „Tattoo and vaccination sites: Possible nest for opportunistic infections, tumors, and dysimmune reactions.” *Clinics in dermatology* 32.5 (2014): 678-684.
6. Serup J, HARRIT N, Linnet JT, Møhl B, Olsen O, Westh H. TATTOOS—HEALTH, RISKS AND CULTURE. With introduction of the” seamless prevention” strategy. Copenhagen: The Council on Health and Disease Prevention. Artikeln finns fritt tillgänglig på www. vidensrad. dk. 2015.
7. Marini L. Tattoo removal using a multilayer Q-switched laser. PRIME J. 2016;6(4):14-23.

В монографии

1. Breitenbach, M. *The Cookie Book: Celebrating the Art, Power and Mystery of Woman’s Sweetest Spot*. Hunter House, 2012.

**Kazandjieva J, TSANKOV N. Temporary henna tattoos – new aspects of allergy to para-phenylene diamine. JIMAB, 2007, book 1,part medicine,73-74**

## **Цитирания – 3**

1. Henna.PPD p-fenilenodiamina, Sintomas, Faculdade de farmacia, Universidade do Porto
2. Waggas A. Neuro and Nephro-Toxicity in Rats Topically Treated with Para-Phenylene Diamine. Am-Eurasian J Toc Sci, 2011,3,3,130-137
3. Petrovajova M et al. Long term risk of tattoo in children. Dermatol. Prax, 2011,5 (2): 80-84

**Demerdjieva Z, Kavaklieva S, TSANKOV N. Epidermal Nevus Syndrome and Didymosis Aplasticosebacea. Pediatric Dermatology, 2007, 24, 5, 514–516**.

**Цитати – 9**

* 1. Happle R. The group of epidermal nevus syndromes: Part II. Less well defined phenotypes. JAAD, 2007, 63, 1 , 25-30

# Pascual-Castroviejo I, Ruggieri M. Schimmelpenning-Feuerstein-Mims Syndrome (Nevus Sebaceous Syndrome. Neurocutaneous Disorders Phakomatoses and Hamartoneoplastic Syndromes. 2008, 559-573

# Brandling-Bennett HA, Morel KD. Epidermal nevi. Pediatr Clin North Am. 2010 Oct;57(5):1177-98

# Happle, Rudolf. „The group of epidermal nevus syndromes: Part I. Well defined phenotypes.” *Journal of the American Academy of Dermatology* 63.1 (2010): 1-22.

# Joshi A et al. Schimmelpenning Syndrome (epidermal nevus syndrome): A case report. The Gulf Journal of Derm and Vener, 2012, 19,1,61-67

# Patel P, Malik K, Khachemoune A. Sebaceus and Becker’s nevus: overview of their presentation, pathogenesis, associations, and treatment. American journal of clinical dermatology. 2015 Jun 1;16(3):197-204.

В монографии

# Weedon D. Chapter 31: Tumors of the epidermis In Weedon’s Skin Pathology, Elsevier, 2010

# William James Chapter 29: Epidermal Nevi, Neoplasms, and Cysts . In Andrews’ Diseases of the Skin. Ed. By William James et al. Elsevier, 2011

# Happle, Rudolf. „Other Binary Genodermatoses, Including “Pseudodidymosis”.” *Mosaicism in Human Skin*. Springer Berlin Heidelberg, 2014. 115-120.

**Tsankov N. The Libyan AIDS crisis and a miscarriage of justice. Clinics in dermatology. 2007;25(1):146.**

## **Цитирания – 1**

1. Cohen PR, Kurzrock R, Parish LC. Warning signal: Unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates. Clinics in dermatology. 2013 Jan 1;31(1):128-30.

**Fluhr, J. W., R. Darlenski, I. Angelova-Fischer, N. Tsankov, and D. Basketter. „Skin irritation and sensitization: mechanisms and new approaches for risk assessment. 1. Skin irritation.” *Skin pharmacology and physiology* 21, no. 3 (2008): 124-135.**

**Цитирания - 88**

1. Moberg, Cecilia. *Living with eczema: A multidisciplinary approach*. Institutionen för medicin/Department of Medicine, 2008.
2. Fluhr, JW., R. Darlenski, E. Berardesca. „Ethnic groups and sensitive skin: two examples of special populations in dermatology.” *Drug Discovery Today: Disease Mechanisms* 5.2 (2008): e249-e263.
3. Ammer, Kurt. „Thermology on the internet–an update.” *Thermology international* 19 (2009): 15-28
4. Davis, Jennifer A. *Role of TNF-alpha polymorphism-308 in irritant contact dermatitis and neurosensory response*. Diss. University of Cincinnati, 2009.
5. Kramer, Axel, et al. „Chancen und Perspektiven der Plasmamedizin durch Anwendung von gewebekompatiblen Atmosphärendruckplasmen (Tissue Tolerable Plasmas, TTP).” *GMS Krankenhaushygiene interdisziplinär* 4 (2009).
6. Molin, S., et al. „Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis.” *British Journal of Dermatology* 161.4 (2009): 801-807.
7. Ott, H., et al. „Tacrolimus modulates dendritic cell activation in the sensitization phase of allergic contact dermatitis.” *Skin pharmacology and physiology* 23.1 (2009): 53-59.
8. Andreassi, Marco. „Advances in the assessment of skin irritants in dermocosmetology.” *Expert Review of Dermatology* 5 (2010): 5-7.
9. Chomiczewska, Dorota, Marta Kieć-Świerczyńska, and Beata Kręcisz. „Kontaktowe zapalenie skóry z podrażnienia. Część III. Nieinwazyjne metody oceny właściwości biofizycznych skóry.” *Medycyna Pracy* 61.4 (2010): 457-466.
10. Czaika, V., et al. „Application of laser scan microscopy in vivo for wound healing characterization.” *Laser Physics Letters* 7.9 (2010): 685.
11. Davis, Jennifer AlClaytese. *Role of TNF-α polymorphism-308 in irritant contact dermatitis and neurosensory response*. University of Cincinnati, 2010.
12. Dickel H, Goulioumis A, Gambichler T, Fluhr JW, Kamphowe J, Altmeyer P, Kuss O. Standardized tape stripping: a practical and reproducible protocol to uniformly reduce the stratum corneum. Skin pharmacology and physiology. 2010;23(5):259-65.
13. Du Plessis, Johannes Lodewykus, and Frederik Christoffel Eloff. „Back to basics the skin barrier and how it is affected in common occupational scenarios.” (2010).
14. Hinwood, A. L., et al. „Mine Voids Management Strategy (II): Review of potential health risks associated with Collie pit lakes.” (2010).
15. Kramer A, Assadian O, Below H, Bender C, Hammann A, Hartmann B, Hübner NO, Kocher T, Lademann J, Matthes R, Koban I. Perspektiven der Plasmamedizin. Vakuum in Forschung Und Praxis. 2010 Apr 1;22(2):33-8.
16. Kieć-Świerczyńska, Marta, Dorota Chomiczewska, and Beata Kręcisz. „WET WORK—PRACA W ŚRODOWISKU MOKRYM.” *Medycyna pracy* 61.1 (2010): 65-77.
17. Kütting, Birgitta, et al. „Non‐invasive bioengineering methods in an intervention study in 1020 male metal workers: results and implications for occupational dermatology.” *Contact dermatitis* 62.5 (2010): 272-278.
18. Lademann, J., et al. „Analysis of the penetration of a caffeine containing shampoo into the hair follicles by in vivo laser scanning microscopy.” *Laser Physics* 20.2 (2010): 551-556.
19. Mahler, V., et al. „Dirt‐binding particles consisting of hydrogenated castor oil beads constitute a nonirritating alternative for abrasive cleaning of recalcitrant oily skin contamination in a three‐step programme of occupational skin protection.” *British Journal of Dermatology* 162.4 (2010): 812-818.
20. Ott H, Baron JM, Heise R, Skazik C, Merk HF. Tacrolimus modulates dendritic cell activation in the sensitization phase of allergic contact dermatitis. Skin pharmacology and physiology. 2010;23(1):53-9.
21. Paudel, Kalpana S., et al. „Challenges and opportunities in dermal/transdermal delivery.” *Therapeutic delivery* 1.1 (2010): 109-131.
22. Abou-Dakn, M., et al. „Positive effect of HPA lanolin versus expressed breastmilk on painful and damaged nipples during lactation.” *Skin pharmacology and physiology* 24.1 (2011): 27.
23. Athanasia, Varvaresou, et al. „Efficacy and tolerance study of an oligopeptide with potential anti-aging activity.” *Journal of Cosmetics, Dermatological Sciences and Applications* 2011 (2011),133
24. Bonnist, E. Y. M., et al. „Measuring the penetration of a skin sensitizer and its delivery vehicles simultaneously with confocal Raman spectroscopy.” *Skin pharmacology and physiology* 24.5 (2011): 274.
25. Guggenbichler, J. P., O. Assadian, M. Boeswald, and A. Kramer. „GMS Hygiene and Infection Control.”,2011
26. Holst, Helle, et al. „Capsaicin‐induced neurogenic inflammation in the skin in patients with symptoms induced by odorous chemicals.” *Skin Research and Technology* 17.1 (2011): 82-90.
27. Meinke, Martina C., et al. „Radical protection by sunscreens in the infrared spectral range.” *Photochemistry and photobiology* 87.2 (2011): 452-456.
28. Molin, S., S. Vollmer, E. H. Weiss, P. Weisenseel, T. Ruzicka, and J. C. Prinz. „6 Deletion of the Late Cornified Envelope Genes LCE3B and LCE3C May Promote Chronic Hand Eczema With Allergic Contact Dermatitis.” *Journal of Investigational Allergology and Clinical Immunology* 21, no. 6 (2011): 472.
29. Neukam K, De Spirt S, Stahl W, Bejot M, Maurette JM, Tronnier H, Heinrich U. Supplementation of flaxseed oil diminishes skin sensitivity and improves skin barrier function and condition. Skin pharmacology and physiology. 2011;24(2):67-74.
30. d’Yvoire, Michel Bouvier, Susanne Bremer, Silvia Casati, Mara Ceridono, Sandra Coecke, Raffaella Corvi, Chantra Eskes et al. „ECVAM and new technologies for toxicity testing.” In *New Technologies for Toxicity Testing*, pp. 154-180. Springer US, 2012.
31. Darlenski R, Fluhr JW. Influence of skin type, race, sex, and anatomic location on epidermal barrier function. Clinics in dermatology. 2012 May 1;30(3):269-73.
32. De Spirt, S., W. Stahl, and U. Heinrich. „Effect of flaxseed-and borage oil ingestion on skin conditions.” In *Handbook of diet, nutrition and the skin*, pp. 232-242. Wageningen Academic Publishers, 2012.
33. Garcia Bartels N, Massoudy L, Scheufele R, Dietz E, Proquitté H, Wauer R, Bertin C, Serrano J, Blume‐Peytavi U. Standardized diaper care regimen: a prospective, randomized pilot study on skin barrier function and epidermal IL‐1α in newborns. Pediatric dermatology. 2012 May 1;29(3):270-6.
34. Gosenca, Mirjam, M. Gašperlin, and Julijana Kristl. "Iritativni kontaktni dermatitis: od mehanizmov do vrednotenja iritantov." *Strokovno Glasilo Slovenske Farmacije• Pharmaceutical Journal Of Slovenia* 63 (2012): 145.
35. Hinwood, Andrea, Jane Heyworth, Helen Tanner, and Clinton Mccullough. "Recreational use of acidic pit lakes—human health considerations for post closure planning." (2012).
36. Hoffmann S, Hartung T, Basketter D. 3 Toward an evidence-based dermatotoxicology. Dermatotoxicology. 2012 Sep 27:21.
37. Hyun-Gon KI, Kil-Soo KI, Tae-Ho OH. Anti-Inflammatory Effects of Poly-γ-Glutamic Acid on DNCB-Induced Allergic Contact Dermatitis in Dogs. 한국임상수의학회지. 2012 Aug;29(4):283-96.
38. Kezic, Sanja. „Genetic Identification of Individuals with Increased Risk of Developing Occupational Skin Diseases.” *Kanerva’s Occupational Dermatology* (2012): 1169-1175.
39. Kieć-Świerczyńska M, Chomiczewska D, Kręcisz B. 3. CZYNNIKI PRZYCZYNOWE CHORÓB ZAWODOWYCH SKÓRY. Publikacja współfinansowana przez Unię Europejską w ramach Europejskiego Funduszu Społecznego, przygotowana w trakcie realizacji programu „Opracowanie kompleksowych programów profilaktycznych” Numer projektu: POKL/Profil/2008–2013/zadanie 3.:15.
40. Piérard, Gérald E., Philippe Paquet, Lorine Preudhomme, Fanchon Noël, and Pascale Quatresooz. „Skin bioengineering.” *Kanerva’s Occupational Dermatology* (2012): 991-1001.
41. Proksch E, Brasch J. Abnormal epidermal barrier in the pathogenesis of contact dermatitis. Clinics in dermatology. 2012 May 1;30(3):335-44.
42. Puri R, Jain S. Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study. Anti-cancer drugs. 2012 Oct 1;23(9):923-34.
43. Sarcon A, Sivamani RK, Zhai H, Pelosi A, Berardesca E, Maibach HI. Tests for sensitive skin. Dermatotoxicology. 2012 Sep 27:414.
44. Kakeda M. Cytokines and Chemokines in Irritant Contact Dermatitis.2013
45. Lee HY, Stieger M, Yawalkar N, Kakeda M. Cytokines and chemokines in irritant contact dermatitis. Mediators of inflammation. 2013;2013.
46. Plessis JD, Stefaniak A, Eloff F, John S, Agner T, Chou TC, Nixon R, Steiner M, Franken A, Kudla I, Holness L. International guidelines for the in vivo assessment of skin properties in non‐clinical settings: Part 2. transepidermal water loss and skin hydration. Skin Research and Technology. 2013 Aug 1;19(3):265-78.
47. Poppe H, Poppe LM, Bröcker EB, Trautmann A. Do‐it‐yourself cement work: the main cause of severe irritant contact dermatitis requiring hospitalization. Contact dermatitis. 2013 Feb 1;68(2):111-5.
48. Strese H, Kuck M, Benken R, Fluhr JW, Schanzer S, Richter H, Meinke MC, Beuthan J, Benderoth C, Frankowski G, Sterry W. Influence of finishing textile materials on the reduction of skin irritations. Skin Research and Technology. 2013 Feb 1;19(1).
49. Szybiak J, Wiechula D. Skin diseases associated with the cosmetics use. Przeglad Dermatologiczny. 2013 Nov 1;100(6):392.
50. Brans, Richard, and Swen Malte John. „Hand Eczema.” In *Filaggrin*, pp. 263-271. Springer Berlin Heidelberg, 2014.
51. Cheong KA, Noh M, Kim CH, Lee AY. S100B as a potential biomarker for the detection of cytotoxicity of melanocytes. Experimental dermatology. 2014 Mar 1;23(3):165-71.
52. Choi YY, Kim MH, Lee JY, Hong J, Kim SH, Yang WM. Topical application of Kochia scoparia inhibits the development of contact dermatitis in mice. Journal of ethnopharmacology. 2014 Jun 11;154(2):380-5.
53. Corazza M, Minghetti S, Bianchi A, Virgili A, Borghi A. Barrier creams: facts and controversies. Dermatitis. 2014 Nov 1;25(6):327-33.
54. Dong-Kyu OH, Tae-Ho OH. Anti-inflammatory Effects of Aroma Oil Complex on DNCB-Induced Allergic Contact Dermatitis in Dogs. 한국임상수의학회지. 2014 Jun;31(3):180-93. Eberting CL. Irritant Contact Dermatitis: Mechanisms to Repair. J Clin Exp Dermatol Res. 2014;5(246):2.
55. Marepally S, Boakye CH, Patel AR, Godugu C, Doddapaneni R, Desai PR, Singh M. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine. 2014;9(14):2157-74.
56. Morganti P, Del Ciotto P, Carezzi F, Guarneri F, Yeo YJ. Skin lightening efficacy of new formulations enhanced by chitin nanoparticles delivery system. Note I. J. Appl. Cosmetol. 2014 Jan;32:57-71.
57. Shima Rasouli et al. "Study of Interleukin-1 and Keratinocyte Growth Factor/Fibroblast Growth Factor-7 Gene Expression in Skin Experimental Irritant Contact Dermatitis Mouse Model Treated with Aqueous Extract of Trachyspermum copticum (L.) Link Dried Seeds." PhD diss., Shahid Beheshti University of Medical Sciences, 2014.
58. Tan CH, Rasool S, Johnston GA. Contact dermatitis: allergic and irritant. Clinics in dermatology. 2014 Jan 1;32(1):116-24.
59. Utz, S. R., A. V. Karakaeva, and E. M. Galkina. "Noninvasive evaluation of the barrier properties of the skin." . Саратовский научно-медицинский журнал. 2014;10(3).
60. Vardar, Neşe. "Filagrin Polimorfizmlerinin Besin Alerjisi ve Atopik Dermatit Ile İlişkisinin Araştırılması." (2014).
61. Arancioğlu S, Ülker Öc, Karakaya A. İrritan Temas Dermatiti ve Allerjik Temas Dermatiti: Mekanizma, Klinik Sonuçlar ve Test Yöntemleri Bakımından Kıyaslanması. Turkiye Klinikleri Journal of Pharmacy Sciences. 2015;4(2):43-9.
62. Barcelos RC, de Mello-Sampayo C, Antoniazzi CT, Segat HJ, Silva H, Veit JC, Piccolo J, Emanuelli T, Bürger ME, Silva-Lima B, Rodrigues LM. Oral supplementation with fish oil reduces dryness and pruritus in the acetone-induced dry skin rat model. Journal of dermatological science. 2015 Sep 30;79(3):298-304.
63. Βαρβαρέσου, Αθανασία, et al. "Efficacy and tolerance study of an oligopeptide with potential anti-aging activity." (2015).
64. Goldner R, Tuchinda P. Irritant contact dermatitis in adults. UpToDate. Waltham, MA: UpToDate. 2015.
65. Du Plessis, Johan L., and Aleksandr B. Stefaniak. "Biometrology Guidelines for the In Vivo Assessment of Transepidermal Water Loss and Skin Hydration in Nonclinical Settings." (2015).
66. Ho KK, Campbell KL, Lavergne SN. Contact dermatitis: a comparative and translational review of the literature. Veterinary dermatology. 2015 Oct 1;26(5):314.
67. Weistenhöfer W, Wacker M, Bernet F, Uter W, Drexler H. Occlusive gloves and skin conditions: is there a problem? Results of a cross‐sectional study in a semiconductor company. British Journal of Dermatology. 2015 Apr 1;172(4):1058-65.
68. Filon FL, Bello D, Cherrie JW, Sleeuwenhoek A, Spaan S, Brouwer DH. Occupational dermal exposure to nanoparticles and nano-enabled products: part I—factors affecting skin absorption. International journal of hygiene and environmental health. 2016 Aug 31;219(6):536-44.
69. Igielska-Kalwat J, Gościańska J, Witkowska B, Nowak I. In vivo studies of substances used in the cosmetic industry. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii. 2016 Jun;33(3):163.
70. Igielska-Kalwat, Joanna. "Badanie wpływu form kosmetycznych na biodostępność wybranych karotenoidów." (2016).
71. Verallo-Rowell VM, Katalbas SS, Pangasinan JP. Natural (Mineral, Vegetable, Coconut, Essential) Oils and Contact Dermatitis. Current allergy and asthma reports. 2016 Jul 1;16(7):1-1.
72. Dickel H, Goulioumis A, Gambichler T, Fluhr JW, Kamphowe J, Altmeyer P, Kuss O. Standardized Tape Stripping: A Practical and Reproducible Protocol to Reduce Uniformly the Stratum Corneum. Agache's Measuring the Skin: Non-invasive Investigations, Physiology, Normal Constants. 2017:289-97.
73. Falcone D, Uzunbajakava N, Richters R, van de Kerkhof PC, van Erp PE. Histamine Iontophoresis as in vivo Model to Study Human Skin Inflammation with Minimal Barrier Impairment: Pilot Study Results of Application of the Model to a Sensitive Skin Panel. Skin Pharmacology and Physiology. 2017;30(5):246-59.
74. Falcone D, Spee P, Salk K, Peppelman M, Kerkhof PC, Erp PE. Measurement of skin surface biomakers by Transdermal Analyses Patch following different in vivo models of irritation: a pilot study. Skin Research and Technology. 2017 Aug 1;23(3):336-45.
75. Lünnemann, Lena. *Klinische Studie zur Untersuchung verschiedener Hautpflegeregime in der Windelregion bei Säuglingen im Alter von 7 bis 11 Lebensmonaten*. Diss. Freie Universität Berlin, 2017.
76. Kim GH, Cheong KA, Lee AY. Increased Skin Irritation by Hydroquinone and Rsetinoic Acid Used in Combination. Annals of dermatology. 2017 Dec 1;29(6):715-21.
77. Mauro M, De Giusti V, Bovenzi M, Larese Filon F. Effectiveness of a secondary prevention protocol for occupational contact dermatitis. Journal of the European Academy of Dermatology and Venereology. 2017 Apr 1;31(4):656-63.
78. van de Kerkhof PC, van Erp PE. Measurement of skin surface biomakers by Transdermal Analyses Patch following different in vivo models of irritation: a pilot study. Novel And Established Techniques For Non-Invasive Skin Assessment. 2017;23 (3):175.

В монографии

1. Hermansky, S. J. 2009. Cutaneous Toxicology. General, Applied and Systems Toxicology.
2. Maier LE, Maibach HI, O’Malley M. Irritant Dermatitis. InHayes' Handbook of Pesticide Toxicology (Third Edition) 2010 (pp. 647-659).
3. Астафьева Н.Г et al. Экспериментальная и клиническая дерматокосметология. Издательский дом «Русский врач»,2010, 51-58
4. Basketter, David, and Ian Kimber. „Predictive tests for irritants and allergens and their use in quantitative risk assessment.” In *Contact Dermatitis*, pp. 229-239. Springer Berlin Heidelberg, 2011.
5. Proksch, Ehrhardt, and Jochen Brasch. „Role of the Permeability Barrier in Contact Dermatitis.” In *Contact Dermatitis*, pp. 121-135. Springer Berlin Heidelberg, 2011.
6. Antonov, Dimitar, Sibylle Schliemann, and Peter Elsner. „Contact dermatitis due to irritation.” *Kanerva’s Occupational Dermatology* (2012): 87-101.
7. Darlenski, Razvigor, and Joachim W. Fluhr. „Moisturizers and emollients.” In *Practical Aspects of Cosmetic Testing*, pp. 123-141. Springer Berlin Heidelberg, 2011.
8. Angelova-Fischer I, John SM, Kezic S. Acute irritancy testing for predicting increased susceptibility to irritant contact dermatitis in atopic individuals. InTextbook of Hand Eczema 2014 (pp. 247-254). Springer Berlin Heidelberg.
9. Angelova-Fischer I. Irritants and skin barrier function. InSkin Barrier Function 2016 (Vol. 49, pp. 80-89). Karger Publishers.
10. Alépée N, Grandidier MH, Tornier C, Cotovio J. An In Vitro Skin Irritation Test Using the SkinEthic™ Reconstructed Human Epidermal (RHE) Model. InAlternatives for Dermal Toxicity Testing 2017 (pp. 59-72). Springer, Cham.

**Pehlivanov G, Kavaklieva S, Kazandjieva J, Kapnilov D, TSANKOV N**. **Foreign body granuloma of the penis in sexually active individuals (penile paraffinoma)** [**Journal of the European Academy of Dermatology & Venereology**](http://www.ingentaconnect.com/content/bsc/jdv;jsessionid=a81dlsi3m15m3.alice)**, 22,  7, 2008 , pp. 845-851(7)**

**Цитирания – 41**

1. Kokkonouzis I, Antoniou G, Droul A. Penis deformity after intra-urethral liquid paraffin administration in a young male: a case report. Ias Cases Journal, 2008
2. Geater, Alan F., Than Winn, and Virasakdi Chongsuvivatwong. "Penile oil injection, penile implantation and condom use among Myanmar migrant fishermen in Ranong, Thailand." *Sexual health* 6.3 (2009): 217-221.
3. Ohnmar et al. Penile oil injection, penile implantation and condom use among Myanmar migrant fishermen in Ranong, Thailand. Sexual Health ,2009, **6**(3) 217–221
4. Sancharoen P. Modified scrotal implantation with immediate detachment: a new designed flap for penile paraffinoma. Buddhachinaraj Medical Journal. 2009 Dec 23;26(2):157.

## El Muayed M, AA Costas, AJ Pick . Case Report: 1, 25-Dihydroxy-Vitamin d Mediated Hypercalcemia in Oleogranulomatous Mastitis (Paraffinoma), Ameliorated by Glucocorticoid Administration Endocrine Practice – AACE, 2010, Vol.16,1,102-6

## Imbert E, B Milpied, T Jouary, Taieb A et al. Penille swelling et ulceration. Acta Derm Venereol, 2010, 81-82

1. Pónyai K, Marschalkó M, Hársing Jt, Ostorházy E, Kelemen Z, P Nyirády , V Várkonyi , S Kárpáti
2. Paraffinoma. JDDG, 2010
3. Rinard K et al. Cross-sectional Study Examining Four Types of Male Penile and Urethral “Play”. Urology, 2010,76,1326-1333
4. Utas S. Penil Parafinoma. Turkderm,2010,44,41-2
5. Bachmeyer C et al. **Penile Paraffinoma Developing During Treatment With Pegylated Interferon Alfa-2a for Chronic Hepatitis C Virus Infection. Arch Dermatol, 2011,** Vol. 147 No. 10,
6. FoxtonG, Vinciullo C, Tait C et al. Sclerosing lipogranuloma of the penis. Australasian Journal of Dermatology, 2011,52, 3, 12–14
7. Prasetyono Th. One-sheet spiraling full thickness skin graft for penile resurfacing after paraffinoma excision. Med J Indones 2011,20,222-5
8. Requena L et al. Adverse reactions to injectable soft tissue fillers. JAAD,2011,64,1,1-34
9. Karakan, Tolga, et al. "Injection of Vaseline under Penis Skin for the Purpose of Penis Augmentation." Case Reports in Urology 2012 (2012).
10. Sasidaran, Ramesh, Mohd Ali Mat Zain, and Normala Hj Basiron. "Low-grade liquid silicone injections as a penile enhancement procedure: Is bigger better?."Urology Annals 4.3 (2012): 181.
11. Oanta A et al. Penile paraffinomas after self-injection with kanamycin ointment. Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences • Vol. 6 (55) No. 1 - 2013
12. Turner, Bruce, Emma Goldstraw, and Jhumur Pati. "Penile paraffinoma."International Journal of Urological Nursing 7.1 (2013): 53-56.
13. Zivković V, Nikolić S Penile pearls: a westward traveling phenomenon. Forensic Science Medicine and Pathology. 10/2013;
14. Bogdanov-Berezovsky, A., et al. "Penile Paraffinoma: A Treatment Dilemma."*The Internet Journal of Plastic Surgery* 11.1 (2014).
15. Cawich, Shamir O., et al. "Topical “Soft Candle” Applications for Infected Diabetic Foot Wounds: A Cause for Concern?." (2014).
16. Cormio, L., Di Fino, G., Scavone, C., Selvaggio, O., Massenio, P., Sanguedolce, F., ... & Carrieri, G. (2014). Magnetic resonance imaging of penile paraffinoma: case report. *BMC medical imaging*, *14*(1), 39.
17. Gómez-Armayones, S., R. M. Penín, and J. Marcoval. "Parafinoma de pene."*Actas Dermo-Sifiliográficas* (2014).
18. Francis, Joe, Angeline Poh Choo Choo, and Gervais Wansaicheong Khin-Lin. "Ultrasound and MRI features of penile augmentation by" Jamaica Oil" injection. A case series." *Medical ultrasonography* 16.4 (2014): 372-376.
19. Kamouna, B., Kazandjieva, J., Balabanova, M., Dourmishev, L., Negentsova, Z., Etugov, D., Nikolova, A., Miteva, L. and Haneke, E., 2014. Oil-Soluble Vitamins: Illegal Use for Lip Augmentation. *Facial plastic surgery*, *30*(06), pp.635-643.
20. Neluis, T., Armstrong, M. L., Young, C., Roberts, A. E., Hogan, L., & Rinard, K. (2014). Prevalence and implications of genital tattoos: A site not forgotten.*British Journal of Medical Practitioners*, *7*(4).
21. Pónyai, Katinka. "Szexuális úton terjedő betegségek, koinfekciók és vonatkozásaik a bőrgyógyászatban." (2014).
22. Rosecker, Ágnes. "Vaseline injection, an inadequate method for penile augmentation." PhD diss., szte, 2014.
23. Živković, V., & Nikolić, S.. Penile pearls: a westward traveling phenomenon. *Forensic science, medicine, and pathology*, (2014) *10*(1), 130-132.
24. Garcia-Castaneda, Jenny, and Alfredo Harb-De la Rosa. "Penile ulceration caused by a foreign body reaction in a crew member on board a cruise ship."*International maritime health* 66.1 (2015): 28-29.
25. El-Khalawany, Mohamed, et al. "Dermal filler complications: a clinicopathologic study with a spectrum of histologic reaction patterns." *Annals of diagnostic pathology* 19.1 (2015): 10-15.
26. Kwon JY, Han JS. A Case of Eyelid Paraffinoma Misdiagnosed as a Chalazion. Journal of the Korean Ophthalmological Society. 2015 Dec 1;56(12):1965-8.
27. 권진영, 한지상. 콩다래끼로 오인된 눈꺼풀의 파라핀종 1 예. J Korean Ophthalmol Soc. 2015;56(12):1965-8.
28. Hakenberg O, Sohn M. Ästhetisch-plastische Eingriffe am Penis. InDie Urologie 2016 (pp. 1461-1469). Springer Berlin Heidelberg.
29. Murali U, Zong YZ, Muniandy K. Coconut Oil Induced Phimosis with Balanoposthitis-A Case Report.
30. Ahmed U, Freeman A, Kirkham A, Ralph DJ, Minhas S, Muneer A. Self injection of foreign materials into the penis. The Annals of The Royal College of Surgeons of England. 2017 Feb;99(2):e78-82.
31. de Almeida Issa MC, Cerqueira Alexandre D, Domingos Almeida R, Barbosa Durães SM. Necrose de parafinoma peniano após injeção de óleo mineral por profissional não médico. Surgical & Cosmetic Dermatology. 2017;9(2).
32. Faveret PL, Santiago F. Surgical Management of Penile Lesions Secondary to Foreign Body Reaction: A Case Report and Systematic Review. Aesthetic surgery journal. 2017 Nov 6.
33. Kervyn A, Le Guern A, Thieffry A, Greliak A, Modiano P. Nodules péniens artificiels. InAnnales de Dermatologie et de Vénéréologie 2018 May 23. Elsevier Masson.
34. Svensøy JN, Travers V, Osther PJ. Complications of penile self-injections: investigation of 680 patients with complications following penile self-injections with mineral oil. World journal of urology. 2018 Jan 1;36(1):135-43.
35. Gemma Sharp, Jayson Oates, Sociocultural Influences on Men’s Penis Size Perceptions and Decisions to Undergo Penile Augmentation: A Qualitative Study, Aesthetic Surgery Journal, 10.1093/asj/sjz154, (2019).
36. Boyke Soebhali, Penile Self-Injections for Girth Augmentation: Treatment of Complications, Textbook of Male Genitourethral Reconstruction, 10.1007/978-3-030-21447-0, (783-794), (2020).
37. N. Kluger, Manifestations cutanées et muqueuses des pratiques sexuelles, Annales de Dermatologie et de Vénéréologie, 10.1016/j.annder.2020.04.022, (2020).
38. Leonie Exterkate, Jean-Paul A. van Basten, Case report. Paraffinoom van de penis na injectie met kanamycinezalfCase report. Penile paraffinoma after injection with kanamycin ointment, Tijdschrift voor Urologie, 10.1007/s13629-019-00277-4, (2020).
39. Rebekah Brennan, Marie Overbye, Marie Claire Van Hout, James McVeigh, “A slippery slope”: a scoping review of the self-injection of unlicensed oils and fillers as body enhancement, Performance Enhancement & Health, 10.1016/j.peh.2020.100185, **8**, 4, (100185), (2021).
40. F. Bourlond, C. Velter, D. Lipsker, Penile edema following self-injection: A report on two cases, Annales de Dermatologie et de Vénéréologie, 10.1016/j.annder.2020.07.015, **148**, 1, (55-56), (2021).

В монографии

1. Weedon D. Panniculitis. In: Weedon's Skin Pathology ed. 3rd Ed.,2010,

**KAZANDJIEVA J, Grozdev I, Darlenski R, TSANKOV N. Climatotherapy of psoriasis. Clin Dermatol 2008;26:4 7 7-8 5**

**Цитирания – 40**

1. Özçelik S, Akyol M. Climatotherapy in psoriasis/Psoriasis-klimaterapi.Arch Turk Dermatol Venereol, 2008; 42 , 2: 51-5
2. Rokowska-Waluch: A, Pielesiak Anna, Pawlaczyk M. Review papers. Spa therapy in the treatment of psoriasis. Przegl Dermatol 2009, 96, 367–370
3. Rokowska-Waluch: A,Katarzyna K, Chojnicki M, , Pawlaczyk M. **Prace oryginalne  
   Wpływ zmian hormonalnych zachodzących w organizmie kobiety na stan skóry.** Przegl Dermatol 2009, 96, 205–210
4. Amaral HAM. Evidencias Cientificas da Medicina Termal-Crenoterapia. Mestrado Integrado em medicina.Instituto de ciencias Biomedicas Abel Salazar, Universidade do Porto,2010
5. **Baschini M et al.** Suitability of natural sulphur-rich muds from Copahue (Argentina) for use as semisolid health care products. Applied Clay Science, 2010,49,3, 205-212
6. Buisson F. L’ANIMAL MÉDICAMENT L’OPOTHÉRAPIE AU DÉBUT DU xxie siècle.THESE, Univ. Cretei, 2010
7. Cezara B. Particularitatile fiziologo-biochimice si de cultivare ale microalgei verzi dunaliella salina-sursa valoroasa de substante bioactive. Teza de doctor in biologie.Chisinau,2010
8. Duman S. Kangal (Sivas) Balikli Cermik Termal Kaplicasi ile Topardic Deresi (Sivas)’nde Yasayan Cyprinion macrostomus Heckel, 1843 ve Garra rufa Heckel, 1843 turu Baliklarda Bazi Hematolojik Parametreler ve Dogal Immun Yanitin Belirlenmesi. Doktora Tezi., Adana, 2010
9. Gutenbrunner Ch, Bender T, Cantista P, Karagülle Z. A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology, International Journal of Biometeorology, 2010,54,5,495-507
10. Kim JY, Lee WJ et al. An Investigation on the Use of Complementary and Alternative Medicine for Psoriasis. Korean J Dermatol,2010,48,6,494-502
11. Колупаева Е. Применение бегущего магнитного поля в комплексной терапии различных форм псориазал Дис, 2010, Новосибирск
12. Avriel A et al. Quality of life at the dead sea region& the lower the better? An observational study. Health and Quality of Life Outcomes, 2011,9,38
13. Denby K, Duffy N. Complementary and alternative therapies.In: Current and Emerging Treatments for Psoriasis.ed. Steven R Feldman, Future Medicine, 2011, 152-164
14. Grom V. UV-doser til psoriasispasienter og behandlingseefekt I lopet av tre ukers klimabehandling pa Gran Canaria. Master I fysikk og matematikk. Norges teknisk-naturvitenskapelige universitet, July,2011
15. Kurtze N et al. Evaluering av ordningen med behandlingsreiser til utlandet. SINTEF, 2011
16. Schuh A. , Nowak D. Klimatherapie im Hochgebirge und im Meeresklima. Evidente Akut- und Langzeiteffekte - ein qualitativer Review. Dtsch med Wochenschr 2011; 136(4): 135-139
17. Silva JS.  Aplicação dermocosmética de geoprodutos. PhD thesis, Porto, 2011
18. Gálvez Galve, Juan José, et al. "Quality of life and assessment after local application of sulphurous water in the home environment in patients with psoriasis vulgaris: A randomised placebo-controlled pilot study." *European Journal of Integrative Medicine* 4.2 (2012): e213-e218.
19. Katz, Uriel, et al. "Scientific evidence of the therapeutic effects of Dead Sea treatments: a systematic review." Seminars in Arthritis and Rheumatism. WB Saunders, 2012. 42,2,186–200
20. Wojtanowska, Jadwiga, Magdalena Niewęgłowska-Wilk, and Tomasz Wilk. "Motywy korzystania i poziom zadowolenia klientów Uzdrowiska Swoszowice." (2012).
21. Álvarez-Blanco, Irene, and Saúl Blanco. "Nitzschia imae sp. nov.(Bacillariophyta, Nitzschiaceae) de Islandia, con una redescripción de Hannaea arcus var. linearis." *Anales del Jardín Botánico de Madrid*. Vol. 70. No. 2. 2013.
22. Iwaniszczuk, Agnieszka, and Włodzisław Kuliński. "Optimization of balneophysiotherapy in psoriasis vulgaris Optymalizacja postępowania balneofizykalnego w łuszczycy pospolitej Оптимизация бальнеофизиотерапевтических процедур при псориазе." Acta balneologica, 2013,tom LV, Nr 1 5-12.
23. Eysteinsdóttir, J. H., et al. "The Role of Th17/Tc17 Peripheral Blood T cells in Psoriasis and Their Positive Therapeutic Response." *Scandinavian journal of immunology* 78.6 (2013): 529-537.
24. Golušin, Z., Jovanović, M., Jeremić, B., & Jolić, S. (2014). Balneotherapy of Psoriasis. *Serbian Journal of Dermatology and Venereology*, *6*(3), 105-112.
25. Ninković-Baroš, Đuka, et al. "Comparative analysis of success of psoriasis treatment with standard therapeutic modalities and balneotherapy." *Medicinski pregled* 67.5-6 (2014): 154-160.
26. Golušin, Zoran, Marina Jovanović, Nataša Magda, Slobodan Stojanović, Milan Matić, and Aleksandra Petrović. "Effects of Rusanda Spa balneotherapy combined with calcipotriol on plaque psoriasis." *Vojnosanitetski pregled* 00 (2015): 95-95
27. Odabaşı E, Tekbaş ÖF. Van Gölü suyu tedavi amacıyla kullanılabilir mi?. TAF Preventive Medicine Bulletin. 2015 Jan 1;14(1).
28. Özçelik S, Hayta SB. Balneotherapy in Kangal hot spring with fish. Cumhuriyet Medical Journal, 2015
29. Quintela, A., Almeida, S. P., Terroso, D., Ferreira da Silva, E., Forjaz, V., & Rocha, F. Chemical modifications and diatom community development on volcanic clayey sediments during an indoor maturation experiment.*Geomicrobiology Journal*, (2015). *32*(2), 103-112.
30. Quintela, Ana, et al. "Characterization and evaluation of hydrothermally influenced clayey sediments from Caldeiras da Ribeira Grande fumarolic field (Azores Archipelago, Portugal) used for aesthetic and pelotherapy purposes."*Environmental Earth Sciences* 73.6 (2015): 2833-2842.
31. Schuh, Angela, and Gisela Immich. "Meeresklima–Klimatherapie am Meer und Thalassotherapie." *Zeitschrift für Komplementärmedizin* 7.03: 18-21.
32. Björnsdóttir, Eva Ösp. "Antimicrobial expression in keratinocytes." (2016).
33. Monasterio AM, Armijo F, Maraver F. Therapeutic Effects of the Mineral Waters from Copahue Spa. InCopahue Volcano 2016 (pp. 273-282). Springer Berlin Heidelberg.
34. Boudenne JL, Parinet J, Demelas C, Manasfi T, Coulomb B. Monitoring and factors affecting levels of airborne and water bromoform in chlorinated seawater swimming pools. Journal of Environmental Sciences. 2017 May 24.
35. Burfoot C. Tourism as a tool for communicating complex environmental issues: Applying the ecosystem services framework to nature-based tourism activities across Iceland. DiVA, 2017
36. Liñán CM. Talasoterapia y enfermedad neurológica. Tesis Doctoral, Madrid 2017
37. Peter I, Jagicza A, Ajtay Z, Boncz I, Kiss I, Szendi K, Kustan P, Nemeth B. Balneotherapy in Psoriasis Rehabilitation. in vivo. 2017 Nov 1;31(6):1163-8.
38. Carbajo JM, Maraver F. Salt water and skin interactions: new lines of evidence. International journal of biometeorology. 2018 Apr 19:1-6.

В монографии

1. Holick et al. Ultraviolettes spectrum.. In Lichterapie, ed by Krause R, Stange R p.153, Springer, 2012
2. Monasterio, A. M., F. Armijo, and F. Maraver. "Therapeutic Effects of the Mineral Waters from Copahue Spa." In *Copahue Volcano*, pp. 273-282. Springer Berlin Heidelberg, 2016.

**Yordanova I, Vassileva S, Demerjieva Z, Gospodinov DK, TSANKOV N. Epidermolysis Bullosa Simplex Dowling-Meara-A Case Report. Journal of IMAB–Annual Proceeding Scientific Papers. 2008 Oct 7;14(1):59-62.**

**цитати - 1**

1. Ghafeer HH, El-Gamal DA, Mohamed NA, Hassanin AI. Histological study of human abdominal skin after repeated pregnancy. Egyptian Journal of Histology. 2015 Mar 1;38(1):41-56.

**Darlenski R, Sassning S, TSANKOV N, Fluhr J. Non-invaseve in vivo methods for investigation of the skin barrier physical properties. Eur J Pharm Biopharm, 2009**

**Цитати – 142**

# Baheri, N.et al. Improved skin xerosis detection by combining extracted features from Raman spectra. This paper appears in: Applied Sciences in Biomedical and Communication Technologies, 2009. ISABEL 2009. 2nd International Symposium

# Davis, Jennifer A. Role of TNF-alpha polymorphism -308 in Irritant Contact Dermatitis and Neurosensory Response. PhD, University of Cincinnati, Pharmacy : Pharmaceutical Sciences, 2009

# Chun, Ng Wu. "Study Of The Characteristics Of Fast Deployable Eeg Electrode." Phd Diss., 2010.

# Guida B et al. The impact of obesity on skin disease and epidermal permeability barrier status. J Eur Acad Dermatol Venereol. 2010 Feb;24(2):191-5.

# Шливко И.. „Возможность индивидуализации, контроля эффективности и безопасности терапии дерматозов на основе оценки морфофункционального состояния кожи методом ОКТ.”,2010, дисертация, Нижни Новгород

# Hahn T et al. Infrared densitometry: a fast and non-destructive method for exact stratum corneum depth calculation for in vitro tape-stripping. Skin Pharmacol Physiol. 2010;23(4):183-92

# Ferreira P. et al. Efficacy of anti-wrinkle products in skin surface appearance: a comparative study using non-invasive methods.Skin Res Technol. 2010 ;16(4) :444-9

# Kim MS, Cho Y, Seo ST, Son CS, Park HJ, Kim YN A new method for non-invasive measurement of skin in the low frequency range. Healthcare Informatics Research,2010, 16(3):143-8

# Narkar Y. Bioequivalence for topical products–an update.Pharm Res. 2010;27(12):2590-601

# Pena Ferreira, M. Rosa, P. C. Costa, and Fernanda M. Bahia. „Efficacy of anti‐wrinkle products in skin surface appearance: a comparative study using non‐invasive methods.” *Skin Research and Technology* 16.4 (2010): 444-449.

# Rice, William L. *Optical, non-invasive monitoring of engineered tissues*. Diss. TUFTS UNIVERSITY, 2010.

# Sharir H et al. Zinc Released from Injured Cells Is Acting via the Zn2+-sensing Receptor, ZnR, to Trigger Signaling Leading to Epithelial Repair. J Biol Chem. 2010 ; 285(34): 26097–26106.

# Zhang J, Liu M, Jin H, Deng L, Xing J, Dong A. In vitro enhancement of lactate esters on the percutaneous penetration of drugs with different lipophilicity. AAPS PharmSciTech. 2010 Jun;11(2):894-903.

# Abdullah G et al. In vitro permeation and in vivo anti-inflammatory and analgesic properties of nanoscaled emulsions containing ibuprofen for topical delivery. Int J Nanomedicine. 2011; 6: 387–396.

# Adlhart C, Baschong W. Surface distribution and depths profiling of particulate organic UV absorbers by Raman imaging and tape stripping. Int J Cosmet Sci. 2011 Dec;33(6):527-34.

# Berthaud F, Boncheva M. Correlation between the properties of the lipid matrix and the degrees of integrity and cohesion in healthy human Stratum corneum. Exp Dermatol. 2011 ;20(3):255-62.

# Camargo Jr, Flávio B., Lorena R. Gaspar, and Patrícia MBG Maia Campos. „Skin moisturizing effects of panthenol-based formulations.” *Journal of cosmetic science* 62.4 (2011): 361.

# Fluhr, Joachim W., et al. „Kinetics of carotenoid distribution in human skin in vivo after exogenous stress: disinfectant and wIRA-induced carotenoid depletion recovers from outside to inside.” *Journal of biomedical optics* 16.3 (2011): 035002-035002.

# Hasanovic, Amra, et al. „Modification of the conformational skin structure by treatment with liposomal formulations and its correlation to the penetration depth of aciclovir.” *European Journal of Pharmaceutics and Biopharmaceutics* 79.1 (2011): 76-81.

# Kleesz, P., R. Darlenski, and J. W. Fluhr. „Full-body skin mapping for six biophysical parameters: baseline values at 16 anatomical sites in 125 human subjects.” *Skin pharmacology and physiology* 25.1 (2011): 25-33.

# Pailler-Mattei C, Guerret-Piécourt C, Zahouani H, Nicoli S Interpretation of the human skin biotribological behaviour after tape stripping. J R Soc Interface. 2011 Jul 6;8(60):934-41. Epub 2011 Jan 12.

# Śliwa, K., E. Sikora, and J. Ogonowski. „Kosmetyki do pielęgnacji skóry atopowej.” *Wiadomości Chemiczne* (2011): 651-673.

# Amarioarei-Iftimie, Gina, Maria Lungu, and Sorin Ciovică. „IN VIVO TESTING OF P. Cerasus GUM WITHIN A COSMETIC FORMULATION.” *Environmental Engineering and Management Journal* 11.8 (2012): 1493-1498.

# Amselgruber, Sarah Emely. *Nanopartikel als Trägersysteme für transepidermale Vakzinierung-Zielgerichteter Transport von Antigenen über die Hautbarriere*. Diss. Medizinische Fakultät Charité-Universitätsmedizin Berlin, 2012.

# Akhtar, Naveed, et al. „Effects of Emblica Officinalis Extract Cream on Human Skin Trans-epidermal Water Loss Measured with Non Invasive Probe.” *Journal of pharmacy and alternative medicine* 1 (2012): 32-37.

# Baheri, Neda, Mohammad Hossein Miranbaygi, and Rasoul Malekfar. „High Performance Method for Skin Roughness Detection Using Raman Spectroscopy.”Lasers in Medicine 2012; 9(2): 28.

# Darlenski, Razvigor, and Joachim W. Fluhr. „Influence of skin type, race, sex, and anatomic location on epidermal barrier function.” *Clinics in dermatology* 30.3 (2012): 269-273

# Firooz, Alireza, Ali Rajabi Estarabadi, and Hamed Zartab. „Methods for skin biophysical analysis and imaging: A review (Part Ι).” *Dermatology and Cosmetic* 3.4 (2012): 219-226.

# Hamed S et al. Construction, in vitro and in vivo evaluation of an in-house conductance meter for measurement of skin hydration. Medical Engineering & Physics. Available online 17 March 2012

# Hamed, Saja H., et al. „Does massage postapplication improve moisturizer’s efficacy? A 2‐week regression study.” *Journal of cosmetic dermatology* 11.3 (2012): 239-244.

# Jaksic I et al. Compounding of a topical drug with prospective natural surfactant-stabilized pharmaceutical bases: physicochemical and in vitro/in vivo characterization–a ketoprofen case study. Eur J Pharm Biopharm. 2012 Jan;80(1):164-75.

# Klang V, et al. In vitro vs. In vivo tape stripping: validation of the porcine ear model and penetration assessment of novel sucrose stearate emulsions. Eur J Pharm Biopharm. 2012 Apr;80(3):604-14.

# Lemeri E Structure et physicochimie des emulsionnants et leurimpactsur l”hydrararion percue,la function barriereet la tolerance cutanee. Journée Jeunes Chercheurs,2012

# Lustosa A. Avaliação do potencial farmacológico da manteiga de bacuri (Platonia insignisMart.)e de forma farmacêutica de uso tópico com ela desenvolvida,2012,Teresina

# MO, MOUSSE, et al. *Evaliation de l’effet d’une lotion,douxocalm mousse mo, sur la reparation de la barrier cutane dans un modele de rupture chronique de la barrier cutaneee chez le chen. Thesis. Universite Claude-Bernard, Lyon.2012*

# Nagashima, Takuto, et al. „Development of A Flat Dry-pH-Sensor for Skin Surface pH Measurement.” *International Proceedings of Chemical, Biological & Environmental Engineering* 45 (2012).

# Pena-Ferreira MR et al. Aplicación de arcillas esmectíticas de la isla de Porto Santo en Máscaras Faciales Anales de Hidrología 2012

# Polańska, Adriana, et al. „Evaluation of selected skin barrier functions in atopic dermatitis in relation to the disease severity and pruritus.” *Postep Derm Alergol* 29 (2012): 373-7

# POLÁŠKOVÁ, J., et al. „Efficacy of cosmetic products used to increase skin hydration feet.”Int J Biol Biomed Engineering, 2012, 4, 6, 204-211

# POLÁŠKOVÁ, J., et al. „The moisturize influence of the commercial cosmetics on the foot skin.” Advances in Environment, Biotechnology and Biomedicine

# Tfayli, Ali, et al. „Raman spectroscopy: feasibility of in vivo survey of stratum corneum lipids, effect of natural aging.” *European Journal of Dermatology* 22.1 (2012): 36-41

# .فيروز, et al. "بررسی خصوصيات بيوفيزيکی و روش‌های تصويربرداری پوست (بخش اول)." *پوست و زیبایی* 3.4 (2012): 219-226

# Vergou T, et al. Comparison between TEWL and laser scanning microscopy measurements for the in vivo characterization of the human epidermal barrier. J Biophotonics. 2012 Feb;5(2):152-8.

# 董依云, and 周国瑜. „非创伤性检测技术在光老化皮肤治疗中的应用进展.” *中国美容医学* 21.9 (2012): 1665-1668

# Ali, Atif, et al. „Moisturizing effect of cream containing Moringa oleifera (Sohajana) leaf extract by biophysical techniques: In vivo evaluation.” *Journal of Medicinal Plants Research* 7.8 (2013): 386-391.

# Fleischli, Franziska D., Stephanie Mathes, and Christian Adlhart. „Label free non-invasive imaging of topically applied actives in reconstructed human epidermis by confocal Raman spectroscopy.” *Vibrational Spectroscopy* 68 (2013): 29-33.

# KhoaWL . *Study of the Characteristics of Scalp Electroencephalography Sensing*. Diss. 2013.

# Kelleher, Maeve M., et al. „Newborn transepidermal water loss values: a reference dataset.” *Pediatric dermatology* 30.6 (2013): 712-716.

# Lu G, Moore DJ. Measuring changes in skin barrier function with skin impedance. HPC Today. 2013 Jan;8(1):28-31.

# Mercurio, D. G., et al. „Clinical scoring and instrumental analysis to evaluate skin types.” *Clinical and experimental dermatology* 38.3 (2013): 302-309.

# Mota, Aline de Carvalho Varjão, et al. „In vivo and in vitro evaluation of octyl methoxycinnamate liposomes.” *International journal of nanomedicine* 8 (2013): 4689.

* 1. Panigrahi, Sudipa, Kavitha Murugesan, and Samares C. Biswas. "Diagnosis of Skin Health Conditions Using Gold Nanoparticles." Nanotechnologist 2013 Vol.3
  2. Pantelic, Ivana, et al. „Development of a prospective isopropyl alcohol-loaded pharmaceutical base using simultaneous in vitro/in vivo characterization methods of skin performance.” *Drug development and industrial pharmacy* 40.7 (2013): 960-971.
  3. Plessis, Johan du, et al. „International guidelines for the in vivo assessment of skin properties in non‐clinical settings: Part 2. Transepidermal water loss and skin hydration.” *Skin Research and Technology* 19.3 (2013): 265-278

# Plessis, J. L., et al. „Dermal exposure and changes in skin barrier function of base metal refinery workers co-exposed to cobalt and nickel.” *Occupational Health Southern Africa* 19.1 (2013): 8-8.

# Polańska, Adriana, et al. „Original paper Nonlesional skin in atopic dermatitis is seemingly healthy skin–observations using noninvasive methods.” Videosurgery Miniinv 2013; 8 (3): 192–199

# Pople, Pallavi V., and Kamalinder K. Singh. „Development and evaluation of colloidal modified nanolipid carrier: Application to topical delivery of tacrolimus, Part II–In vivo assessment, drug targeting, efficacy, and safety in treatment for atopic dermatitis.” *European Journal of Pharmaceutics and Biopharmaceutics* 84.1 (2013): 72-83.

# Ribeiro, Helena, et al. „From coffee industry waste materials to skin‐friendly products with improved skin fat levels.” *European Journal of Lipid Science and Technology* 115.3 (2013): 330-336

# Sturesdotter Hoppe, Torborg. „Skin Barrier Function and mRNA Expression Profiles in Patients with Atopic Dermatitis, Ichthyosis Vulgaris, and X-linked Recessive Ichthyosis: Aetiopathogenic Differences and the Impact of Moisturizing Treatment.” (2013).

# Tavares, Liliana Patrícia da Veiga Durão. „Caracterização da pele humana in vivo para melhor compreender a pele do doente obeso.” . *Biomed Biopharm Res.* , 2013; (10) 1: 55-63

# Tfaili, Sana, Cyril Gobinet, Gwendal Josse, Jean-François Angiboust, Arlette Baillet, Michel Manfait, and Olivier Piot. „Vibrational spectroscopies for the analysis of cutaneous permeation: experimental limiting factors identified in the case of caffeine penetration.” *Analytical and bioanalytical chemistry* 405, no. 4 (2013): 1325-1332..

# Vyumvuhore, Raoul. *Validation et implémentation des descripteurs de l’hydratation et des propriétés mécaniques du stratum corneum ex vivo et in vivo*. Diss. Université Paris Sud-Paris XI, 2013.

# Wang, Siyu, et al. „Effect of Exercise‐induced Sweating on facial sebum, stratum corneum hydration, and skin surface pH in normal population.” *Skin Research and Technology* 19.1 (2013): e312-e317.

# Yapar, Evren Algin, Özge Ýnal, and M. Sedef Erdal. „Design and in vivo evaluation of emulgel formulations including green tea extract and rose oil.” *Acta Pharmaceutica* 63.4 (2013): 531-544.

# Yuan C, Wang XM, Galzote C, Tan YM, Bhagat KV, Yuan ZK, Du JF, Tan Y. Meteorology and ethnicity as critical factors in HRIPT: Comparing responses between Chinese and Indian ethnicities. Regulatory Toxicology and Pharmacology. 2013 Jun 1;66(1):59-65.

# 胡珍, and 于春水. „皮肤屏障功能的研究进展.”. Chin J Clinician,７(2013)

# Faria, Wanessa Costa Silva, Gabriel Azevedo de Brito Damasceno, and Márcio Ferrari. „Moisturizing effect of a cosmetic formulation containing pequi oil (Caryocar brasiliense) from the Brazilian cerrado biome.” *Brazilian Journal of Pharmaceutical Sciences* 50.1 (2014): 131-136.

# Fox, Lizelle Trifena. *Transdermal penetration enhancement and clinical efficacy of Aloe marlothii and Aloe ferox compared to Aloe vera*. Diss. North-West University, 2014.

# Fox, Lizelle T., et al. „In Vivo skin hydration and anti-erythema effects of Aloe vera, Aloe ferox and Aloe marlothii gel materials after single and multiple applications.” *Pharmacognosy magazine* 10.Suppl 2 (2014): S392.

# Hua, W., et al. „Comparison of two series of non‐invasive instruments used for the skin physiological properties measurements: the ‘Soft Plus’ from Callegari SpA vs. The series of detectors from Courage & Khazaka.” *Skin Research and Technology* 20.1 (2014): 74-80.

# Junior, João Augusto Oshiro, et al. „Development of Cutaneous Bioadhesive Ureasil-polyether Hybrid Films.”,2014

# Khan, H., N. Akhtar, and A. Ali. „Effects of cream containing ficus carica L. Fruit extract on skin parameters: In vivo evaluation.” *Indian journal of pharmaceutical sciences* 76.6 (2014): 560.

# Pantelic I, Lukic M, Markovic B, Lusiana, Hoffmann C, Mueller-Goymann C, Milic J, Daniels R, Savic S. Development of a prospective isopropyl alcohol-loaded pharmaceutical base using simultaneous in vitro/in vivo characterization methods of skin performance. Drug development and industrial pharmacy. 2014 Jul 1;40(7):960-71.

# du Plessis, Jeanetta, Josias H. Hamman, Lizelle T. Fox, Sterna van Zyl, Banie Boneschans, and Minja Gerber. "In Vivo skin hydration and anti-erythema effects of Aloe vera, Aloe ferox and Aloe marlothii gel materials after single and multiple applications." (2014).

# Ribeiro, Maximiano José Prata. "Development of new biomaterials to be applied as Skin Substitutes." PhD diss., Universidade da Beira Interior (Portugal), 2014.

# Tavares, Liliana Patrícia da Veiga Durão Barbosa, et al. „Impacto do excesso de peso sobre a fisiologia normal da pele humana in vivo.” (2014).

# Tichota, Deise Michele, et al. „Design, characterization, and clinical evaluation of argan oil nanostructured lipid carriers to improve skin hydration.” *International journal of nanomedicine* 9 (2014): 3855.

# Tunç, Yasin. "Elektrik Stimülasyonunda Kullanılan Farklı Akımların Derinin Biyofiziksel Özellikleri Üzerine Etkisi." (2014).

# Vitorino, Carla, et al. „Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. In vivo studies.” *European Journal of Pharmaceutics and Biopharmaceutics* 86.2 (2014): 133-144.

# Vyumvuhore, Raoul, et al. „Raman spectroscopy: in vivo quick response code of skin physiological status.” *Journal of biomedical optics* 19.11 (2014): 111603-111603.

* 1. 胡珍, and 于春水. „期刊订阅.”, 2015
  2. Depieri LV, Garcia Praça FS, Campos PM, Lopes Badra Bentley MV. Advances in the bioanalytical study of drug delivery across the skin. Therapeutic delivery. 2015 May;6(5):571-94.
  3. Du Plessis JL, Stefaniak AB. Biometrology Guidelines for the In Vivo Assessment of Transepidermal Water Loss and Skin Hydration in Nonclinical Settings. Measuring the Skin. 2015:1-11
  4. Falcone D, Uzunbajakava NE, Varghese B, de Aquino Santos GR, Richters RJ, van de Kerkhof PC, van Erp PE. Microspectroscopic confocal Raman and macroscopic biophysical measurements in the in vivo assessment of the skin barrier: perspective for dermatology and cosmetic sciences. Skin pharmacology and physiology. 2015;28(6):307-17.
  5. Hosono M, Isozaki A, Katoh K, Ichikawa Y, Iwase E, Matsumoto K, Shimoyama I. Moisture sensor based on heat transfer possessing insusceptibility to coating materials on skin. Sensors and Actuators A: Physical. 2015 Nov 1;235:265-72.
  6. Kanlayavattanakul M, Lourith N. Biopolysaccharides for skin hydrating cosmetics. Polysaccharides: Bioactivity and Biotechnology. 2015:1867-92.
  7. Koh JH, Miller C, McKenzie G, McGuiness W. The relationship between periwound skin condition and venous leg ulcer chronicity. Wound Practice & Research: Journal of the Australian Wound Management Association. 2015 Jun;23(2):82.
  8. Komane B, Vermaak I, Summers B, Viljoen A. Safety and efficacy of Sclerocarya birrea (A. Rich.) Hochst (Marula) oil: A clinical perspective. Journal of ethnopharmacology. 2015 Dec 24;176:327-35.
  9. Kubalová, Marie. "In vivo hodnocení účinnosti kosmetických formulací s obsahem včelích produktů na pokožku." (2015).
  10. Nagashima T, Komeda T, Yamamoto SI, Yajima T, Kemuriyama T. Measurement of Skin Surface pH with a Non-invasive Dry pH Sensor. In5th International Conference on Biomedical Engineering and Technology (ICBET 2015), IPCBEE 2015 (Vol. 81).
  11. Oshiro Junior, João Augusto, et al. "Development of Cutaneous Bioadhesive Ureasil-Polyether Hybrid Films." International Journal of Polymer Science 2015 (2015).
  12. Peres, Daniela D'Almeida. "Ácido ferúlico em protetores solares: desenvolvimento e eficácia multifuncional in vitro, ex vivo e in vivo." PhD diss., Universidade de São Paulo, 2015.
  13. Rosado, Catarina, Filipa Antunes, Raquel Barbosa, Raquel Fernando, and L. Monteiro Rodrigues. "Cutiscan®-A new system of biomechanical evaluation of the skin in vivo-comparative study of use depending on the anatomical site." (2015).
  14. Schario, Marianne Sonja. "Kinder mit trockener Haut und atopischer Prädisposition." PhD diss., Freie Universität Berlin, 2015.
  15. Araújo A, Nunes F, Ribeiro M, Coutinho P. Development, characterization and efficacy evaluation of dermocosmetic formulations based on a thermal water of Beira Interior of Portugal. Artigos em Acta de Conferência Internacional (ESS),2016
  16. Boer M, Duchnik E, Maleszka R, Marchlewicz M. Structural and biophysical characteristics of human skin in maintaining proper epidermal barrier function. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii. 2016 Feb;33(1):1.
  17. BOUHLALA, Nadia. "Méthodes d’évaluation des produits cométiques." (2016).
  18. Choimet, Maëla. "Particules colloïdales multifonctionnalisées pour la vectorisation d'un principe actif: vers une nouvelle formulation pour la dermatologie." PhD diss., 2016.
  19. Damasceno GA, Silva RM, Fernandes JM, Ostrosky EA, Langassner SM, Ferrari M. Use of Opuntia ficus-indica (L.) Mill extracts from Brazilian Caatinga as an alternative of natural moisturizer in cosmetic formulations. Brazilian Journal of Pharmaceutical Sciences. 2016 Sep;52(3):459-70.
  20. de Farias Pires T, Azambuja AP, Horimoto AR, Nakamura MS, de Oliveira Alvim R, Krieger JE, Pereira AC. A population-based study of the stratum corneum moisture. Clinical, cosmetic and investigational dermatology. 2016;9:79.
  21. Hadi H, Awadh AI, Hanif NM, Md Sidik NF, Mohd Rani MR, Suhaimi MS. The investigation of the skin biophysical measurements focusing on daily activities, skin care habits, and gender differences. Skin Research and Technology. 2016 May 1;22(2):247-54.
  22. Igielska-Kalwat, Joanna. "Badanie wpływu form kosmetycznych na biodostępność wybranych karotenoidów." (2016).
  23. Laing R, Swan P. Wool in Human Health and Well-Being. InNatural Fibres: Advances in Science and Technology Towards Industrial Applications 2016 (pp. 19-34). Springer Netherlands.
  24. Mathanda TR, M Bhat R, Hegde P, Anand S. Transepidermal Water Loss in Neonates: Baseline Values Using a Closed‐Chamber System. Pediatric dermatology. 2016 Jan 1;33(1):33-7.
  25. Nunes, Felipe de Freitas. "Sulfato de glucosamina como modelo de fármaco hidrófilico em sistema emulsionado e nanoparticulado para aplicação dermocosmética." (2016).
  26. Ruela AL, Perissinato AG, Lino ME, Mudrik PS, Pereira GR. Evaluation of skin absorption of drugs from topical and transdermal formulations. Brazilian Journal of Pharmaceutical Sciences. 2016 Sep;52(3):527-44.
  27. Tavares L, Palma L, Santos O, Roberto M, Bujan MJ, Rodrigues LM. Impact of Excess Body Weight on Skin Hydration and Biomechanics. Measuring the Skin. 2016:1-9.
  28. 文谦, 李芳梅, 杨志波. 当归饮子对银屑病模型豚鼠神经酰胺含量, AQP-3 基因及蛋白表达的干预研究. 环球中医药. 2016;9(8):914-7.
  29. 長島 拓人, et al. "皮膚 pH 計測用乾式センサシステムの開発―乾式測定手法の検討―." *ライフサポート* 28.3 (2016): 78-84.
  30. Darlenski R, Fluhr JW. Measurement of Skin Surface Acidity: Measuring Skin pH. Agache's Measuring the Skin: Non-invasive Investigations, Physiology, Normal Constants. 2017:113-20.
  31. Filipović, Mila Đ. Kozmetičke emulzije na bazi prirodnog alkil poliglukozidnog emulgatora sa liposominkapsuliranim biljnim matičnim ćelijama: proučavanje fenomena na granici faza i biofizička merenja na koži. Diss. Univerzitet u Beogradu-Farmaceutski fakultet, 2017.
  32. Hua W, Fan LM, Dai R, Luan M, Xie H, Li AQ, Li L. Comparison of two series of non‐invasive instruments used for the skin physiological properties measurements: the DermaLab® from Cortex Technology vs. the series of detectors from Courage & Khazaka. Skin Research and Technology. 2017 Feb 1;23(1):70-8.
  33. Huimin K, Rowledge AM, Borzdynski CJ, Miller C, Frescos N, McKenzie G, Perry E, McGuiness W. Reliability of a Skin Diagnostic Device in Assessing Hydration and Erythema. Advances in Skin & Wound Care. 2017 Oct 1;30(10):452-9.
  34. Khoirunisa AR. Uji penetrasi gamma-oryzanol dalam sediaan emulgel dengan variasi konsentrasi polimer karbopol 940 sebagai gelling agent menggunakan sel difusi franz (Bachelor's thesis, UIN Syarif Hidayatullah Jakarta: Fakultas Kedokteran dan Ilmu Kesehatan, 2017).
  35. Mauro M, De Giusti V, Bovenzi M, Larese Filon F. Effectiveness of a secondary prevention protocol for occupational contact dermatitis. Journal of the European Academy of Dermatology and Venereology. 2017 Apr 1;31(4):656-63.
  36. Mesrar J, Ognard J, Garetier M, Chechin D, Misery L, Ben Salem D. In vivo skin moisturizing measurement by high‐resolution 3 Tesla magnetic resonance imaging. Skin Research and Technology. 2017 Aug 1;23(3):289-94.
  37. Rayner, R.L., 2017. *Skin Tear Prediction in the Elderly: A Cohort Study* (Doctoral dissertation, Curtin University).
  38. Richters RJ, Uzunbajakava NE, van de Kerkhof PC, van Erp PE. Conclusions and general discussion. on the pathomechanism of sensitive skin. 2017:203.
  39. Sethi, Bhawana, and Anil Kumar Sahdev. "WORLD JOURNAL OF PHARMACEUTICAL RESEARCH." (2017).
  40. Sriram G, Alberti M, Dancik Y, Wu B, Wu R, Feng Z, Ramasamy S, Bigliardi PL, Bigliardi-Qi M, Wang Z. Full-thickness human skin-on-chip with enhanced epidermal morphogenesis and barrier function. Materials Today. 2017 Dec 6.
  41. Yuan, Chao. "Exploratory research for pathogenesis of papulopustular rosacea and skin barrier research in Besançon and Shanghai." PhD diss., Université Bourgogne Franche-Comté, 2017.
  42. Зайнуллина ОН, Хисматуллина ЗР, Печкуров ДВ. СОВРЕМЕННЫЕ МЕТОДЫ ОЦЕНКИ СОСТОЯНИЯ КОЖИ ПРИ АТОПИЧЕСКОМ ДЕРМАТИТЕ У ДЕТЕЙ. Аллергология и иммунология в педиатрии. 2017(4):4-9.
  43. 孫詩芸. 非侵入性分段剝離對經皮傳導小型干擾 RNA 與質體 DNA 載體之影響: 飛梭雷射與飛梭電波拉皮. 臺北醫學大學醫學科學研究所學位論文. 2017 Jan 1:1-87.
  44. Choi JY, Kim EJ, Jang SI, Kim AR, Lee TJ, Lee HK. A new technique for evaluating heel xerosis grade and the effects of moisturizer on heel skin dryness. Skin Research and Technology. 2018 Mar 1.
  45. Darlenski R, Hristakieva E, Aydin U, Gancheva D, Gancheva T, Zheleva A, Gadjeva V, Fluhr JW. Epidermal barrier and oxidative stress parameters improve during in 311 nm narrow band UVB phototherapy of plaque type psoriasis. Journal of dermatological science. 2018 Mar 21.
  46. Dancik Y, Sriram G, Rout B, Yu FZ, Bigliardi-Qi M, Bigliardi PL. Physical and compositional analysis of differently cultured 3D human skin equivalents by confocal Raman spectroscopy. Analyst. 2018 Jan 22.
  47. Pereira MI. Relatórios de Estágio realizados na Farmácia Moreno e no Centro Hospitalar de Vila Nova de Gaia/Espinho.Doctor Thesis, 2018
  48. Wakeman M.An open label pilot study to evaluate the effectiveness of a proprietary nutraceutical formulation on elements of skin function associated with aging International Journal Of Scientific Research.2018 ; 7 :437-8
  49. Wang X, Shu X, Li Z, Huo W, Zou L, Tang Y, Li L. Comparison of two kinds of skin imaging analysis software: VISIA® from Canfield and IPP® from Media Cybernetics. Skin Research and Technology. 2018 Jan 27.

# В монографии

# JJ Escobar-Chávez et al. Conventional Methods of Cutaneous Drug Sampling. In Dermatokinetics of Therapeutic Agents ed by S. Narasimha Murthy, Amazon com, 2011,82-122

# Medina W. Nanocarriers to Deliver Photosensitizers in Topical Photodynamic Therapy and Photodiagnostics. In Nanocosmetics and Nanomedicines: New Approaches for Skin Care  By Ruy Beck, Silvia Guterres, Adriana Pohlmann, Chapter 15, 2011

# Darlenski, R and Joachim W. Fluhr. „Moisturizers and emollients.” *Practical Aspects of Cosmetic Testing*. Springer Berlin Heidelberg, 2011. 123-141.

# Danby SG et al. Current and Future Trends: Skin Diseases and Treatment. In Transdermal and Topical Drug Delivery: Principles and Practice by By Heather A. E. Benson, Adam C. Watkinson, (2011): 367-407.

# Mohamad, M., A. R. Msabbri, and M. Z. MatJafri. „Non invasive measurement of skin hydration and transepidermal water loss in normal skin.” In *Humanities, Science and Engineering (CHUSER), 2012 IEEE Colloquium on*, pp. 859-862. IEEE, 2012.

# Yuan, Chao, Xue-Min Wang, Carlos Galzote, Yi-Mei Tan, Kamlesh V. Bhagat, Zhi-Kang Yuan, Jian-Fei Du, and Yuan Tan. „Meteorology and ethnicity as critical factors in HRIPT: Comparing responses between Chinese and Indian ethnicities.” *Regulatory Toxicology and Pharmacology* 66, no. 1 (2013): 59-65.

# Darlenski, Razvigor, Joachim W. Fluhr, and Jürgen Lademann. „Stripping Techniques: Tape Stripping.” In *Non Invasive Diagnostic Techniques in Clinical Dermatology*, pp. 287-292. Springer Berlin Heidelberg, 2014.

# Fluhr, Joachim W., and Razvigor Darlenski. „Transepidermal Water Loss (TEWL).” In *Non Invasive Diagnostic Techniques in Clinical Dermatology*, pp. 353-356. Springer Berlin Heidelberg, 2014.

# Kanlayavattanakul, Mayuree, and Nattaya Lourith. „Biopolysaccharides for Skin Hydrating Cosmetics.” In *Polysaccharides*, pp. 1-23. Springer International Publishing, 2014.

# van der Pol, André, and Peter J. Caspers. „10 Confocal Raman Spectroscopy for In.” *Handbook of Cosmetic Science and Technology* (2014): 115.

* 1. Antonov D, Schliemann S, Elsner P. Methods for the assessment of barrier function. InSkin Barrier Function 2016 (Vol. 49, pp. 61-70). Karger Publishers.
  2. Estanqueiro M, Conceição J, Amaral MH, Lobo JM. The role of liposomes and lipid nanoparticles in the skin hydration. InNanobiomaterials in Galenic Formulations and Cosmetics 2016 (pp. 297-326).
  3. Briançon S, Bolzinger MA, Chevalier Y. Confocal Raman Spectroscopy as a Tool to Investigate the Action of Penetration Enhancers Inside the Skin. InPercutaneous Penetration Enhancers Drug Penetration Into/Through the Skin 2017 (pp. 229-246). Springer Berlin Heidelberg.

**Dreno B, Castell A, TSANKOV N, Lipozencic J, Serdaroglu S, Gutierrez V, Gadroy A, Merial-Kieny C, Mery S. Interest of the association retinaldehyde/glycolic acid in adult acne.2009, 23, Issue 5, 529 – 532**

**Цитати -24**

1. Bergstrom, KG. Beyond tretinoin: cosmeceuticals for aging skin.  J Drugs in Dermatology, 2009 , 8, 7O.
2. Bergler-Czop Beata , Ligia Brzezińska-Wcisło.**Ocena parametrów skóry – nawilżenia, zawartości melaniny, pH oraz sekrecji łoju – u pacjentów leczonych doustną izotretynoiną – doniesienie wstępne.** Post Dermatol Alergol 2010; XXVII, 2: 83–89
3. Bergler-Czop Beata. **Przegląd współczesnych poglądów na etiopatogenezę trądziku pospolitego.** Post Dermatol Alergol 2010; XXVII, 6: 467–476
4. Isard et al. Anti-inflammatory properties of a new undecyl-rhamnoside (APRC11) against *P. Acnes* Archives of Dermatological Research , 2011, [303, 10](http://www.springerlink.com/content/0340-3696/303/10/)
5. Bergler-Czop Beata , Ligia Brzezińska-Wcisło The new therapy schema of the various kinds of acne based on the mucosa-skin side effects of the retinoids. Cutaneous and Ocular Toxicology,2011
6. Dréno, B., et al. „Expert Opinion: Efficacy of superficial chemical peels in active acne management–what can we learn from the literature today? Evidence‐based recommendations.” *Journal of the European Academy of Dermatology and Venereology* 25.6 (2011): 695-704.
7. Isard, O., et al. „Anti-inflammatory properties of a new undecyl-rhamnoside (APRC11) against P. Acnes.” *Archives of dermatological research* 303.10 (2011): 707-713.
8. 이우건, et al. „PubMed 를 통해 살펴 본 최신 여드름 치료 연구 경향.” *한방안이비인후피부과학회지 제* 24.2 (2011).
9. Placek W. **Leczenie miejscowe trądziku.** Przegl Dermatol 2011, 98, 442–448
10. Bergler-Czop, Beata, and Ligia Brzezinska-Wcislo. „The new therapy schema of the various kinds of acne based on the mucosa-skin side effects of the retinoids.” *Cutaneous and ocular toxicology* 31.3 (2012): 188-194.
11. Tedeschi, Aurora, et al. „Cosmeceuticals in Dermatology.” *Update in Cosmetic Dermatology*. Springer Berlin Heidelberg, 2013. 87-113.
12. Dréno, B., et al. „Large‐scale international study enhances understanding of an emerging acne population: adult females.” *Journal of the European Academy of Dermatology and Venereology* (2014).
13. Kaminaka, Chikako, et al. „Clinical Evaluation of Glycolic Acid Chemical Peeling in Patients with Acne Vulgaris: A Randomized, Double‐Blind, Placebo‐Controlled, Split‐Face Comparative Study.” *Dermatologic Surgery* 40.3 (2014): 314-322.
14. Masini, F., et al. „Combination therapy with retinaldehyde (0.1%) glycolic acid (6%) and efectiose (0.1%) in mild to moderate acne vulgaris during the period of sun exposure–efficacy and skin tolerability.” *European review for medical and pharmacological sciences* 18.16 (2014): 2283-2286.
15. Rademaker, M., J. M. Wishart, and N. M. Birchall. „Isotretinoin 5 mg daily for low‐grade adult acne vulgaris–a placebo‐controlled, randomized double‐blind study.” *Journal of the European Academy of Dermatology and Venereology* 28.6 (2014): 747-754.
16. Thielitz A, Lux A, Wiede A, Kropf S, Papakonstantinou E, Gollnick H. A randomized investigator‐blind parallel‐group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology. 2015 Apr 1;29(4):789-96.
17. Araviiskaia E, Dréno B. The role of topical dermocosmetics in acne vulgaris. Journal of the European Academy of Dermatology and Venereology. 2016 Jun 1;30(6):926-35.
18. Gold LS, Baldwin H, Rueda MJ, Kerrouche N, DrÉno B. Adapalene-benzoyl Peroxide Gel is Efficacious and Safe in Adult Female Acne, with a Profile Comparable to that Seen in Teen-aged Females. The Journal of clinical and aesthetic dermatology. 2016 Jul;9(7):23.
19. 林伸和, 赤松浩彦, 岩月啓氏, 大森遼子, 上中智香子, 黒川一郎, 幸野健, 小林美和, 谷岡未樹, 古川福実, 古村南夫. 尋常性痤瘡治療ガイドライン 2016. 日本皮膚科学会雑誌. 2016 May 20;126(6):1045-86.
20. Al-Talib H, Al-khateeb A, Hameed A, Murugaiah C. Efficacy and safety of superficial chemical peeling in treatment of active acne vulgaris. Anais brasileiros de dermatologia. 2017 Mar;92(2):212-6.
21. Ferreira RA. Relatórios de Estágio realizado na Farmácia Sá da Bandeira e nos Serviços Farmacêuticos do Hospital Privado de Alfena.2017
22. 林伸和, 赤松浩彦, 岩月啓氏, 大森遼子, 上中智香子, 黒川一郎, 幸野健, 小林美和, 谷岡未樹, 古川福実, 古村南夫. 尋常性痤瘡治療ガイドライン 2017. 日本皮膚科学会雑誌. 2017 May 20;127(6):1261-302.
23. Hayashi N, Akamatsu H, Iwatsuki K, Shimada‐Omori R, Kaminaka C, Kurokawa I, Kono T, Kobayashi M, Tanioka M, Furukawa F, Furumura M. Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017. The Journal of dermatology. 2018 May 21.
24. Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Cabal MI, Bettoli V, Casintahan F, Chow S, da Costa A, El Ouazzani T. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology. 2018 Feb 1;78(2):S1-23.

**Mehrabian S, Radoslavova M, Petrova E, TSANKOV N, Traykov L.Neurosyphilis presenting with dementia, chronic chorioretinitis and adverse reactions to treatment: a case report. Cases Journal,2009,2,8334**

**Цитати -25**

1. Mehrabian, S. „Jarisch-Herxheimer reaction and Hoigné reaction: case report.” *Reactions* 1308 (2010): 3.
2. 以癫痫为首发症状的神经梅毒.王庆 – 神经损伤与功能重建, 2010
3. 汤荟冬, and 刘晓英. „麻痹性痴呆.” *中国现代神经疾病杂志* 3 (2010): 316-318.
4. 王庆. „以癫痫为首发症状的神经梅毒.” *神经损伤与功能重建* 5.3 (2010): 228-228.
5. TANG Hui-dong　 LIU Xiao-ying, **General Paresis of Insane**, Chinese J of Contemporary Neurology and Neurosurgery, 2010 Vol.10 No.3 P.316-318
6. Friedrich, Fabian, and Martin Aigner. *Psychiatric Manifestations of Neurosyphilis*. INTECH Open Access Publisher, 2011.
7. Куляш, Г. Ю. „Диагностика нейросифилиса: проблемы трактовки результатов лабораторных исследований.” *Клин. Дерматол. И венерол* 2011 (2011): 68t69.
8. Wang Jianhong et al. Cognitive Impairment in Mild General Paresis of the Insane : AD-Like Pattern. *Dement Geriatr Cogn Disord* 2011 ;31 :284-290
9. Fabian F. The Chameleon of Psychiatry – Psychiatric Manifestations of Neurosyphilis**.** Psychiat Prax 2012; 39(1): 7-13
10. HIV 抗体阴性神经梅毒 31 例临床分析. 曹小丽， 陈莉… - 实用医学杂志, 2012
11. Mehrabian, Shima, Margarita Raycheva, Martina Traykova, Tonya Stankova, Latchezar Penev, Olga Grigorova, and Latchezar Traykov. „Neurosyphilis with dementia and bilateral hippocampal atrophy on brain magnetic resonance imaging.” *BMC neurology* 12, no. 1 (2012): 96.
12. 曹小丽, 陈莉, and 尹瑞兴. „HIV 抗体阴性神经梅毒 31 例临床分析.” *实用医学杂志* 28.4 (2012): 626-628.
13. Balasa, R. et al. Pitfalls in the diagnosis of neurosyphilis-case report and literature review. *Acta Medica Transilvanica*, (2014). *19*(4).
14. Balasa, R., Baiko Z., et al. Capcane în diagnosticul neurosifilisului–prezentare de caz şi date din literatură. *Acta Medica Transilvanica*, (2014). *19*(4).
15. Moulton, Calum D., and Ivan Koychev. „The effect of penicillin therapy on cognitive outcomes in neurosyphilis: a systematic review of the literature.” *General hospital psychiatry* 37.1 (2015): 49-52.
16. Thompson TM, Theobald JL. Hoigne syndrome: a little-known adverse effect of lidocaine. The American journal of emergency medicine. 2016 Mar 1;34(3):679-e3.
17. Bologa C, Lionte C, Halit D, Luca C. Case report. Neurosyphilis Masquerading as Stroke in an 84-year-old. The Journal of Critical Care Medicine. 2017 Apr 25;3(2):70-2.
18. Guarneri C, Tchernev G, Wollina U, Lotti T. Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate. Open Access Macedonian Journal of Medical Sciences. 2017 Jul 25;5(4):483.
19. Njiru E, Abdulkadir J, Kamuren Z, Kigen G. Early neurosyphilis presenting with facial palsy and an oral ulcer in a patient who is human immunodeficiency virus positive: a case report. Journal of medical case reports. 2017 May 13;11(1):134.
20. 吕萍, 方昶, 黄进梅, 曾仁山, 黄涛, 杨斌. 神经梅毒患者脑脊液蛋白芯片分析. 皮肤性病诊疗学杂志. 2017;24(1):3-7.
21. Halperin JJ, García-Moncó JC. The Human Borreliosis: Lyme Neuroborreliosis and Relapsing Fever. InCNS Infections 2018 (pp. 233-249). Springer, Cham.

В монографии:

# Tore Midtvedi. Chapter 25. Penicillins, cephalosporins other betalactam antibiotics and tetracyclins. In: Jeffrey K Aronson. Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Elsevier, 2011,p.505

1. Halperin, John J., and Juan Carlos García-Moncó. „The Human Borreliosis: Lyme Neuroborreliosis and Relapsing Fever.” In *CNS Infections*, pp. 211-226. Springer London, 2014.
2. Salazar, Juan C. „Neurosyphilis.” In *CNS Infections*, pp. 227-247. Springer London, 2014.
3. Salazar JC, Rice DP. Neurosyphilis. InCNS Infections 2018 (pp. 251-273). Springer, Cham.

[**TSANKOV N.**](http://www.scopus.com/search/submit/author.url?author=Tsankov+N.&origin=resultslist&authorId=7006410879)**,** [**Grozdev I.**](http://www.scopus.com/search/submit/author.url?author=Grozdev+I.&origin=resultslist&authorId=12244908300) **Rifampicin in the treatment of psoriasis (2009) Journal of the European Academy of Dermatology and Venereology, 23 (1), pp. 93-95.**

Цитати – 8

1. Baker, Nancy C. "Methods in literature-based drug discovery." PhD diss., The University of North Carolina at Chapel Hill, 2010.
2. Dubrac, S., Elentner, A., Ebner, S., Horejs-Hoeck, J., Schmuth, M.Modulation of T lymphocyte function by the pregnane X receptor.  2010 *Journal of Immunology* 184 (6), pp. 2949-2957
3. Gao, Jie, and Wen Xie. „Targeting xenobiotic receptors PXR and CAR for metabolic diseases.” *Trends in pharmacological sciences* 33.10 (2012): 552-558.
4. Schmuth, M., and S. Dubrac. „Nukleäre Hormonrezeptoren: Perspektiven der Dermatotherapie.” *Aktuelle Dermatologie* 38.03 (2012): 80-84.
5. Nikolova, Biliana, et al. „Fluorescent Imaging for Assessment of the Effect of Combined Application of Electroporation and Rifampicin on HaCaT Cells as a New Therapeutic Approach for Psoriasis.” *Sensors* 13.3 (2013): 3625-3634.
6. Mehlis, S., 2015. Guttate psoriasis. *UpToDate, Waltham, MA.(Accessed on June 5, 2014)*.
7. Shehu AI, Li G, Xie W, Ma X. The pregnane X receptor in tuberculosis therapeutics. Expert opinion on drug metabolism & toxicology. 2016 Jan 2;12(1):21-30.
8. Scheinfeld N. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system. Dermatology online journal. 2016 Jan 1;22(6).

**Slavov, C., Venkov, G., Velikova, K., Christova, S., Popov, E., & Tsankov, N. (2009). Malignant melanoma of glans penis and prepuce treated with organ-preserving surgical procedure. *Acta dermatovenerologica Croatica: ADC*, *17*(2), 131.**

**Цитати -2**

1. 王毓斌, 邵晋凯, and 高 龙. "阴茎恶性黑色素瘤诊治分析." *上海交通大学学报 (医学版)* 30.11 (2010): 1437.
2. 赵涛, 刘家骥. 阴茎包皮原发性恶性黑色素瘤的诊断与治疗. 局解手术学杂志. 2016;25(1):33-5.

**Darlenski R., Neykov N., Vlahov V., TSANKOV N. Evidence-based medicine: Facts and controversies. Clin Dermatol, 2010,28, 5, 553-557  
Controversies in Dermatology: Part III**

**Цитати – 18**

1. Ghotbi, Elena, Akbar Soltani, and Armin Hirbod-Mobarakeh. „Analysis of Scientific Activity Addressing Evidence Based Medicine: A Bibliometric Study.” (2010).
2. Toke, Valelia Muni. „Deontological issues, language ideologies and reflexivity in linguistics:‘Native’competence vs scientific knowledge?.” *Pragmatics and Society* 2.2 (2011): 205-233.
3. Bourke, Lisa. „Evidence-based Practice Meets Patient Choice.” *Journal of Community Medicine & Health Education* (2012).
4. Darlenski, Razvigor, and Joachim W. Fluhr. „Influence of skin type, race, sex, and anatomic location on epidermal barrier function.” *Clinics in dermatology* 30.3 (2012): 269-273.
5. Parish, Lawrence Charles. „Evidence-Based Procedural Dermatology.” *JAMA* 308.5 (2012): 517-518.
6. Oliver, Jonathan D. *Examining barriers of using evidence-based decision making by managers in practice*. Diss. University of Prince Edward Island, 2013.
7. Saltman, Deborah, et al. „In pursuit of certainty: can the systematic review process deliver?.” *BMC medical informatics and decision making* 13.1 (2013): 25.
8. Bogdanova, Liliya, et al. „Ad Hoc Study Of The Role Of Hospital Pharmacists In Clinical Trials In Bulgaria.” *Scripta Scientifica Pharmaceutica* 1.1 (2014): 20-24.
9. Darlenski, R, J Kazandjieva, E Hristakieva, JW. Fluhr. „Atopic dermatitis as a systemic disease.” *Clinics in dermatology* 32, no. 3 (2014): 409-413.
10. Getov, Ilko, et al. „Study Of Pharmacy Students’attitudes For Scientific Researches And/Or Academic Career In Bulgaria.” *Scripta Scientifica Pharmaceutica* 1.2 (2015): 18-22.
11. Gibson A, Boddy K, Maguire K, Britten N. Exploring the impact of providing evidence-based medicine training to service users. Research Involvement and Engagement. 2015 Aug 20;1(1):10.
12. Golden I. The Immunisation Dilemma—Part Four: A Comparison of Effectiveness. Homoeopathic Links. 2015 Mar;28(01):008-13.
13. Jegzentis K. *Analyse und Interpretation von Schlüsselprozessen in der Durchführung klinischer Studien am Beispiel des Centrums für Schlaganfallforschung Berlin (CSB)* (Doctoral dissertation, Freie Universität Berlin).
14. Saad M, de Medeiros R. Distant Healing Techniques and Distant Intercessory Prayer–A Tentative Scientific Conciliation. InComplementary Therapies for the Body, Mind and Soul 2015. InTech.
15. Atwa H, Abdelaziz A. Evidence-based medicine (EBM) for undergraduate medical students: A six-step, integrative approach. Medical teacher. 2017 Mar 16;39(sup1):S27-32.
16. Castaño FA, Hernández AM. Motion Artifacts Recognition in Electrocardiographic Signals through Artificial Neural Networks and Support Vector Machines for Personalized Health Monitoring. InVII Latin American Congress on Biomedical Engineering CLAIB 2016, Bucaramanga, Santander, Colombia, October 26th-28th, 2016 2017 (pp. 425-428). Springer, Singapore.
17. Kasch C, Haimerl P, Heuwieser W, Arlt S. Evaluation of a CAT Database and Expert Appraisal of CATs Developed by Students. Journal of Veterinary Medical Education. 2017 Jun 5:1-0.
18. Tilburt JC, Allyse M, Hafferty FW. The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work?. AMA Journal of Ethics. 2017 Feb 1;19(2):199.

**Kazandjieva J, Balabanova M, Kircheva K, TSANKOV N. Contact dermatitis due to temporary henna tattoos. Skin med 2010,8,191-192**

**Цитирания – 6**

1. Petrovajova M et al. Long term risk of tattoo in children. Dermatol. Prax, 2011,5 (2): 80-84
2. Choulis, N. H. „14 Dermatological drugs, topical agents, and cosmetics.” *Side Effects of Drugs Annual* 34 (2012): 257.
3. Ilyas, Saher, Komal Wasif, and Muhammad Wasif Saif. „Topical henna ameliorated capecitabine-induced hand-foot syndrome.” *Cutaneous and ocular toxicology* 0 (2013): 1-3.
4. Choulis, N. H. „Dermatological Drugs, Topical Agents, and Cosmetics.” *Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions* (2014): 203.
5. Lee HJ, Kim WJ, Kim JY, Kim HS, Kim BS, Kim MB, Ko HC. Patch tests with commercial hair dye products in patients with allergic contact dermatitis to para-phenylenediamine. Indian Journal of Dermatology, Venereology, and Leprology. 2016 Nov 1;82(6):645.

**В монографии**

# Aronson J. Dermatological drugs, topical agents and cosmetic. Chapter 14 In: Side Effects of Drugs Annual: 34, 2012, p.267

**Holst R. F, Reitamo S, Yankova R., Worm M.,Kadurina M., Thaci K., Bieber T, TSANKOV N, Enk A., Luger T., Duffy M., Tansley R The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study. Allergy, 2010, 65, 12, 1594–1599**

**Цитати – 11**

1. Dupuy, A. „Quoi de neuf en thérapeutique dermatologique?.” *Annales de Dermatologie et de Vénéréologie*. Vol. 138. Elsevier Masson, 2011.
2. Simon, Dagmar ; Kernland Lang, Kristin. Atopic dermatitis : from new pathogenic insights toward a barrier-restoring and anti-inflammatory therapy. Current Opinion in Pediatrics: 2011 – Volume 23 – Issue 6 – p 647–652
3. Gunten, S., et al. „Update in clinical allergy and immunology.” *Allergy* 67.12 (2012): 1491-1500.
4. Nankervis, Helen, et al. „Prospective registration and outcome-reporting bias in randomized controlled trials of eczema treatments: a systematic review.” *Journal of Investigative Dermatology* 132.12 (2012): 2727-2734.
5. Apfelbacher CJ, Heinl D, Nankervis H, Chalmers J. Eczema Trials: Quality of Life Instruments Used and Their Relation to Patient-reported Outcomes. A Systematic Review. Acta Dermato Venereologica. 2015 Dec 17;2016(96):1-24.
6. Heinl D, Chalmers J, Nankervis H, Apfelbacher CJ. Eczema trials: quality of life instruments used and their relation to patient-reported outcomes. A systematic review. Acta dermato-venereologica. 2016 Jul 1;96(5):596-604.
7. Hill MK, Pishkenari AK, Braunberger TL, Armstrong AW, Dunnick CA. Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: a systematic review. Journal of the American Academy of Dermatology. 2016 Nov 30;75(5):906-17.
8. Nakatsuji T, Chen TH, Chun KA, Narala S, Geha RS, Hata TR, Gallo RL. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression. Journal of Investigative Dermatology. 2016 Nov 30;136(11):2192-200.
9. Nankervis H, Thomas KS, Delamere FM, Barbarot S, Rogers NK, Williams HC. Scoping systematic review of treatments for eczema. Programme Grants for Applied Research. 2016 May 1;4(7):1-480.
10. Vives Vilagut, Roser, and Caridad Pontes García. "Design of an exploratory development plan for the assessment of the activity of drugs for the treatment of chronic inflammatory dermatological diseases." Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia (2016).
11. Nankervis H, Thomas KS, Delamere FM, Barbarot S, Smith S, Rogers NK, Williams HC. What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials. British Journal of Dermatology. 2017 Apr 1;176(4):910-27.

**Popova L, Darlenski R, TSANKOV N. Penicillin and vitamin A as possible therapeutic agents in pityriasis rubra pilaris. *JDDG.: Journal der Deutschen Dermatologischen Gesellschaft*, 2010; *8*(5):354-356.**

**Цитати – 4**

1. 심성용. 호뇨자: 모공성 홍색 비강진 치험례. 한방안이비인후피부과학회지 제. 2015 Nov;28(4).
2. Andreas Katsambas, Clio Dessinioti, Kristina Callis Duffin, and Abena O. Ofori. "Pityriasis rubra pilaris."uptodate.com
3. Roenneberg S, Biedermann T. Pityriasis rubra pilaris: Algorithms for diagnosis and treatment. Journal of the European Academy of Dermatology and Venereology. 2017 Dec 15.
4. Wang D, Chong VC, Chong WS, Oon HH. A Review on Pityriasis Rubra Pilaris. American journal of clinical dermatology. 2018 Jan 4:1-4.

**Grozev I, Kazandjeva J, Tsankov N. Alternative treatment of psoriasis-is rifampicin a mild immunosupressor?/Alternativna terapija psorijaze: da li rifampicin ima blago imunosupresivno dejstvo?. Serbian Journal of Dermatology and Venerology. 2010 Jan 1;2(1):5-12.**

**Цитати – 1**

1. Golušin Z, Jovanović M, Magda N, Stojanović S, Matić M, Petrović A. Effects of Rusanda Spa balneotherapy combined with calcipotriol on plaque psoriasis. Vojnosanitetski pregled. 2015;72(11):1010-7.

**Petkov T, Dencheva R, TSANKOV N. Skin Changes of Patients on Dialysis Treatment. J Turk Acad Dermatol. 2010;4(3):04301r.**

**Цитати – 2**

1. Paucar K, Del Solar M, Bravo F, Salomón M, Puell L, Feria K, Ramos C, Cieza PG. Manifestaciones cutáneas de pacientes en hemodiálisis crónica intermitente (HDCI) en 3 centros de Lima Metropolitana. REVISIONES BIBLIOGRÁFICAS GALERÍA FOTOGRÁFICA. 2011 Dec:141.
2. Rashpa RS, Mahajan VK, Kumar P, Mehta KS, Chauhan PS, Rawat R, Sharma V. Mucocutaneous manifestations in patients with chronic kidney disease: A cross-sectional study. Indian Dermatology Online Journal. 2018 Jan 1;9(1):20.

**TSANKOV N, Meymandi S, Grozdev I, Shafiei H. Palmoplantar Psoriasis: Treatment with Calcipotriol and Local UVA Radiation Compared with Local PUVA. *Journal of Lasers in Medical Sciences*, (2011). *2*(1), 1-5.**

**Цитати – 2**

1. Girish, U. "Comparative Study Of Different Topical Treatment Modalities For Palmoplantar Psoriasis." (2011).
2. Punniyaseelan A, Mathan R. A comparative study of efficacy of hand foot psoralen-ultraviolet a therapy versus sequential therapy of topical clobetasol propionate with topical calcipotriol ointment in palmoplantar psoriasis. Journal of Evolution of Medical and Dental Sciences. 2017 Jun 5;6(45):3528-34.

**Darlenski R, Kazandjieva J, TSANKOV N. Is there an increased skin irritation and contact sensitization in atopic dermatitis? Expert Rev Dermatol, 2011, 6(2)**

**Цитати – 4**

1. Spiewak R. Contact Dermatitis in atopic individuals. Curr Opin Aller Top Imun, 2012
2. Lubbes S. Contact Dermatitis In Children With And Without Atopic Dermatitis; Which Are The Frequent Allergens? PhD thesis, 2014
3. Lubbes S, Rustemeyer T, Sillevis Smitt JH, Schuttelaar ML, Middelkamp‐Hup MA. Contact sensitization in Dutch children and adolescents with and without atopic dermatitis–a retrospective analysis. Contact dermatitis. 2017 Mar 1;76(3):151-9.
4. Su JC, Dailey R, Zallmann M, Leins E, Taresch L, Donath S, Heah SS, Lowe AJ. Determining Effects of Superfine Sheep wool in INfantile Eczema (DESSINE): a randomized paediatric crossover study. British Journal of Dermatology. 2017 Jul 1;177(1):125-33.

**Darlenski R, Kazandjieva J, TSANKOV N. Skin barrier function: morphological basis and regulatory mechanisms. J Clin Med. 2011; 4(1):36-45**

**Цитирания – 19**

1. Mahmood, Tariq, and Naveed Akhtar. "Improvement in skin barrier function following long-term treatment with green tea and lotus in healthy adults, a step towards future treatment of atopic dermatitis." *HealthMed* 7.2 (2013).
2. Lee, W. R., Shen, S. C., Chen, W. Y., Aljuffali, I. A., Suen, S. Y., & Fang, J. Y. (2014). Noninvasive delivery of siRNA and plasmid DNA into skin by fractional ablation: Erbium: YAG laser versus CO 2 laser. *European Journal of Pharmaceutics and Biopharmaceutics*, *86*(3), 315-323.
3. 이동혁, et al. "콜라겐과 무세포진피를 이용한 혼합형 인공피부 개발 및 쥐 모델에서 창상치료 적용." *KSBB Journal* 29.1 (2014): 42-49.
4. Unkovič, Ana. "Prisotnost in varnost uporabe parabenov in ftalatov v kozmetičnih izdelkih na slovenskem tržišču." PhD diss., A. Unkovič, 2014.
5. Arshad AI, Khan SH, Akhtar NA. Formulation development of topical cream loaded with ananas comosus extract: in vivo evaluation for changes in skin barrier function using biophysical techniques. Acta poloniae pharmaceutica. 2015 Dec;73(2):485-94.
6. Mourelle, M. L., C. P. Gómez, and J. L. Legido. "Cosmética dermotermal: valor añadido para los centros termales."2015
7. Mourelle, M. L., and C. P. Gómez. "Cosmética termal. Aplicaciones en el ámbito de la salud y la belleza."2015
8. Kubalová, Marie. "In vivo hodnocení účinnosti kosmetických formulací s obsahem včelích produktů na pokožku." (2015).
9. Carvalho AR. *Estudo da libertação de lisozima usando implantes lipídicos como sistemas de veiculação* (Master's thesis).
10. Komane BM, Vermaak I, Kamatou GP, Summers B, Viljoen AM. Beauty in Baobab: a pilot study of the safety and efficacy of Adansonia digitata seed oil. Revista Brasileira de Farmacognosia. 2016 Aug 12.
11. Mohammed A, Koorbanally NA, Islam MS. Phytochemistry, antioxidative activity and inhibition of key enzymes linked to type 2 diabetes by various parts of aframomum melegueta in vitro. Acta poloniae pharmaceutica. 2016 Apr;73:403.
12. Vaishali, Londhe. "Studies on Novel Topical Formulations." (2016).
13. Wohlman IM. *Chemical-induced alterations in the endocannabinoid system in mouse skin* (Doctoral dissertation, Rutgers University-Graduate School-New Brunswick). (2016).
14. Dai X. *Electrospun curcumin gelatin blended nanofibrous mats accelerate wound healing by Dkk-1 mediated fibroblast mobilization and MCP-1 mediated anti-inflammation* (Doctoral dissertation, Dissertation, München, Technische Universität München, 2017).
15. Joo D, An S, Choi BG, Kim K, Choi YM, Ahn KJ, An IS, Cha HJ. MicroRNA‑378b regulates α‑1‑type 1 collagen expression via sirtuin 6 interference. Molecular Medicine Reports. 2017 Sep 28.
16. Komane BM, Vermaak I, Kamatou GP, Summers B, Viljoen AM. Beauty in Baobab: a pilot study of the safety and efficacy of Adansonia digitata seed oil. Revista Brasileira de Farmacognosia. 2017 Feb 28;27(1):1-8.
17. Kim K, An S, Choi BG, Joo D, Choi YM, Ahn KJ, An IS, Cha HJ. Arctiin regulates collagen type 1α chain 1 mRNA expression in human dermal fibroblasts via the miR‑378b‑SIRT6 axis. Molecular Medicine Reports. 2017 Oct 2.
18. Mokrejs P, Hutta M, Pavlackova J, Egner P, Benicek L. The cosmetic and dermatological potential of keratin hydrolysate. Journal of Cosmetic Dermatology. 2017 Feb 1.
19. Tanjung C, Rzehak P, Mansyur M, Munasir Z, Sudoyo H, Immanuel S, Irawan R, Reischl E, Demmelmair H, Koletzko B, Hadinegoro SR. Study protocol to investigate the environmental and genetic aetiology of atopic dermatitis: the Indonesian Prospective Study of Atopic Dermatitis in Infants (ISADI). BMJ open. 2017 Mar 1;7(3):e012475.

**Tsankov, N. Grozdev I. „Rifampicin-a mild immunosuppressive agent for psoriasis.” *Journal of Dermatological Treatment* 22.2 (2011): 62-64.**

**Цитати: 11**

1. Wenink MH, Santegoets K, Butcher J, van Bon L, Lamers‐Karnebeek FG, van den Berg WB, van Riel PL, McInnes IB, Radstake TR. Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis & Rheumatology. 2011 Nov 1 ; 63(11) :3313-22.
2. McFadden, J., et al. "Concepts in psoriasis: psoriasis and the extracellular matrix." *British Journal of Dermatology* 167.5 (2012): 980-986
3. Sánchez Moya, Ana Isabel. "Infección y enfermedad tuberculosa en el paciente con psoriasis en tratamiento biológico." (2012).
4. Manczinger, Mate, and Lajos Kemeny. "Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach." *PloS one* 8.11 (2013): e80751.
5. Management of psoriasis vulgaris. "CLINICAL PRACTICE GUIDELINES."2013, Malaysia
6. Mas, Jean Louis, and Guillaume Taieb. "Nicolas Mélé, MD Vincent Guiraud, MD Pierre Labauge, MD, PhD Catherine Oppenheim, MD, PhD." (2014).
7. Mélé, Nicolas, et al. "Effective antituberculous therapy in a patient with CLIPPERS: New insights into CLIPPERS pathogenesis." *Neurology-Neuroimmunology Neuroinflammation* 1.1 (2014): e6.
8. Schmuth, Matthias, et al. "Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation." *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids* 1841.3 (2014): 463-473.
9. Manczinger, Máté. "High Throughput Screening of Gene Expression for the Investigation of Multifactorial Dermatological Disorders." PhD diss. szte, 2016.
10. Scheinfeld N. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa : a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system. Dermatology online journal. 2016 Jan 1 ; 22(6).
11. Cansu DÜ, Özbülbül NI, Akyol G, Arık D, Korkmaz C. Do pulmonary findings of granulomatosis with polyangiitis respond to anti-tuberculosis treatment ? Rheumatology international. 2018 Apr 9 :1-8.

**Darlenski, Razvigor, and Nikolai Tsankov. "Aquagenic syringeal acrokeratoderma." *JDDG: Journal der Deutschen Dermatologischen Gesellschaft* 10.3 (2012): 198-198.**

**Цитирания –6**

1. Ibusuki, Chieko, et al. "Unilateral aquagenic wrinkling of the palms with a peculiar clinical course." *European journal of dermatology: EJD* 22.5 (2012): 679.
2. Kent, Jeremy B., et al. "Watersport Hands." *Sports Health: A Multidisciplinary Approach* 6.4 (2014): 360-362.
3. Li, C‐X., et al. "Clinical, demographic and histopathological features of symmetrical acral keratoderma." *British Journal of Dermatology* 170.4 (2014): 948-951.
4. Gönül M, Canpolat F, Kurmuş GI, Gökçe A, Şaşmaz R. Akuajenik Siringeal Akrokeratoderma. Turkish Journal of Dermatology. 2015 Sep 1;9(3).
5. Megna M, Cantelli M, Martellotta D, Calabrò G, Balato A, Ayala F. Aquagenic wrinkling of the palms : a case report and literature review. Dermatology online journal. 2016 Jan 1 ; 22(9).
6. Peña-Romero AG, Toussaint-Caire S, Charli-Joseph Y, Barreda-Becerril FD, Domínguez-Cherit J. From Classical to Unusual : Report on 5 Cases of Transient Reactive Aquagenic Pseudokeratoderma and Review of the Literature. The American Journal of Dermatopathology. 2017 Dec 1;39(12):935-42.

**Semkova, K., J. Kazandjieva, and N. K. Tsankov. "What's new in infantile hemangiomas: current insights and future perspectives." *Skinmed* 11.6 (2012): 341-349**.

**Цитирания – 4**

1. 熊耕. *婴幼儿血管瘤 survivin 基因启动子甲基化的研究* (Master's thesis, 泸州医学院).
2. Muradov, M., et al. "Surgical treatment of extensive hemangiomas of the neck among children." *«Вестник хирургии Казахстана», ежеквартальный научно-практический журнал Национального научного центра хирургии им. АН Сызганова* 3 (2014): 44.
3. Kita AE, Long JL. Hemangioma. Ear, Nose & Throat Journal. 2016 Jan 1;95(1):19.
4. Thompson JD, Moore JE, Sataloff RT. Laryngitis obscuring an anterior glottic mass. Ear, Nose & Throat Journal. 2016 Jan 1;95(1):16.

**Bogdanov I, Kircheva K, Miteva L, Tsankov N. Quality of life in patients undergoing combined climatotherapy and phototherapy. Romanian Medical Journal. 2012 Sep 1;59(3).**

Цитирания – 1

1. Smith MK, Puczkó L, editors. The Routledge handbook of health tourism. Routledge; 2016 Nov 10.

**Darlenski R, Kazandjieva J, TSANKOV N, Fluhr J. Acute irritant threshold correlates with barrier function, skin hydration and contact hypersensitivity in atopic dermatitis and rosacea. Experimental Dermatology, 2013**

**Цитирания –40**

|  |
| --- |
| 1. Mark V Dahl Reviewing Darlenski R et al in NEJM Journal Watch. Dermatology. Summary and comment. Barriers to Rosacea Treatment. Alert for December 13, 2013 2. Worm M. Allergic contact dermatitis beyond IL-1β-role of additional family members.Experimental Dermatology (Impact Factor: 3.58). 12/2013; 3. Aquino, Marcella, and Luz Fonacier. "The role of contact dermatitis in patients with atopic dermatitis." *The Journal of Allergy and Clinical Immunology: In Practice* 2.4 (2014): 382-387. 4. Flo, Ana, et al. "Circadian rhythms on skin function of hairless rats: light and thermic influences." *Experimental dermatology* 23.3 (2014): 214-216. 5. Garg, Nitin, and Jonathan I. Silverberg. "Epidemiology of childhood atopic dermatitis." *Clinics in Dermatology* (2014). 6. Jacob, S., and S. Admani. "The ‘Pull Test’Delineation of Irritant Patch Test Reactions." *J Clin Exp Dermatol Res* 5 (2014): e104. 7. Melnik, Bodo C. "Endoplasmic reticulum stress: key promoter of rosacea pathogenesis." *Experimental dermatology* 23.12 (2014): 868-873. 8. Panzer, Rüdiger, et al. "TLR2 and TLR4 expression in atopic dermatitis, contact dermatitis and psoriasis." *Experimental Dermatology* (2014). 9. Wollina, Uwe. "Recent advances in the understanding and management of rosacea." *F1000prime reports* 6 (2014). 10. Garg, Nitin, and Jonathan I. Silverberg. "Epidemiology of childhood atopic dermatitis." *Clinics in dermatology* 33.3 (2015): 281-288. 11. Dimitriades VR, Wisner E. Treating pediatric atopic dermatitis: current perspectives. Pediatric health, medicine and therapeutics. 2015;6:93. 12. da Rosa, Joel Correa, et al. "Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin."*Journal of Allergy and Clinical Immunology* (2015). 13. Dobos, Gabor, et al. "Weight‐bearing–induced changes in the microtopography and structural stiffness of human skin in vivo following immobility periods."*Wound Repair and Regeneration* 23.1 (2015): 37-43. 14. Fabbrocini, Gabriella, et al. "Fragility of the epidermis, a common pathophysiological mechanism of acne vulgaris, rosacea and reactive skin involving inflammasome activation." *Inflammation and Cell Signaling* 2.2 (2015). 15. Garg, Nitin, and Jonathan I. Silverberg. "Epidemiology of childhood atopic dermatitis." *Clinics in dermatology* 33, no. 3 (2015): 281-288. 16. Hu, Lizhi, et al. "Herbal medicines that benefit epidermal permeability barrier function." *Dermatologica Sinica* (2015). 17. Kim OK, Chang JY, Nam DE, Park YK, Jun W, Lee J. Effect of Canavalia gladiata extract fermented with Aspergillus oryzae on the development of atopic dermatitis in NC/Nga mice. International archives of allergy and immunology. 2015;168(2):79-89. 18. Кубанова, Анна Алексеевна, and Юлия Буяндылгеровна Махакова. "Розацеа: распространенность, патогенез, особенности клинических проявлений." *Вестник дерматологии и венерологии* 3 (2015): 36-45. 19. Махакова, Юлия Буяндылгеровна. "Лечение Больных Розацеа Широкополосным Импульсным Светом С Диапазоном Длин Волн 500–670 Нм И 870–1200 Нм С Учетом Клинической Картины И Оценки Показателей Комплекса Неинвазивных Методов Исследования." (2015). 20. Neha Prakash, M. D., Negar Foolad, M. D. Vivian Shi, M. D. Faranak Kamangar, and Raja K. Sivamani MD MS AHE. "The association of sebum levels with the presence of erythemotelangiectatic rosacea and melasma."2015 21. Neha Prakash, M. D., Negar Foolad, M. D. Vivian Shi, M. D. Faranak Kamangar, and Raja K. Sivamani MD MS AHE. "The association of sebum levels with the presence of erythemotelangiectatic rosacea and melasma."2015 22. Zhong, Shaomin, et al. "Topical tranexamic acid improves the permeability barrier in rosacea." *Dermatologica Sinica* 33.2 (2015): 112-117. 23. Admani S, Matiz C, Jacob SE. Countering Staphylococcus Overgrowth During Patch Testing in Children with Moderate to Severe Atopic Dermatitis. Pediatric dermatology. 2016 Jan 1;33(1):56-61. 24. Blume‐Peytavi U, Tan J, Tennstedt D, Boralevi F, Fabbrocini G, Torrelo A, Soares‐Oliveira R, Haftek M, Rossi AB, Thouvenin MD, Mangold J. Fragility of epidermis in newborns, children and adolescents. Journal of the European Academy of Dermatology and Venereology. 2016 May 1;30(S4):3-56. 25. Cremisini C, Armiento G. High geochemical background of potentially harmful elements. The “geochemical risk” and “natural contamination” of soils and water: awareness and policy approach in Europe with a focus on Italy. Rendiconti Lincei. 2016 Mar 1;27(1):7-20. 26. Lee WJ, Jung JM, Lee YJ, Won CH, Chang SE, Choi JH, Moon KC, Lee MW. Histopathological analysis of 226 patients with rosacea according to rosacea subtype and severity. The American Journal of Dermatopathology. 2016 May 1;38(5):347-52. 27. Melnik BC. Rosacea: the blessing of the celts–an approach to pathogenesis through translational research. Acta dermato-venereologica. 2016 Feb 1;96(2):147-61. 28. Pelletier JL, Perez C, Jacob SE. Contact Dermatitis in Pediatrics. Pediatric Annals. 2016 Aug 18;45(8):e287-92. 29. Zhou M, Xie H, Cheng L, Li J. Clinical characteristics and epidermal barrier function of papulopustular rosacea: A comparison study with acne vulgaris. Pak J Med Sci. 2016;32(6):1344-1348. 30. Christensen, C.E., Andersen, F.S., Wienholtz, N., Egeberg, A., Thyssen, J.P. and Ashina, M., 2017. The relationship between migraine and rosacea: Systematic review and meta-analysis. *Cephalalgia*, p.0333102417731777. 31. Давыдова Ав. Клинико-Лабораторные Аспекты Оценки Тяжести Розацеа И Качество Жизни Пациентов. Диссертация на соискание ученой степени кандидата медицинских наук Саратов 2017 32. Egeberg A, Fowler JF, Gislason GH, Thyssen JP. Rosacea and risk of cancer in Denmark. Cancer Epidemiology. 2017 Apr 30;47:76-80. 33. Kim J, Ahn JW, Ha S, Kwon SH, Lee O, Oh C. Clinical assessment of rosacea severity: oriental score vs. quantitative assessment method with imaging and biomedical tools. Skin Research and Technology. 2017 May 1;23(2):186-93. 34. Lubbes S, Rustemeyer T, Sillevis Smitt JH, Schuttelaar ML, Middelkamp‐Hup MA. Contact sensitization in Dutch children and adolescents with and without atopic dermatitis–a retrospective analysis. Contact dermatitis. 2017 Mar 1;76(3):151-9. 35. Silverberg NB, Durán-McKinster C. Special Considerations for Therapy of Pediatric Atopic Dermatitis. Dermatologic Clinics. 2017 Jul 1;35(3):351-63. 36. Yuan, Chao. "Exploratory research for pathogenesis of papulopustular rosacea and skin barrier research in Besançon and Shanghai." PhD diss. Université Bourgogne Franche-Comté, 2017. 37. Danby SG, Brown K, Wigley AM, Chittock J, Pyae PK, Flohr C, Cork MJ. The Effect of Water Hardness on Surfactant Deposition after Washing and Subsequent Skin Irritation in Atopic Dermatitis Patients and Healthy Control Subjects. Journal of Investigative Dermatology. 2018 Jan 1;138(1):68-77. 38. Diczig B, Németh I, Sárdy M, Pónyai G. Contact hypersensitivity in rosacea–a report on 143 cases. Journal of the European Academy of Dermatology and Venereology. 2018 Mar 10. 39. Erdogan HK, Bulur I, Saracoglu ZN, Bilgin M. The Evaluation of Contact Sensitivity with Standard and Cosmetic Patch Test Series in Rosacea Patients. Annals of Dermatology. 2018 Jun 1;30(3):290-5.   В монографии   1. Richters RJ, Uzunbajakava NE, van de Kerkhof PC, van Erp PE. Conclusions and general discussion on the pathomechanism of sensitive skin. In: Novel perspectives on the pathomechanism of sensitive skin. 2017:203.   **Darlenski R, Kazandjieva J, Tsankov N. Phytodermatitis to Euphorbia trigona. Skinmed. 2013 Dec;12(4):253-5.**  Цитирания – 1   1. Huerth KA, Hawkes JE, Meyer LJ, Powell DL. The Scourge of the Spurge Family—An Imitator of Rhus Dermatitis. Dermatitis. 2016 Nov 1;27(6):372-81.   **Staikov I, Neykov N, Marinovic B, Lipozenčić J, Tsankov N. "Herpes zoster as a systemic disease." *Clinics in dermatology* 32, no. 3 (2014): 424-429. IF -** 1.93  **Цитирания –15**   1. 李崎, et al. "CT 引导下椎旁阿霉素注射治疗顽固性带状疱疹后神经痛短期及中期疗效的临床观察." *中南大学学报 (医学版)* 39.9 (2014): 930-934. 2. Boumaa, Nynke, et al. "Incidence and severity of herpes zoster after organ transplantation." *Erasmus Journal of Medicine*: 25.2015 3. Cohen PR. Zosteriform impetigo: Wolf’s isotopic response in a cutaneous immunocompromised district. Dermatology practical & conceptual. 2015 Jul;5(3):35. 4. Leung, Alexander KC, and Benjamin Barankin. "Bilateral Symmetrical Herpes Zoster in an Immunocompetent 15-Year-Old Adolescent Boy." *Case Reports in Pediatrics* 2015 (2015) 5. Leung AK, Barankin B. Herpes zoster in childhood. Open Journal of Pediatrics. 2015 Jan 29;5(01):39. 6. Moreno D, Barroso J, Garcia A. Vaccines for patients with COPD. Recent patents on inflammation & allergy drug discovery. 2015 Apr 1;9(1):23-30. 7. 费勇, 姚明, 黄兵, 过建国, 周煦燕, 陆雅萍, 倪华栋, 张伟, 任小姝. 背根神经节脉冲射频联合加巴喷丁对老年 PHN 患者免疫功能的影响. 中华医学杂志. 2015(028):2319-21. 8. Lai SW, Lin CL, Liao KF, Chen WC. Herpes zoster could be an early manifestation of undiagnosed human immunodeficiency virus infection. Journal of the Formosan Medical Association. 2016 May 1;115(5):372-6. 9. Park H. Diverse clinical manifestations caused by varicella-zoster virus reactivation. Yeungnam University Journal of Medicine. 2016 Jun 1;33(1):1-7. 10. Sampathkumar P. Herpes zoster and post-herpetic neuralgia. Current Geriatrics Reports. 2016 Mar 1;5(1):9-15. 11. 申洁, 吴跃申, 水润英, 朱荣艺, 吕婷, 缪飞, 王宏伟. 老年带状疱疹后遗神经痛的危险因素研究. 老年医学与保健. 2016;22(1):48-51. 12. 박호선. 수두-대상포진 바이러스의 재활성에 의해 유발되는 다양한 임상질환. 영남의대학술지. 2016;33(1):1-7. 13. Yun KH, Song SH, Kim CH, Hwang CH, Lee JH, Choi JH, Kim SY. Partial spontaneous remission of small cell lung carcinoma with neurologic symptom. Yeungnam University Journal of Medicine. 2017 Dec 1;34(2):275-8. 14. Hastuti R, Ulya I, Mustifah EF, Risman M, Dharmawan N. Herpes Zoster Lumbalis Sinistra pada Pasien Terinfeksi HIV. Alamat Korespondensi,2018 15. Stocker A, Theus C, Boggian K, Mueller NJ, Fleisch F, Fehr T. Hohe Inzidenz von Varizella-Zoster-Meningoenzephalitiden in Graubünden im Jahr 2014. Praxis. 2018 Mar 28.   **Darlenski R, Kazandjieva J, Zuberbier T, TSANKOV N. Chronic urticaria as a systemic** **disease. Clin Dermatol,  2014 May-Jun;32(3):420-3 IF 1.93**  **Цитирания –17**   1. Grzanka, Alicja, Aleksandra Damasiewicz-Bodzek, Edyta Machura, Magdalena Szumska, Krystyna Tyrpień-Golder, Bogdan Mazur, and Alicja Kasperska-Zajac. "Chronic Spontaneous Urticaria Is Characterized by Lower Serum Advanced Glycation End-Products." *BioMed research international* 2014 (2014). 2. Linscott MS. Urticaria. Medscape,2014, RefN 11 3. 林大东, 谢明新, 许道淼. 南方汉族人群慢性荨麻疹与幽门螺杆菌感染的关系研究. 临床军医杂志. 2014(9):935-7. 4. Giménez‐Arnau AM, Grattan C, Zuberbier T, Toubi E. An individualized diagnostic approach based on guidelines for chronic urticaria (CU). Journal of the European Academy of Dermatology and Venereology. 2015 Jun 1;29(S3):3-11. 5. Kramberger U. Kronična urtikarija in njen vpliv na kvaliteto življenja.2015 6. Poliak N, Chang C. Epigenetics of allergic and inflammatory skin diseases. InEpigenetics and Dermatology 2015 (pp. 275-306). 7. 侯秀芳, 张力军. 慢性荨麻疹 400 例变应原检测分析. 陕西医学杂志. 2015(3):348-50. 8. Dionigi PL, Menezes MC, Forte WC. A prospective ten-year follow-up of patients with chronic urticaria. Allergologia et immunopathologia. 2016 Jul 1;44(4):286-91. 9. Göncü EK, Aktan S, Atakan N, Baskan EB, Erdem T, Koca R, Savk E, Taskapan O, Utas S. Türkiye Ürtiker Tani ve Tedavi Kilavuzu-2016/The Turkish Guideline for the Diagnosis and Management of Urticaria-2016. Turkderm. 2016 Jul 1;50(3):82. 10. Lu T, Jiao X, Si M, He P, Zou J, Zhang S, Zeng K. The correlation of serums CCL11, CCL17, CCL26, and CCL27 and disease severity in patients with urticaria. Disease markers. 2016;2016. 11. Marques RZ, Criado RF, Machado Filho CD, Tamanini JM, Mello CV, Speyer C. Correlation between the histopathology of chronic urticaria and its clinical picture. Anais brasileiros de dermatologia. 2016 Dec;91(6):760-3. 12. Rodrigues K, Chibli LA, Santos B, Temponi VS, Pinto NC, Scio E, Del-Vechio-Vieira G, Alves MS, Sousa OV. Evidence of bioactive compounds from vernonia polyanthes leaves with topical anti-inflammatory potential. International journal of molecular sciences. 2016 Dec 1;17(12):1929. 13. Eskeland S, Halvorsen JA, Tanum L. Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review. Acta dermato-venereologica. 2017 Sep 1;97(8). 14. Goyal V, Gupta A, Gupta O, Lal D, Gill M. Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. Journal of clinical and diagnostic research: JCDR. 2017 Mar;11(3):WC06. 15. Matheus B, Cristina D. ¿ Determinar la correlación de la urticaria crónica y marcadores de autoinmunidad, en los pacientes con diagnóstico de Urticaria Crónica que acuden a la consulta externa del Servicio de Alergología del Hospital Universitario del Vinalopó?. 16. Pinheiro RP, Moraes MA, Santos BC, Fabri RL, Del-Vechio-Vieira G, Yamamoto CH, Araújo AL, Araújo AL, Sousa OV. Identification of compounds from Palicourea rigida leaves with topical anti-inflammatory potential using experimental models. Inflammopharmacology. 2017 Nov 14:1-2. 17. Godse K, De A, Zawar V, Shah B, Girdhar M, Rajagopalan M, Krupashankar DS. Consensus statement for the diagnosis and treatment of urticaria: a 2017 update. Indian journal of dermatology. 2018 Jan;63(1):2. |

**Grozdev, I., Korman, N., & Tsankov, N. (2014). Psoriasis as a systemic disease. *Clinics in dermatology*, *32*(3), 343-350.IF -** 1.93

**Цитирания – 56**

1. Slesarenko NA, Utz SR, Kulaev KA, Resnikova MA, Panina LV, Popova OV. The role of infectious stimulus in the initiation and immune inflammation in psoriasis. Saratovskij Naučno-medicinskij Žurnal. 2014 Jan 1;10(3):530-7.
2. Barrea, Luigi, et al. "Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?." *Journal of Translational Medicine* 13.1 (2015): 18.
3. Cummins, Ewen, Neil Scott, Moira Cruickshank, Cynthia Fraser, Anthony Ormerod, and Miriam Brazzelli. "Secukinumab for treating moderate to severe plaque psoriasis." (2015).
4. Fiorino G, Omodei PD. Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin?.
5. Gruev I, Staneva M, Karamfiloff K, Toncheva A, Staikov I. Psoriatic Arthritis And Subclinical Atherosclerosis. Comptes rendus de l’Académie bulgare des Sciences. 2015;68(9).
6. Irimie M, Oanta A, Alexandrina Irimie C, Gyula Fekete L, Ioan Minea D, Pascu A. Cardiovascular risk factors in patients with chronic plaque psoriasis: a case-control study on the Brasov County population. Acta Dermatovenerologica Croatica. 2015 May 8;23(1):28-.
7. Jiang S, Hinchliffe TE, Wu T. Biomarkers of an autoimmune skin disease—psoriasis. Genomics, proteomics & bioinformatics. 2015 Aug 31;13(4):224-33.
8. Lotti T. Erfolgreiche Kombinationsbehandlung der Psoriasis mit Phototherapie und niedrig dosierten Zytokinen. Der Hautarzt. 2015 Nov 1;66(11):849-54.
9. May BH, Deng S, Zhang AL, Lu C, Xue CC. In silico database screening of potential targets and pathways of compounds contained in plants used for psoriasis vulgaris. Archives of dermatological research. 2015 Sep 1;307(7):645-57.
10. Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. The Scientific World Journal. 2015;2015.
11. Teixeira PC. Psoriasis patients with obesity and type 2 biabetes: the effect of glucagon-like peptide 1 (GLP-1) receptor agonists.
12. Утц СР, Райгородский ЮМ, Зуев АВ. Транскраниальная активационная физиотерапия при псориазе. Российский журнал кожных и венерических болезней. 2015;18(3).
13. 景璟, 郑敏. 银屑病共患疾病的临床研究进展. 中华皮肤科杂志. 2015;48(012):899-901.
14. 罗丽敏, 李军, 刘劲松, 刘菡. 复方甘草酸苷对寻常型银屑病患者血浆内皮素分泌的影响. 检验医学与临床. 2015;12(23):3542-3.
15. Barrea L, Macchia PE, Somma C, Napolitano M, Balato A, Falco A, Savanelli MC, Balato N, Colao A, Savastano S. Bioelectrical phase angle and psoriasis: A novel association with psoriasis severity, quality of life and metabolic syndrome. Journal of translational medicine. 2016 Dec;14(1):130.
16. Balato, N., M. Megna, R. Di Caprio, M. Napolitano, C. Patruno, and S. Bietolini. "Alimentazione e psoriasi: Questionario." *A+ A* (2016).
17. Majewski P, Majchrzak-Gorecka M, Grygier B, Skrzeczynska-Moncznik J, Osiecka O, Cichy J. Inhibitors of serine proteases in regulating the production and function of neutrophil extracellular traps. Frontiers in immunology. 2016 Jun 30;7:261.
18. Mejía XP, Soto CM, Bravo RE. Psoriasis y esclerosis sistémica: una vía inmunológica común. Reporte de un caso. Piel. 2016 Jun 1;31(6):393-6.
19. Srirama L. Serum concentration of 25-hydroxy vitamin D in psoriatic patients in a tertiary care hospital: a case–control study. Egyptian Journal of Dermatology and Venerology. 2016 Jul 1;36(2):29.
20. Vachatova S, Andrys C, Krejsek J, Salavec M, Ettler K, Rehacek V, Cermakova E, Malkova A, Fiala Z, Borska L. Metabolic syndrome and selective inflammatory markers in psoriatic patients. Journal of immunology research. 2016;2016.
21. Опруженкова ЕП. "современный взгляд на проблему псориаза у женщин старшего возраста."2016, PhD Ростовский Государствений Медицинский Университет
22. Слесаренко НА, Утц СР. Роль бактериальной инфекции в патогенезе псориаза. Вестник дерматологии и венерологии. 2016(3):29-35.
23. Srirama L. Serum concentration of 25-hydroxy vitamin D in psoriatic patients in a tertiary care hospital: a case–control study. Egyptian Journal of Dermatology and Venerology. 2016 Jul 1;36(2):29.
24. Abidoye O, Lediju O, Zahid Z, Naseeruddin R, Patel P, Lal M, Dhongade V, Chapadia H, Korra R, Vadher10 A, Vakharia11 H. European Journal of Biomedical AND Pharmaceutical sciences. European Journal of Biomedical. 2017;4(9):746-8.
25. Brandt D, Sergon M, Abraham S, Mäbert K, Hedrich CM. TCR+ CD3+ CD4− CD8− effector T cells in psoriasis. Clinical Immunology. 2017 Aug 1;181:51-9.
26. Choi BG, Kim MJ, Yang HS, Lee YW, Choe YB, Ahn KJ. Assessment of arterial stiffness in korean patients with psoriasis by cardio-ankle vascular index. Angiology. 2017 Aug;68(7):608-13.
27. Gungor S, Rezigue M. Nanocarriers mediated topical drug delivery for psoriasis treatment. Current drug metabolism. 2017 May 1;18(5):454-68.
28. Feng C, Bai M, Yu NZ, Wang XJ, Liu Z. MicroRNA‐181b negatively regulates the proliferation of human epidermal keratinocytes in psoriasis through targeting TLR4. Journal of cellular and molecular medicine. 2017 Feb 1;21(2):278-85.
29. Hu SC, Lan CC. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. International journal of molecular sciences. 2017 Oct 21;18(10):2211.
30. Kalkan G. Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management. TURKDERM-Archieves of The Turkish Dermatology and Venerology. 2017 Jan 1;51(3):71-7.
31. Kilic A, Yorulmaz A, Erdogan S, Cakmak SK, Guney E, Sen O, Erel O. An evaluation of thiol/disulphide homeostasis in patients with psoriasis. Advances in Dermatology & Allergology/Postepy Dermatologii i Alergologii. 2017 Oct 1;34(5).
32. Kostovic K, Zuzul K, Ceovic R, Mokos ZB. Psoriasis in the mature patient-therapeutic approach in the era of biologics. Clinics in Dermatology. 2017 Oct 3.
33. Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD. Increased incidence and prevalence of psoriasis in multiple sclerosis. Multiple sclerosis and related disorders. 2017 Apr 1;13:81-6.
34. Narbutt J, Trelińska M, Woźniacka A, Olejniczak-Staruch I, Lesiak A. Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis. Przeglad Dermatologiczny. 2017 Mar 1;104(2):103.
35. Ponce Torres, Christian David. "Psoriasis, factor de riesgo para desarrollar enfermedades cardiovasculares y síndrome metabólico." Bachelor's thesis, PUCE, 2017.
36. Rui W, Xiangyu D, Fang X, Long G, Yi Y, Wenjuan W, Tian H, Xiaoning Z, Yong Z, Jianfeng F, Hengjin L. Metabolic syndrome affects narrow-band UVB phototherapy response in patients with psoriasis. Medicine. 2017 Dec 1;96(50):e8677.
37. Salomon J, Matusiak Ł, Nowicka-Suszko D, Szepietowski JC. Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis. Mediators of inflammation. 2017;2017.
38. Solak B, Dikicier BS, Erdem T. Impact of elevated serum uric acid levels on systemic inflammation in patients with psoriasis. Angiology. 2017 Mar;68(3):266-70.
39. Solak B, Dikicier BS, Erdem T. The role of uric acid in metabolic syndrome in patients with psoriasis. TURKDERM-Archieves of The Turkish Dermatology and Venerology. 2017 Jan 1;51(2):37-40.
40. Solak B, Dikicier BS, Erdem T. Metabolik sendromlu psoriazis hastalarında ürik asitin rolü. Turkderm. 2017 Apr 1;51(2):37.
41. 塔依尔, 吐尔松, 马丽娜, 阿米尔, 艾力. 维药成熟与清除疗法对咸味黏液质型银屑病血清代谢组学的影响. 中国中医药信息杂志. 2017;24(4):24-8.
42. Assarsson M, Duvetorp A, Dienus O, Söderman J, Seifert O. Significant Changes in the Skin Microbiome in Patients with Chronic Plaque Psoriasis after Treatment with Narrowband Ultraviolet B. Acta dermato-venereologica. 2018 Mar 1;98(3-4):428-36.
43. Brandt D, Hedrich CM. TCRαβ+ CD3+ CD4− CD8−(double negative) T cells in autoimmunity. Autoimmunity reviews. 2018 Feb 9.
44. Cafaro G, McInnes IB. Psoriatic arthritis: tissue-directed inflammation?. Clinical rheumatology. 2018 Feb 23:1-0.
45. Coveñas, Ramos, and Sarita del Rosario. "Ansiedad como factor de riesgo para exacerbación de psoriasis en paciente del hospital ESSALUD II talara." (2018).
46. Gęgotek A, Domingues P, Wroński A, Wójcik P, Skrzydlewska E. Proteomic plasma profile of psoriatic patients. Journal of pharmaceutical and biomedical analysis. 2018 Jun 5;155:185-93.
47. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clinics in dermatology. 2018 Jan 1;36(1):21-8.
48. Gui XY, Yu XL, Jin HZ, Zuo YG, Wu C. Prevalence of metabolic syndrome in Chinese psoriasis patients: A hospital‐based cross‐sectional study. Journal of diabetes investigation. 2018 Jan;9(1):39-43.
49. Dattilo G, Imbalzano E, Casale M, Guarneri C, Borgia F, Mondello S, Laganà P, Romano P, Oreto G, Cannavò S. Psoriasis and cardiovascular risk: correlation between psoriasis and cardiovascular functional indices. Angiology. 2018 Jan;69(1):31-7.
50. Krishna KH, Aruna G. 25-HYDROXY VITAMIN D LEVELS IN PSORIASIS. INDIAN JOURNAL OF APPLIED RESEARCH. 2018 Apr 9;8(2).
51. Krueger JG, Brunner PM. Interleukin‐17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Experimental dermatology. 2018 Feb;27(2):115-23.
52. Mahrous EA. The relationship between platelet volume and risk of atherosclerosis in patients with psoriasis. Egyptian Journal of Dermatology and Venerology. 2018 Jan 1;38(1):29.
53. Moskot M, Bocheńska K, Jakóbkiewicz-Banecka J, Banecki B, Gabig-Cimińska M. Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders. International journal of molecular sciences. 2018 Jan 15;19(1):247.
54. Parish LC. A potpourri of dermatologic writings. Clinics in Dermatology. 2018 Jan 1;36(1):102-4.
55. de AsoColDerma, Página Oficial, and Apoyo Educativo. "Síndrome Metabólico, enfermedad cardiovascular y Psoriasis."
56. Sondermann W, Leister L, Rompoti N, Dissemond J, Klode J, Körber A. Unzureichender Tetanusimpfschutz bei Psoriasis und systemischer Immunsuppression. Der Hautarzt.:2018р 1-6.

**Kazandjieva, Jana, Nikolai Tsankov, and Kyrill Pramatarov. "The red face revisited: Connective tissue disorders." *Clinics in dermatology* 32.1 (2014): 153-158**. IF - 1.93

**Цитирания – 6**

1. Auriemma, M., Capo, A., Meogrossi, G., & Amerio, P. Cutaneous signs of classical dermatomyositis.*Dermatologia е Venereologia*,(2014). *147*, 505-17.
2. Dahl MV. Approach to the patient with facial erythema.2013Uptodate.com
3. Orme CM, Shvartsbeyn M, Meehan SA, Kornreich C, Ramachandran S, Soter NA. Possible photoactivated dermatitis with features of post-inflammatory pigmentary alteration (PIPA) and rosacea. Dermatology online journal. 2015 Jan 1;21(12).
4. Saleem MD, Wilkin JK. Evaluating and Optimizing the Diagnosis of Erythematotelangiectatic Rosacea. Dermatologic Clinics. 2017 Dec 21.
5. Ramachandran MD, Soter NA. Case presentation Possible photoactivated dermatitis with features of post-inflammatory pigmentary alteration (PIPA) and rosacea. Dermatology Online Journal. 2015 Dec;21(12):3.
6. В монографии
7. Hughes R, Kirby B. Other environmental risk factors. InPsoriasis, Second Edition 2017 Apr 11 (pp. 49-54). CRC Press.

**Tsankov N, Kazandjieva J, Darlenski R. Are skin diseases systemic ones?: I. Clinics in dermatology. 2014 May 1;32(3):341-2.**

**Цитирания – 2**

1. Eskeland S, Halvorsen JA, Tanum L. Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review. Acta Derm Venereol. 2017 Aug 31;97:897-905.
2. Darlenski R, Hristakieva E, Aydin U, Gancheva D, Gancheva T, Zheleva A, Gadjeva V, Fluhr JW. Epidermal barrier and oxidative stress parameters improve during in 311 nm narrow band UVB phototherapy of plaque type psoriasis. Journal of dermatological science. 2018 Mar 21.

**Darlenski R, Kazandjieva J, Fluhr J, Maurer M, Tsankov N. Lactic acid sting test does not differentiate between facial and generalized skin functional impairment in sensitive skin in atopic dermatitis and rosacea. Journal of dermatological science. 2014 Nov 30;76(2):151-3.**

**Цитирания – 9**

1. Lee HJ, Yang NW, Choi JY, Lee JB, Lee SC. CSP0510 Lotion as a Novel Moisturizer Containing Citric Acid and Trisodium Phosphate Relieves Objective and Subjective Symptoms of Atopic Dermatitis. Annals of dermatology. 2016 Jun 1;28(3):344-51.
2. Lee WJ, Jung JM, Lee YJ, Won CH, Chang SE, Choi JH, Moon KC, Lee MW. Histopathological analysis of 226 patients with rosacea according to rosacea subtype and severity. The American Journal of Dermatopathology. 2016 May 1;38(5):347-52.
3. Misery L, Loser K, Ständer S. Sensitive skin. Journal of the European Academy of Dermatology and Venereology. 2016 Feb 1;30(S1):2-8.
4. Sun L, Wang X, Zhang Y, Wang T, Li X, Ma Y. The evaluation of neural and vascular hyper‐reactivity for sensitive skin. Skin Research and Technology. 2016 Feb 1.
5. Zane LT, Hughes MH, Shakib S. Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers. American Journal of Clinical Dermatology. 2016 Oct 1;17(5):519-26.
6. Cheape AC, Murrell DF. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. Expert Review of Clinical Immunology. 2017 May 4;13(5):415-23.
7. Ma YF, Yuan C, Jiang WC, Wang XL, Humbert P. Reflectance confocal microscopy for the evaluation of sensitive skin. Skin Research and Technology. 2017 May 1;23(2):227-34.
8. Yatagai T, Shimauchi T, Yamaguchi H, Sakabe JI, Aoshima M, Ikeya S, Tatsuno K, Fujiyama T, Ito T, Ojima T, Tokura Y. Sensitive skin is highly frequent in extrinsic atopic dermatitis and correlates with disease severity markers but not necessarily with skin barrier impairment. Journal of dermatological science. 2018 Jan 1;89(1):33-9.
9. Springmann G, Bielfeldt S, Wilhelm KP. Supporting claims for sensitive skin. Personal care today. 2017 ;12(6) :54-56

**Darlenski RB, Demerdjieva Z, Kazandjieva JS, Tsankov NK. Systemic contact dermatitis to nickel. OA Dermatol. 2014;11:7.**

**Цитирания – 1**

1. Suwarsa O, Rahardjo RM, Sutedja E, Dharmadji HP, Hindritiani R, Gunawan H. Systemic contact dermatitis due to corrosion of titanium-coated nickel and cobalt bone plate fixation: A case report. Medicine. 2017 Dec 1;96(50):e9120.

**Tsankov N, Kazandjieva J, Darlenski R. The skin as a target organ in multisystemic diseases II. Clinics in dermatology. 2015 Sep 1;33(5):509-11.**

**Цитирания – 1**

1. Darlenski R, Hristakieva E, Aydin U, Gancheva D, Gancheva T, Zheleva A, Gadjeva V, Fluhr JW. Epidermal barrier and oxidative stress parameters improve during in 311 nm narrow band UVB phototherapy of plaque type psoriasis. Journal of dermatological science. 2018 Mar 21.

**Kamouna B, Darlenski R, Kazandjieva J, Balabanova M, Dourmishev L, Negenzova Z, Etugov D, Mirchevska B, Tsankov N. Complication of injected Vitamin E as a filler for lip augmentation: case series and therapeutic approuch. Dermatologic therapie, 2015; 28(2):94-7.**

**Цитирания – 5**

1. Patel D, Holaway CS, Thomas S, Parihar H, Wu Z, Bickett S, Mody VV. Vitamins, Amino Acids, and Drugs and Formulations Used in Nutrition. InSide Effects of Drugs Annual 2016 Jan 1 (Vol. 38, pp. 355-364). Elsevier.
2. Zhang F, Chen Y. Lipogranuloma after facial cosmetic procedures. Oral surgery, oral medicine, oral pathology and oral radiology. 2017 Apr 30;123(4):e123-32.
3. Durdu M, Bozca C, Koçer NE. Filler Reactions: Case Report and Review of the Literature. Turk Dermatoloji Dergisi. 2017 Sep 1;11(3):131.
4. Kurulu, Editörler, and Türk Dermatoloji Derneği Web Sitesi. "Dolgu Reaksiyonları: Olgu Sunumu ve Literatürün Gözden Geçirilmesi."
5. Koçer NE. Dolgu Reaksiyonları: Olgu Sunumu ve Literatürün Gözden Geçirilmesi.

**Semkova K, Gergovska M, Kazandjieva J, Tsankov N. Hyperhidrosis, Bromhidrosis, Chlorhidrosis. Clin Dermatol, 2015, 33,4,** **483-491**

**Цитирания – 12**

1. Tüzün Y, Wolf R. Commentary: Fold (intertriginous) dermatoses: When skin touches skin. Clinics in dermatology. 2015 Jul 1;33(4):411-3.
2. Owczarczyk-Saczonek A, Place W. Skin Lesion And Diseases In Obesity-Part I: The Skin Disorders Related To Insulin Resistance And Secondary Infections. International Education and Research Journal. 2016 Dec 15;2(12).
3. Owen K. Excessive Sweating: Are Patients Suffering Unnecessarily?. The Journal for Nurse Practitioners. 2016 Jan 31;12(1):35-40.
4. Hu Y, Converse C, Lyons MC, Hsu WH. Neural control of sweat secretion: a review. British Journal of Dermatology. 2017 Jul 17.
5. Köse Ök, Özden Mg. Geç Başlangıçlı Bir Genital Apokrin Kromhidroz Olgusu. Turkiye Klinikleri Journal of Dermatology. 2017;27(1):24-7
6. Khuntayaporn P, Suksiriworapong J. Efficacy of essential oil formulations against malodor causing bacteria. Pharm Sci Asia 2017; 44 (4), 209-216
7. Nocivin, I., Tiplica, G. S. Synopsis of Therapeutic Options in Hyperhidrosis. DermatoVenerol. 2017(Buc.), 63(1): 35-45
8. Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. Journal of Dermatological Treatment. 2017 Oct 3;28(7):582-90.
9. Wong MD, Wan S, Hamilton J, Pope E, Lara-Corrales I. Live Posters. Ped Dermatol 2017; 34 : S28–S99
10. Heckmann M. Erkrankungen der Schweißdrüsen. InBraun-Falco’s Dermatologie, Venerologie und Allergologie 2018 (pp. 1337-1349). Springer, Berlin, Heidelberg.
11. Hodge, Bonnie D., and Robert T. Brodell. "Anatomy, Integument, Sweat Glands." (2018).
12. Orchard A, Viljoen A, van Vuuren S. Antimicrobial Essential Oil Combinations to Combat Foot Odour. Planta medica. 2018 Mar 26.

**Tsankov N, Kazandjieva J, Darlenski R. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS, Clin Dermatol, 05/2015**

**Цитирания – 7**

1. Balaban J, Ninković-Baroš Đ. Lamotrigine Associated DRESS Syndrome–a Case Report. Serbian Journal of Dermatology and Venereology. 2015 Mar 1;7(1):23-33.
2. Wolski Jr TP, Blasick S, Blackford MG. The Case of the Previously Shaky, Unimmunized, Itchy Infant With Rash and Pancytopenia. Clinical pediatrics. 2016 Dec;55(14):1366-8.
3. Corneli HM. DRESS syndrome: drug reaction with eosinophilia and systemic symptoms. Pediatric emergency care. 2017 Jul 1;33(7):499-502.
4. Eginli A, Shah K, Watkins C, Krishnaswamy G. Stevens-Johnson syndrome and toxic epidermal necrolysis. Annals of Allergy, Asthma & Immunology. 2017 Feb 28;118(2):143-7.
5. Pishmisheva M, Baymakova M, Stanchev G, Metodieva N, Karamisheva M, Velkova D, Andonova R, Popov GT. Stevens-Johnson syndrome and toxic epidermal necrolysis. In Varna Medical Forum 2017 Mar 2 (Vol. 6, No. 1, pp. 63-68).
6. Holfinger S, Roy A, Schmidt M. Stevens-Johnson Syndrome After Armodafinil Use. Journal of Clinical Sleep Medicine. 2018 May 15;14(05):885-7.
7. Millán GG, López-Bran E. Toxicodermias. Medicine-Programa de Formación Médica Continuada Acreditado. 2018 Feb 28;12(48):2846-53.

**Staikov IN, Neykov NV, Kazandjieva JS, Tsankov NK. Is herpes simplex a systemic disease?. Clinics in dermatology. 2015 Oct 31;33(5):551-5.**

Цитирания - 1

1. Damato, Mariana Bueno de Paula. "Identificação de bactérias oriundas da Antártica e investigação do potencial antiviral." (2016).

**Semkova K, Kazandjieva J, Kadurina M, Tsankov N. Hemangioma Activity and Severity Index (HASI), an instrument for evaluating infantile hemangioma: development and preliminary validation. Int J Dermatol (Impact Factor: 1.18). 2015;54(4), 494-498**

**Цитирания - 3**

1. Janmohamed SR, Oranje AP. Scoring systems for infantile hemangioma: the Hemangioma Activity Score versus the Hemangioma Activity and Severity Index. International journal of dermatology. 2016 Jul;55(7):e416-7.
2. Moyakine AV, van der Vleuten CJ. Review Propranolol for infantile hemangioma: Current state of affairs.World Journal of. World Journal of. 2016 Feb 2;5(1):4.
3. Moyakine AV, Herwegen B, van der Vleuten CJ. Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas. Journal of the American Academy of Dermatology. 2017 Nov 1;77(5):868-73.

**Kazandjieva J, TSANKOV N. Drug induced acne. Clinics in Dermatology. 2017 30; 35(2):156-62.**

**Цитирания – 7**

1. Dréno B. What is new in the pathophysiology of acne, an overview. Journal of the European Academy of Dermatology and Venereology. 2017 Sep 1;31(S5):8-12.
2. Dlova NC, Sagoe D. Acneiform lesions in a female performance and image-enhancing drug user : the first African case report. African Journal of Drug and Alcohol Studies. 2017 ; 16(1) :33-6.
3. Melnik BC. p53: key conductor of all anti-acne therapies. Journal of Translational Medicine. 2017 Sep 19;15(1):195.
4. Katsambas A, Dessinioti C. The changing faces of acne, rosacea, and hidradenitis suppurativa. Clinics in Dermatology. 2017 Mar 1;35(2):115-7.
5. Claudel JP, Auffret N, Leccia MT, Poli F, Dréno B. Acne and nutrition : Hypotheses, myths and facts. Journal of the European Academy of Dermatology and Venereology. 2018 Apr 6.
6. Dréno B, Bettoli V, Araviiskaia E, Sanchez Viera M, Bouloc A. The influence of exposome on acne. Journal of the European Academy of Dermatology and Venereology. 2018 May 1.
7. Ferner RE, Anton C. Twenty years of adverse drug reactions : a look back–part 1. Adverse Drug Reaction Bulletin. 2018 Apr 1 ; 309(1) :1195-8.

**Kazandjieva J, Antonov D, Kamarashev J, TSANKOV N. Acrally distributed dermatoses: Vascular dermatoses (purpura and vasculitis). Clinics in Dermatology. 2017 Feb 28;35(1):68-80.**

**Цитирания – 5**

1. Kim YR, Lee JA, Ryu SS, Sun SH, Park S. Pigmented purpuric dermatosis in adults treated with herbal medicine : Report of five cases. EXPLORE. 2017 Dec 23.
2. Roy SF, Ghazawi FM, Provost N. Rust-colored patches on the lower extremities: lichen aureus. International journal of dermatology. 2017 Nov 24.
3. Tüzün Y, Wolf R. Acrally distributed dermatoses. Clinics in dermatology. 2017 ; 35(1) :1.
4. Pedraz J, López-Bran E. Protocolo diagnóstico de los exantemas cutáneos eritematopurpúricos. Medicine-Programa de Formación Médica Continuada Acreditado. 2018 Feb 28 ; 12(48) :2872-6.
5. Plachouri KM, Florou V, Georgiou S. Therapeutic Strategies for Pigmented Purpuric Dermatoses : A Systematic Literature Review. Journal of Dermatological Treatment. 2018 May:1-6.

**Darlenski R. Tsankov N. COVID-19 pandemic and the skin: what should dermatologists know? Clin Dermatol, 2020; 38(6):785-787**

**Цитирания – 138**

1. Barker-Davies, Robert M., et al. "The Stanford Hall consensus statement for post-COVID-19 rehabilitation." *British journal of sports medicine* 54.16 (2020): 949-959.
2. Gefen, Amit, and Karen Ousey. "Update to device-related pressure ulcers: SECURE prevention. COVID-19, face masks and skin damage." *Journal of wound care* 29.5 (2020): 245-259.
3. Wollina, Uwe. "Challenges of COVID‐19 pandemic for dermatology." *Dermatologic therapy* 33.5 (2020): e13430.
4. Singh, Mehak, et al. "Personal protective equipment induced facial dermatoses in healthcare workers managing Coronavirus disease 2019." *Journal of the European Academy of Dermatology and Venereology* 34.8 (2020): e378-e380.
5. Akbari, Hamed, et al. "The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis." *Life sciences* (2020): 118167.
6. Tuncer, Turker, Sengul Dogan, and Fatih Ozyurt. "An automated Residual Exemplar Local Binary Pattern and iterative ReliefF based COVID-19 detection method using chest X-ray image." *Chemometrics and Intelligent Laboratory Systems* 203 (2020): 104054.
7. Dover, Jeffrey S., et al. "A path to resume aesthetic care: executive summary of Project AesCert guidance supplement—practical considerations for aesthetic medicine professionals supporting clinic preparedness in response to the SARS-CoV-2 outbreak." *Facial plastic surgery & aesthetic medicine* 22.3 (2020): 125-151.
8. Fahmy, Dina Hassan, et al. "COVID‐19 and dermatology: a comprehensive guide for dermatologists." *Journal of the European Academy of Dermatology and Venereology* 34.7 (2020): 1388-1394.
9. Campanati, A., et al. "Active implications for dermatologists in ‘SARS‐CoV‐2 ERA’: Personal experience and review of literature." *Journal of the European Academy of Dermatology and Venereology* 34.8 (2020): 1626-1632.
10. Calvão, J., et al. "Acro‐ischaemia and COVID‐19 infection: clinical and histopathological features." *Journal of the European Academy of Dermatology and Venereology* (2020).
11. Rosner, E. "Adverse effects of prolonged mask use among health care professionals during COVID-19." *J Infect Dis Epidemiol* 6 (2020): 130.
12. Jain, Uday. "Effect of COVID-19 on the Organs." *Cureus* 12.8 (2020).
13. Marraha, Farah, Ibtissam Al Faker, and Salim Gallouj. "A review of the dermatological manifestations of coronavirus disease 2019 (COVID-19)." *Dermatology research and practice* 2020 (2020).
14. Murrell, Dedee F., et al. "A dermatologist's perspective of the COVID‐19 outbreak." *Dermatologic therapy* (2020).
15. Hoenig, Leonard J., and Frederick A. Pereira. "Eruption as a clinical manifestation of COVID-19: photographs of a patient." *Clinics in dermatology* (2020).
16. Lee, H. C., and C. L. Goh. "Occupational dermatoses from Personal Protective Equipment during the COVID‐19 pandemic in the tropics–A Review." *Journal of the European Academy of Dermatology and Venereology* 35.3 (2021): 589-596.
17. Varghese, Praveen Mathews, et al. "Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies." *Immunobiology* (2020): 152008.
18. Rojas, Jose Pablo Madrigal, et al. "SARS CoV-2, manifestaciones clínicas y consideraciones en el abordaje diagnóstico de COVID-19." *Revista Auspiciada por el Hospital Dr. Rafael Ángel Calderón Guardia* 86.629 (2020).
19. Bhargava, Shashank, et al. "Global impact on dermatology practice due to the COVID-19 pandemic." *Clinics in Dermatology* (2021).
20. Kannangara, Ajith P. "Reply: Introducing special cutaneous “sign” tribute to health care workers managing new coronavirus disease (COVID-19)—new additions." *Clinics in dermatology* (2020).
21. Goodarzi, Azadeh. "A comprehensive review on COVID-19 infection and comorbidities of various organs." *Acta Medica Iranica* (2021): 4-14.
22. Daneshpazhooh, Maryam, and HamidReza Mahmoudi. "COVID-19: The experience from Iran." *Clinics in Dermatology* 39.1 (2021): 23-32.
23. Nejati, Amir, et al. "Clinical Recommendation for Emergency Physicians to Approach to Signs and Symptoms Related to COVID-19; a Preliminary Study." *Frontiers in Emergency Medicine* 4.2s (2020): e56-e56.
24. Gül, Ülker. "COVID-19 and dermatology." *Turkish Journal of Medical Sciences* 50.8 (2020): 1751-1759.
25. Zeouk, Ikrame, Khadija Bekhti, and Jacob Lorenzo-Morales. "From Wuhan to COVID-19 Pandemic: An Up-to-Date Review of Its Pathogenesis, Potential Therapeutics, and Recent Advances." *Microorganisms* 8.6 (2020): 850.
26. Velázquez, María del Rosario Herrera, et al. "Management of the Nursing Processes of Internal Students in the Confrontation of the COVID-19." *International Journal of Health Sciences* 4.2: 24-30.
27. Shubhanshu, Kumar, and Avaneesh Singh. "Prolonged Use of n95 Mask a Boon or Bane to Healthcare Workers During Covid–19 Pandemic." *Indian Journal of Otolaryngology and Head & Neck Surgery* (2021): 1-4.
28. [HTML]SH Dagher, [G Lamé](https://scholar.google.com/citations?user=zlsjWSsAAAAJ&hl=en&oi=sra), T Hubiche… - JMIR Public Health …, [The influence of media coverage and governmental policies on Google queries related to COVID-19 cutaneous symptoms: Infodemiology study](https://publichealth.jmir.org/2021/2/e25651/)2021 - publichealth.jmir.org
29. X Duan, H Sun, Y He, J Yang, X Li…  [HTML][HTML][Personal Protective Equipment in COVID-19: Impacts on Health Performance, Work-Related Injuries, and Measures for Prevention](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934332/)2021 - ncbi.nlm.nih.gov
30. V Campbell, D Middleton, J Donnell[Localized mid‐face miliaria as a consequence of filtering face piece respirator use during the COVID‐19 pandemic](https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16624) y… - Journal of the …, 2020 - Wiley Online Library
31. E Kordzadeh-Kermani, [H Khalili](https://scholar.google.com/citations?user=pnIT098AAAAJ&hl=en&oi=sra)[Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19)](https://www.futuremedicine.com/doi/abs/10.2217/fmb-2020-0110)Future microbiology, 2020 - Future Medicine
32. A Pawełczyk, [L Zaprutko](https://scholar.google.com/citations?user=aiPqmEgAAAAJ&hl=en&oi=sra)[Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives](https://www.future-science.com/doi/abs/10.4155/fmc-2020-0204). Future Medicinal Chemistry, 2020 - Future Science
33. Altam, Saleh. "Influence of social media on EFL Yemeni learners in Indian Universities during Covid-19 Pandemic." *Linguistics and Culture Review* 4.1 (2020): 35-47.
34. Mahmud, SM Hasan, et al. "Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients." *Briefings in Bioinformatics* (2021).
35. Hoenig, Leonard J. "The eye and COVID-19 pandemic." *Clinics in dermatology* (2020).
36. Gadarowski, Mary Beth, et al. "Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries." *Journal of Dermatological Treatment* (2020): 1-5.
37. Padula, William V., et al. "Best‐Practices for Preventing Skin Injury Beneath Personal Protective Equipment During the COVID‐19 Pandemic: A Position Paper from the National Pressure Injury Advisory Panel (NPIAP)." *Journal of Clinical Nursing* (2021).
38. Calvache, Natalia, et al. "Perspectiva de la dermatología y COVID-19." *Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica* 28.1 (2020): 17-26.
39. Bahadir-Yilmaz, Emel, and Arzu Yüksel. "State anxiety levels of nurses providing care to patients with COVID-19 in Turkey." *Perspectives in Psychiatric Care* (2020).
40. Kini, Ganesh, Ravichandra Karkal, and Madhavi Bhargava. "All’s not well with the “worried well”: understanding health anxiety due to COVID-19." *Journal of preventive medicine and hygiene* 61.3 (2020): E321.
41. Yazdanpanah, Fariba, Hamid Yazdanpanah Asmarz, and Shahrad Shadman. "Multidimensional Literature Review of COVID-19, Pulmonary and Extrapulmonary Disease." *The American journal of the medical sciences* (2021).
42. Almutairi, Abdulelah, Mohammed Alfaleh, and Muath Alasheikh. "Dermatological Manifestations in Patients With SARS-CoV-2: A Systematic Review." *Cureus* 12.7 (2020).
43. Stamu‐O’Brien, Caroline, et al. "Psychological aspects of COVID‐19." *Journal of cosmetic dermatology* 19.9 (2020): 2169-2173.
44. Ivanoska-Dacikj, Aleksandra, and Urszula Stachewicz. "Smart textiles and wearable technologies–opportunities offered in the fight against pandemics in relation to current COVID-19 state." *Reviews on Advanced Materials Science* 59.1 (2020): 487-505.
45. Dheemant, M., E. S. Sushmitha, and A. S. Madhan Jeyaraman. "Unveiling the dermatological manifestations of nCOVID-19." *International Journal of Research* 6.4 (2020): 1.
46. Moore, Zena, et al. "Facial pressure injuries and the COVID-19 pandemic: skin protection care to enhance staff safety in an acute hospital setting." *Journal of wound care* 30.3 (2021): 162-170.
47. Mushtaq, Sabha, et al. "Cutaneous adverse effects due to personal protective measures during COVID‐19 pandemic: a study of 101 patients." *International journal of dermatology* 60.3 (2021): 327-331.
48. Korrapati, Naga Harika, et al. "Assessing the Impact of Social Distance on Skin Condition during COVID-19 Pandemic Based on an Online Survey." *International Journal of Progressive Sciences and Technologies* 24.1 (2021): 110-125.
49. Shahbaznejad, Leila, et al. "Knowledge, attitude and practice of Sari Birth Cohort members during early weeks of COVID-19 outbreak in Iran." *BMC public health* 21.1 (2021): 1-12.
50. Daye, Munise, Fatma Gökşin Cihan, and Yasemin Durduran. "Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID‐19 pandemic." *Dermatologic therapy* 33.6 (2020): e14346.
51. Metin, Nurcan, Çağrı Turan, and Zeynep Utlu. "Changes in dermatological complaints among healthcare professionals during the COVID-19 outbreak in Turkey." *Acta dermatovenerologica Alpina, Pannonica, et Adriatica* 29.3 (2020): 115-122.
52. Gross, J. Valérie, et al. "Contribution of Occupational Health to multidisciplinary team work for COVID-19 prevention and management." *La Medicina del Lavoro* 112.2 (2021): 171.
53. Kisielinski, Kai, et al. "Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?." *International journal of environmental research and public health* 18.8 (2021): 4344.
54. Luz, Alessandra Rocha, Rogério Mendonça de Noronha, and Túlio Pinho Navarro. "COVID–19: medidas de prevenção de lesão por pressão ocasionadas por equipamentos de proteção individual em profissionais da saúde." *Revista Enfermagem Atual In Derme* 93 (2020).
55. Cucunawangsih, Cucunawangsih. "Adverse skin reaction to personal protective equipment among health-care workers during COVIS-19 pandemic: a multicenter cross-sectional study in Indonesia." *Journal of Dermatology and Venereology* 3.4 (2020).
56. Williams, Abhilasha, Amrutha Dirisala, and Monika Sharma. "Dermatological manifestations in children and adults with COVID-19 infections." *CHRISMED Journal of Health and Research* 7.4 (2020): 240.
57. Janah, H., A. Zinebi, and J. Elbenaye. "consent to publication of their case details." (2020).
58. Alluhayyan, Omar B., et al. "Occupational-Related Contact Dermatitis: Prevalence and Risk Factors Among Healthcare Workers in the Al'Qassim Region, Saudi Arabia During the COVID-19 Pandemic." *Cureus* 12.10 (2020).
59. Miharja, Marjan, Sri Setiawati, and Amanda Lestari Putri Lubis. "How Dangerous the Indonesian Recession Due to COVID-19 Pandemic: Review Policy and Strategy to Recovery." *International Journal of Social Sciences and Humanities* 4.3: 121-129.
60. Lavery, Michael Joseph, Charles Alexis Bouvier, and Ben Thompson. "Cutaneous manifestations of COVID-19 in children (and adults): A virus that does not discriminate." *Clinics in Dermatology* (2020).
61. Putri, Santy Irene, and Ayu Anulus. "Preventive Actions to Minimizing the Covid-19 Transmissions among Health Workers: A Systematic Review." *Journal of the Medical Sciences (Berkala ilmu Kedokteran)* 52.3.
62. Nottingham, Aberdeen Edinburgh Lancaster, et al. "DermSoc UK Newsletter."
63. زهرابیگم موسوي, and علیرضا فیروز. "(2) متخصصین پوست و بیماري COVID-19." *Dermatology & Cosmetic* 11.2 (2020).‎
64. Shanshal, Mohammed, et al. "Impact of COVID-19 on medical practice: A nationwide survey of dermatologists and health care providers in Iraq." *Clinics in Dermatology* (2020).
65. Soares, Samira Silva Santos, et al. "From caregiver to patient: in the Covid-19 pandemic, who defends and cares for Brazilian nursing?." *Escola Anna Nery* 24 (2020).
66. Alario, Dario, et al. "Orange discoloration of the skin in mother and newborn with SARS-CoV-2 infection: is hypercarotenosis a sign of COVID-19?." *Journal of Pediatric and Neonatal Individualized Medicine (JPNIM)* 10.1 (2021): e100101-e100101.
67. Larasati, Venny, and Soilia Fertilita. "Maintaining Healthy Skin During COVID-19 Pandemic." *Conferences of Medical Sciences Dies Natalis Faculty of Medicine Universitas Sriwijaya*. Vol. 2. No. 1. Fakultas Kedokteran Universitas Sriwijaya (Faculty of Medicine, Universitas Sriwijaya) Indonesia, 2020.
68. Kuravi, Nagaraju, Karthik Nagaraju, and Venkata Kasyapi Voorakaranam. "Management of asthma and allergic diseases during the coronavirus disease 2019 pandemic in India." *Indian Journal of Allergy, Asthma and Immunology* 34.1 (2020): 15.
69. Haasbroek, Kyle, Masayuki Yagi, and Yoshikazu Yonei. "Why are people with glycative stress so susceptible to COVID-19 infection?." *Glycative Stress Research* 7.3 (2020): 232-239.
70. Jafferany, Mohammad. "Psychological aspects of COVID-19."
71. Kar, Debjit, Anupam Das, and Abheek Sil. "An upsurge of hand dermatitis cases amidst COVID-19 pandemic." *Indian Journal of Dermatology* 66.2 (2021): 218.
72. Al-Khateeb, Badr. "Primary health care and family physicians provide frontline care to the dermatology patients during the era of COVID-19: Recommendations and future directions." *Journal of Family Medicine and Primary Care* 9.12 (2020): 5862.
73. Were, CDC Says Some Vaccine Reactions, and Caused By Anxiety–HuffPost. "Pandemic-Related Lifestyle Changes Could Affect the Epigenetic Regulation of Your Skin–WhatIsEpigenetics. com."
74. Paudel, V. "Dermatological Aspects of COVID-19 in Nepal." *Kathmandu University Medical Journal* 18.2 (2020): 115-116.
75. Alkubaisi, Thamir. "Annoying Skin Reaction Among The Medical Staff Using Personal Protective Equipment During COVID-19." (2020).
76. Sharma, Akanksha, and Rishabha Malviya. "Effects of corona virus on the skin: Symptoms and risks." *The Open Dermatology Journal* 14.1 (2020).
77. Abdel-Fattah, H. M. M. "Long COVID-19 syndrome precaution and management." *American Journal of Psychiatric Research and Reviews* 4.1 (2021): 28-28.
78. Bukar, Maryam, and Abdulsalam S. Mustafa. "Integrating ICT and Education for Administrative Purposes: Analysis of Access to Information at Khazar University, Azerbaijan."
79. Ferreira, Gonçalves. "The day after: the impact of Covid-19 pandemic on Dermatology residency." *Actas Dermo-sifiliograficas* (2020).
80. Dey, P., S. Vaijayanthimala, and V. S. Dalvi. "COVID-19: Understanding the Pandemic Emergence, Impact and Infection Prevalence Worldwide." *J Pure Appl Microbiol* 14.4 (2020): 2235-2251.
81. Etgu, Fatma, and Sevda Onder. "Skin problems related to personal protective equipment among healthcare workers during the COVID-19 pandemic (online research)." *Cutaneous and Ocular Toxicology* just-accepted (2021): 1-17.
82. Saeed, Mohammed Yousif, Mahdi Fattah, and Dler R. Abdulkareem. "Teledermatology in the time of Coronavirus Disease (COVID-19); Has its time arrived in Kurdistan."
83. Kosasih, Laura Pauline. "MASKNE: Mask-Induced Acne Flare During Coronavirus Disease-19. What is it and How to Manage it?." *Open Access Macedonian Journal of Medical Sciences* 8.T1 (2020): 411-415.
84. Spence, Nicole Z., et al. "COVID-19 and occupational skin hazards for anaesthesiologists." *BJA: British Journal of Anaesthesia* (2020).
85. Lee, Ju-Yeon, et al. "The Experiences of Health Care Workers during the COVID-19 Pandemic in Korea: a Qualitative Study." *Journal of Korean Medical Science* 36.23 (2021).
86. Alsaidan, Mohammed Saud, et al. "The Prevalence and Determinants of Hand and Face Dermatitis during COVID-19 Pandemic: A Population-Based Survey." *Dermatology research and practice* 2020 (2020).
87. Godse, Kiran, Anant Patil, and Gauri Godse. "Urticaria and its management in the context of coronavirus disease-19 (COVID-19)." *IP Indian Journal of Clinical and Experimental Dermatology* 6.2 (2020): 102-104.
88. Muzaffar, Farhana. "Cutaneous Manifestations of COVID-19 in Children." *Journal of Pakistan Association of Dermatologists* 31.1 (2021): 93-102.
89. Wilcha, Robyn-Jenia. "Does Wearing a Face Mask During the COVID-19 Pandemic Increase the Incidence of Dermatological Conditions in Health Care Workers? Narrative Literature Review." *Jmir Dermatology* 4.1 (2021): e22789.
90. Wilcha, Robyn-Jenia. "Does Wearing a Face Mask During the COVID-19 Pandemic Increase the Incidence of Dermatological Conditions in Health Care Workers? Narrative Literature Review." *Jmir Dermatology* 4.1 (2021): e22789.
91. Sobh, Eman, et al. "Novel coronavirus disease 2019 (COVID-19) non-respiratory involvement." *The Egyptian Journal of Bronchology* 14.1 (2020): 1-6.
92. Merhand, Stéphanie, et al. "Wearing a mask and skin disease: patients with atopic dermatitis speak it out." *Journal of the European Academy of Dermatology and Venereology* (2020).
93. Faghihi, Gita, Yalda Radan, and Mohammad Reza Radan. "Irritant hand dermatitis during the COVID-19 outbreak." *Clin Microbiol Rev* 17 (2004): 863-93.
94. Mahto, Anjali. "Skin health and masks." *Dental Nursing* 16.8 (2020): 376-377.
95. Aguilar-Gamboa, Franklin R., et al. "Pityriasis rubra pilaris post-infection due COVID-19: case report." *Colombia Médica* 52.1 (2021).
96. Altun, Ece. "The most common pediatric and adult dermatology patient complaints in a month of the COVID‐19 Pandemic in turkey." *Dermatologic therapy* 33.6 (2020): e13972.
97. Akl, J., et al. "Skin Disorders associated with the COVID‐19 Pandemic: A Review." *Journal of Cosmetic Dermatology* (2021).
98. Christopher, Paulus Mario, et al. "Adverse Skin Reactions to Personal Protective Equipment Among Health-Care Workers During COVID-19 Pandemic: A Multicenter Cross-sectional Study in Indonesia." *International Journal of Dermatology and Venereology* 3.4 (2020): 211-218.
99. Hamid, Khaled, et al. "Too long and persistent hiccups can be the only symptom of COVID-19." (2020).
100. Wollina, Uwe. "Dermatologic challenges of COVID-19 pandemic for dermatology."
101. Subhalakshmi, R. T., S. Appavu alias Balamurugan, and S. Sasikala. "Deep learning based fusion model for COVID-19 diagnosis and classification using computed tomography images." *Concurrent Engineering* (2021): 1063293X211021435.
102. Subhalakshmi, R. T., S. Appavu alias Balamurugan, and S. Sasikala. "Deep learning based fusion model for COVID-19 diagnosis and classification using computed tomography images." *Concurrent Engineering* (2021): 1063293X211021435.
103. Birihane, Binyam Minuye, et al. "Health care provider's risk perception, and preparedness towards COVID-19 pandemic in North Central Ethiopia, 2020." *Heliyon* 7.3 (2021): e06610.
104. Al-Ani, Muzhir Shaban, and Dimah Mezher Al-Ani. "Review Study on Sciencedirect Library Based on Coronavirus Covid-19." *UHD Journal of Science and Technology* 4.2 (2020): 46-55.
105. Dahy, Abdullah, et al. "Telemedicine approach for psoriasis management, time for application? A systematic review of published studies." *Dermatologic Therapy* (2020): e13908.
106. Santana, Neuranides, et al. "Safety of health professionals in facing the new coronavirus in Brazil." *Escola Anna Nery* 24 (2021).
107. Pourani, Mohammad Reza, Soheila Nasiri, and Fahimeh Abdollahimajd. "Prevalence of hand contact urticaria and related risk factors among healthcare workers during the COVID‐19 pandemic: A self‐reported assessment." *Dermatologic therapy* (2020).
108. Goyal, Shivam, Smitha S. Prabhu, and M. Mukhyaprana Prabhu. "Dermatological concerns of healthcare workers (HCWs) amidst the COVID-19 pandemic." *Iranian Journal of Dermatology* 23.Suppl. 1 (COVID-19) (2020): 54-59.
109. Zare, Elham, Maryam Panahi, and Zahra Mahboubi Fooladi. "A Challenging Case of COVID-19 With Skin Manifestatons and Normal Chest Computed Tomography." *Case Reports in Clinical Practice* 5.4 (2020): 118-120.
110. Tekinalp, Atakan, et al. "EVALUATION OF HEMATOLOGY CONSULTATIONS IN COVID-19 PANDEMIC." *Authorea Preprints* (2020).
111. DURSUN, Recep. "COVID-19 ve Dermatoloji Poliklinikleri."
112. Sabio, Rodrigo, Gabriela Giaccaglia, and Pascual Valdez. "COVID-19 associated acro-ischemia." *Revista Virtual de la Sociedad Paraguaya de Medicina Interna* 7.2 (2020): 105-108.
113. Cordova Arriluz, Claudia Mercedes. "Efectos de un protocolo preventivo ante lesiones cutáneas por uso de EPP faciales en enfermeras de uci Covid19, Lima 2021." (2021).
114. Soares, Samira Silva Santos, et al. "De cuidador a paciente: na pandemia da Covid-19, quem defende e cuida da enfermagem brasileira?." *Escola Anna Nery* 24.SPE (2020).
115. Mailiani, Sandora Rizky, Yuli Kurniawati, and Msy Adnindya. *HUBUNGAN ANTARA PENGGUNAAN MASKER DENGAN KELAINAN KULIT PADA TENAGA KESEHATAN DI ERA PANDEMI COVID-19*. Diss. Sriwijaya University, 2021.
116. Poyanco, Poliana Wada, et al. "Manifestações dermatológicas em crianças com COVID-19: revisão de literatura."
117. Santana, Neuranides, et al. "Segurança dos profissionais de saúde no enfrentamento do novo coronavírus no Brasil." *Escola Anna Nery* 24 (2021).
118. Hackett, Sharon, Bibiana Prieto, and Sylvain LeQuoc. "Lésions et allergies au visage associées au port de masques."
119. Jeseňák, Miloš, et al. "Covid-19, alergické choroby a antialergická liečba." *PEDIATRIA* 111 (2020): 2.
120. Arcos, Julieth Fernanda Urbano, et al. "SARS-CoV-2 en pediatría. Historia de una pandemia desde China hasta Colombia." *Interdisciplinary Journal of Epidemiology and Public Health* 3.1 (2020).
121. Científico, C., Pimentel, A. M., Fonseca, A. R., Binotto, C. N., Amoretti, C. F., & de Lima Fonseca, A. B. (2020). Nota de Alerta.
122. Ramírez, Paola Carolina Buitrago, et al. "Lesiones cutáneas y COVID-19, más allá de lo elemental." *Scientific and Educational Medical Journal* 2.1 (2021): 152-162.
123. Cáceda, S. I., Andrade, A. B., Montenegro, E. P., Monge, E. P., & Colina, A. V. SOCIEDAD PERUANA DE MEDICINA INTERNA (SPMI).
124. Sabio, R., Giaccaglia, G., & Valdez, P. (2020). Acroisquemia asociada a COVID 19. *Revista Virtual de la Sociedad Paraguaya de Medicina Interna*, 105-108.
125. Soares, Samira Silva Santos, et al. "De cuidador a paciente: en la pandemia de Covid-19,¿ quién defiende y cuida la enfermera brasileña?." *Escola Anna Nery* 24.spe (2020).
126. Carrión-Álvarez, Diego, et al. "Manifestaciones cutáneas en pacientes con COVID-19." *Dermatol Rev Mex* 65.2 (2021): 166-189.
127. Velasquez Vera, Jeniffer Stefania, and Darwin Wladimir Guerrero Paredes. *Análisis de la gravedad por COVID-19, Hospital Carlos Andrade Marín, Quito, 2020*. BS thesis. Universidad Nacional de Chimborazo, 2020.
128. Meireles, Andreia Luísa Neto. "Relatórios de Estágio realizado na Farmácia da Mata Real e no Centro Hospitalar Universitário do Porto." (2020).
129. Uinarni, Herlina, et al. "Corona Virus Infectious Disease 19 (COVID-19) in Various Reviews." *Systematic Reviews in Pharmacy* 11.6 (2020).
130. Pigliacelli, Flavia, and Antonio Cristaudo. "COVID-19: la corretta gestione dei dispositivi di protezione individuale (DPI) e la prevenzione dei possibili effetti avversi dermatologici." *www. dermatologyreports. org* 1 (2020): 7.
131. Dikicier, Bahar Sevimli, and Mahizer YALDIZ. "COVİD 19 Enfeksiyonu: Dermatolojik bulgu var mı?." *Journal of Biotechnology and Strategic Health Research* 4: 135-139.
132. de Melo Silva, Rillary Caroline, Maria Caroline de Melo Silva, and Christefany Régia Braz Costa. "Segurança do trabalho no ambiente hospitalar frente à pandemia da COVID-19." *Revista de Atenção à Saúde* 18.65 (2020).

Библиографският списък на цитиранията в литературата на научните трудове е съставен въз основа на данни от :

Web of Science

Google Scholar

Google Search

Science Finder

Yahoo Search

Harzing’s Publish or Parish